ANG LIFESCIENCES INDIA LIMITED CIN: U24230PB006PLC030341

Transcription

1 Draft Prospectus Fixed Price Issue Dated: March 21, 2017 Please read Section 26 of the Companies Act, 2013 LEAD MANAGER TO THE ISSUE ANG LIFESCIENCES INDIA LIMITED CIN: U24230PB006PLC Our Company was originally incorporated as ANG Lifesciences India Private Limited on June 14, 2006 with the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh as a private limited Company under the Companies Act, On conversion into public limited Company the name of our Company was changed to ANG Lifesciences India Limited pursuant to special resolution passed at the Extra Ordinary General Meeting held on January 18, 2010 and a fresh certificate of incorporation dated March 02, 2010 issued by the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh. Our company was further converted into private limited Company and the name of our Company was changed to ANG Lifesciences India Private Limited pursuant to special resolution passed at the Extra Ordinary General Meeting held on August 31, 2010 and a fresh certificate of incorporation was issued by Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh dated September 22, Subsequently, on conversion into public limited Company the name of our company again changed to ANG Lifesciences India Limited pursuant to special resolution passed at the Extra Ordinary General Meeting held on May 04, 2016 and a fresh certificate of incorporation dated May 18, 2016 issued by the Registrar of Companies, Chandigarh. For further details of our Company, please refer to the chapter titled History and Certain Corporate Matters on page 83 of the Draft Prospectus. Registered Office: - Darbara Complex, SCO 113, First Floor, District Shopping Centre B Block, Ranjit Avenue, Amritsar Tel: , ; Website: Company Secretary and Compliance Officer: Mr. Chandan Kapoor; cs@anglifesciences.com PROMOTERS: MR. RAJESH GUPTA AND MRS. SARUCHI GUPTA PUBLIC ISSUE OF 15,00,800, EQUITY SHARES OF FACE VALUE OF ` EACH OF ANG LIFESCIENCES INDIA LIMITED ( ANG OR ALIL OR THE COMPANY OR THE ISSUER ) FOR CASH AT A PRICE OF ` PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ` PER EQUITY SHARE) ( ISSUE PRICE ) AGGREGATING TO ` LAKHS ( THE ISSUE ) OF WHICH, 76,800 EQUITY SHARES OF FACE VALUE OF ` 10/- EACH AT A PRICE OF ` PER EQUITY SHARE AGGREGATING TO ` LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER ( MARKET MAKER RESERVATION PORTION ). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 14,24,000 EQUITY SHARES OF FACE VALUE OF ` EACH AT AN ISSUE PRICE OF ` PER EQUITY SHARE AGGREGATING TO ` LAKHS IS HEREINAFTER REFERRED TO AS THE NET ISSUE. THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 28.95% AND 27.47%, RESPECTIVELY OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY. THIS ISSUE IS BEING MADE IN TERMS OF CHAPTER XB OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2009 (THE SEBI (ICDR) REGULATIONS ), AS AMENDED. THIS ISSUE IS A FIXED PRICE ISSUE AND ALLOCATION IN THE NET ISSUE TO THE PUBLIC WILL BE MADE IN TERMS OF REGULATION 43(4) OF THE SEBI (ICDR) REGULATIONS, AS AMENDED. FOR FURTHER DETAILS, PLEASE REFER TO SECTION TITLED "ISSUE PROCEDURE" ON PAGE 178 OF THE DRAFT PROSPECTUS. All potential investors may participate in the Issue through an Application Supported by Blocked Amount ( ASBA ) process providing details about the bank account which will be blocked by the Self Certified Syndicate Banks ( SCSBs ) for the same. THE FACE VALUE OF THE EQUITY SHARES IS ` 10 EACH AND THE ISSUE PRICE OF ` IS 8 TIMES OF THE FACE VALUE RISKS IN RELATION TO FIRST ISSUE This being the first public issue of the Issuer, there has been no formal market for our Equity Shares. The face value of the Equity Shares of our Company is ` 10 and the Issue price of ` per Equity Share is 8 times of the face value. The Issue Price (as determined by our Company in consultation with the Lead Manager, as stated under the chapter titled Basis for the Issue Price on page 55 of the Draft Prospectus) should not be taken to be indicative of the market price of the Equity Shares after such Equity Shares are listed. No assurance can be given regarding an active and/or sustained trading in the Equity Shares or regarding the price at which the Equity Shares will be traded after listing. GENERAL RISKS Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Issue. For taking an investment decision, investors must rely on their own examination of the Issuer and this Issue, including the risks involved. The Equity Shares have not been recommended or approved by the Securities and Exchange Board of India ( SEBI ), nor does SEBI guarantee the accuracy or adequacy of the contents of the Draft Prospectus. Specific attention of the investors is invited to the section titled Risk Factors on page 11`of the Draft Prospectus. ISSUER S ABSOLUTE RESPONSIBILITY Our Company, having made all reasonable inquiries, accepts responsibility for and confirms that this Draft Prospectus contains all information with regard to our Company and the Issue, which is material in the context of the Issue, that the information contained in this Draft Prospectus is true and correct in all material aspects and is not misleading in any material respect, that the opinions and intentions expressed herein are honestly held and that there are no other facts, the omission of which makes this Draft Prospectus as a whole or any of such information or the expression of any such opinions or intentions, misleading in any material respect. LISTING The Equity Shares offered through the Draft Prospectus are proposed to be listed on the SME Platform of BSE Limited. In terms of the Chapter XB of the SEBI (ICDR) Regulations 2009, as amended from time to time, our Company has received an approval letter dated [ ] from BSE Limited ( BSE ) for using its name in this Draft Prospectus for listing of our shares on the SME Platform of BSE Limited. For the purpose of this Issue, the designated Stock Exchange will be the BSE. REGISTAR TO THE ISSUE GUINESS CORPORATE ADVISORS PRIVATE LIMITED 18 Deshapriya Park Road, Kolkata West Bengal, India Tel: Fax: gcapl@guinessgroup.net Website: Contact Person: Ms. Alka Mishra / Ms. Nimisha Joshi SEBI Registration No.: INM ISSUE OPENS ON: [ ] ISSUE PROGRAMME BIG SHARE SERVICES PRIVATE LIMITED E/2, Ansa Industrial Estate, Sakivihar Road, Sakinaka, Andheri (East), Mumbai Tel: Fax: ipo@bigshareonline.com Website: www. bigshareonline.com Contact Person: Mr. Babu Raphael SEBI Registration No.: INR ISSUE CLOSES ON: [ ]

2 TABLE OF CONTENTS SECTION I - GENERAL... 2 DEFINITIONS AND ABBREVIATIONS... 2 PRESENTATION OF FINANCIAL, INDUSTRY AND MARKET DATA... 8 FORWARD LOOKING STATEMENTS SECTION II - RISK FACTORS SECTION III - INTRODUCTION SUMMARY OF OUR INDUSTRY SUMMARY OF OUR BUSINESS SUMMARY OF FINANCIALS ISSUE DETAILS IN BRIEF GENERAL INFORMATION CAPITAL STRUCTURE OBJECTS OF THE ISSUE BASIC TERMS OF THE ISSUE BASIS FOR ISSUE PRICE STATEMENT OF TAX BENEFITS SECTION IV - ABOUT OUR COMPANY INDUSTRY OVERVIEW OUR BUSINESS KEY INDUSTRY REGULATIONS AND POLICIES HISTORY AND CERTAIN CORPORATE MATTERS OUR MANAGEMENT OUR PROMOTERS AND PROMOTER GROUP GROUP COMPANIES / ENTITIES RELATED PARTY TRANSACTIONS DIVIDEND POLICY SECTION V - FINANCIAL INFORMATION AUDITOR S REPORT ON RESTATED FINANCIAL STATEMENTS STATEMENT OF FINANCIAL INDEBTEDNESS MANAGEMENT DISCUSSION & ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS SECTION VI: LEGAL AND OTHER INFORMATION OUTSTANDING LITIGATIONS AND MATERIAL DEVELOPMENTS GOVERNMENT AND OTHER APPROVALS SECTION VII- OTHER REGULATORY AND STATUTORY DISCLOSURES SECTION VIII ISSUE RELATED INFORMATION TERMS OF THE ISSUE ISSUE STRUCTURE ISSUE PROCEDURE RESTRICTION ON FOREIGN OWNERSHIP OF INDIAN SECURITIES SECTION IX - MAIN PROVISIONS OF THE ARTICLES OF ASSOCIATION LIST OF MATERIAL CONTRACTS AND DOCUMENTS FOR INSPECTION DECLARATION

3 SECTION I - GENERAL DEFINITIONS AND ABBREVIATIONS DEFINITIONS TERMS ANG Lifesciences India Limited, ALIL, ANG, We or us or our Company the Company you, your or yours DESCRIPTION Unless the context otherwise requires, refers to ANG Lifesciences India Limited, a Company incorporated under the Companies Act, 1956 having Registered Office at Darbara Complex, SCO 113, First Floor, District Shopping Centre B Block, Ranjit Avenue, Amritsar Prospective Investors in this Issue CONVENTIONAL/GENERAL TERMS TERMS AOA / Articles / Articles of Association Audit Committee Banker to the Company Board of Directors/the Board/our Board/Director(s) BSE CIN Companies Act / Act Demographic Details Depositories Act Depositories DIN Equity Shares / Shares Key Managerial Personnel / Key Managerial Employees MOA / Memorandum / Memorandum of Association Non Resident Non-Resident Indian/ NRI DESCRIPTION Articles of Association of ANG Lifesciences India Limited, as amended from time to time The committee of the Board of Directors constituted as the Company s Audit Committee in accordance with Regulation 18 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015 Punjab National Bank The Board of Directors of ANG Lifesciences India Limited, including all duly constituted committees thereof BSE Limited (the Designated Stock Exchange) Corporate Identification Number The Companies Act, 1956 and Companies Act, 2013, to the extent amended and applicable. The demographic details of the Applicants such as their address, PAN, occupation and bank account details The Depositories Act, 1996 as amended from time to time National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) Directors Identification Number Equity Shares of our Company of face value of Rs. 10 each unless otherwise specified in the context thereof Key managerial personnel of our Company in terms of the SEBI Regulations and the Companies Act, 2013, as described in the section titled Our Management on page 87of this Draft Prospectus. Memorandum of Association of ANG Lifesciences India Limited, as amended A person resident outside India, as defined under FEMA Regulations A person resident outside India, who is a citizen of India or a Person of Indian Origin as defined under FEMA Regulations, as amended Overseas Corporate Body / A company, partnership, society or other corporate body owned directly or OCB indirectly to the extent of at least 60% by NRIs, including overseas trusts in which not less than 60% of beneficial interest is irrevocably held by NRIs directly or indirectly as defined under the Foreign Exchange Management (Deposit) Regulations, OCBs are not allowed to invest in this Issue. Peer Review Auditor M/s. Vishal H. Shah & Co., Chartered Accountants, the Peer Review Auditor of our Company Person or Persons Any Individual, Sole Proprietorship, Unincorporated Association, Unincorporated Organization, Body Corporate, Corporation, Company, Partnership Firm, Limited Liability Partnership, Joint Venture, or Trust or Any 2

4 TERMS DESCRIPTION Other Entity or Organization validly constituted and/or incorporated in the jurisdiction in which it exists and operates, as the context requires Promoters Promoters of the Company being Mr. Rajesh Gupta and Mrs. Saruchi Gupta Promoter Group Companies Unless the context otherwise specifies, refers to those entities mentioned in the /Group Companies / Group section titled Our Promoters and Promoter Group and Group Companies / Enterprises Entities on page 98 and 102 of this Draft Prospectus. Registered office of our Darbara Complex, SCO 113, First Floor, District Shopping Centre B Block, Company Ranjit Avenue, Amritsar RoC Registrar of Companies, Chandigarh SEBI The Securities and Exchange Board of India constituted under the SEBI Act. SEBI Act Securities and Exchange Board of India Act, 1992 SEBI FPI Regulations Securities and Exchange Board of India (Foreign Portfolio Investors) Regulations, 2014 SEBI Regulation/ SEBI The SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009, as (ICDR) Regulations amended, including instructions and clarifications issued by SEBI from time to time SEBI Takeover Regulations Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeover) Regulations, 2011, as amended from time to time SEBI Insider Trading SEBI (Prohibition of Insider Trading) Regulations 2015as amended from time to Regulations time SEBI LODR Regulations SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time SEBI (Venture Capital) Securities Exchange Board of India (Venture Capital) Regulations, 1996 as Regulations amended from time to time SICA Sick Industrial Companies (Special Provisions) Act, 1985 SME Platform of BSE/Stock The SME platform of BSE for listing of equity shares offered under Chapter X-B Exchange of the SEBI (ICDR) Regulations Statutory Auditor / Auditors M/s. Ajay K. Khanna & Co., Chartered Accountants the statutory auditors of our Company SWOT Analysis of strengths, weaknesses, opportunities and threats ISSUE RELATED TERMS TERMS Allotment/Allot Allottee Applicant Application Form Application Supported by Blocked Amount (ASBA) ASBA Account ASBA Applicant(s) Basis of Allotment DESCRIPTION Unless the context otherwise requires, Transfer of the Equity Shares pursuant to the Issue The successful applicant to whom the Equity Shares are being / have been allotted Any prospective investor who makes an application for Equity Shares in terms of this Draft Prospectus The form in terms of which the applicant shall apply for the Equity Shares of the Company Means an application for subscribing to an Issue containing an authorization to block the application money in a bank account Account maintained with SCSBs which will be blocked by such SCSBs to the extent of the appropriate application amount of the ASBA applicant, as specified in the ASBA Application Form Prospective investors in this Issue, who apply through the ASBA process. Pursuant to SEBI circular no. CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015, all the potential Investors i.e. QIBs and Non-Institutional and Retail participating in this Issue are required to mandatorily use the ASBA facility to submit their applications. The basis on which Equity Shares will be allotted to the Investors under the Issue 3

5 TERMS Broker Centre Broker to the Issue Business Day Category I FPI Category II FPI Category III FPI CAN / Confirmation of Allocation Note Compliance Officer Collection Centres Collecting Participant or CDP Depository Controlling Branches of the SCSBs DESCRIPTION and which is described in Issue Procedure Basis of Allotment on page -- of this Draft Prospectus Broker Centre notified by the Stock Exchanges, where applicants can submit the Application Forms to a Registered Broker. The details of such Broker Centres along with the names and contact details of the Registered Brokers are available on the website of the Stock Exchanges All recognized members of the stock exchange would be eligible to act as the Broker to the Issue Any day on which commercial banks are open for the business FPIs who are registered as Category I Foreign Portfolio Investors under SEBI FPI Regulations FPIs who are registered as Category II Foreign Portfolio Investors under SEBI FPI Regulations FPIs who are registered as Category III Foreign Portfolio Investors under SEBI FPI Regulations The note or advice or intimation sent to each successful Applicant indicating the Equity Shares which will be Allotted, after approval of Basis of Allotment by the Designated Stock Exchange. The Company Secretary of our Company, Mr. Chandan Kapoor Centres at which the designated intermediaries shall accept the ASBA forms, i.e. Designated Branches for SCSBs, Broker Centres for Registered Brokers, Designated RTA locations for RTAs and designated CDP locations for CDPs A depository participant as defined under the Depositories Act, 1996, registered with SEBI and who is eligible to procure applications at the designated CDP locations in terms of circular No. CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015 issued by SEBI Such branches of the SCSBs which co-ordinate Applications by the ASBA Applicants with the Registrar to the Issue and the Stock Exchanges and a list of which is available at or at such other website as may be prescribed by SEBI from time to time Depository Participant / DP A Depository Participant as defined under the Depositories Act, 1996 Designated Branches Such branches of the SCSBs which shall collect the ASBA Application Form used by ASBA Applicant and a list of which is available on Designated Date The date on which funds are transferred from the Escrow Account(s) to the Public Issue Account or the Refund Account, as appropriate, and the amounts blocked by the SCSBs are transferred from the bank accounts of the ASBA Applicant to the Public Issue Account, as the case may be, after the Prospectus is filed with the RoC, following which the Board of Directors shall Allot Equity Shares to the Allottees Designated Market Maker Guiness Securities Limited having Registered office at 216, 2 nd Floor, P.J. Towers, Dalal Street, Mumbai , Mumbai, Maharashtra and Corporate office at Guiness House, 18, Deshapriya Park Road, Kolkata , West Bengal, India Designated Stock Exchange BSE Limited Draft Prospectus The Draft Prospectus dated March 21, 2017 filed with the BSE Limited Eligible NRI NRIs from jurisdictions outside India where it is not unlawful to make an Issue or invitation under the Issue and in relation to whom the Prospectus constitutes an invitation to subscribe to the Equity Shares Allotted herein. Eligible QFIs QFIs from such jurisdictions outside India where it is not unlawful to make an offer or invitation under the Issue and in relation to whom the Prospectus constitutes an invitation to purchase the Equity Shares offered thereby and who have opened demat accounts with SEBI registered qualified depositary 4

6 TERMS DESCRIPTION participants Issue/Issue size/ initial public issue/initial Public Offer/Initial Public Offering/IPO Public Issue of 15,00,800 Equity Shares of Rs. 10/- each of ANG Lifesciences India Limited for cash at a price of Rs. 80/- per share aggregating to Rs Lakhs Issue Closing date The date on which Issue closes for subscription Issue Opening date The date on which issue opens for subscription Issue Period The period between the Issue Opening Date and the Issue Closing Date inclusive of both days and during which prospective applicants may submit their application Issue Price The price at which the Equity Shares are being issued by our Company under this Draft Prospectus being Rs. 80/- Lead Manager/LM Lead Manager to the Issue being Guiness Corporate Advisors Private Limited Listing Agreement Unless the context specifies otherwise, this means the Equity Listing Agreement to be signed between our Company and the SME Platform of BSE. Market Maker Member Brokers of BSE who are specifically registered as Market Makers with the BSE SME Platform. In our case, Guiness Securities Limited is the sole Market Maker. Market Maker Reservation Portion The Reserved portion of 76,800 Equity shares of Rs. 10/- each at Rs. 80/- per Equity Share aggregating to Rs Lacs for Designated Market Maker in the Public Issue of ANG Lifesciences India Limited Market Making Agreement The agreement entered between our Company, Market Maker and Lead Manager dated December 05, 2016 Mutual Funds A mutual Fund registered with SEBI under SEBI (Mutual Funds) Regulations, 1996 Memorandum of Understanding The arrangement entered into on December 05, 2016 between our Company, and Lead Manager pursuant to which certain arrangements are agreed in relation to the Issue Net Issue The Net Issue (excluding the Market Maker Reservation Portion) of 14,24,000 Equity Shares of Rs.10/- each at Rs. 80/- per Equity Share aggregating to Rs Lacs by ANG Lifesciences India Limited NIF National Investment Fund set up by resolution F. No. 2/3/2005-DD-II dated November 23, 2005 of Government of India published in the Gazette of India Non-Institutional Investors / Applicant All Applicants that are not Qualified Institutional Buyers or Retail Individual Investors, who apply for the Equity Shares of a value of more than Rs. 200,000. Prospectus The Prospectus, filed with the RoC containing, inter alia, the Issue opening and closing dates and other information. Public Issue Account/ Issue Account opened with Bankers to the Issue for the purpose of transfer of monies Account from the Escrow Account on or after the Issue Opening Date Qualified Institutional Buyers or QIBs Registrar/Registrar to the Issue Retail Individual Investor(s) Self-Certified Syndicate Banks or SCSBs Public financial institutions as defined in Section 2(72) of the Companies Act, 2013, Foreign Portfolio Investor other than Category III Foreign Portfolio Investor, AIFs, VCFs, FVCIs, Mutual Funds, multilateral and bilateral financial institutions, scheduled commercial banks, state industrial development corporations, insurance companies registered with the IRDA, provident funds and pension funds with a minimum corpus of Rs. 250 million, insurance funds set up and managed by the army, navy or air force of the Union of India and insurance funds set up and managed by the Department of Posts, Government of India, eligible for Bidding and does not include FVCIs and multilateral and bilateral institutions. Registrar to the Issue being Big Share Services Private Limited Individual investors (including HUFs, in the name of Karta and Eligible NRIs) who apply for the Equity Shares of a value of not more than Rs. 2,00,000 The banks which are registered with SEBI under the Securities and Exchange Board of India (Bankers to an Issue) Regulations, 1994 and offer services in 5

7 TERMS DESCRIPTION relation to ASBA, including blocking of an ASBA Account in accordance with the SEBI Regulations and a list of which is available on or at such other website as may be prescribed by SEBI from time to time. Underwriter Guiness Corporate Advisors Private Limited Underwriting Agreement The Agreement among the Underwriter and our Company dated December 05, 2016 Working Days All trading days of Stock Exchanges excluding Sundays and Bank Holidays in accordance with SEBI circular No. SEBI/HO/CFD/DIL/CIR/P/2016/26 dated January 21, 2016 COMPANY/INDUSTRY RELATED TERMS/TECHNICAL TERMS TERMS API GMP GLP ISO R & D SOP WHO DESCRIPTION Active Pharmaceutical Ingredients Good Manufacturing Practises Good Laboratory Practises International Organisation for Standardization Research and Development Standard Operating Procedures World Health Organisation ABBREVIATIONS TERMS DESCRIPTION AGM Annual General Meeting AIF Alternative Investment Fund AS Accounting Standards issued by the Institute of Chartered Accountants of India A. Y. Assessment Year B. A Bachelor of Arts B.Com Bachelor of Commerce BG/LC Bank Guarantee / Letter of Credit CAGR Compounded Annual Growth Rate C. A Chartered Accountant CDSL Central Depository Services (India) Limited CEO Chief Executive Officer CFO Chief Financial Officer C. S. Company Secretary DP Depository Participant ECS Electronic Clearing System EGM / EOGM Extra Ordinary General Meeting EPS Earning Per Equity Share ESOP Employee Stock Option Plan EMD Earnest Money Deposit FCNR Account Foreign Currency Non Resident Account FDI Foreign Direct Investments FEMA Foreign Exchange Management Act, 1999, as amended from time to time and the regulations issued there under. Foreign Institutional Investor (as defined under SEBI (Foreign Institutional FII Investors) Regulations, 1995, as amended from time to time) registered with SEBI under applicable laws in India. 6

8 TERMS DESCRIPTION FIs Financial Institutions FIPB Foreign Investment Promotion Board, Department of Economic Affairs, Ministry of Finance, Government of India. FPIs Foreign Portfolio Investor means a person who satisfies the eligibility criteria prescribed under regulation 4 and has been registered under Chapter II of Securities And Exchange Board Of India (Foreign intermediary in terms of the provisions of the SEBI Act,1992 regulation 4 and has been registered under Chapter II of Securities And Exchange Board Of India (Foreign Portfolio Investors) Regulations, 2014, which shall be deemed to be an intermediary in terms of the provisions of the SEBI Act,1992 FY / Fiscal Financial Year FVCI Foreign Venture Capital Investors registered with SEBI under the SEBI (Foreign Venture Capital Investor) Regulations, GAAP Generally Accepted Accounting Principles GDP Gross Domestic Product GIR Number General Index Registry Number GOI/ Government Government of India H.P. Himachal Pradesh HUF Hindu Undivided Family ICAI Institute of Chartered Accountants of India ICSI Institute of Company Secretaries of India INR / Rs./ Rupees Indian Rupees, the legal currency of the Republic of India Indian GAAP Generally Accepted Accounting Principles in India IPO Initial Public Offering IFRS International Financial Reporting Standards ISIN International Securities Identification Number M. A Master of Arts M.B.A Master of Business Administration M. Com Master of Commerce NAV Net Asset Value No. Number NR Non Resident NSDL National Securities Depository Limited P/E Ratio Price/Earnings Ratio PAN Permanent Account Number RBI The Reserve Bank of India RBI Act The Reserve Bank of India Act, 1934, as amended from time to time ROC/Registrar of Companies The Registrar of Companies RONW Return on Net Worth RTA Registrar and Transfer Agent Sec Section SME Small And Medium Enterprises USD/ $/ US$ The United States Dollar, the legal currency of the United States of America VCF Venture Capital Fund 7

9 FINANCIAL DATA PRESENTATION OF FINANCIAL, INDUSTRY AND MARKET DATA Unless stated otherwise, the financial data in this Draft Prospectus is extracted from the financial statements of our Company for the fiscal years 2012, 2013, 2014, 2015 and 2016 and for the period ended September 30, 2016 and the restated financial statements of our Company for the fiscal years 2012, 2013, 2014, 2015 and 2016 and for the period ended September 30, 2016 prepared in accordance with the applicable provisions of the Companies Act and Indian GAAP and restated in accordance with SEBI (ICDR) Regulations, 2009, as stated in the report of our Auditors and the SEBI Regulations and set out in the section titled Financial Information on page 107. Our restated financial statements are derived from our audited financial statements prepared in accordance with Indian GAAP and the Companies Act, and have been restated in accordance with the SEBI Regulations. Our fiscal years commence on April 1 and end on March 31. In this Draft Prospectus, any discrepancies in any table between the total and the sums of the amounts listed are due to rounding off. All decimals have been rounded off to two decimal points. There are significant differences between Indian GAAP, US GAAP and IFRS. Our Company has not attempted to explain those differences or quantify their impact on the financial data included herein and we urge you to consult your own advisors regarding such differences and their impact on our financial data. Accordingly, the degree to which the Indian GAAP financial statements included in this Draft Prospectus will provide meaningful information is entirely dependent on the reader s level of familiarity with Indian accounting practices. Any reliance by persons not familiar with Indian accounting practices on the financial disclosures presented in this Draft Prospectus should accordingly be limited. CURRENCY OF PRESENTATION All references to "Rupees" or "Rs.", ` or "INR" are to Indian Rupees, the official currency of the Republic of India. All references to "$", "US$", "USD", "U.S.$" or "U.S. Dollar(s)" are to United States Dollars, if any, the official currency of the United States of America. This Draft Prospectus contains translations of certain U.S. Dollar and other currency amounts into Indian Rupees (and certain Indian Rupee amounts into U.S. Dollars and other currency amounts). These have been presented solely to comply with the requirements of the SEBI Regulations. These translations should not be construed as a representation that such Indian Rupee or U.S. Dollar or other amounts could have been, or could be, converted into Indian Rupees, at any particular rate, or at all. In this Draft Prospectus, throughout all figures have been expressed in Lacs, except as otherwise stated. The word "Lacs", "Lac", "Lakhs" or "Lakh" means "One hundred thousand". Any percentage amounts, as set forth in "Risk Factors", "Our Business", "Management's Discussion and Analysis of Financial Conditions and Results of Operation" and elsewhere in this Draft Prospectus, unless otherwise indicated, have been calculated based on our restated financial statement prepared in accordance with Indian GAAP. INDUSTRY & MARKET DATA Unless otherwise stated, Industry & Market data used throughout this Draft Prospectus has been obtained from internal Company reports and Industry publications and the information contained in those publications has been obtained from sources believed to be reliable but their accuracy and completeness are not guaranteed and their reliability cannot be assured. Although we believe that industry data used in this Draft Prospectus is reliable, it has not been independently verified. Similarly, internal Company reports, while believed by us to be reliable, have not been verified by any independent sources. The extent to which the market and industry data used in this Draft Prospectus is meaningful depends on the reader s familiarity with and understanding of the methodologies used in compiling such data. 8

10 DEFINITIONS For definitions, please see the chapter titled Definitions and Abbreviations beginning on page 2 of this Draft Prospectus. In the section titled Main Provisions of the Articles of Association beginning on page 217 of this Draft Prospectus, defined terms have the meaning given to such terms in the Articles of Association. INDUSTRY & MARKET DATA Unless otherwise stated, Industry & Market data used throughout this Draft Prospectus has been obtained from internal Company reports and Industry publications and the information contained in those publications has been obtained from sources believed to be reliable but their accuracy and completeness are not guaranteed and their reliability cannot be assured. Although we believe that industry data used in this Draft Prospectus is reliable, it has not been independently verified. Similarly, internal Company reports, while believed by us to be reliable, have not been verified by any independent sources. The extent to which the market and industry data used in this Draft Prospectus is meaningful depends on the reader s familiarity with and understanding of the methodologies used in compiling such data. 9

11 FORWARD LOOKING STATEMENTS Our Company has included statements in this Draft Prospectus, that contain words or phrases such as "will", "aim", "will likely result", "believe", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "shall", "contemplate", "seek to", "future", "objective", "goal", "project", "should", "will continue", "will pursue" and similar expressions or variations of such expressions that are "forward-looking statements". However, these words are not the exclusive means of identifying forward-looking statements. All statements regarding our Company objectives, plans or goals, expected financial condition and results of operations, business, plans and prospects are also forwardlooking statements. These forward-looking statements include statements as to business strategy, revenue and profitability, planned projects and other matters discussed in this Draft Prospectus regarding matters that are not historical fact. These forward-looking statements contained in this Draft Prospectus (whether made by us or any third party) involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. All forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated by the relevant forward-looking statement. Important factors that could cause actual results to differ materially from expectations include, among others General economic conditions, political conditions, regulatory changes pertaining to the relevant industry scenario in India, technological changes, our exposure to market risks which have an impact on our business activities or investments, the monetary and fiscal policies of India, inflation, etc. Further, the other important factors that could cause actual results to differ materially from expectations are as follows: Our ability to successfully implement our strategy, our growth and expansion, technological changes. Our exposure to market risks that have an impact on our business activities or investments. The monetary and fiscal policies of India, inflation, deflation, unanticipated turbulence in interest rates, foreign exchange rates, equity prices or other rates or prices, the performance of the financial markets in India and Globally. Changes in foreign exchange rates or other rates or prices; Our failure to keep pace with rapid changes in the industry; Our ability to protect our intellectual property rights and not infringing intellectual property rights of other parties; Changes in domestic and foreign laws, regulations and taxes and changes in competition in our industry. Changes in the value of the Rupee and other currencies. The occurrence of natural disasters or calamities. Changes in political conditions in India. The outcome of legal or regulatory proceedings that we are or might become involved in; Our ability to compete effectively, particularly in new markets and businesses; Our dependence on our Key Management Personnel and Promoter; Conflicts of interest with affiliated companies, the Group Entities and other related parties; Other factors beyond our control; and Our ability to manage risks that arise from these factors. For further discussion of factors that could cause Company s actual results to differ, see the section titled "Risk Factors" on page 11 of this Draft Prospectus. By their nature, certain risk disclosures are only estimates and could be materially different from what actually occurs in the future. As a result, actual future gains or losses could materially differ from those that have been estimated. Our Company, the Lead Manager, and their respective affiliates do not have any obligation to, and do not intend to, update or otherwise revise any statements reflecting circumstances arising after the date hereof or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition. In accordance with SEBI requirements, our Company, and the Lead Manager will ensure that investors in India are informed of material developments until such time as the grant of listing and trading permission by the Stock Exchange. 10

12 SECTION II - RISK FACTORS An Investment in equity involves higher degree of risks. Prospective investors should carefully consider the risks described below, in addition to the other information contained in this Draft Prospectus before making any investment decision relating to the Equity Shares. The occurrence of any of the following events could have a material adverse effect on the business, results of operation, financial condition and prospects and cause the market price of the Equity Shares to decline and you may lose all or part of your investment. Prior to making an investment decision, prospective investors should carefully consider all of the information contained in this Draft Prospectus, including the sections titled "Our Business", "Management s Discussion and Analysis of Financial Condition and Results of Operations" and the "Financial Information" included in this Draft Prospectus beginning on pages 68, 137 & 107 respectively. The occurrence of any of the following events could have a material adverse effect on our business, results of operation, financial condition and prospects and cause the market price of the Equity Shares to fall significantly. Unless otherwise stated in the relevant risk factors set forth below, we are not in a position to specify or quantify the financial or other implications of any of the risks mentioned herein. Materiality The risk factors have been determined on the basis of their materiality. The following factors have been considered for determining the materiality: Some events may not be material individually, but may be found material collectively. Some events may have material impact qualitatively instead of quantitatively. Some events may not be material at present but may have material impact in the future. The risk factors are as envisaged by the management. Wherever possible, the financial impact of the risk factors has been quantified. INTERNAL RISK FACTORS 1. There are certain outstanding legal proceedings involving our Company, Promoters and our Directors. Failure to defend these proceedings successfully may have an adverse effect on our business prospects, financial condition, result of ongoing operations and reputation. There are certain outstanding legal proceedings involving our Company, our Promoters and our Directors. These proceedings are pending at different levels before various courts, tribunals, enquiry officers etc. For further details relating to legal proceedings initiated against of the chapter titled Outstanding Litigations and Material Developments beginning on page 148 of this Draft Prospectus. Brief details of such outstanding litigation as of the date of this Draft Prospectus are set forth below and the amounts involved in these litigations have been disclosed to the extent they are ascertainable/quantifiable: Litigations involving our Company Nature of Cases No. of Amount* (Rs. in Lacs) outstanding cases Litigations involving Criminal Laws Litigations involving Tax Liabilities *to the extent quantifiable 11

13 Litigation involving our Promoters/Directors Nature of Cases No. of outstanding Amount * (Rs. in Lacs) cases Litigations involving Tax Liabilities *to the extent quantifiable Note: The amounts mentioned at above tables may be subject to additional interest rates being levied by the concerned authorities for delay in making payment. Amount of interest that may be levied is unascertainable as on the date of this Draft Prospectus Any developments in the proceedings, such as a change in Indian law or rulings against us, our Directors and/ or our Promoters by appellate courts or tribunals may constrain us to make provisions in our financial statements that could increase our expenses and current liabilities and same may result in an adverse material impact on our business, goodwill, result of operations and financial condition. For further details please refer to the chapter titled Outstanding Litigations and Material Developments beginning on page 148 of this Draft Prospectus. 2. Our Company operates under several statutory and regulatory permits, licenses and approvals. Failure to obtain and/or renew any approvals or licenses in future may have an adverse impact on our business operations. Our Company requires several statutory and regulatory permits, licenses and approvals to operate the business. Many of these approvals are granted for fixed periods of time and need renewal from time to time. There can be no assurance that the relevant authorities will issue any of such permits or approvals in time or at all. Further, these permits, licenses and approvals are subject to several conditions, and our Company cannot assure that it shall be able to continuously meet such conditions or be able to prove compliance with such conditions to statutory authorities, and this may lead to cancellation, revocation or suspension of relevant permits/ licenses/ approvals. Failure by our Company to renew, maintain or obtain the required permits, licenses or approvals, or cancellation, suspension or revocation of any of the permits, licenses or approvals which may result in the interruption of our Company s operations and may have a material adverse effect on the business. For details please refer to Chapter titled Government and Other Approvals beginning on page 155 of this Draft Prospectus. 3. We, being a pharmaceutical company, operate in a highly regulated and controlled industry. Any change in regulatory environment may have an impact on the business of the Company. We being a pharmaceutical company operate in an industry which is highly regulated and controlled. The industry has extensive regulations pertaining to research, testing, manufacturing, quality standards, selling and marketing of pharmaceutical products etc. The Company keeps itself abreast of the various developments relating to the regulatory environment and gears itself in order to comply with such regulatory changes, application and the renewal of regulatory approvals. However, in case the Company is unable to adapt itself to such regulatory changes, obtain the necessary approvals / renewals for all our products the business of the Company may be impacted adversely. 4. We are yet to receive certain registrations in connection with the protection of our intellectual property rights, especially trademarks relating to our products. Any failure to protect our intellectual property rights could adversely affect our competitive position, business, financial condition and profitability. We have applied for certain registrations in connection with the protection of intellectual property rights, including trademarks, which are currently pending. The registration of any intellectual property right is a time-consuming process, and there can be no assurance that any such registration will be granted. In the absence of such registration, competitors or other companies may challenge the validity or scope of our intellectual property. Unless our trademarks are registered, we may only get passing off relief for our Trademarks, if used by others, which could materially and adversely affect our brand image, goodwill and business. Similarly, in case these registrations are rejected, our competitors may start marketing the 12

14 products resulting in us losing out on market share and first mover protection, which could adversely affect our competitive position, business, financial condition and profitability. For more details please refer to the chapter Government and Other Approvals on page 155 of this Draft Prospectus. 5. Logo of our Company is not registered under Trademark authorities. We are unable to assure that the future viability or value of any of our intellectual property or that the steps taken by us to protect the proprietary rights of our Company will be adequate. Our Company has made application for registration of our logo under trademark authorities, which is under process of registration. The registration for the said trademark in our name is important to retain our brand equity. If our application for registration is not accepted or if the oppositions filed against our trademark application if any, are successful, we may lose the statutory protection available to us under the Trade Marks Act, 1999 for such trademark. Further, we cannot assure that our pending application would be granted registration or if granted registration, will not be invalidated or circumvented. We are unable to assure that the future viability or value of any of our intellectual property or that the steps taken by us to protect the proprietary rights of our Company will be adequate. For further details please refer to chapter titled Government and Other Approvals on page 155 of this Draft Prospectus. 6. Our Company does not own the premises of our Registered Office. Our Registered Office is situated at Darbara Complex, SCO 113, First Floor, District Shopping Centre B Block, Ranjit Avenue, Amritsar , Punjab, is on leased premises and is not owned by us. As per the lease agreements, any breach of the terms / non renewal of the license agreement may require us to vacate the said premises which may cause disruption in our corporate affairs and business and impede our effective operations and thus adversely affect our profitability. For more information, please refer to chapter titled Our Business Properties on page 74 of this draft Prospectus. 7. Our Promoters play key role in our functioning and we heavily rely on their knowledge and experience in operating our business and therefore, it is critical for our business that our Promoters remain associated with us. We benefit from our relationship with our Promoters and our success depends upon the continuing services of our Promoters who have been responsible for the growth of our business and are closely involved in the overall strategy, direction and management of our business. Our Promoters have been actively involved in the day to day operations and management since the incorporation of the Company. Accordingly, our performance is heavily dependent upon the services of our Promoters. If our Promoters are unable or unwilling to continue in their present position, we may not be able to replace them easily or at all. The loss of their services could impair our ability to implement our strategy, and our business, financial condition, results of operations and prospects may be materially and adversely affected. 8. We are dependent on our management team for success whose loss could seriously impair the ability to continue to manage and expand business efficiently. Our success largely depends on the continued services and performance of our management and other key personnel. The loss of service of the management team and staff could seriously impair the ability to continue to manage and expand the business efficiently. Further, the loss of any of the senior management or other key personnel may adversely affect the operations, finances and profitability of our Company. Any failure or inability of our Company to efficiently retain and manage its human resources would adversely affect our ability to implement new projects and expand our business. 9. Our success is dependent on the quality control processes and any failure to maintain the quality of our products may affect our reputation and business. We believe that our success is dependent on our quality control processes. Our quality assurance department ensures quality control at every stage of production, packaging and dispatch. We believe that 13

15 we have built strong relationships with our customers due to the quality of our products which has translated into operational growth. In the event we are unable to maintain our quality control processes, for any reason whatsoever, our business, reputation and results of operations would be adversely affected. 10. Any delay in production at, or shutdown of, any of our manufacturing facilities, could adversely affect our business, results of operations and financial condition. The success of our manufacturing activities depends on, among others, the productivity of our workforce, compliance with regulatory requirements and the continued functioning of our manufacturing processes and machinery. Disruptions in our manufacturing activities could delay production or require us to shut down the affected manufacturing facility, which could adversely affect our finance and operations. 11. Any fluctuations in prices of raw materials or shortage in supply of raw material for manufacturing our products, could adversely impact our business. Our Company is dependent mainly on the various raw materials and packaging materials for the manufacture of its products. Our Company is exposed to upward fluctuations in the prices of various raw materials and packing materials, as well as its availability, as we do not enter into any supply agreements with our suppliers and all raw materials are bought by our Company from various suppliers on order to order basis. Any upward fluctuation in the prices of the major raw materials or shortage in supply of any major raw material or any increase would result in increase of cost of production which may adversely impact the business of the Company. Further, with a view to reduce the cost of production and insulate itself from future rise in prices or mitigate the risk of shortage of raw material, the Company has always been innovative in sourcing of raw materials and packaging materials, and will continue to maintain this approach. In case the Company is not able to pass on any such increase to the consumers because of competition or otherwise, it may affect the profitability of the Company. 12. Failure to effectively manage labour or failure to ensure availability of sufficient labour could affect the business operations of the Company. Our business activities are dependent on availability of skilled and unskilled labour. Non-availability of labour at any time or any disputes with them may affect our production schedule and timely delivery of our products to customers which may adversely affect our business and result of operations. Though we have not faced any labour problem in the past we cannot assure that we will not experience disruptions to our operations due to disputes or other problems with our work force, which may lead to strikes, lock- outs or increased wage demands. Such issues could have adverse effect on our business, and results of operations. 13. Our funding requirements and proposed deployment of the issue proceeds are based on management estimates and have not been independently appraised by any bank or financial institution and actual cost may vary compared with the estimated amount. Our funding requirements and the proposed deployment of the proceeds of the Issue are based on management estimates, quotations from suppliers and on our current business plan and have not been appraised by bank or financial institution. In view of the competitive and dynamic nature of our business, we may have to revise our expenditure and fund requirements as a result of variations including in the cost structure, changes in estimates and other external factors, which may not be within the control of our management. This may entail rescheduling, revising or cancelling the planned expenditure and fund requirement and increasing or decreasing the expenditure for a particular purpose from its planned expenditure at the discretion of our board. In addition, schedule of implementation as described herein are based on management s current expectations and are subject to change due to various factors some of which may not be in our control. The deployment of the funds towards the objects of the issue is entirely at the discretion of the Board of Directors/Management and is not subject to monitoring by external independent agency. However, the deployment of funds is subject to monitoring by our Audit Committee. Any inability on our part to effectively utilize the Issue proceeds could adversely affect our financials. 14

16 14. The capacity of our current plant at Himachal Pradesh unit is not fully utilized. Consecutively, if there is also any under-utilization of our capacities in next three years, it could affect our ability to fully absorb fixed costs and thus may adversely impact our financial performance. The capacity of our current plant at Village Kishanpura, Baddi, Himachal Pradesh is not fully utilized. Even though the capacity utilization of our plants has been increasing on a year on year basis in the last three years, the capacities of our product Dry Injectable Powder at our current Plant has not been fully utilized over the last three financial years. Further, we propose to fully utilize our production capacities in next three year based on our estimates of market demand and profitability. In the event of nonmaterialization of our estimates and expected order flow for our product and/or failure of optimum utilization of our capacities, due to factors including adverse economic scenario, change in demand or for any other reason, our capacities may not be fully utilized thereby impairing our ability to fully absorb our fixed cost and may adversely impact our financial performance. For details regarding the existing installed and utilised capacity, kindly refer to Our Business Capacity and Capacity Utilization on page 70 of this Draft Prospectus. 15. If we are unable to source business opportunities effectively, we may not achieve our financial objectives. Our ability to achieve our financial objectives will depend on our ability to identify, evaluate and accomplish business opportunities. To grow our business, we will need to hire, train, supervise and manage new employees and to implement systems capable of effectively accommodating our growth. However, we cannot assure you that any such employees will contribute to the success of our business or that we will implement such systems effectively. Our failure to source business opportunities effectively could have a material adverse effect on our business, financial condition and results of operations. It is also possible that the strategies used by us in the future may be different from those presently in use. No assurance can be given that our analysis of market and other data or the strategies we use or plans in future to use will be successful under various market conditions. 16. Our insurance coverage may not adequately protect us against certain operational hazards and this may have a material adverse effect on our business. Our Company has, in the ordinary course of business, availed insurance cover for certain risks. While we believe that the insurance coverage we maintain would reasonably be adequate to cover all normal risks associated with the operation of our business, there can be no assurance that any claim under the insurance policies maintained by us will be honoured fully, in part or on time. To the extent that we suffer loss or damage that is not covered by insurance or exceeds our insurance coverage, or the insurance policy covering such risk is not honoured, our results of operations may be adversely affected. For details of our insurance policies please refer to the section titled Our Business on page 68 of this Draft Prospectus. 17. We have had experienced growth in the recent past years and if we are unable to sustain or manage our growth, our business, result of operations and financial condition may be adversely affected. We have experienced significant growth in the recent past years. For FY our revenue from operations is Rs Lakhs as compared to Rs Lakh for FY Our operations have also grown considerably over the past two years. We may not be able to sustain our rate of growth due to various reasons such as decreased demand, increased competition, non availability of raw material or labour, general slowdown in the economy. A failure to sustain our growth may have an adverse effect on our business and result of operations. Though we are embarking on a growth strategy and focusing on increasing operational efficiencies, such strategy may place pressure on our overall operational efficiencies, and financial, accounting and operating system. We can not assure that our future performance or growth strategy will be successful. Our failure to manage growth effectively may have an adverse effect on our business, result of operations and financial condition. 15

17 18. We have entered into certain related party transactions and may continue to do so. We have entered into related party transactions with our Promoters, its promoter group members/ entities and Directors. While we believe that all such transactions have been conducted on the arms length basis, however it is difficult to ascertain whether more favorable terms would have been achieved had such transactions been entered with unrelated parties. Furthermore, it is likely that we may enter into related party transactions in the future. For details of these transactions, please refer to section titled "Related Party Transactions" at page 105 of this Draft Prospectus. 19. Our Group entity has posted negative profits in the past. One of our Group entity Srishti Interiors, a proprietary concern of our Promoter, Mr. Rajesh Gupta has posted negative profits in the past. The details are as mentioned below: Particulars March 31, 2015 March 31, 2014 March 31, 2013 Srishti Interiors (32.11) (90.20) (25.98) 20. Conflict of interest may arise due to common business activities by our Company and our Group Company ANG Healthcare India Private Limited Our Group Company ANG Healthcare India Private Limited is authorised to carry on business activities similar to our business. As a result conflict of interest may arise in allocating business opportunities between our Company and our Group Company in circumstances where our interests diverge. Although ANG Healthcare India Private Limited has not commenced its commercial operations yet there is no assurance that our Company and our group Company will not compete with each other for any existing or future business opportunities. Any such present or future conflicts could have material adverse effect on our reputation, business, result of operations and financial condition. 21. Our Statutory Auditors have qualified audit report as of and for the year ended March 31, 2013 and March 31, Our Statutory Auditors Bhupinder Singh & Associates, Chartered Accountants, have qualified the audit report on our financial statements as of and for the year ended March 31, 2013 and March 31, 2014 as mentioned below: The balances of the trade receivables, trade payables and loans and advances are subject to confirmation/reconciliation and subsequent adjustments, if any. As such we are unable to express any opinion as to the effect thereof on the financial statements for the year. The consequential effect of the above on assets and liabilities as at March 31, 2013 & March 31, 2014 and on loss for the year ended 31 st March, 2013 & 31 st March, 2014 is not ascertainable. The financial impact of the said qualifications is not quantifiable. 22. We have reported negative cash flows. The detailed break up of cash flows is summarized in below mentioned table and our Company has reported negative cash flow in certain financial years and which could affect our business and growth: Particulars Net Cash Flow from/(used in) Operating Activities (Rs. In Lacs) As at As at 31 st March September 30, (759.14)

18 Net Cash Flow from/(used in) Investing Activities Net Cash Flow from/(used in) Financing Activities (119.83) (291.86) (231.72) (213.74) (216.66) (211.33) (71.84) (88.61) (142.64) (547.37) If the negative cash flow trend persists in future, our Company may not be able to generate sufficient amounts of cash flow to finance our Company s working capital, make new capital expenditure, pay dividends, repay loans, make new investments or fund other liquidity needs which could have a material adverse effect on our business and results of operations. 23. Our Company has availed the 15% Central Capital Subsidy Scheme 2003 and failure to comply with the terms of the same may inter-alia lead to the amount of subsidy being repayable and it would adversely affect our financial conditions. Our Company has availed certain subsidy benefits under 15% Central Capital Subsidy Scheme 2003 ( the Subsidy Scheme ) from Government of India. As per the terms of the Subsidy Scheme, the Government has sanctioned the subsidy of Rs Lac to our Company subject to certain conditions such as shifting the whole or part location of the unit, submission of Annual Progress Report to the Ministry of Commerce etc. In the event of the non compliance of the conditions laid down in the sanction order of subsidy by our Company, we will require to repay the subsidy to the Government. The same shall adversely affect the financial condition and business prospects of the Company. 24. We are subject to the restrictive covenants of banks in respect of the Loans/ Credit Limits and other banking facilities availed from them. Our financing arrangements with contain restrictive covenants whereby we are required to obtain approval from our lender Punjab National Bank, regarding, among other things such as major changes in share capital, creation of any other charge, not to issue any personal guarantee by the guarantors, formulate any scheme of merger/amalgamation/acquisition/reconstitution, implement any schemes of expansion/ modernisation/ diversification/ renovation, substantial change in management of the company, extending finance to associate concerns etc. There can be no assurance that such consents will be granted or that we will be able to comply with the financial covenants under our financing arrangements. In the event we breach any financial or other covenants contained in any of our financing arrangements, we may be required under the terms of such financing arrangements to immediately repay our borrowings either in whole or in part, together with any related costs. This may adversely impact our results of operations and cash flows. For further details on the Cash Credit Limits and other banking facilities, please refer chapter titled Statement of Financial Indebtedness on page 133 of this Draft Prospectus. 25. We have not obtained Consent / No objection Certificate from our bankers for this IPO pursuant to the terms of agreements entered with them while obtaining financing facilities. Pursuant to the Financing Agreements entered into by us with the Punjab National Bank, we require to obtain Consent / No Objection Certificate from Punjab National Bank to undertake certain corporate actions, including this IPO. Though, we have informed our bankers about our intention to undertake this IPO, we have not yet obtained written Consent / No Objection Certificate from our bankers for undertaking this IPO, and the same is awaited. While our Company intends to obtain all the necessary consents in relation to this IPO from our bankers prior to this IPO, undertaking this IPO without obtaining the Banker s consents, may constitute a breach of the Financing Agreements. Any breach of such Financing Agreements may enable our bankers to revise terms of our Financial Arrangements. If our obligations under the Financing Agreements are accelerated, our financial condition and operations could adversely be affected. 26. Our Company has obtained unsecured loans, which are repayable on demand. Any demand from lenders for repayment of such unsecured loans, may adversely affect our business operations and financial condition of our Company. 17

19 As on September 30, 2016 our Company has unsecured loans aggregating to Rs Lacs which are repayable on demand. For further details of these unsecured loans, please refer to chapter titled Financial Information beginning on page 107 of this Draft Prospectus. In case of any demand from lenders for repayment of such unsecured loans, the resultant cash outgo, may adversely affect our business operations and financial position of our Company. 27. Our lender, Punjab National Bank, has rescheduled the loans availed by us, aggregating to Rs Lacs including the Funded Interest vide letter dated January 05, Company s borrowings from Punjab National Bank have been rescheduled alongwith payment terms pursuant to request for rescheduling being made by our Company. During the relevant period, our Company s business was adversely affected by restructuring of the board and overall industrial slowdown. Consequently our Company made an applications to Punjab National Bank for the reschedulement of the said loans and our lender, Punjab National Bank, has rescheduled the existing term loans availed by us, aggregating to Rs Lacs including sanction of Funded Interest Term Loan of Rs Lacs vide letter dated January 05, For further details in this regard, please see the chapters titled History and Certain Corporate Matters and Statement of Financial Indebtedness on pages 83 and 133 of this Draft Prospectus. 28. Our operations are subject to high working capital requirements. Our inability to obtain and/or maintain sufficient cash flow, credit facilities and other sources of funding, in a timely manner, or at all, to meet our requirement of working capital or pay our debts, could adversely affect our operations Our business requires significant amount of working capital. In many cases, significant amount of our working capital is required for purchasing and maintaining of stock of primary raw materials. These raw materials are purchased locally. Though, presently we have availed working capital limits to the extent of Rs Lacs from our lenders, we may need to incur additional indebtedness in the future to satisfy our working capital needs. All these factors may result in increase in the quantum of our current assets and short-term borrowings. Our inability to obtain and/or maintain sufficient cash flow, credit facilities and other sources of funding, in a timely manner, or at all, to meet our requirement of working capital or pay our debts, could adversely affect our financial condition and results of operations. 29. We have not made any alternate arrangements for meeting our working capital requirements mentioned in the Objects of the Issue further we have not identified any alternate source of financing the Objects of the Issue. Any shortfall in raising/meeting the same could adversely affect our growth plans. Operations and financial performance. As on date we have not made any alternate arrangements for meeting our working capital requirement mentioned in the Objects of the Issue We meet our working capital requirement through bank finance and internal accruals. Any shortfall in our internal accruals and our inability to raise debt in future would result in non availability to meet the working capital requirement, which in turn will affect our financial condition and result of operations. Further we have not identified any alternate source of funding and hence any failure or delay on our part to raise money from this IPO or any shortfall in the Issue Proceeds may delay the implementation schedule and could adversely affect our growth plans. For further details please refer to the chapter titled Objects of the Issue beginning on page 50 of this draft prospectus. 30. The Promoter and Promoter Group will continue to exercise control post completion of the Issue and will have considerable influence over the outcome of matters. Upon completion of this Issue, our Promoters and Promoter Group will continue to own a majority of our Equity Shares. As a result, our Promoters will have the ability to exercise significant influence over all matters requiring shareholders approval. Our Promoters will also be in a position to influence any shareholder action or approval requiring a majority vote, except where they may be required by applicable law to abstain from voting. This control could also delay, defer or prevent a change in control of our Company, impede a merger, consolidation, takeover or other business combination involving our 18

20 Company, or discourage a potential acquirer from obtaining control of our Company even if it is in the best interests of our Company. The interests of our Promoters could conflict with the interests of our other equity shareholders, and the Promoters could make decisions that materially and adversely affect your investment in the Equity Shares. 31. The Promoters and Directors hold Equity Shares in our Company and are therefore interested in the Company's performance in addition to their remuneration and reimbursement of expenses. Certain of our Directors and our Promoters are interested in our Company, in addition to regular remuneration or benefits and reimbursement of expenses, to the extent of their shareholding in our Company. We cannot assure you that our Promoters will exercise their rights as shareholders to the benefit and best interest of our Company. Our Promoters will continue to exercise significant control over us, including being able to control the composition of our Board of Directors and determine decisions requiring simple or special majority voting of shareholders, and our other shareholders may be unable to affect the outcome of such voting. Our Promoters may take or block actions with respect to our business which may conflict with the best interests of the Company or that of minority shareholders. For details on the interest of our Promoters and Directors of our Company please refer chapter titled Our Management at page 87 of this Draft Prospectus. 32. Our company has not complied certain provisions of The Companies Act, 2013 such non compliances may attract penalties. Our Company has not complied with certain provisions of Section 185 of the Companies Act, 2013 while giving loan to a Sole proprietary firm owned by our Promoter Mr. Rajesh Gupta. Though we have not received any notice for such non compliance, we cannot assure that no penalties will be imposed by relevant authorities in this respect which may affect our financial condition. 33. We do not have a track record for payment of dividend on Equity Shares. We have not declared any dividend on our Equity Shares since inception as we had been deliberately pursuing the policy of covering back our profits to fund our expansion plans. The future payment of dividends, if any, would be based on the then available distributable profits and the recommendations of our Board of Directors. 34. We may not be successful in implementing our business strategies. The success of our business depends substantially on our ability to implement our business strategies effectively or at all. Even though we have successfully executed our business strategies in the past, there is no guarantee that we can implement the same on time and within the estimated budget going forward, or that we will be able to meet the expectations of our targeted customers. Changes in regulations applicable to us may also make it difficult to implement our business strategies. Failure to implement our business strategies would have a material adverse effect on our business and results of operations. 35. Some of the transfer deeds in relation to the Company are misplaced and currently not traceable. The transfer deed in relation to transfer of shares of our Company dated September 02, 2011 for 10,000 Equity Shares from Mr. Rajesh Gupta to Ms. Saruchi Gupta and dated October 15, 2012 for 2000 Equity Shares from Mr. Rajesh Gupta to various public shareholders, were misplaced while transporting them for certain purposes. Further, while details of such transfers have been included in the register of transfer and register of members maintained by the Company in accordance with the provisions of Companies Act, we cannot assure you that these deeds will be available in the future or that we will not be subject to any penalty imposed by the competent regulatory authority in this respect. 36. The requirements of being a listed company may strain our resources. As a listed company, we will incur significant legal, accounting, corporate governance and other expenses 19

21 that we did not incur as an unlisted company. We will be subject to the SME Listing Agreement with the BSE Limited, which require us to file audited annual and unaudited quarterly reports with respect to our business and financial condition. If we experience any delays, we may fail to satisfy our reporting obligations and/or we may not be able to readily determine and accordingly report any changes in our results of operations as timely as other listed companies. As a listed company, we will need to maintain and improve the effectiveness of our disclosure controls and procedures and internal control over financial reporting, for which significant resources and management overview will be required. RISKS RELATING TO THE EQUITY SHARES 37. Any future issue of Equity Shares may dilute the shareholding of investors and sales of Equity Shares by our Promoters or other major shareholders may adversely affect the trading price of the Equity Shares. Any future equity issues by us, including in a primary offering, may lead to the dilution of investors' shareholdings in us. Any future equity issuances by us or sales of its Equity Shares by the Promoters may adversely affect the trading price of the Equity Shares. In addition, any perception by investors that such issuances or sales might occur could also affect the trading price of our Equity Shares. 38. Our ability to pay any dividends in the future will depend upon future earnings, financial condition, cash flows, working capital requirements and capital expenditures. The amount of our future dividend payments, if any, will depend upon our Company s future earnings, financial condition, cash flows, working capital requirements, capital expenditures, applicable Indian legal restrictions and other factors. There can be no assurance that our Company will be able to pay dividends. 39. The price of our Equity Shares may be volatile, and you may be unable to resell your Equity Shares at or above the Issue Price, or at all. Prior to the offer, there has been no public market for our Equity Shares, and an active trading market on the SME Platform of BSE. The Issue Price of the Equity Shares may bear no relationship to the market price of the Equity Shares after the Issue. The market price of the Equity Shares after the Issue may be subject to significant fluctuations in response to, among other factors, variations in our operating results, market conditions specific to the Education Sector, developments relating to India and volatility in the Exchange and securities markets elsewhere in the world. However, the LM will arrange for compulsory market making for a period of 3 years from the date of listing as per the regulations applicable to the SME Platforms under SEBI (ICDR) Regulations, There is no guarantee that the Equity Shares issued pursuant to the Issue will be listed on the SME Platform of BSE in a timely manner, or at all. In terms of Chapter XB of the SEBI (ICDR) Regulations, 2009, as amended from time to time, we are not required to obtain any in-principle approval for listing of shares issued. We have only applied to BSE Limited to use its name as the Stock Exchange in this offer document for listing our shares on the SME Platform of BSE. In accordance with Indian law and practice, permission for listing and trading of the Equity Shares issued pursuant to the Issue will not be granted until after the Equity Shares have been issued and allotted. Approval for listing and trading will require all relevant documents authorizing the issuing of Equity Shares to be submitted. There could be a failure or delay in listing the Equity Shares on the SME Platform of BSE. Any failure or delay in obtaining the approval would restrict your ability to dispose of your Equity Shares. 41. The price of our Equity Shares may be volatile, or an active trading market for our Equity Shares may not develop. Prior to this Issue, there has been no public market for our Equity Shares. Guiness Securities Limited is acting as Designated Market Maker for the Equity Shares of our Company. However, the trading price of our Equity Shares may fluctuate after this Issue due to a variety of factors, including our results of 20

22 operations and the performance of our business, competitive conditions, general economic, political and social factors, the performance of the Indian and global economy and significant developments in India s fiscal regime, volatility in the Indian and global securities market, performance of our competitors, the Indian Capital Markets, changes in the estimates of our performance or recommendations by financial analysts and announcements by us or others regarding contracts, acquisitions, strategic partnerships, joint ventures, or capital commitments. In addition, if the stock markets experience a loss of investor confidence, the trading price of our Equity Shares could decline for reasons unrelated to our business, financial condition or operating results. The trading price of our Equity Shares might also decline in reaction to events that affect other companies in our industry even if these events do not directly affect us. Each of these factors, among others, could materially affect the price of our Equity Shares. There can be no assurance that an active trading market for our Equity Shares will develop or be sustained after this Issue, or that the price at which our Equity Shares are initially offered will correspond to the prices at which they will trade in the market subsequent to this Issue. For further details of the obligations and limitations of Market Makers please refer to the section titled General Information Details of the Market Making Arrangement for this Issue on page 37 of this Draft Prospectus. 42. There are restrictions on daily movements in the price of the Equity Shares, which may adversely affect a shareholder s ability to sell, or the price at which it can sell, Equity Shares at a particular point in time. Following the Issue, we will be subject to a daily circuit breaker imposed by BSE, which does not allow transactions beyond specified increases or decreases in the price of the Equity Shares. This circuit breaker operates independently of the index-based, market-wide circuit breakers generally imposed by SEBI on Indian stock exchanges. The percentage limit on our circuit breakers will be set by the stock exchanges based on the historical volatility in the price and trading volume of the Equity Shares. The BSE may not inform us of the percentage limit of the circuit breaker in effect from time to time and may change it without our knowledge. This circuit breaker will limit the upward and downward movements in the price of the Equity Shares. As a result of this circuit breaker, no assurance can be given regarding your ability to sell your Equity Shares or the price at which you may be able to sell your Equity Shares at any particular time. EXTERNAL RISK FACTORS 43. Political, economic and social changes in India could adversely affect our business. Our business, and the market price and liquidity of our Company s shares, may be affected by changes in Government policies, including taxation, social, political, economic or other developments in or affecting India could also adversely affect our business. Since 1991, successive governments have pursued policies of economic liberalization and financial sector reforms including significantly relaxing restrictions on the private sector. In addition, any political instability in India may adversely affect the Indian economy and the Indian securities markets in general, which could also affect the trading price of our Equity Shares. 44. Our business may be adversely affected by competition laws in India and any adverse application or interpretation of the Competition Act could adversely affect our business. The Competition Act, 2002, as amended (the Competition Act ), regulates practices having an appreciable adverse effect on competition in the relevant market in India. Under the Competition Act, any formal or informal arrangement, understanding or action in concert, which causes or is likely to cause an appreciable adverse effect on competition is considered void and results in the imposition of substantial monetary penalties. Further, any agreement among competitors which directly or indirectly involves the determination of purchase or sale prices, limits or controls production, supply, markets, technical development, investment or provision of services, shares the market or source of production or provision of services by way of allocation of geographical area, type of goods or services or number of clients in the relevant market or directly or indirectly results in bid-rigging or collusive bidding is presumed to have an appreciable adverse effect on competition. The Competition Act also prohibits abuse of a dominant position by any enterprise. 21

23 The applicability or interpretation of the Competition Act to any merger, amalgamation or acquisition proposed or undertaken by us, or any enforcement proceedings initiated by CCI for alleged violation of provisions of the Competition Act may adversely affect our business, financial condition or results of operation. 45. The nationalised goods and services tax (GST) regimes proposed by the Government of India may have material impact on our operations. The Government of India has proposed a comprehensive national goods and service tax (GST) regime that will combine taxes and levies by the central and state governments into a unified rate structure. Given the limited liability of information in the public domain covering the GST we are unable to provide/ measure the impact of this tax regime may have on our operations. 46. Our business is subject to a significant number of tax regimes and changes in legislation governing the rules implementing them or the regulator enforcing them in any one of those jurisdictions could negatively and adversely affect our results of operations. The revenues recorded and income earned is taxed on differing bases, including net income actually earned, net income deemed earned and revenue-based tax withholding. The final determination of the tax liabilities involves the interpretation of local tax laws as well as the significant use of estimates and assumptions regarding the scope of future operations and results achieved and the timing and nature of income earned and expenditures incurred. Changes in the operating environment, including changes in tax laws, could impact the determination of the tax liabilities of our Company for any year. 47. Natural calamities and force majeure events may have an adverse impact on our business. Natural disasters may cause significant interruption to our operations, and damage to the environment that could have a material adverse impact on us. The extent and severity of these natural disasters determines their impact on the Indian economy. Prolonged spells of deficient or abnormal rainfall and other natural calamities could have an adverse impact on the Indian economy, which could adversely affect our business and results of operations. 48. Our transition to IFRS reporting could have a material adverse effect on our reported results of operations or financial condition. Our Company may be required to prepare annual and interim financial statements under IFRS in accordance with the roadmap for the adoption of, and convergence with, the IFRS announced by the Ministry of Corporate Affairs, Government of India through a press note dated January 22, 2010 ( IFRS Convergence Note ). The Ministry of Corporate Affairs by a press release dated February 25, 2011 has notified that 32 Indian Accounting Standards are to be converged with IFRS. The date of implementation of such converged Indian accounting standards has not yet been determined and will be notified by the Ministry of Corporate Affairs after various tax related issues are resolved. We have not yet determined with certainty what impact the adoption of IFRS will have on our financial reporting. Our financial condition, results of operations, cash flows or changes in shareholders' equity may appear materially different under IFRS than under Indian GAAP or our adoption of IFRS may adversely affect our reported results of operations or financial condition. This may have a material adverse effect on the amount of income recognized during that period. 49. Restrictions on foreign investment limit our ability to raise debt or capital outside India. Indian laws constrain our ability to raise capital outside India through the issuance of equity or convertible debt securities and restrict the ability of non-indian companies to invest in us. Foreign investment in, or an acquisition of, an Indian company requires approval from the relevant government authorities in India, including the Reserve Board of India and the Foreign Investment Promotion Board. 50. Any downgrading of India s debt rating by a domestic or international rating agency could 22

24 negatively impact our business. Any adverse revisions to India s credit ratings for domestic and international debt by domestic or international rating agencies may adversely impact our ability to raise additional financing, and the interest rates and other commercial terms at which such additional financing is available. This could have an adverse effect on our financial results and business prospects, ability to obtain financing for capital expenditures and the price of our Equity Shares. 51. Hostilities, terrorist attacks, civil unrest and other acts of violence could adversely affect the financial markets and our business. Terrorist attacks and other acts of violence or war may adversely affect the Indian markets on which our Equity Shares will trade. These acts may result in a loss of business confidence, make travel and other services more difficult and have other consequences that could have an adverse effect on our business. In addition, any deterioration in international relations, especially between India and its neighboring countries, may result in investor concern regarding regional stability which could adversely affect the price of our Equity Shares. In addition, India has witnessed local civil disturbances in recent years and it is possible that future civil unrest as well as other adverse social, economic or political events in India could have an adverse impact on our business. Such incidents could also create a greater perception that investment in Indian companies involves a higher degree of risk and could have an adverse impact on our business and the market price of our Equity Shares. 52. Third party statistical and financial data in this Draft Prospectus may be incomplete or unreliable. We have not independently verified any of the data from industry publications and other sources referenced in this Draft Prospectus and therefore cannot assure you that they are complete or reliable. Discussions of matters relating to India, its economies or the industries in which we operate in this Draft Prospectus are subject to the caveat that the statistical and other data upon which such discussions are based may be incomplete or unreliable. 53. The Companies Act, 2013 has effected significant changes to the existing Indian company law framework, which may subject us to greater compliance requirements and increase our compliance costs. A majority of the provisions and rules under the Companies Act, 2013 have been notified and have come into effect from the date of their respective notification, resulting in the corresponding provisions of the Companies Act, 1956 ceasing to have effect. The Companies Act, 2013 provides for, among other things, changes to the regulatory framework governing the issue of capital by companies, corporate governance, audit procedures, corporate social responsibility, specific compliance requirements such as obtaining prior approval from audit committee, board of directors and shareholders for certain related party transactions and the requirements for independent directors, director s liability, class action suits, and the inclusion of women directors on the boards of companies. The Companies Act, 2013 is expected to be complemented by a set of rules that shall set out the procedure for compliance with the substantive provisions of the Companies Act, In the absence of such rules, it is difficult to predict with any degree of certainty the impact, adverse or otherwise, of the Companies Act, 2013 on the issue, and on the business, prospects and results of operations of the Company. 23

25 Prominent Notes: 1. Public Issue of 15,00,800 Equity Shares of face value of Rs.10 each of ANG Lifesciences India Limited ( the Company or the Issuer or ANG or ALIL ) for cash at a price of Rs per Equity Share (including a share premium of Rs per Equity Share) ( Issue Price ) aggregating to Rs Lacs ( the Issue ) of which, 76,800 Equity Shares of face value of Rs. 10/- each will be reserved for subscription by market maker to the Issue (The market Maker reservation portion). The Issue less the Market Maker Reservation Portion i.e. Issue of 14,24,000 Equity Shares of Rs each at an Issue price of Rs per equity share is hereinafter referred to as the net issue. The Issue and the Net Issue will constitute 28.95% and 27.47%, respectively of the post Issue paid up Equity Share Capital of our company. 2. This Issue is being made for at least 25% of the post issue paid up Equity Share capital of our Company, pursuant to Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957 as amended. This Issue is being made in terms of Chapter XB of the SEBI (ICDR) Regulations, 2009, as amended from time to time. As per Regulation 43(4) of the SEBI (ICDR) Regulations, as amended, since our is a fixed price issue the allocation is the net issue to the public category shall be made as follows: a) Minimum fifty percent to retail individual investors; and b) Remaining to: i. Individual applicants other than retail individual investors; and ii. Other investors including corporate bodies or institutions, irrespective of the number of specified securities applied for; c) The unsubscribed portion in either of the categories specified in (a) or (b) above may be allocated to the applicants in the other category. If the retail individual investor category is entitled to more than fifty per cent on proportionate basis, accordingly the retail individual investors shall be allocated that higher percentage. 3. The average cost of acquisition of Equity Shares by our Promoters: Name of the Promoters No. of Shares held Average cost of Acquisition (in Rs.) Mr. Rajesh Gupta 36,70, Mrs. Saruchi Gupta 10, Note :The average cost of acquisition of our Equity Shares by our Promoters has been calculated by taking into account the amount paid by them to acquire, by way of fresh issuance or transfer of the Equity Shares. For more information, please refer to the section titled Capital Structure on page 40 of this Draft Prospectus. 4. Our Net worth as on March 31, 2016 is Rs Lacs and as on September 30, 2016 is Rs Lacs as per Restated Financial Statements. 5. The Book Value per share as on March 31, 2016 is Rs and as on September 30, 2016 is Rs as per Restated Financial Statements. 6. There has been no financing arrangement whereby the Promoter Group, our Directors and their relatives have financed the purchase, by any other person, of securities of our Company other than in the normal course of the business of the financing entity during the period of six months immediately preceding the date of this Draft Prospectus. 7. Our Company was originally incorporated as ANG Lifesciences India Private Limited on June 14, 2006 with the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh as a private limited Company under the Companies Act, On conversion into public limited Company the name of our Company was changed to ANG Lifesciences India Limited pursuant to special resolution passed at the Extra Ordinary General Meeting held on January 18, 2010 and a fresh certificate of incorporation dated March 02, 2010 issued by the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh. Our company was further converted into private limited Company and the name of our Company was changed to ANG Lifesciences India Private Limited pursuant to special resolution passed at the Extra Ordinary General Meeting held on August 31, 2010 and a fresh certificate of incorporation was issued by Registrar of Companies, Punjab, Himachal Pradesh and 24

26 Chandigarh dated September 22, Subsequently, on conversion into public limited Company the name of our company again changed to ANG Lifesciences India Limited pursuant to special resolution passed at the Extra Ordinary General Meeting held on May 04, 2016 and a fresh certificate of incorporation dated May 18, 2016 issued by the Registrar of Companies, Chandigarh. 8. In the event of over subscription, allotment shall be made on proportionate basis in consultation with the BSE Limited, the Designated Stock Exchange. For more information, please refer to "Basis of Allotment" on page 210 of this Draft Prospectus. The Registrar to the Issue shall be responsible to ensure that the basis of allotment is finalized in a fair and proper manner as set out therein. 9. Investors are advised to refer to the paragraph on "Basis for Issue Price" on page 55 of this Draft Prospectus before making an investment in this Issue. 10. No part of the Issue proceeds will be paid as consideration to Promoters, Promoter Group, Directors, Key Managerial Personnel, associate companies, or Group Companies. 11. Investors may contact the Lead Manager or the Compliance Officer for any complaint/clarifications/information pertaining to the Issue. For contact details of the Lead Manager and the Compliance Officer, refer the front cover page. 12. Other than as stated in the section titled Capital Structure beginning on page 40 of this Draft Prospectus, our Company has not issued any Equity Shares for consideration other than cash. 13. Except as mentioned in the sections titled Capital Structure beginning on page 40 of this Draft Prospectus, we have not issued any Equity Shares in the last twelve months. 14. Except as disclosed in the sections titled Our Promoters and Promoter Group or Our Management beginning on pages 98 and 87 respectively of this Draft Prospectus, none of our Promoters, our Directors and our Key Managerial Employees have any interest in our Company except to the extent of remuneration and reimbursement of expenses and to the extent of the Equity Shares held by them or their relatives and associates or held by the companies, firms and trusts in which they are interested as directors, member, partner and/or trustee and to the extent of the benefits arising out of such shareholding. 15. Any clarification or information relating to the Issue shall be made available by the LM and our Company to the investors at large and no selective or additional information would be available for a section of investors in any manner whatsoever. Investors may contact the LM for any complaints pertaining to the Issue. Investors are free to contact the LM for any clarification or information relating to the Issue who will be obliged to provide the same to the investor. 16. For transactions in Equity Shares of our Company by the Promoters, Promoter Group and Directors of our Company in the last six (6) months, please refer to paragraph under the section titled "Capital Structure" on page 40 of this Draft Prospectus. 17. The is no contingent liabilities as on September 30, For details of any hypothecation, mortgage or other encumbrances on the movable and immovable properties of our Company please refer to the section titled "Financial Information" on page 107 of this Draft Prospectus. 19. Except as disclosed in the section titled "Group Companies / Entities" on page 102, none of our Group Companies have business interest in our Company. 20. For interest of Promoters please refer to the section titled Our Promoters and Promoter Group beginning on page 98 of this Draft Prospectus. 21. The details of transactions with the Group Companies/ Group Entities and other related party transactions are disclosed as Annexure XXI of restated financial statement under the section titled Financial Information beginning on page 107 of this Draft Prospectus 25

27 This is only the summary and does not contain all information that you shall consider beforee investing in Equity Shares. You should read the entire Draft Prospectus, including the information on Risk Factors and related notes on page 11 of this Draft Prospectus before deciding to invest in Equity Shares The Indian Pharmaceutical Industry Introduction The Indian pharmaceuticals market is the third largest in terms of volume and thirteenth largest in terms of value#. Branded generics dominate the pharmaceuticals market, constituting nearly 70 to 80 per cent of the market. India is the largest provider of generic drugs globally with the Indian generics accounting for 20 per cent of global exports in terms of volume. Of late, consolidationn has become an important characteristic of the Indian pharmaceutical market as the industry is highly fragmented. India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers who have the potential to steer the industry ahead to an even higher level. Presently over 80 per cent of the antiretroviral drugs used globally to combat AIDS (Acquired Immuno Deficiency Syndrome) are supplied by Indian pharmaceutical firms. The UN-backed Medicines Patent Pool has signed six sub-licences with Aurobindo, Cipla, Desano, Emcure, Hetero Labs and Laurus Labs, allowing them to make generic anti-aids medicine Tenofovir Alafenamide (TAF) for 112 developing countries. Overview SECTION III - INTRODUCTION SUMMARY OF OUR INDUSTRY Leading pharma producer Indian pharmaceutical sector accounts for about 2.4 percent of the global pharmaceutical industry in value terms and 10 percent in volume terms One of the highest exports India accounts for 20 percent of global exports in generics Among fastest growing industries Rapidly growing healthcare sector Growing generics market Ranked 5th in terms of attracting FDI The country s pharmaceutical industry is expected to expand at a CAGR of percent over to reach USD 55 billion Indian healthcare sector, one of the fastest growing sectors,is expected to advance at a CAGR of 17 percent to reach USD 250 billion over The generics market is expected to grow to USD 26.1 billion by 2016 from USD 14.2 billion in 2015; India s generics market has immense potential for growth Cumulative FDI inflows worth USD13.3 billion from April 2000 to May 15 Attracted 5.19 percent of the total FDIs into India from April 2000 to May 15 26

28 Structure of Pharmaceutical Sector in India Pharmaceuticals Active Pharmaceutical Ingredients/ Bulk Drugs Formulations Branded Generic Chronic Acute. Advantage for India Cardiovasvular Anti diabetic Gastro - intestinal Neurological Anti infective Respiratory Pain Gyn naecology Cost efficiency Low cost of production and R&D boosts efficiency of Indian pharma companies India s cost of production is approximately 60 per cent lower than that of the US and almost half of that of Europe Due to lower cost of treatment, India is emerging as a leading destination for medical tourism Economic drivers Economic prosperity to improve drug affordability Increasing penetration of health insurance With increasing penetration of chemists, especially in rural India, OTC drugs will be readily available Policy support Government unveiled PharmaVision 2020 aimed at making India a global leader in end-to-end drug manufacturer Reduced approval time for new facilities to boost investments In this sector,100 percent FDI is allowed under automatic route Diversified portfolio Accounts for over 10 percent of the global pharmaceutical production Over 60,000 generic brands across therapeutic categories. Manufactures more than500 different APIs 49 percent of all drug master filings from India is registered in the USA 27

29 SUMMARY OF OUR BUSINESS This is only the summary and does not contain all information that you shall consider before investing in Equity Shares. You should read the entire Draft Prospectus, including the information on Risk Factors and related notes on page 11 of this Draft Prospectus before deciding to invest in Equity Shares Overview Our company ANG Lifesciences Limited incorporated in the year 2006, engaged in the business of manufacturing and marketing of finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials. Our registered office is located at Darbara Complex, SCO 113, First Floor, District Shopping Centre B Block, Ranjit Avenue, Amritsar We carry out our production through our state-of-the-art manufacturing unit spread over 35,000 Sq. Ft. situated at Village Kishan pura, P.O. Manpura Baddi Nalagarh Road, Tehsil Nalagarh, Dist. Solan, Himachal Pradesh. Presently, our total built up area of 45,000 Sq. Ft. is dedicated to manufacturing of Dry Powder Injectables. Our manufacturing unit is well equipped with the most modern and validated manufacturing and analytical equipments and detailed standard operating procedures (SOP s) are in place with respect to Quality management, Personnel, Premises, Equipment, Documentation, Production, Complaints and Self Inspection/Audits. Our company is ISO-9001:2008 certified and has the most modern & sophisticated plant, equipments, technique and manpower. The planning and construction of plant has been done to conform to the regulatory requirements as per the norms of WHO G.M.P. and G.L.P. as per schedule-m (revised). We manufacture our products in compliance with GMP requirements. We have dedicated area, machinery, facilities and advanced equipments for manufacturing of B-Lactum & Non-B Lactum products as per GMP Norms. The production block provides appropriate personnel and material flow. As per GMP norms, all the production processes are documented and validated to establish the accuracy of the procedures and the control measures. Our production capacity is 2,100 Lacs Pcs per annum on three shift basis. Our products include sterile dry powder vials for Anti Biotics, Anti Ulcerant, Gluco corticoid and Anti inflammatory, Anti malarial and Anesthetic. Our Competitive Strength Experienced Promoters and management team Our Promoters who also form part of Board of Directors of our Company have played a key role in developing our business and we benefit from their significant experience in the pharmaceuticals business. Our senior management team has a vide experience in the domestic and international pharmaceutical industries, including in the areas of R&D, regulatory affairs, manufacturing, quality control, sales, marketing and finance, our middle management is able and our workers are well trained. We believe that experience of our Promoters and our management team provides us with a significant competitive advantage as we seek to grow in our existing markets and enter new geographies. It is also expected to help us in addressing and mitigating various risks inherent in our business, including technical problems, significant competition, reliance on independent contractors and the global economic crisis etc. Quality Assurance and Standards We always aim to offer quality products to our customers. We adopt quality check to ensure the adherence to desired specifications and quality. We have established world class quality standards and our production is based on standards laid down by standard operating procedure (SOP S) and defined method of working by SOP's. We have set up a laboratory which is fully equipped for checking the quality of the inputs, processes and finished products and packaging of the products. Our Company maintains complete traceability record of goods as per batch wise, order wise and sale bill wise. Since, our Company is dedicated towards quality products, processes and inputs; we get repetitive orders from our customers as we are capable of meeting their standards. 28

30 Strong Marketing capability Our marketing and distribution network in India comprises a specialized team of over 70 representatives, which enables us to market our products across various states in India. Our distribution network comprises of sales depots and consignment agent. We also market our products to various hospitals and medical institutions, which constitute an important channel for the distribution of our products. Our domestic marketing infrastructure consists of dedicated team, which formulate marketing and promotional strategies for our products. We also conduct periodic training programs for our marketing team. We believe that our marketing strategies, trained sales representatives and distribution network enable us to increase our market share. Cordial relationship with Customers, suppliers and employees Our core competency lies in the relationship with our customers and suppliers. Our cordial relationship with our customers help us getting repetitive orders and relationship with suppliers help us in uninterruptive supply of raw materials. We also enjoy cordial relations with our employees and there has been no union of employees. Further, there have been no strikes, lock-out or any labour protest in our organization since inception. Focus on Research and Development Our R&D efforts are integral to our business and we devote significant resources towards this aspect of our business. We believe in the importance of developing our R&D facilities to maintain our competitiveness. We also recognize the importance of maintaining a workforce of highly qualified employees for R&D. Our Company has set up its own laboratory for quality control and further improvements in technology. Various trials are undertaken in the laboratory to improve the quality and to reduce cost of production. The facilities available are for checking the different parameter of raw materials, Processes and Finished products. Our Strategies Expand Product Range Currently our reveune is largely driven from manufacturing dry injection powder. We have a fully integrated plant capable of manufactuirng various other products. Currently we also utilize our plant to manufacture customer specific products. We plan to utilise our manufacturing plant for other products including tablets, liquids injections etc. Increasing Geographical Presence We plan to expand our presence in PAN India as well as international market. We intend to expand our global footprint and become a preferred supplier in the industry with the help of increased utilization of capacities, reduced costs, wider range of products adhering to global standards, marketing initiatives, competitive pricing and more efficient use of resources. Focus on consistently meeting quality standards Our Company intends to focus on adhering to the quality standards of the products. Our driving force has always been the quality of our products, as the same would enable us for long standing relationship with our customers. Our technically qualified persons are determined to achieve the objective of zero defects and zero rejection. To complement the efforts of our technical team, we are equipped with testing facilities to ensure that all our products are thoroughly tested prior to dispatch from our factory. Our testing and development laboratory will play an integral role in making improvements in quality of our products and development of special products. Further, we propose to enhance our efficiency by introducing advanced machinery and reducing our dependency on manual labor thereby capitalizing our method of production. This is necessary so as to make sure that we get repeat orders from our customers. 29

31 SUMMARY OF FINANCIALS STATEMENT OF ASSETS AND LIABLITIES, AS RESTATED Sr. No. A B C D E F Particulars (Rs. in Lacs) As at As at March 31, September 30, EQUITY AND LIABILITIES Shareholders Funds a. Share Capital b. Reserves & Surplus (56.67) (97.03) (141.32) (135.11) Share Application Money Pending Allotment Non Current Liabilities a. Long Term Borrowings , b. Deferred Tax Liabilities c. Other Long Term Liabilities d. Long Term Provisions Current Liabilities a. Short Term Borrowings b. Trade Payables 1, , c. Other Current Liabilities , d. Short Term Provisions T O T A L 3, , , , , , ASSETS Non Current Assets a. Fixed Assets i. Tangible Assets 1, , , , , , Less: Accumulated Depreciation ii. Intangible Assets iii. Intangible Assets under development iv. Capital Work in Progress Net Block , , b. Deferred Tax Assets (Net) c. Non-current Investments d. Other Non current assets Current Assets a. Current Investment b. Inventories c. Trade Receivables 1, , d. Cash and Cash Equivalents e. Short Term Loans & Advances f. Other Current Assets T O T A L 3, , , , , ,

32 Sr. No. Particulars STATEMENT OF PROFIT AND LOSS, AS RESTATED September 30, For the period ended March 31, (Rs. in Lacs) A INCOME Revenue from Operations 2, , , , , Other Income Total Income (A) 2, , , , , B EXPENDITURE Cost of Material Consumed 2, , , , , Purchase of Stock in Trade Changes in inventories of (94.47) (20.80) (87.18) (43.34) (32.02) (27.81) finished goods, traded goods and work-in-progress Employee benefit expenses Finance costs Depreciation and amortisation expense Other Expenses Total Expenses (B) 2, , , , , C Profit before extraordinary (199.60) items and tax Extraordinary items D Profit before tax (199.60) Tax expense : (i) Current tax Less:MAT Credit - (3.09) (5.43) (0.45) - - (ii) Deferred tax (1.44) (28.43) (iii) Tax in respect of earlier year E Total Tax Expense (28.43) F Profit for the year (D-E) (6.21) (171.16) 31

33 STATEMENT OF CASH FLOW, AS RESTATED (Rs. in Lacs) Particulars September For the year ended March 31, 30, Net Profit before tax as per Profit And (199.60) Loss A/c Adjusted for: Depreciation & Amortisation Interest & Financial Charges Profit on Sale of Fixed Assets Interest earned - (4.94) (4.61) (4.35) (1.96) (0.51) Operating Profit Before Working Capital Changes Adjusted for (Increase)/ Decrease: Inventories (95.41) (31.10) (162.65) (141.74) (46.35) Trade Receivables (81.57) (1,009.54) (325.74) (195.05) Short Term Loans & Advances (101.87) (205.34) (144.72) 2.18 (21.27) Other Non Current Assets (3.35) Trade Payables (244.28) Other Current Liabilities (1,009.34) Short Term Provisions Cash Generated From Operations (759.14) Before Extra-Ordinary Items Cash Generated From Operations (759.14) Direct Tax Paid (45.99) (42.19) (8.38) (9.25) - - Net Cash Flow from/(used in) (759.14) Operating Activities: (A) Cash Flow From Investing Activities: Purchase of Fixed Assets (50.51) (130.86) (70.39) (67.26) (35.31) (54.81) Interest & Financial Charges (69.32) (165.94) (165.94) (150.82) (183.30) (157.02) Interest earned Net Cash Flow from/(used in) (119.83) (291.86) (231.72) (213.74) (216.66) (211.33) Investing Activities: (B) Cash Flow from Financing Activities: Proceeds from Long Term borrowings (45.95) (130.17) (165.61) (122.58) (547.37) (net) Proceeds from Short Term borrowings (25.89) (45.06) (net) Increase in Capital Reserve Net Cash Flow from/(used in) (71.84) (88.61) (142.64) (547.37) Financing Activities ( C) Net Increase/(Decrease) in Cash & (7.71) (8.07) Cash Equivalents (A+B+C) Cash & Cash Equivalents As At Beginning of the Year Cash & Cash Equivalents As At End of the Year

34 ISSUE DETAILS IN BRIEF PRESENT ISSUE IN TERMS OF THIS DRAFT PROSPECTUS Equity Shares Offered: Public Issue of Equity Shares by our Company consisting: Of which: Issue Reserved for the Market Maker Net Issue to the Public Equity Shares outstanding prior to the Issue Equity Shares outstanding after the Issue Objects of the Issue 15,00,800 Equity Shares of Rs. 10/- each (the Equity Shares ) for cash at a price of Rs. 80/- per Equity Share (including a Share premium of Rs. 70/- per Equity Share) aggregating to Rs Lacs 76,800 Equity Shares of Rs. 10/- each at a price of Rs. 80/- per Equity Share aggregating Rs Lacs 14,24,000 Equity Shares of Rs. 10/- each at a price of Rs. 80/-,per Equity Share aggregating Rs Lacs 36,82,515 Equity Shares of face value of Rs. 10/- each 51,83,315 Equity Shares of face value of Rs. 10/- each Please refer section titled Objects of the Issue on page 50 of this Draft Prospectus This issue is being made in terms of Chapter XB of the SEBI (ICDR) Regulations, 2009, as amended from time to time. For further details, please see the section titled Issue Related Information beginning on page no. 172 of this Draft Prospectus. The Issue has been authorized by a resolution of the Board of Directors, dated September 03, 2016 and by a resolution of the shareholders of our Company in the AGM held on September 30, 2016 under section 62(1) (c) of the Companies Act,

35 GENERAL INFORMATION Our Company was originally incorporated as ANG Lifesciences India Private Limited on June 14, 2006 with the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh as a private limited Company under the Companies Act, On conversion into public limited Company the name of our Company was changed to ANG Lifesciences India Limited pursuant to special resolution passed at the Extra Ordinary General Meeting held on January 18, 2010 and a fresh certificate of incorporation dated March 02, 2010 issued by the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh. Our company was further converted into private limited Company and the name of our Company was changed to ANG Lifesciences India Private Limited pursuant to special resolution passed at the Extra Ordinary General Meeting held on August 31, 2010 and a fresh certificate of incorporation was issued by Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh dated September 22, Subsequently, on conversion into public limited Company the name of our company again changed to ANG Lifesciences India Limited pursuant to special resolution passed at the Extra Ordinary General Meeting held on May 04, 2016 and a fresh certificate of incorporation dated May 18, 2016 issued by the Registrar of Companies, Chandigarh. Registered Office Darbara Complex, SCO 113, First Floor, District Shopping Centre, B Block Ranjit Avenue, Amritsar , Punjab, India. Tel: , info@anglifesciences.com Website: Registration Number Company Identification Number Address of Registrar of Companies Designated Stock Exchange Listing of Shares offered in this Issue Contact Person: Board of Directors: Our Board of Directors comprise of the following members: U24230PB2006PLC Registrar of Companies, Chandigarh, Corporate Bhawan, Plot No. 4 B, Sector 27 B, Madhya Marg, Chandigarh , India Tel.: , Fax: roc.chandigarh@mca.gov.in BSE Limited SME Platform of BSE Mr. Chandan Kapoor Company Secretary and Compliance Officer Darbara Complex, SCO 113, First Floor, District Shopping Centre, B Block Ranjit Avenue, Amritsar , Punjab, India. Tel: , , cs@anglifesciences.com Name Designation DIN Address Mr. Rajesh Gupta Managing Director House No. 85, Guru Nanak Avenue, Majitha Road, Amritsar , Punjab, India. Mrs. Saruchi Gupta Whole Time Director House No. 85, Guru Nanak Avenue, Majitha Road, Amritsar , Punjab, India. Mrs. Nipur Gupta Non Executive and Non Independent Director , First Floor, Sector 11, Panchkula , Haryana, India. Mr. Pawanjit Singh Non Executive and Independent Director House No. 3438, Street No. 3, Rock House, Putlighar, Azad Nagar, Amritsar , Punjab, India. Mr. Sukhpal Singh Non Executive and Independent Director A-701, A Block, New Amritsar, Amritsar , Punjab, India. 34

36 For further details of Management of our Company, please refer to section titled "Our Management" on page 87 of this Draft Prospectus. Company Secretary & Compliance Officer Chief Financial Officer Mr. Chandan Kapoor Mrs. Saruchi Gupta Darbara Complex, SCO 113, First Floor, District Darbara Complex, SCO 113, First Floor, District Shopping Centre, B Block Ranjit Avenue, Shopping Centre, B Block Ranjit Avenue, Amritsar , Punjab India. Amritsar , Punjab India Tel: , Tel: , cs@anglifesciences.com cfo@anglifesciences.com Note: Investors can contact our Compliance Officer in case of any pre-issue or post-issue related matters such as non-receipt of letters of allotment, credit of allotted shares in the respective beneficiary account, refund orders etc. Details of Key Intermediaries pertaining to this Issue and our Company: Lead Manager of the Issue Guiness Corporate Advisors Private Limited Registered Office:18, Deshapriya Park Road, Kolkata , West Bengal, India Tel: Fax: gcapl@guinessgroup.net Website: Contact Person: Ms. Alka Mishra/Ms. Nimisha Joshi SEBI Registration No.: INM Banker to the Company Punjab National Bank Sector 9-D, Chandigarh, India. Tel: bo1488@pnb.co.in Website: Banker to the Issue [ ] To be appointed prior to filing of prospectus with RoC Registrar to the Issue Big Share Services Private Limited E/2, Ansa Industrial Estate, Sakivihar Road, Sakinaka, Andheri (East), Mumbai , Maharashtra, India. Tel: Fax: ipo@bigshareonline.com Website: Contact Person: Mr. Babu Raphael SEBI Registration No.: INR Legal Advisor to the Issue K Asher & Co. Medows House, 39, Nagindas Master Road, Fort, Mumbai , Maharashtra, India. Tel: Fax: mihir@kasherindia.com Website: Contact Person: Mr. Mihir Mody Statutory Auditor of the Company Ajay K. Khanna & Co., Chartered Accountants, 64, Mishra Singh Colony, Tarn Taran Road, Amritsar , Punjab, India. Tel: cabhupinder29@gmail.com Contact Person: Mr. Bhupinder Singh Firm Registration No.: N Peer Review Certified Auditor Vishal H. Shah & Associates, Chartered Accountants A-302, Kailas Esplanade, Opp. Shreyas Cinema, LBS Marg, Ghatkopar (W), Mumbai , Maharashtra, India. Tel: vishalhs@yahoo.com Contact Person: Mr. Vishal Shah 35

37 Self Certified Syndicate Banks The lists of banks that have been notified by SEBI to act as SCSB for the Applications Supported by Blocked Amount ( ASBA ) Process are provided on the website of SEBI at The details on designated branches of SCSBs collecting the ASBA Application Form, are provided on the website of SEBI at Registered Brokers In accordance with SEBI Circular No. CIR/CFD/14/2012 dated October 4, 2012 and CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015, Applicants can submit Application Forms with the Registered Brokers at the Broker Centres, CDPs at Designated CDP Locations or the RTAs at the Designated RTA Locations, respective lists of which, including details such as address and telephone numbers, are available at the websites of the BSE at respectively, as updated from time to time. For further details, please see Issue Procedure on page 178 of this Draft Prospectus. Registrar and Share Transfer Agents The list of the RTAs eligible to accept ASBA Forms at the Designated RTA Locations, including details such as address, telephone number and address, are provided on the website of Stock Exchange at as updated from time to time. Collecting Depository Participants The list of the CDPs eligible to accept ASBA Forms at the Designated CDP Locations, including details such as name and contact details, are provided on the websites of Stock Exchange at as updated from time to time. Credit Rating As the Issue is of Equity Shares, credit rating is not mandatory. Trustees As the Issue is of Equity Shares, the appointment of Trustees is not mandatory. IPO Grading Since the Issue is being made in terms of Chapter XB of the SEBI (ICDR) Regulations, there is no requirement of appointing an IPO Grading agency. Brokers to the Issue All members of the recognized stock exchanges would be eligible to act as Brokers to the Issue. Monitoring Agency As per Regulation 16(1) of the SEBI (ICDR) Regulations, 2009 the requirement of Monitoring Agency is not mandatory if the Issue size is below Rs Crores. Since the Issue size is below Rs Crores, our Company has not appointed any monitoring agency for this Issue. However, as per the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015, the SME Listing Agreement to be entered into with BSE upon listing of the equity shares and the corporate governance requirements, the audit committee of our Company, would be monitoring the utilization of the proceeds of the Issue. 36

38 Debenture Trustees As the Issue is of Equity Shares, the appointment of Debenture trustees is not required. Details of the Appraising Authority The objects of the Issue and deployment of funds are not appraised by any independent agency/ bank/ financial institution. Inter-se Allocation of Responsibilities Since Guiness Corporate Advisors Private Limited is the sole Lead Manager to this Issue, a statement of inter-se allocation responsibilities among Lead Manager s is not required. Expert Opinion Except the report of the Peer reviewed Auditor on the Restated Financial Statements and report of our Statutory Auditor on the Statement of Tax Benefits included in this Draft Prospectus, our Company has not obtained any other expert opinion. Underwriting Agreement This Issue is 100% Underwritten. The Underwriting agreement is dated December 05, Pursuant to the terms of the Underwriting Agreement, the obligations of the Underwriter are several and are subject to certain conditions specified therein. The Underwriter has indicated their intention to underwrite the following number of specified securities being offered through this Issue: Name and Address of the Underwriter Guiness Corporate Advisors Private Limited Registered office: 18, Deshapriya Park Road, Kolkata , West Bengal, India. Tel: Fax: gcapl@guinessongroup.net Website: Contact Person: Ms. Alka Mishra /Ms. Nimisha Joshi SEBI Regn. No: INM Number of Equity shares Underwritten* Amount Underwritten (Rs. in Lacs) % of the Total Issue Size Underwritten 15,00, % *Includes 76,800 Equity shares of the Market Maker Reservation Portion which are to be subscribed by the Market Maker in its own account in order to claim compliance with the requirements of Regulation 106V(4) of the SEBI (ICDR) Regulations, 2009, as amended. In the opinion of the Board of Directors of the company, considering the resources of the above mentioned underwriter and the potential investment lined up by it for the issue, underwriter is in a position to discharge its underwriting obligation. Details of the Market Making Arrangement for this Issue Our Company has entered into an agreement dated December 05, 2016 with the Lead Manager and Market Maker to fulfil the obligations of Market Making. 37

39 Name and Address of the Market Maker Guiness Securities Limited Guiness House 18, Deshapriya Park Road, Kolkata , West Bengal, India. Tel: Fax: Contact Person: Mr. Kuldeep Mohanty kmohanty@guinessgroup.net Website: SEBI Regn. No: INB The Market Maker shall fulfil the applicable obligations and conditions as specified in the SEBI (ICDR) Regulations, and its amendments from time to time and the circulars issued by the BSE, and SEBI regarding this matter from time to time. Following is a summary of the key details pertaining to the Market Making arrangement: 1. The Market Maker(s) shall be required to provide a 2-way quote for 75% of the time in a day. The same shall be monitored by the Stock Exchange. Further, the Market Maker(s) shall inform the exchange in advance for each and every black out period when the quotes are not being offered by the Market Maker(s). The minimum depth of the quote shall be Rs. 1,00,000/-. However, the investors with holdings of value less than Rs. 1,00,000/- shall be allowed to offer their holding to the Market Maker(s) in that scrip provided that they sell his entire holding in that scrip in one lot along with a declaration to the effect to the selling broker. 2. After a period of three (3) months from the market making period, the market maker would be exempted to provide quote if the Shares of market maker in our Company reaches to 25 %. (Including the 5 % of Equity Shares of the Issue.) Any Equity Shares allotted to Market Maker under this Issue over and above 5% of Issue Size would not be taken in to consideration of computing the threshold of 25%. As soon as the Shares of market maker in our Company reduce to 24%, the market maker will resume providing 2-way quotes. 3. There shall be no exemption/threshold on downside. However, in the event the market maker exhausts his inventory through market making process, the concerned stock exchange may intimate the same to SEBI after due verification. 4. Execution of the order at the quoted price and quantity must be guaranteed by the Market Maker(s), for the quotes given by him. 5. There would not be more than five Market Makers for a script at any point of time and the Market Makers may compete with other Market Makers for better quotes to the investors. 6. The shares of the company will be traded in continuous trading session from the time and day the company gets listed on SME Platform of BSE and market maker will remain present as per the guidelines mentioned under BSE and SEBI circulars. 7. There will be special circumstances under which the Market Maker may be allowed to withdraw temporarily/fully from the market for instance due to system problems or any other problems. All controllable reasons require prior approval from the Exchange, while force-majeure will be applicable for non-controllable reasons. The decision of the Exchange for deciding controllable and non-controllable reasons would be final. 38

40 8. The Market Maker(s) shall have the right to terminate said arrangement by giving a three months notice or on mutually acceptable terms to the Merchant Banker, who shall then be responsible to appoint a replacement Market Maker(s). In case of termination of the above mentioned Market Making agreement prior to the completion of the compulsory Market Making period, it shall be the responsibility of the Lead Manager to arrange for another Market Maker in replacement during the term of the notice period being served by the Market Maker but prior to the date of releasing the existing Market Maker from its duties in order to ensure compliance with the requirements of regulation 106V of the SEBI (ICDR) Regulations, Further the Company and the Lead Manager reserve the right to appoint other Market Makers either as a replacement of the current Market Maker or as an additional Market Maker subject to the total number of Designated Market Makers does not exceed five or as specified by the relevant laws and regulations applicable at that particulars point of time. The Market Making Agreement is available for inspection at our Registered Office from a.m. to 5.00 p.m. on working days. 9. Risk containment measures and monitoring for Market Makers: BSE SME Exchange will have all margins which are applicable on the BSE Main Board viz., Mark-to-Market, Value-At-Risk (VAR) Margin, Extreme Loss Margin, Special Margins and Base Minimum Capital etc. BSE can impose any other margins as deemed necessary from time-to-time. 10. Punitive Action in case of default by Market Makers: BSE SME Exchange will monitor the obligations on a real time basis and punitive action will be initiated for any exceptions and/or non-compliances. Penalties / fines may be imposed by the Exchange on the Market Maker, in case he is not able to provide the desired liquidity in a particular security as per the specified guidelines. These penalties / fines will be set by the Exchange from time to time. The Exchange will impose a penalty on the Market Maker in case he is not present in the market (offering two way quotes) for at least 75% of the time. The nature of the penalty will be monetary as well as suspension in market making activities / trading membership. The Department of Surveillance and Supervision of the Exchange would decide and publish the penalties / fines / suspension for any type of misconduct/ manipulation/ other irregularities by the Market Maker from time to time. 11. Pursuant to SEBI Circular number CIR/MRD/DSA/31/2012 dated November 27, 2012, limits on the upper side for market maker(s) during market making process has been made applicable, based on the issue size and as follows: Issue Size Buy quote exemption threshold (including mandatory initial inventory of 5% of the Issue Size) Re-Entry threshold for buy quote (including mandatory initial inventory of 5% of the Issue Size) Up to Rs.20 Crores 25% 24% Rs.20 to Rs.50 Crores 20% 19% Rs.50 to Rs.80 Crores 15% 14% Above Rs.80 Crores 12% 11% 39

41 CAPITAL STRUCTURE The share capital of the Company as at the date of this Draft Prospectus, before and after the Issue, is set forth below. (Rs. in Lacs, except share data) Sr. Particulars No. Aggregate value at face value Aggregate value at Issue Price A. Authorized Share Capital 55,00,000 Equity Shares of face value of Rs.10 each B. Issued, subscribed and paid-up Equity Share Capital before the Issue 36,82,515 Equity Shares of face value of Rs. 10 each C. Present Issue in terms of this Draft Prospectus Issue of 15,00,800 Equity Shares of Rs. 10 each at a price of Rs. 80 per Equity Shares Which comprises 76,800 Equity Shares of Rs.10 each at a price of Rs. 80 per Equity Share reserved as Market Maker Portion Net Issue to Public of 14,24,000 Equity Shares of Rs. 10 each at a price of Rs. 80 per Equity Share to the Public Of which 7,12,000 Equity Shares of Rs.10 each at a price of Rs. 80 per Equity Share will be available for allocation to Retail Individual Investors up to Rs Lacs 7,12,000 Equity Shares of Rs.10 each at a price of Rs. 80 per Equity Share will be available for allocation to Other than Retail Individual Investors of above Rs Lacs D. Equity Capital after the Issue 51,83,315 Equity Shares of Rs. 10 each E. Securities Premium Account Before the Issue After the Issue Nil Rs The Issue has been authorized by a resolution of the Board of Directors, dated September 03, 2016 and by a resolution of the shareholders of our Company in the AGM held on September 30, 2016 under section 62(1) (c) of the Companies Act, Our Company has no outstanding convertible instruments as on the date of this Draft Prospectus. Classes of Shares The Company has only one class of Share Capital i.e. Equity Shares of Rs. 10 each. Changes in the Authorized Share Capital of our Company: Sr. No. Particulars of Change Date of Meeting From To Shareholders Meeting AGM/EGM 1 10,00,000 Equity Shares of Rs. 10 each - Incorporation 2 10,00,000 Equity Shares of 32,50,000 Equity Shares of EGM Rs. 10 each Rs. 10 each 3 32,50,000 Equity Shares of 35,50,000 Equity Shares of EGM Rs. 10 each Rs. 10 each 4 35,50,000 Equity Shares of 37,00,000 Equity Shares of EGM Rs. 10 each Rs. 10 each 5 37,00,000 Equity Shares of Rs. 10 each 55,00,000 Equity Shares of Rs. 10 each AGM 40

42 Notes Forming Part of Capital Structure 1. Equity Share capital history of our Company Date of issue/ allotment of Shares No. of Equity Shares Issued Face value (Rs.) Issue price (Rs.) Conside ration (cash, bonus, consider ation other than cash) Nature of allotment (Bonus, swap etc.) Cumulative no. of Equity Shares Cumulative paid-up share capital (Rs.) Cumul ative share premiu m (Rs.) On Subscription to 20, Cash incorporation MOA 20,000 2,00,000 Nil ,43, Cash Further Allotment (i) 9,63,366 96,33,660 Nil ,79, Cash Further Allotment (ii) 32,42,815 3,24,28,150 Nil ,89, Cash Further Allotment (iii) 35,32,515 3,53,25,150 Nil ,50, Cash Further Allotment (iv) 36,82,515 3,68,25,150 Nil (i) Allotment of 9,43,366 Equity Shares made to our promoter Mr. Rajesh Gupta (ii) Allotment to Mr. Marut Arora 7,35,175 Equity Shares, Mr. Hemant Arora 7,35,175 Equity Shares and Mr. Rajesh Gupta 8,09,099 Equity Shares aggregating to 22,79,449 Equity Shares (iii) Allotment to Mr. Marut Arora 50,600 Equity Shares, Mr. Hemant Arora 50,600 Equity Shares and Mr. Rajesh Gupta 1,88,500 Equity Shares aggregating to 2,89,700 Equity Shares (iv) Allotment of 1,50,000 Equity Shares to Mr. Rajesh Gupta 2. Our Company has not issued any Equity Shares for consideration other than cash or out of revaluation reserves or in terms of any scheme approved under Sections of the Companies Act, 1956 or Section of the Companies Act, We have not issued any Equity Shares at a price below the Issue Price in the last one year from the date of this Draft Prospectus. 4. We have not issued any Equity Shares within last two years from the date of this Draft Prospectus. 5. Capital Build up of our Promoters: Set forth below are the details of the build-up of our Promoters:- Date of Allotment / Transfer Consid eration Mr. Rajesh Gupta Nature of Issue No of Equity Shares Sources of Funds (Owned /Borrowed) Face Value Per Share (Rs.) Issue Price/Acq uisition Price / Transfer Prices % Pre - Issue paid up capital % Post - Issue paid up capital Cash Subscription to 10,000 Owned MOA Cash Allotment 9,43,366 Owned Cash Allotment 8,09,099 Owned

43 Cash Allotment 1,88,500 Owned Cash Allotment 1,50,000 Owned Cash Transfer 7,90,775 Owned received from Marut Arora Cash Transfer 7,90,775 Owned received from Hemant Arora Cash *Transfer to (10,000) (0.27) (0.19) Saruchi Gupta Cash *Transfer to (400) (0.01) (0.01) Marut Arora and Yukti Dammi (200 shares each) Cash *Transfer to (1600) (0.04) (0.03) Arun Bhanot, BimlaWati, Davinder Kumar, Chawla Khanna, Yashpal Setia, Gauri Arora, Hemant Arora, Kapil Mehra, Pawanjit Singh, Krishna Arora, Priya Chopra, Ravi Goel, S.S Bhola, Shivam Traders, Rajesh Gupta, and Surjit Singh (100 shares each) Total 36,70, Mrs. Saruchi Gupta Cash *Transfer 10,000 Owned received from Rajesh Gupta Total 10, *We have been unable to locate share transfer deeds executed in relation to these share transfers. However, our Company has relied on the limited information available in the Register of Members maintained by the Company, from where we have ascertained the same. 3. Shareholding of our Promoters and Promoter Group The table below presents the current shareholding pattern of our Promoters and Promoter Group 42

44 Sr. No. Name of the Shareholder Pre-Issue Post-Issue Shares pledged or otherwise encumbered No. of Equity Shares As a % of Issued Share Capital No. of Equity Shares As a % of Issued Share Capital Number As a percentage As a % of grand Total A Promoters 1 Mr. Rajesh Gupta 36,70, ,70, Mrs. Saruchi Gupta 10, , Total (A) 36,80, ,80, B Promoter Group, Relatives and other Associates 1 Nil Nil Nil Nil Nil Total (B) Nil Nil Nil Nil TOTAL (A+B) 36,80, ,80, There are no transactions in our Equity Shares during the past six months, which have been purchased/(sold) by our Promoters, their relatives and associates, persons in Promoter Group (as defined under sub-clause (zb) sub regulation (1) Regulation 2 of the SEBI (ICDR) Regulations, 2009) or the Directors of the Company 5. None of the members of the Promoter Group, Directors and their immediate relatives have financed the purchase of Equity shares of our Company, by any other person during the period of six months immediately preceding the date of this Draft Prospectus. 6. There is no shareholding of persons belonging to the category Public and holding more than 1% of our Equity Shares 7. There has been no subscription to or sale or purchase of the securities of our Company within three years preceding the date of filing of this Draft Prospectus by our Promoters or Directors or Promoter Group which in aggregate equals to or is greater than 1% of the pre-issue share capital of our Company 8. The average cost of acquisition of or subscription to Equity Shares by our Promoters is set forth in the table below: Name of the Promoter No. of Shares held Average Cost of Acquisition (in Rs.) Mr. Rajesh Gupta 36,70, Mrs. Saruchi Gupta 10, None of our Directors hold Equity Shares in our Company, other than as follows: Name of the Director No. of Equity Shares % of Pre-Issue Capital Mr. Rajesh Gupta 36,70, Mrs. Saruchi Gupta 10, The Shareholding pattern of our Company before and after the Issue is set forth below: Particulars Pre Issue Post Issue No. of Shares % of holding No. of Shares % of holding Promoters 36,80, ,80, Promoter Group Nil Nil Nil Nil Public 2, ,26, Non Promoter Non Public Nil Nil 76, Total 36,82, ,83, Details of Promoters contribution locked in for three years: 43

45 Pursuant to Regulation 32 and 36 of SEBI (ICDR) Regulations aggregate of 20% of the post issue capital held by our Promoters shall be considered as promoters contribution ( Promoters Contribution ) and locked-in for a period of three years from the date of Allotment. The lock-in of the Promoters Contribution would be created as per applicable law and procedure and details of the same shall also be provided to the Stock Exchange before listing of the Equity Shares. Our Promoters have granted consent to include such number of Equity Shares held by them as may constitute 20% of the post issue Equity Share capital of our Company as Promoters Contribution and have agreed not to sell or transfer or pledge or otherwise dispose of in any manner, the Promoters Contribution from the date of filing of this Draft Prospectus until the commencement of the lock-in period specified above. Date of Allotment / Transfer Mr. Rajesh Gupta Consideration Nature of Issue No of Equity Shares Face Value Per Share (Rs.) Issue Price/Acqui sition Price / Transfer Prices % Pre - Issue paid up capital % Post - Issue paid up capital Cash Allotment 9,43, Cash Allotment 1,00, Total 10,43, We further confirm that the minimum Promoter Contribution of 20% which is subject to lock-in for three years does not consist of: Equity Shares acquired during the preceding three years for consideration other than cash and out of revaluation of assets or capitalization of intangible assets or bonus shares out of revaluation reserves or reserves without accrual of cash resources. Equity Shares acquired by the Promoters during the preceding one year, at a price lower than the price at which Equity Shares are being offered to public in the Issue. Private placement made by solicitation of subscription from unrelated persons either directly or through any intermediary. The Equity Shares held by the Promoters and offered for minimum 20% Promoters Contribution are not subject to any pledge. Equity Shares for which specific written consent has not been obtained from the shareholders for inclusion of their subscription in the minimum Promoters Contribution subject to lock-in. Equity shares issued to our Promoters on conversion of partnership firms into limited companies. Specific written consent has been obtained from the Promoters for inclusion of the Equity Shares for ensuring lockin of three years to the extent of minimum 20% of post -Issue paid-up Equity Share Capital from the date of allotment in the proposed public Issue. Promoters' Contribution does not consist of any private placement made by solicitation of subscription from unrelated persons either directly or through any intermediary. The minimum Promoters Contribution has been brought to the extent of not less than the specified minimum lot and from the persons defined as Promoters under the SEBI (ICDR) Regulations, The Promoters Contribution constituting more than 20% of the post issue capital shall be locked-in for a period of three years from the date of Allotment of the Equity Shares in the Issue. 44

46 All Equity Shares, which are to be locked-in, are eligible for computation of Promoters Contribution, in accordance with the SEBI (ICDR) Regulations, Accordingly we confirm that the Equity Shares proposed to be included as part of the Promoters Contribution: a) have not been subject to pledge or any other form of encumbrance; or b) have not been acquired, during preceding three years, for consideration other than cash and revaluation of assets or capitalization of intangible assets is not involved in such transaction; c) is not resulting from a bonus issue by utilization of revaluation reserves or unrealized profits of the Issuer or from bonus issue against Equity Shares which are ineligible for minimum Promoters Contribution; d) have not been acquired by the Promoters during the period of one year immediately preceding the date of filing of this Draft Prospectus at a price lower than the Issue Price. The Promoters Contribution can be pledged only with a scheduled commercial bank or public financial institution as collateral security for loans granted by such banks or financial institutions, in the event the pledge of the Equity Shares is one of the terms of the sanction of the loan. The Promoters Contribution may be pledged only if in addition to the above stated, the loan has been granted by such banks or financial institutions for the purpose of financing one or more of the objects of this Issue. The Equity Shares held by our Promoters may be transferred to and among the Promoter Group or to new Promoters or persons in control of our Company, subject to continuation of the lock-in in the hands of the transferees for the remaining period and compliance with the Takeover Code, as applicable. 12. Details of share capital locked in for one year: In addition to 20% of the post issue shareholding of our Company held by the Promoters (locked in for three years as specified above), in accordance with regulation 36 of SEBI (ICDR) Regulations, 2009, the entire pre issue share capital of our Company (including the Equity Shares held by our Promoters) shall be locked in for a period of one year from the date of Allotment in this Issue. The Equity Shares held by persons other than our Promoters and locked-in for a period of one year from the date of Allotment, in accordance with regulation 37 of SEBI (ICDR) Regulations, 2009, in the Issue may be transferred to any other person holding Equity Shares which are locked-in, subject to the continuation of the lock-in the hands of transferees for the remaining period and compliance with the Takeover Code. 45

47 Categ ory code 13. Shareholding pattern of our Company: The following table presents the shareholding pattern of Our Company. Category of shareholders No. of share holde rs No. of fully paid up equity shares held No. of Partl y paidup equit y share s held No. of shares underl ying Deposi tory Receip ts Total nos. shares held Shareh olding as a % of total no. of shares (calcul ated as per SCRR, 1957) Number of Voting Rights held in each class of securities No. of Shares Underl ying Outsta nding conver tible securiti es (includ ing Warra nts) Shareholdi ng, as % assuming full conversion of convertible securities ( as a % of diluted share capital) (I) (II) (III) (IV) (V) (VI) (VII) (VIII) (IX) (X) (XI)= (VII)+(X) (A) Promoter & Promoter Group As a % of (A+B+ C2) No of Voting Rights Total as a % of (A+B+ C) As a % of (A+B+C2) No. (a) Number of Locked in shares Number of Shares pledged or otherwise encumbered Numb er of equity shares held in demat erialis ed form* (XII) (XIII) (XIV) Equity Prefe Total rence (B) Public (C ) Non Promoter-Non Public (C1) Shares underlying DRs (C2) Shares held by Employee Trusts Total *The Equity Shares of Promoter and Promoter Group are in process of dematerialization As a % of total shares held (b) No.( a) As a % of total share s held (b) 46

48 14. Equity Shares held by top ten shareholders (a) Our top ten shareholders and the number of Equity Shares held by them as on date of this Draft Prospectus are as under: Sr. No. Name of shareholder No. of Shares % age of Pre-Issue Capital 1 Rajesh Gupta 36,70, Saruchi Gupta 10, Neeraj Gupta * Marut Arora 200 Negligible 4* Yukti Dhammi 200 Negligible 5** Arun Bhanot 100 Negligible 5** BimlaWati 100 Negligible 5** Davinder Kumar 100 Negligible 5** Yashpal Setia 100 Negligible 5** Gauri Arora 100 Negligible 5** Hemant Arora 100 Negligible 5** Kapil Mehra 100 Negligible 5** Ravi Goel 100 Negligible 5** S.S Bhola 100 Negligible 5** Rajesh Gupta 100 Negligible 5** Surjit Singh 100 Negligible Total 36,82, *On Sr. No. 4 there are 2 shareholders holding 200 Shares each ** On Sr. No 5 there are 11 shareholders holding 100 Shares each (b) Our top ten shareholders and the number of Equity Shares held by them ten days prior to the date of this Draft Prospectus are as under: Sr. No. Name of shareholder No. of Shares % age of pre-issue capital 1 Rajesh Gupta 36,70, Saruchi Gupta 10, Neeraj Gupta * Marut Arora 200 Negligible 4* Yukti Dhammi 200 Negligible 5** Arun Bhanot 100 Negligible 5** BimlaWati 100 Negligible 5** Davinder Kumar 100 Negligible 5** Yashpal Setia 100 Negligible 5** Gauri Arora 100 Negligible 5** Hemant Arora 100 Negligible 5** Kapil Mehra 100 Negligible 5** Ravi Goel 100 Negligible 5** S.S Bhola 100 Negligible 5** Rajesh Gupta 100 Negligible 5** Surjit Singh 100 Negligible Total 36,82, *On Sr. No. 4 there are 2 shareholders holding 200 Shares each ** On Sr. No 5 there are 11 shareholders holding 100 Shares each 47

49 (c) Our top ten shareholders and the number of Equity Shares held by them two years prior to date of this Draft Prospectus are as under: Sr. No. Name of shareholder No. of Shares % age of pre-issue capital 1 Rajesh Gupta 36,70, Saruchi Gupta 10, * Marut Arora 200 Negligible 3* Yukti Dammi 200 Negligible 4** Arun Bhanot 100 Negligible 4** BimlaWati 100 Negligible 4** Davinder Kumar 100 Negligible 4** Chawla Khanna 100 Negligible 4** Yashpal Setia 100 Negligible 4** Gauri Arora 100 Negligible 4** Hemant Arora 100 Negligible 4** Kapil Mehra 100 Negligible 4** Pawanjit Singh 100 Negligible 4** Krishna Arora 100 Negligible 4** Priya Chopra 100 Negligible 4** Ravi Goel 100 Negligible 4** S.S Bhola 100 Negligible 4** Shivam Traders 100 Negligible 4** Rajesh Gupta 100 Negligible 4** Surjit Singh 100 Negligible Total 36,82, *On Sr. No. 3 there are 2 shareholders holding 200 Shares each ** On Sr. No 4 there are 16 shareholders holding 100 Shares each 15. There is no "Buyback", "Standby", or similar arrangement for the purchase of Equity Shares by our Company/Promoters/Directors/Lead Manager for purchase of Equity Shares offered through this Draft Prospectus. 16. Our Company has not raised any bridge loans against the proceeds of this Issue. 17. Investors may note that in case of over-subscription, allotment will be on proportionate basis as detailed in paragraph on "Basis of Allotment" on page 210 of this Draft Prospectus. 18. As on date of filing of this Draft Prospectus, the entire issued share capital of our Company is fully paid-up. 19. The Equity Shares Issued pursuant to this Issue shall be made fully paid-up. 20. An over-subscription to the extent of 10% of the Issue can be retained for the purpose of rounding off while finalizing the basis of allotment to the nearest integer during finalizing the allotment, subject to minimum allotment, which is the minimum application size in the Issue. Consequently, the actual allotment may go up by a maximum of 10% of the Issue, as a result of which, the post issue paid up capital after the Issue would also increase by the excess amount of allotment so made. In such an event, the Equity Shares held by the Promoters and subject to lock-in shall be suitably increased to ensure that 20% of the post issue paid-up capital is locked-in. 21. Under subscription, if any, in any of the categories, would be allowed to be met with spill-over from any of the other categories or a combination of categories at the discretion of our Company in consultation with the Lead Manager and Designated Stock Exchange. Such inter-se spill over, if any, would be affected in accordance with applicable laws, rules, regulations and guidelines. 48

50 22. On the date of filing this Draft Prospectus, there are no outstanding financial instruments or any other rights that would entitle the existing Promoters or shareholders or any other person any option to receive Equity Shares after the Issue. 23. Our Company has neither issued any Equity Shares out of revaluation reserves nor issued any bonus shares out of capitalization of revaluation reserves or no shares have been issued for consideration other than cash. 24. Lead Manager to the Issue viz. Guiness Corporate Advisors Private Limited does not hold any Equity Shares of our Company. 25. Our Company has not revalued its assets since incorporation. 26. Our Company has not made any public issue since incorporation. 27. There will be only one denomination of the Equity Shares of our Company unless otherwise permitted by law, our Company shall comply with such disclosure, and accounting norms as may be specified by SEBI from time to time. 28. There will be no further issue of capital whether by way of issue of bonus shares, preferential allotment, and rights issue or in any other manner during the period commencing from submission of this Draft Prospectus until the Equity Shares to be issued pursuant to the Issue have been listed. 29. Except as disclosed in this Draft Prospectus, our Company presently does not have any intention or proposal to alter its capital structure for a period of six (6) months from the date of opening of the Issue, by way of spilt/consolidation of the denomination of Equity Shares or further issue of Equity Shares (including issue of securities convertible into Equity Shares) whether preferential or otherwise. However, during such period or a later date, it may issue Equity Shares or securities linked to Equity Shares to finance an acquisition, merger or joint venture or for regulatory compliance or such other scheme of arrangement if an opportunity of such nature is determined by its Board of Directors to be in the interest of our Company. 30. At any given point of time, there shall be only one denomination for a class of Equity Shares of our Company. 31. Our Company does not have any ESOS/ESPS scheme for our employees and we do not intend to allot any shares to our employees under ESOS/ESPS scheme from the proposed Issue. As and when, options are granted to our employees under the ESOP scheme, our Company shall comply with the SEBI (Employee Stock Option Scheme and Employees Stock Purchase Plan) Guidelines An investor cannot make an application for more than the number of Equity Shares offered in this Issue, subject to the maximum limit of investment prescribed under relevant laws applicable to each category of investor. 33. No payment, direct, indirect in the nature of discount, commission, and allowance, or otherwise shall be made either by us or by our Promoters to the persons who receive allotments, if any, in this Issue. 34. Our Company has 16 members as on the date of filing of this Draft Prospectus been issued and allotted as fully paid-up shares at the time of allotment. 49

51 OBJECTS OF THE ISSUE The objects of the issue are primarily to raise the capital for following business and operational requirements of the Company: 1. To meet the working capital requirement 2. To meet the expenses of the Issue The objects of the Issue are also to achieve the benefits of listing on the SME platform of BSE Ltd. We believe that listing will enhance the visibility and corporate image of our Company. The main objects of our Memorandum of Association permit us to undertake our existing activities and the activities for which the funds are being raised by us, through the present issue. The fund requirement and deployment is based on internal management estimates and has not been appraised by any bank or financial institution. The Details of the proceeds of the Issue are as mentioned below: Particulars (Rs. in Lacs) Amount To meet the working capital requirement To meet the Issue Expenses Total Means of Finance (Rs. in Lacs) Particulars Amount Proceeds from the Issue Internal Accruals Nil Total We propose to meet the entire requirement of funds for the Objects from the Proceeds of the issue. Accordingly, the requirement under Regulation 4(2)(g) of the SEBI ICDR Regulations of firm arrangements of finance through verifiable means for the 75% of the stated means of finance is not applicable. In the event of a shortfall in raising the requisite capital from the proceeds of the issue, towards meeting the Objects of the issue, the extent of the shortfall will be met by internal accruals and/or from fresh debt. The fund requirements, the deployment of funds and the intended use of the Issue Proceeds as described herein are based on our current business plan, management estimates, and have not been appraised by any bank, financial institution or any other external agency. Given the dynamic nature of our business, we may have to revise our business plan from time to time and consequently our funding requirements and deployment on account of variety of factors such as our financial condition, business and strategy, including external factors such as market conditions, competitive environment, costs of commodities and interest/ exchange rate fluctuations which may not be within the control of our management. In case of variations in the actual utilisation of funds earmarked for the purposes set forth above or shortfall in the Issue Proceeds, increased fund requirements for a particular purpose may be financed by surplus funds, if any, available in respect of the other purposes for which funds are being raised in this Issue. DETAILS OF THE OBJECTS OF THE ISSUE I. To meet the working capital requirement of the Company Our business is working capital intensive. We finance our working capital requirement from various banks / financial institutions and from our internal accruals. As on date, the Company s working capital funding sanctioned from Punjab National Bank is of Rs Lakhs (fund based). Considering the existing and future growth, the total working capital needs of our Company, as assessed based on the internal workings of our Company is 50

52 expected to reach Rs Lakhs for FY and Rs Lakhs for FY We intend to meet our working capital requirements to the extent of Rs Lakhs from the Proceeds of this Issue and the balance will be met from internal accruals and borrowings at an appropriate time as per the requirement. Basis of estimation of working capital requirement and estimated working capital requirement: (Rs. In Lakhs) Particulars Restated Estimated Estimated Current Assets Inventories Trade receivables Short term Loans and advances Total Current Assets (A) (Excluding Cash and cash equivalents) Current Liabilities Trade Payables Other Current Liabilities Short Term Provisions Total Current Liabilities (B) Net Working Capital (A-B) Sources of working capital From Bank Funding From Internal accruals From Issue Proceeds Nil Nil Assumptions for working capital requirements (In Number of Days) Particulars Holding level as of Holding level as of Holding level as of Current Assets Inventories Raw Material Stock in Process Finished Goods Trade receivables Current Liabilities Trade Payables Justification of Holding Period levels Particulars Inventories Trade Receivables Trade Payables Justification In FY and FY , we have assumed Raw Material Inventory around 30 days and 23 days which is slightly higher than FY level of 15 days, as we aim to achieve higher production. We have assumed Stock in Process Inventory around 11 days in FY and 6 Days in FY in line with our expansion process. Further we have assumed finished goods inventory of around 19 days and 12 days in FY and FY as compared to 15 days in FY as we aim to expand our manufacturing operations. In FY and FY , the trade receivable holding period is estimated to slightly decrease from 109 days in FY to 72 and 79 days respectively. The decrease is expected as we intend to have a stringent debtors management policy. In FY and FY , the credit period is expected to be 63 days and 47 days respectively as compared to 138 days in FY as the company will strive to adhere to 51

53 stricter credit policy to achieve better and favourable pricing terms and ensure continued relationship with existing suppliers II. Issue Expenses The total estimated issue expenses are Rs Lacs which is 3.08 % of issue size. The details of issue expenses are tabulated below: (Rs. in Lacs) Sr. No. Particulars Rs. In Lacs % of Total Expenses 1. Issue management fees including fees selling commissions, brokerages, and payment to other intermediaries such as Legal Advisors, Registrars and other out of pocket expenses. 2. Printing & Stationery, Distribution, Postage, etc % of Total Issue Size 3. Advertisement & Marketing Expenses Regulatory & other expenses Proposed year-wise deployment of funds: Total The overall cost of the proposed Project and the proposed year wise break up of deployment of funds are as under: (Rs. In Lacs) Particulars Already Incurred FY Total To meet the working capital requirement of the Company Issue Expenses Total Details of funds already deployed till date and sources of funds deployed The funds deployed up to December 26, 2016 pursuant to the object of this issue as certified by the Auditors of our Company, viz. M/s Ajay K. Khanna & Co., Chartered Accountants pursuant to their certificate dated January 03, 2017 is given below: (Rs. in Lacs) Deployment of Funds Amount Issue Expenses 1.43 Total 1.43 (Rs. in Lacs) Sources of Funds Amount Internal Accruals 1.43 Total 1.43 Note: The amount deployed so far towards Objects of the Issue out of internal accruals will be recouped from the proceeds of the Issue. Appraisal by appraising agency None of the objects have been appraised by any bank or financial institution or any other independent third party organization. The funding requirements of our Company and the deployment of the proceeds of the Issue are currently based on quotations received by us and management estimates. The funding requirements of our Company

54 are dependent on a number of factors which may not be in the control of our management, including variations in interest rate structures, changes in our financial condition and current commercial conditions and are subject to change in light of changes in external circumstances or in our financial condition, business or strategy. Bridge financing facilities We have currently not raised any bridge loans against the proceeds of the issue. However, depending on our requirement, we might consider raising bridge financing facilities, pending receipt of the proceeds of the issue. Shortfall of funds Any shortfall in meeting the Objects of the issue will be met by way of internal accruals. Interim use of funds Our Company, in accordance with the policies established by the Board from time to time, will have flexibility to deploy the issue proceeds. The issue proceeds of the issue pending utilization for the purposes stated in this section, shall be deposited only in scheduled commercial banks included in the Second Schedule of Reserve Bank of India Act, In accordance with Section 27 of the Companies Act, 2013, our Company confirms that it shall not use the issue proceeds of the issue for any investment in the equity markets. Monitoring of utilization of funds There is no requirement for a monitoring agency as the Issue size is less than Rs. 50,000 Lacs. Pursuant to Regulation 32(3) of the SEBI Listing Regulations, our Company shall on a half yearly basis disclose to the Audit Committee the uses and application of the issue proceeds. Until such time as any part of the issue proceeds remains unutilized, our Company will disclose the utilization of the issue proceeds under separate heads in our Company s balance sheet(s) clearly specifying the amount of and purpose for which issue proceeds have been utilized so far, and details of amounts out of the issue proceeds that have not been utilized so far, also indicating interim investments, if any, of such unutilized issue proceeds. In the event that our Company is unable to utilize the entire amount that we have currently estimated for use out of the issue proceeds in a fiscal year, we will utilize such unutilized amount in the next fiscal year. Further, in accordance with Regulation 32(1)(a) of the SEBI Listing Regulations, our Company shall furnish to the Stock Exchange on a half yearly basis, a statement indicating material deviations, if any, in the utilization of the issue proceeds for the objects stated in this Draft Prospectus. Variation in Objects In accordance with Section 27 of the Companies Act 2013, our Company shall not vary object of the Issue without our Company being authorized to do so by our shareholders in relation to the passing of such special resolution shall specify the prescribed details as required under the Companies Act and shall be published in accordance with the Companies Act and the rules thereunder. As per the current provisions of the Companies Act, our Promoters or controlling shareholders would be required to provide an exit opportunity to such shareholders who do not agree to the proposal to vary the objects, at such price, and in such manner as may be prescribed by SEBI in this regard. Other confirmations There is no material existing or anticipated transactions with our Promoter, our Directors, our Company s key Managerial personnel and Group Entities, in relation to the utilisation of the proceeds of the Issue. No part of the proceeds of the Issue will be paid by us as consideration to our Promoter, our Directors or key managerial personnel or our Group Entities, except in the normal course of business and in compliance with the applicable laws. 53

55 BASIC TERMS OF THE ISSUE The Equity Shares, now being issued, are subject to the terms and conditions of this Draft Prospectus, Prospectus, Application form, Confirmation of Allocation Note ( CAN ), the Memorandum and Articles of Association of our Company, the guidelines for listing of securities issued by the Government of India and SEBI (ICDR) Regulations, 2009, the Depositories Act, Stock Exchanges, RBI, ROC and/or other authorities as in force on the date of the Issue and to the extent applicable. In addition, the Equity Shares shall also be subject to such other conditions as may be incorporated in the Share Certificates, as per the SEBI (ICDR) Regulations, 2009 notifications and other regulations for the issue of capital and listing of securities laid down from time to time by the Government of India and/or other authorities and other documents that may be executed in respect of the Equity Shares. Authority for the Issue The present issue has been authorized pursuant to a resolution of our Board dated September 03, 2016 and by Special Resolution passed under Section 62 (1) (c) of the Companies Act, 2013 at the Annual General Meeting of our shareholders held on September 30, Other Details Face Value Issue Price Market Lot and Trading Lot Terms of Payment Ranking of the Equity Shares Equity Share shall have the face value of Rs.10/- each. Equity Share is being offered at a price of Rs. 80/- each. The Market lot and Trading lot for the Equity Share is 1600 (One Thousand Six Hundred) and the multiple of 1,600; subject to a minimum allotment of 1,600 Equity Shares to the successful applicants. 100% of the issue price of Rs.80/- shall be payable on Application. For more details please refer to Issue Procedure to page 178 of this Draft Prospectus. The Equity Shares shall be subject to the Memorandum and Articles of Association of the Company and shall rank pari-passu in all respects including dividends with the existing Equity Shares of the Company. Minimum Subscription This Issue is not restricted to any minimum subscription level. This Issue is 100% underwritten. If the issuer does not receive the subscription of 100% of the Issue through this offer document including devolvement of Underwriters within sixty days from the date of closure of the issue, the issuer shall forthwith refund the entire subscription amount received. If there is a delay beyond fifteen days after the issuer becomes liable to pay the amount, the issuer shall pay interest prescribed under Section 40 of the Companies Act, For further details, please refer to section titled "Terms of the Issue" beginning on page 172 of this Draft Prospectus. 54

56 BASIS FOR ISSUE PRICE Investors should read the following basis with the Risk Factors beginning on page 11 and the details about the Our Business and its Financial Information included in this Draft Prospectus on page 68 & 107 respectively to get a more informed view before making any investment decisions. Qualitative Factors Some of the qualitative factors which may form the basis for computing the Issue Price include the following: Experienced Promoters and management team Quality Assurance and Standards Strong Marketing capability Cordial relationship with Customers, suppliers and employees Focus on Research and Development Quantitative Factors 1. Information presented in this section is derived from our Company s restated financial statements prepared in accordance with Indian GAAP. Some of the quantitative factors, which form the basis for computing the price, are as set forth below: Basic Earnings and Diluted Earnings Per Equity Share (EPS) as per Accounting Standard 20 Period Basic and Diluted EPS (in Rs.) Weight March 31, March 31, March 31, Weighted Average 2.70 For the period ended September 30, 2016* 4.02 *Not annualised Notes: i. The Figures disclosed above are based on the restated financial statements of the Company. ii. The earnings per share has been calculated by dividing the net profit as restated, attributable to equity shareholders by restated weighted average number of Equity Shares outstanding during the period/year. Restated weighted average number of equity shares has been computed as per AS 20. The face value of each Equity Share is Rs. 10/- iii. The above ratios should be read with Significant Accounting Policies and the Notes to the Restated Financial Statements. 2. Price / Earnings Ratio (P/E) in relation to the Issue Price of Rs Particulars PE Ratio P/E ratio based on the Basic & Diluted EPS, as restated for FY P/E ratio based on the Weighted Average EPS, as restated Industry PE: Industry P/E Pharmaceuticals Indian - Formulations PE Ratio Highest (Medicamen Biotech Limited ) Lowest ( Lincoln Pharmaceuticals Limited ) Average of Highest and Lowest (Source: Capital Market, Vol. XXXI/25 dated January 30 February 12, 2017) 3. Return on Net Worth Period RONW (%) Weight March 31, % 1 55

57 March 31, % 2 March 31, % 3 Weighted Average 22.85% For the period ended September 30, 2016* 23.69% *Not annualised. Note: The RONW has been computed by dividing net profit after tax (as restated), by Networth (as restated) 4. Minimum return on post Issue Net Worth to maintain the Pre-issue EPS for the year ended March 31, 2016 Based on Basic and Diluted EPS, as restated of FY Rs at an Issue Price of Rs. 80: % on the restated financial statements. Based on Adjusted Weighted Average EPS, as restated of Rs at an Issue Price of Rs. 80: 7.66 % on the restated financial statements. 5. Net Asset Value (NAV) per Equity Share: S. No. Particulars (Rs.) a) As on March 31, b) As on September 30, c) After Issue d) Issue Price Note: NAV has been calculated as restated networth divided by number of Equity Shares at the end of the year 6. Peer Group Comparison of Accounting Ratios: Particulars EPS (Rs) ( ) PE Ratio RONW (%) NAV(Rs) Face Value ANG Lifesciences India Limited Peer Group* Kwality Pharmaceuticals Limited (Standalone) Bliss GVS Pharma Limited (Standalone) Caplin Point Laboratories Limited (Nine months period ended ) *Source: bseindia.com and Annual Reports of respective Companies For calculating PE ratio market price as on March 06, 2017 is considered Notes: i) All comparisons of the Peers and our Company are as per the Financials for the year/period ended March 31, 2016 ii) The peer group identified is broadly based on the service lines that we are into, but their scale of operations is not comparable to us. iii) The figures of ANG Lifesciences India Limited are based on restated financial statements. 7. The face value of our share is Rs.10/- per share and the Issue Price is of Rs.80 per share are 8.00 times of the face value. 8. The Company in consultation with the Lead Manager believes that the Issue Price of Rs. 80/- per share for the Public Issue is justified in view of the above parameters. The investors may also want to peruse the Risk Factors on page 11 and Financial Information on page 107 including important profitability and return ratios, as set out in the Auditors Report in this Draft Prospectus to have more informed view about the investment proposition. 56

58 STATEMENT OF TAX BENEFITS To, The Board of Directors ANG Lifesciences India Limited Darbara Complex, SCO 113, First Floor, District Shopping Centre B Block, Ranjit Avenue, Amritsar Dear Sirs, Sub: Statement of possible special tax benefits available to ANG Lifesciences India Limited (the Company) and its shareholders on proposed Public Issue of Shares under the existing tax laws prepared in accordance with the requirements in Schedule VIII Clause (VIII) (L) of the SEBI (ICDR) Regulations 2009 and amendments thereof. We hereby confirm that the enclosed Annexure, prepared by the management of the Company, states the possible tax benefits available to the Company and the shareholders of the Company under the Income-tax Act, 1961 ( IT Act ) and as amended by the Finance Act, 2016 (i.e. applicable for financial year , relevant to the assessment year ), presently in force in India. Several of these benefits are dependent on the Company or its shareholders fulfilling the conditions prescribed under the relevant tax laws. Hence, the ability of the Company or its shareholders to derive the tax benefits is dependent upon fulfilling such conditions which, based on business imperatives which the Company may face in the future, the Company may or may not fulfil. The benefits discussed in the enclosed Annexure cover only special tax benefits available to the Company and its shareholders and do not cover any general tax benefits available to the Company or its Shareholders. We are informed that this statement is only intended to provide general information to the investors and hence is neither designed nor intended to be a substitute for professional tax advice. In view of the individual nature of the tax consequences, the changing tax laws, each investor is advised to consult his or her own tax consultant with respect to the specific tax implications arising out of their participation in the issue. Our confirmation is based on the information, explanations and representations obtained from the Company and on the basis of our understanding of the business activities and operations of the Company and the interpretation of the current tax laws in force in India. We do not express any opinion or provide any assurance whether: The Company or its shareholders will continue to obtain these benefits in future; or The Conditions prescribed for availing the benefits have been or would be met. The contents of the annexure are based on information, explanations and representations obtained from the Company and on the basis of our understanding of the business activities and operations of the Company. No assurance is given that the revenue authorities / courts will concur with the views expressed herein. The views are based on the existing provisions of law and its interpretation, which are subject to change from time to time. We would not assume responsibility to update the view, consequence to such change. We shall not be liable to the Company for any claims, liabilities or expenses relating to this assignment except to the extent of fees relating to this assignment, as finally judicially determined to have resulted primarily from bad faith of intentional misconduct. Thanking you, Yours faithfully, For Ajay K. Khanna & Co. Chartered Accountants Firm Registration No.: N Sd/- CA Bhupinder Singh Partner Membership No

59 Place: Amritsar Date: Annexure STATEMENT OF POSSIBLE TAX BENEFITS AVAILABLE TO OUR COMPANY AND ITS SHAREHOLDERS A) SPECIAL TAX BENEFITS AVAILABLE TO OUR COMPANY AND ITS SHAREHOLDERS I. Special Benefits available to our Company ANG Lifesciences India Limited has an undertaking in Himachal Pradesh which is eligible for the purpose of deduction under section 80IC of the Income-tax Act, 1961 ( the Act ). In accordance with and subject to the conditions specified in section 80IC of the Act, the Company may be entitled for a deduction of an amount equal to 100 percent of profits or gains derived for first 5 years and 30 percent of profits or gains derived for next 5 years in respect of profits derived by such undertaking. II. Special Benefits available to the Shareholders of our Company There are no special tax benefits available to the Equity Shareholders. 58

60 The Global Pharmaceutical Industry SECTION IV - ABOUT OUR COMPANY INDUSTRY OVERVIEW According to the Economic Intelligence Unit (EIU), pharmaceutical sales are projected to increase an average of 6.9 percent annually over , outpacing the estimated global health care spending rate of 5.2 percent during that same period. Total pharma revenues are expected to increase from $1.23 trillion in 2014 to $1.61 trillion in In addition to oncology drugs, the cardiovascular therapeutic class will likely prosper, with four of the 10 projected blockbusters drugs belonging to the category. Spending on midmarket prescription drugs used for treating common chronic diseases is likely to stagnate as prices fall. Demand for generic drugs will continue to rise as payors take advantage of patent expiries to reduce costs. The Global pharmaceutical revenues are presented in below mentioned graph. Source: Deloitte Report on Global Life Sciences Outlook The Indian Pharmaceutical Industry Introduction The Indian pharmaceuticals market is the third largest in terms of volume and thirteenth largest in terms of value#. Branded generics dominate the pharmaceuticals market, constituting nearly 70 to 80 per cent of the market. India is the largest provider of generic drugs globally with the Indian generics accounting for 20 per cent of global exports in terms of volume. Of late, consolidation has become an important characteristic of the Indian pharmaceutical market as the industry is highly fragmented. India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers who have the potential to steer the industry ahead to an even higher level. Presently over 80 per cent of the antiretroviral drugs used globally to combat AIDS (Acquired Immuno Deficiency Syndrome) are supplied by Indian pharmaceutical firms. The UN-backed Medicines Patent Pool has signed six sub-licences with Aurobindo, Cipla, Desano, Emcure, Hetero Labs and Laurus Labs, allowing them to make generic anti-aids medicine Tenofovir Alafenamide (TAF) for 112 developing countries. 59

61 Overview Leading pharma producer Indian pharmaceutical sector accounts for about 2.4 percent of the global pharmaceutical industry in value terms and 10 percent in volume terms One of the highest exports India accounts for 20 percent of global exports in generics Among fastest growing industries Rapidly growing healthcare sector Growing generics market Ranked 5th in terms of attracting FDI The country s pharmaceutical industry is expected to expand at a CAGR of percent over to reach USD 55 billion Indian healthcare sector, one of the fastest growing sectors,is expected to advance at a CAGR of 17 percent to reach USD 250 billion over The generics market is expected to grow to USD 26.1 billion by 2016 from USD 14.2 billion in 2015; India s generics market has immense potential for growth Cumulative FDI inflows worth USD13.3 billion from April 2000 to May 15 Attracted 5.19 percent of the total FDIs into India from April 2000 to May 15 Structure of Pharmaceutical Sector in India Pharmaceuticals Active Pharmaceutical Ingredients/ Bulk Drugs Formulations Branded Generic Chronic Acute Cardiovasvular Anti diabetic Gastro - intestinal Neurological Anti infective Respiratory Pain Gyn naecology 60

62 Revenue trend of Indian Pharmaceutical Sector The Indian Pharmaceuticals market increased at a CAGR of 17.46% in 2015 from USD 6 billion in 2005, and is expected to expand at a CAGR of 15.92% to USD 55 billion by 2020 By 2020, India is likely to be among the top three pharmaceutical markets by incremental growth and sixth largest market globally in absolute size India s cost of production is significantly lower than of the US and almost half of that of Europe. It gives a competitive edge to India over others. Increase in the size of middle class households couples with the improvement in medical infrastructure and increase in the penetration of health insurance in the country will also influence in the growth of pharmaceuticals sector Indian Pharmaceutical market segments by value Anti infective drugs command the largest share (16 percent) in the Indian pharma market The cardiovascular segment represents 13 percent of the market share; its contribution is likely to rise due to the growing number of cardiac cases in India Gastro- intestinal contributes around 11percent of the total value of pharma industry in India. With increasing number of research in gastroenterology, segment is going to grow at significant pace in coming years Top five segments contribute nearly 57 percent to the total drugs consumption In FY 15, anti infectives grew at 22%, gastrointestinal at 23.4%, pain and analgesics at 16.5%, cardiovascular at 19.1% antidiabetic grew at 32.9% respiratory segment grew at 27.8%, derma market grew by 19.2% and urology by 29.5% 61

63 Advantage for India Cost efficiency Low cost of production and R&D boosts efficiency of Indian pharma companies India s cost of production is approximately 60 per cent lower than that of the US and almost half of that of Europe Due to lower cost of treatment, India is emerging as a leading destination for medical tourism Economic drivers Economic prosperity to improve drug affordability Increasing penetration of health insurance With increasing penetration of chemists, especially in rural India, OTC drugs will be readily available Policy support Government unveiled PharmaVision 2020 aimed at making India a global leader in end-to-end drug manufacturer Reduced approval time for new facilities to boost investments In this sector,100 percent FDI is allowed under automatic route Diversified portfolio Accounts for over 10 percent of the global pharmaceutical production Over 60,000 generic brands across therapeutic categories. Manufactures more than500 different APIs 49 percent of all drug master filings from India is registered in the USA Growth Drivers Pharmaceutical Sector driven by confluence of Demand, Capabilities and policy 62

64 Supply side growth drivers Cost efficiency and competency Cost efficiency India s cost of production is nearly 60 percent lower than that of the US and almost half of that of Europe Labour costs are percent cheaper than in western countries The cost of setting up a production plant in India is 40 percent lower than in western countries Cost efficiency continues to create opportunities for Indian Companies in emerging markets and Africa Competency India has a skilled workforce as well as as high managerial and technical competence in comparison to its peers in Asia India has the second largest number of USDFAapproved manufacturing plants outside the US India has 2633 FDA-approved drug products India has over 546 USFDA-approved company sites, the highest number outside the US 63

65 Accessibility Over USD 200 bn to be spend on medical infrastruture in the next decade New business models expected to penetrate tier 2 and tier 3 cities Over hospital beds expected to be added each year in the next decade India's generic drug account for 20 percent of global exports in terms of volume, making the country the largest provider of generic medicines globally Acceptability Rising levels of education to increase acceptability of pharmaceuticals Patients to show greater propensity to the OTC market Acceptance of preventive medicines A skilled workforce as well as high managerial and technical competence Surge in medical tourism Demand Drivers Affordability Rising income could drive 73 million households to the middle class over the next 10 years Over 650 million people expected to be covered by health insurance by 2020 Government sponsored programmes to provide health benefits to over 380 million BPL people by 2017 By 2017, the government plans to provide free generic medicines to half the population at an estimated cost of SD 5.4 billion Epidemiological Factors Patient pool expected to increase over 20 percent in the next 10 years New diseases and life style changes to boost demand increasing prevelance of lifestyle diseases Demand side growth drivers Anticipated steep growth in expenditure on pharmaceuticals Over , total healthcare spending is expected to rise at a CAGR of 7.04 percent to USD 91.2 billion Pharmaceutical sales, as a percentage of total health care spending, are expected to increase to percent by

66 Growing per Capita sales of Pharmaceuticals Growing per capita sales of pharmaceuticals in India offers ample opportunities for players in this market Per capita sales of pharmaceuticals is expected to expand at a CAGR of 19.4 percent to USD33 by 2016F Economic prosperity would improve affordability for generic drugs in the market and improve per capita sales of pharmaceuticals in India Government Policy Support The Addendum 2015 of the Indian Pharmacopoeia (IP) 2014, published by the Indian Pharmacopoeia Commission (IPC) on behalf of the Ministry of Health & Family Welfare, is expected to play a significant role in enhancing the quality of medicines that would in turn promote public health and accelerate the growth and development of pharmaceutical sector. The Government of India unveiled 'Pharma Vision 2020' aimed at making India a global leader in end-to-end drug manufacture. Approval time for new facilities has been reduced to boost investments. Further, the government introduced mechanisms such as the Drug Price Control Order and the National Pharmaceutical Pricing Authority to deal with the issue of affordability and availability of medicines. Some of the major initiatives taken by the government to promote the pharmaceutical sector in India are as follows: Government of India's decision to increase Foreign Direct Investment (FDI) in existing pharmaceuticals companies to 74 per cent is expected to boost Mergers and Acquisitions (M&As) and Private Equity (PE) investments in the pharmaceuticals sector in the country. Indian Pharmaceutical Association (IPA), the professional association of pharmaceutical companies in India, plans to prepare data integrity guidelines which will help to measure and benchmark the quality of Indian companies with global peers. The Government of India plans to incentivise bulk drug manufacturers, including both state-run and private companies, to encourage Make in India programme and reduce dependence on imports of Active Pharmaceutical Ingredients (API), The Department of Pharmaceuticals has set up an inter-ministerial co-ordination committee, which would periodically review, coordinate and facilitate the resolution of the issues and constraints faced by the Indian pharmaceutical companies. The Department of Pharmaceuticals has planned to launch a venture capital fund of Rs 1,000 crore (US$ 148 million) to support start-ups in the research and development in the pharmaceutical and biotech industry. 65

67 Investments in the Sector The Union Cabinet has given its nod for the amendment of the existing Foreign Direct Investment (FDI) policy in the pharmaceutical sector in order to allow FDI up to 100 per cent under the automatic route for manufacturing of medical devices subject to certain conditions. The drugs and pharmaceuticals sector attracted cumulative FDI inflows worth US$ billion between April 2000 and March 2016, according to data released by the Department of Industrial Policy and Promotion (DIPP). Some of the major investments in the Indian pharmaceutical sector are as follows: Pink Blue Supply Solutions Pvt. Ltd, a clinical supplies provider, has raised Rs 1.5 crore (US$ 0.22 million) in a seed round of funding from TermSheet.io, a transaction-focused service provider for start-ups and investors. Dr Reddy's Laboratories, one of the major pharmaceutical companies of India, has entered into a strategic collaboration agreement with Turkey-based TR-Pharm, to register and subsequently commercialise three biosimilar products in Turkey. Lupin has completed the acquisition of US-based GAVIS Pharmaceuticals in a deal worth US$ 880 million, which is expected to enhance its product pipeline in dermatology, controlled substances and highvalue speciality products. Cipla Ltd, one of the major pharmaceutical and biotechnology companies in India, has acquired two USbased generic drug makers, InvaGen Pharmaceuticals Inc. and Exelan Pharmaceuticals Inc., for US$ 550 million, which is expected to strengthen Cipla's US business. Emcure Pharmaceuticals has acquired Canada's International Pharmaceutical Generics Ltd and its marketing arm Marcan Pharmaceuticals in order to boost its global expansion drive. Cipla announced the acquisition of two US-based companies, InvaGen Pharmaceuticals Inc. and Exelan Pharmaceuticals Inc., for US$550 million. Glaxosmithkline Pharmaceuticals has started work on its largest greenfield tablet manufacturing facility in Vemgal in Kolar district, Karnataka, with an estimated investment of Rs1,000 crore (US$ million). Lupin has acquired two US based pharmaceutical firms, Gavis Pharmaceuticals LLC and Novel Laboratories Inc, in a deal worth at US$ 880 million. Several online pharmacy retailers like PharmEasy, Netmeds, Orbimed, are attracting investments from several investors, due to double digit growth in the Rs 97,000 crore ( US$ billion) Indian pharmacy market. Stelis Biopharma announced the breakthrough construction of its customised, multi-product, biopharmaceutical manufacturing facility at Bio-Xcell Biotechnology Park in Nusajaya, Johor, Malaysia's park and ecosystem for industrial and healthcare biotechnology at a total project investment amount of US$ 60 million. Strides Arcolab entered into a licensing agreement with US-based Gilead Sciences Inc to manufacture and distribute the latter's cost-efficient TenofovirAlafenamide (TAF) product to treat HIV patients in developing countries. The licence to manufacture Gilead's low-cost drug extends to 112 countries. CDC, the UK s development finance institution, invested US$ 48 million in Narayana Hrudayalaya hospitals, a multi-speciality healthcare provider, with an aim to expand affordable treatment in eastern, central and western India. Torrent Pharmaceuticals entered into an exclusive licensing agreement with Reliance Life Sciences for marketing three biosimilars in India Rituximab, Adalimumab and Cetuximab. Indian Immunologicals Ltd plans to set up a new vaccine manufacturing facility in Pondicherry with an investment of Rs 300 crore (US$ million). SRF Ltd has acquired Global DuPont Dymel, the pharmaceutical propellant business of DuPont, for US$ 20 million. 66

68 Future Growth The Indian pharmaceutical market size is expected to grow to US$ 100 billion by 2025, driven by increasing consumer spending, rapid urbanisation, and raising healthcare insurance among others. Going forward, better growth in domestic sales would also depend on the ability of companies to align their product portfolio towards chronic therapies for diseases such as such as cardiovascular, anti-diabetes, antidepressants and anti-cancers that are on the rise. The Indian government has taken many steps to reduce costs and bring down healthcare expenses. Speedy introduction of generic drugs into the market has remained in focus and is expected to benefit the Indian pharmaceutical companies. In addition, the thrust on rural health programmes, lifesaving drugs and preventive vaccines also augurs well for the pharmaceutical companies. Source: IBEF, Consolidated FDI Policy, Department of Industrial Policy & Promotion (DIPP), Press Information Bureau (PIB), Media Reports, Pharmaceuticals Export Promotion Council, TechSci Research 67

69 OUR BUSINESS In this section our Company refers to the Company, while we, us and our refers to ANG Lifesciences India Limited. Unless otherwise stated or the context otherwise requires, the financial information used in this section is derived from our restated financial information. This section should be read together with "Risk Factors" on page 11 and "Industry Overview" on page 59. Overview Our company ANG Lifesciences India Limited incorporated in the year 2006, engaged in the business of manufacturing and marketing of finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials. Our registered office is located at Darbara Complex, SCO 113, First Floor, District Shopping Centre B Block, Ranjit Avenue, Amritsar We carry out our production through our state-of-the-art manufacturing unit spread over 45,000 Sq. Ft. situated at Village Kishan pura, P.O. Manpura Baddi Nalagarh Road, Tehsil Nalagarh, Dist. Solan, Himachal Pradesh. Presently, our total built up area of 45,000 Sq. Ft. is dedicated to manufacturing of Dry Powder Injectables. Our manufacturing unit is well equipped with modern and validated manufacturing and analytical equipments and detailed standard operating procedures (SOP s) are in place with respect to Quality management, Personnel, Premises, Equipment, Documentation, Production, Complaints and Self Inspection/Audits. Our company is ISO-9001:2008 certified and has modern & sophisticated plant, equipments, technique and manpower. The planning and construction of plant has been done to conform to the regulatory requirements as per the norms of WHO GMP and GLP as per schedule-m (revised). We manufacture our products in compliance with GMP requirements. We have dedicated area, machinery, facilities and advanced equipments for manufacturing of B- Lactum & Non-B Lactum products as per GMP Norms. As per GMP norms, all the production processes are documented and validated to establish the accuracy of the procedures and the control measures. Our production capacity is 700 Lacs Pcs per annum on per shift basis. Our products include sterile dry powder vials for Anti Biotics, Anti Ulcerant, Gluco corticoid and Anti inflammatory, Anti malarial and Anesthetic. Our company s revenues have increased at a CAGR of 68.76% from Rs Lacs in FY to Rs. 5, Lacs in FY ; and our Profit after Tax has shown increase from loss of Rs. (171.16) Lacs in FY to profit Rs Lacs in FY Our Competitive Strength Experienced Promoters and management team Our Promoters who also form part of Board of Directors of our Company have played a key role in developing our business and we benefit from their significant experience in the pharmaceuticals business. Our senior management team has a vide experience in the domestic and international pharmaceutical industries, including in the areas of R&D, regulatory affairs, manufacturing, quality control, sales, marketing and finance, our middle management is able and our workers are well trained. We believe that experience of our Promoters and our management team provides us with a significant competitive advantage as we seek to grow in our existing markets and enter new geographies. It is also expected to help us in addressing and mitigating various risks inherent in our business, including technical problems, significant competition, reliance on independent contractors and the global economic crisis etc. Quality Assurance and Standards We always aim to offer quality products to our customers. We adopt quality check to ensure the adherence to desired specifications and quality. We have established world class quality standards and our production is based on standards laid down by standard operating procedure (SOP S) and defined method of working by SOP's. We have 68

70 set up a laboratory which is fully equipped for checking the quality of the inputs, processes and finished products and packaging of the products. Our Company maintains complete traceability record of goods as per batch wise, order wise and sale bill wise. Since, our Company is dedicated towards quality products, processes and inputs; we get repetitive orders from our customers as we are capable of meeting their standards. Strong Marketing capability Our marketing and distribution network in India comprises a specialized team of over 70 representatives, which enables us to market our products across various states in India. Our distribution network comprises of sales depots and consignment agent. We also market our products to various hospitals and medical institutions, which constitute an important channel for the distribution of our products. Our domestic marketing infrastructure consists of dedicated team, which formulate marketing and promotional strategies for our products. We also conduct periodic training programs for our marketing team. We believe that our marketing strategies, trained sales representatives and distribution network enable us to increase our market share. Cordial relationship with Customers, suppliers and employees Our core competency lies in the relationship with our customers and suppliers. Our cordial relationship with our customers help us getting repetitive orders and relationship with suppliers help us in uninterrruptive supply of raw materials. We also enjoy cordial relations with our employees and there has been no union of employees. Further, there have been no strikes, lock-out or any labour protest in our organization since inception. Focus on Research and Development (R & D) Our R&D efforts are integral to our business and we devote significant resources towards this aspect of our business. We believe in the importance of developing our R&D facilities to maintain our competitiveness. We also recognize the importance of maintaining a workforce of highly qualified employees for R&D. Our Company has set up its own laboratory for quality control and further improvements in technology. Various trials are undertaken in the laboratory to improve the quality and to reduce cost of production. The facilities available are for checking the different parameter of raw materials, Processes and Finished products. Our Strategies Expand Product Range Currently our revenue is largely driven from manufacturing dry injection powder. We have a fully integrated plant capable of manufacturing various other products. Currently we also utilize our plant to manufacture customer specific products. We plan to utilise our manufacturing plant for other products including tablets, liquids injections etc. Increasing Geographical Presence We plan to expand our presence in PAN India as well as international market. We intend to expand our global footprint and become a preferred supplier in the industry with the help of increased utilization of capacities, reduced costs, wider range of products adhering to global standards, marketing initiatives, competitive pricing and more efficient use of resources. Focus on consistently meeting quality standards Our Company intends to focus on adhering to the quality standards of the products. Our driving force has always been the quality of our products, as the same would enable us for long standing relationship with our customers. Our technically qualified persons are determined to achieve the objective of zero defects and zero rejection. To complement the efforts of our technical team, we are equipped with testing facilities to ensure that all our products are thoroughly tested prior to dispatch from our factory. Our testing and development laboratory will play an integral role in making improvements in quality of our products and development of special products. Further, we propose to enhance our efficiency by introducing advanced machinery and reducing our dependency on manual 69

71 labor thereby capitalizing our method of production. This is necessary so as to make sure that we get repeat orders from our customers. Product Portfolio Anti Biotics Anesthetic Anti Ulcerant Anti Malarial Dry Powder for Injection Anti Inflammat ory Gluco Corticoid We manufacture finished pharmaceutical formulation category of Dry Powder for Injections in the various segments such as: Anti Biotics Anti Ulcerant Gluco Corticoid Anti Inflammatory Anti Malarial Anesthetic Capacity and Capacity Utilisation The production and utilized capacities of our Company for manufacturing of Dry Powder for injection are set forth in the following table: Existing Proposed Year FY FY FY FY FY FY Installed Capacity (Pieces in Lacs)* Capacity Utilization Capacity Utilization (%) *Installed production capacity is determined in terms of no of pieces in single shift basis. 70

72 MANUFACTURING PROCESS FLOW DIAGRAM RAW MATERIAL STORE PACKING MATERIAL STORE VIAL RUBBER BUNG FLIP OFF SEAL WASHING & STERILIZATION/ DEPYROGINATION WASHING, STERILIZATION AND DRYING FLIP OFF SEAL DISINFECTION DISPENSED RAW MATERIALS ONE INGREDIENT DRY POWDER FILLING AND BUNGING VIAL SEALING Bulk Analysis/ Sampling a MIXING OF RAW MATERIALS FILTRATION THROUGH 0.22 µ In case of more than one ingredients a PRE AND POST PURGING NITROGEN GAS LABELS LABEL CODING IPQA VISUAL INSPECTION THEN Sampling/ Testing I P Q A LEAFLET (When Applicable) CARTON CARTON CODING CARTON PACKING Sampling/ Testing Sampling Testing a Sterile WFI Ampoules (When Applicable) SHIPPER SHIPPER LABEL SHIPPER PACKING SHIPPER TAPING QUARANTINE FINISHED GOODS STORE DISPATCH Released by QA 71

73 Collaborations The Company has so far not entered into any technical or financial collaboration agreement. Manufacturing Facilities We carry out our production through our state-of-the-art manufacturing unit spread over 45,000 Sq. Ft. situated at Village Kishanpura, P.O. Manpura Baddi Nalagarh Road, Tehsil Nalagarh, Dist. Solan, Himachal Pradesh. Presently, our total built up area of 45,000 Sq. Ft. is dedicated to manufacturing of Dry Powder Injectables. For further details of ownership / lease of the above location, please refer to Our Business Properties on page 74 of this Draft Prospectus. Plant and Machinery Major plant and machinery located at our manufacturing unit is mentioned below: Sr. No Name of Machine Capacity Qty. in Nos. 1 Purified water system with mixed & double pass RO 2000 Ltrs/hrs 1 2 Multi column Distillation Plant 300Ltr./Hr. 1 3 Boiler 400kg 1 4 D G Set 380 KVA 1 5 Air Compressor 120CFM 1 6 Effluent Treatment Plant (ETP) 3000 Ltr. 1 7 D G set 62 KVA 1 8 Air Compressor 114 CFM 1 9 Nitrogen Plant 4000 Ltrs Wood Fire Boiler 800kg 1 11 Bung Processor with HPHV System ( ) mm 2 12 Vial Washing Machine with Turn Table 300 vials/min Sterilizing & Depyrogenating Tunnel 300 vials/min Powder Filling And Stoppering Machine with Turn 300 vials/min. (Single dose) 2 Table & Swing Conveyer 15 Vial Sealing Machine with Turn Table & Swing 300 vials /Min. 2 Conveyer 16 Hi Speed Sticker Labeling Machine with Turn Table 10000/hr SS Packing Conveyor NA 5 18 Carton Coding Machine (Automatic) NA 1 19 Dynamic Pass Box Between Blending Room and NA 6 Corridor 20 Laminar Air Flow NA Visual Inspection Machine NA 2 Raw Material We use the highest quality API s in our formulations as a principal raw material. We procure the APIs from local importers and packing material from domestic market. We generally maintain adequate stock of raw material to cover the existing order book position, which mitigates any adverse effect of non availability of Raw Material. Each raw material is inspected for purity, potency and uniformity assuring only the highest quality products in every formula in order to meet current Good Manufacturing Practices (cgmp). 72

74 Water-supply We require purified and distilled water for our manufacturing process. Water is procured from borewell situated at our factory premises. We store raw water in water tanks having capacity of around 5,000 Ltrs. Water from this tank is distributed to purification and distillation plants. Distilled water used for the manufacturing process is monitored continuously for its conductivity, ph and for the compliance of the tests. The distilled water for injection is distributed to the manufacturing areas through pipelines in a closed loop system with a pressure 1.2kg/sq.mtr. Power We have availed of a power connection from Himachal Pradesh State Electricity Board with connected and sanctioned load of 498 KVA which is sufficient to meet our plant requirement at 490 KVA. In addition to the said sanctioned power we have also installed a 380 KVA DG Set with the sanction from Himachal Pradesh State Electricity Board for installing the same. Human Resources We require an appropriate mix of skilled, and un-skilled manpower, which is readily available in Himachal Pradesh and at Amritsar where our registered office is located. As on , our Company had 134 employees. The details of the same are mentioned below: S. No. Particulars Total Number of Employees Skilled Unskilled 1 Plant (Baddi, Himachal Pradesh) Generic Team Ethical Team Registered Office (Amritsar, Punjab ) Total Health Safety and Environment We are committed to protecting the health and safety of our employees and workers working in our factory. We have policy in place for health and safety for our workmen which has the following salient features: Compliance with relevant Safety and Statutory Regulations and Rules Ensuring cleanliness of work place in compliance with the relevant regulations. Providing work force with gloves, aprons, face masks and other appropriate tools i.e. helmets at service areas. Conducting training lectures on safety, first aid training, fire fighting, mock drills, safety audit, risk analysis, etc. Conducting regular assessment on the status of safety, health and environment at the work place and take appropriate measures to improve the same. Obligation and responsibility on every employee and worker to perform the tasks ensuring complete safety. Competition The pharmaceuticals market is highly competitive and fragmented, and we face competition from various domestic and international manufacturers. Moreover, as we seek to diversify into new geographical areas globally, we may face competition from existing players that have presence in respective markets. In order to counter the competition, our focus would be to provide products that would be in consonance with technical and quality requirements of our customer as well as by trying to offer a competitive pricing model without compromise on the quality. 73

75 Export possibility and obligation We do not have any export possibility and obligation. Approach to marketing and marketing set-up The efficiency of the marketing and sales network is critical success of our Company. Our success lies in the strength of our relationship with our customers who have been associated with our Company. Our marketing team through their vast experience and good rapport with clients owing to timely and quality delivery of service plays an instrumental role in creating and expanding a work platform for our Company. To retain our customers, our marketing team, regularly interacts with them and focuses on gaining an insight into the additional needs of customers. Our Properties Properties owned by us Sr. No. Date of Purchase Description and area Used as Purchase Consideration 1. March 22, 2007 Area Used as Factory Amount Paid: No. 440/542 Khasra premises Rs. 6,30,000/- 687Kitta 1, Tadadi Stamp Duty: 3 Bigha 3 Biswe Rs. 50,400/- Location Village Kishanpura, Tehsil Nalagarh District Solan, Himachal Pradesh 2. March 22, 2007 Area Used as Factory Amount Paid: Khasra 688 /1/2-12 Kitta premises Rs. 5,20,000/- 1, Tadadi Stamp Duty: 2 Bigha 12 Biswe Rs. 41,600/- Location Village Kishanpura, Tehsil Nalagarh District Solan, Himachal Pradesh Vendors Mr. Gurnaam Singh,Mr. Jagannath, Mr. Bhag Singh, Mr. Ranjit Singh, Mr. Rajeev Kumar Mr. Bharat Bhushan, Mr. Gurnaam Singh Properties taken on lease by us Sr. No. Details/ Location Description and area Agreement dated /Valid from Agreement Valid till 1 Darbara Complex, SCO 113, First Floor, District Shopping Centre B Block, Ranjit Avenue, Amritsar Area : 1900 Sq Ft. Used as Registered Office of the Company May 01, 2014 April 30, 2017 Intellectual Properties Our Company has five registered and valid trademark approvals for various products granted by the Registrar of Trademarks under the Trademark Act, 1999 in India. Further our Company has applied for registration of our logo and also new product related trademarks. For more details about our trademarks please refer to chapter titled Government and Other Approvals beginning on page 155 of this Draft Prospectus. 74

76 Insurance Policies S. No. 1 Name of the policy Standard Fire and Special Perils Policy Policy No. Insurance Company /11/2017/233 Oriental Insurance Company Limited Policy tenure to Assets Covered Factory Building, Plant and Machinery, Stocks Insured Amount Rs. 19,00,00,000/- Insurance Premium (Rs.) Rs. 1,82,995/- 75

77 KEY INDUSTRY REGULATIONS AND POLICIES The following description is a summary of the relevant sector specific laws, policies and regulations, as prescribed by the Government or State Governments which are applicable for our Company. The information detailed in this chapter has been obtained from publications available in the public domain. The regulations set out below are not exhaustive and are only intended to provide general information to the investors and is neither designed nor intended to be a substitute for professional legal advice. Our Company is engaged in the business of manufacturing, selling pharmaceutical products. Our Company is governed by a number of central and state legislations that regulate its business. The following discussion summarizes certain significant Indian laws and regulations that govern our Company s business. A. LAWS APPLICABLE TO THE PHARMACEUTICAL INDUSTRY The Drugs and Cosmetics Act, 1940 ( DCA ) The DCA regulates the import, manufacture, distribution and sale of drugs and cosmetics. In view of the provisions of the DCA, no person can import, manufacture, distribute, stock and sell any drugs and cosmetics, except under the licence granted for respective operations by the authority notified under the DCA. The DCA prescribes the standards for purity, identity and strength of drugs and cosmetics while also prohibiting the import of certain categories of drugs and cosmetics. The DCA mandates that every person holding a license must keep and maintain such records, registers and other documents as may be prescribed which may be subject to inspection by the relevant authority. The Drugs and Cosmetics Rules, 1945 ( DC Rules ) have been enacted to give effect to the provisions of the DCA to regulate the manufacture, distribution and sale of drugs and cosmetics in India. The DC Rules prescribe the procedure for submission of report to the Central Drugs Laboratory, of samples of drugs for analysis or test, the forms of Central Drugs Laboratory s reports thereon and the fees payable in respect of such reports. The DC Rules also prescribe the drugs or classes of drugs or cosmetics or classes of cosmetics for the import of which a licence is required, and prescribe the form and conditions of such licences, the authority empowered to issue the same and the fees payable therefor. The DC Rules provide for the cancellation or suspension of such licence in any case where any provisions or rule applicable to the import of drugs and cosmetic is contravened or any of the conditions subject to which the licence is issued is not complied with. The DC Rules further prescribe the manner of labelling and packaging of drugs. The Essential Commodities Act, 1955 ( ECA ) The ECA gives powers to the Central Government, to control production, supply and distribution of, trade and commerce in certain essential commodities for maintaining or increasing supplies and for securing their equitable distribution and availability at fair prices or for securing any essential commodity for the defence of India or the efficient conduct of military operations. Using the powers under it, various ministries/ departments of the Central Government have issued control orders for regulating production, distribution, quality aspects, movement and prices pertaining to the commodities which are essential and administered by them. The State Governments have also issued various control orders to regulate various aspects of trading in essential commodities such as food grains, edible oils, sugar and drugs. Penalties in terms of fine and imprisonment are prescribed under the ECA for contravention of its provisions. National Pharmaceuticals Pricing Policy, 2012 ( 2012 Policy ) The 2012 Policy replaced the drug policy of 1994 and laid down the principles for pricing of essential drugs as specified in the National List of Essential Medicines ( NLEM ) declared by the Ministry of Health and Family Welfare, Government of India and modified from time to time, so as to ensure the availability of such medicines at reasonable price, while providing sufficient opportunity for innovation and competition to support the growth of the Industry. The prices are regulated based on the essential nature of the drugs rather than the economic criteria/ market share principle adopted in the drug policy of Further, the 2012 Policy regulates the price of formulations only, through market based pricing which is different from the earlier principle of cost based pricing. 76

78 Accordingly, the formulations are priced by fixing a ceiling price and the manufacturers of such drugs will be free to fix any price equal to or below the ceiling price. The Drugs (Price Control) Order, 2013 ( DPCO 2013 ) The DPCO was issued by the Central Government under section 3 of the ECA and in supersession of the Drugs (Prices Control) Order, 1995, thereby giving effect to the 2012 Policy. The DPCO 2013, inter alia, provides that the Central Government may issue directions to the manufacturers of active pharmaceutical ingredients or bulk drugs and formulations to increase production or sell such active pharmaceutical ingredient or bulk drug to such manufacturer of formulations and direct the formulators to sell the formulations to institutions, hospitals or any agency, procedures for fixing the ceiling price of scheduled formulations of specified strengths or dosages, retail price of new drug for existing manufacturers of scheduled formulations, method of implementation of prices fixed by Government and penalties for contravention of its provisions. The Government has the power under the DPCO 2013 to recover amounts charged in excess of the notified price from the manufacturer, importer or distributor and the said amounts are to be deposited in the Drugs Prices Equalization Account. The DPCO 2013 prescribes certain instances in which case the provision of the DPCO 2013 will not be applicable. These provisions are applicable to all scheduled formulations irrespective of whether they are imported or patented, unless they are exempted. However, the prices of other drugs can be regulated, if warranted in public interest. Clinical Establishments (Registration and Regulation) Act, 2010 ( CERR Act ) The CERR Act has been enacted by the Central Government to provide for registration and regulation of all clinical establishments in the country with a view to prescribing the minimum standards of facilities and services provided by them. The CERR Act also seeks to prescribe minimum standards of facilities and services which may be provided by such clinical establishments. The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 ( DMRA ) The DMRA seeks to control advertisements of drugs in certain cases and prohibits advertisement of remedies that claim to possess magic qualities. In terms of the DMRA, advertisements include any notice, circular, label, wrapper or other document or announcement. It also specifies the ailments for which no advertisement is allowed and prohibits advertisements that misrepresent, make false claims or mislead. Further, the Drugs and Magic Remedies (Objectionable Advertisements) Rules, 1955 have been framed for effective implementation of the provisions of the DMRA. The Sales Promotion Employees (Conditions of Service) Act, 1976 ( Sales Promotion Act ) The Sales Promotion Act regulates the conditions of service of sales promotion employees and applies to pharmaceutical industry. It provides the conditions of appointment, leave and maintenance of registers and other documents of such employees. It provides enabling provision for application of the provisions of labour laws including The Workmen s Compensation Act, 1923, The Industrial Disputes Act, 1947, The Minimum Wages Act, 1948, The Maternity Benefit Act, 1961, The Payment of Bonus Act 1965 and The Payment of Gratuity Act, 1972 to sales promotion employees. The Sales Promotion Act provides monetary penalties for breach of its provisions. The Indian Boilers Act, 1923 ( Boiler Act ) Under the provisions of the Boilers Act, an owner of a boiler is required to get the boiler registered and certified for its use. The Boilers Act also provide for penalties for illegal use of boilers. The Legal Metrology Act, 2009 ( Legal Metrology Act ) The Legal Metrology Act, replaces the Standard Weights and Measures Act, The Legal Metrology Act seeks to establish and enforce standards of weights and measures, regulate trade and commerce in weights, measures and other goods which are sold or distributed by weight, measure or number and for matters connected therewith or incidental thereto. The key features of the Legal Metrology Act are (a) appointment of Government approved test 77

79 centres for verification of weights and measures; (b) allowing the companies to nominate a person who will be held responsible for breach of provisions of the Legal Metrology Act; and (c) more stringent punishment for violation of provisions. B. ENVIRONMENTAL LAWS Pharmaceutical manufacturers must also ensure compliance with environmental legislation. Some of the important environmental legislations that are applicable to us are the Water (Prevention and Control of Pollution) Act, 1974, the Air (Prevention and Control of Pollution) Act, 1981, the Water (Prevention and Control of Pollution) Cess Act, 1977 and the Environment Protection Act, Prior to the undertaking of a project for construction, development or modification of a plant, system or structure, our Company will be required to file an Environment Impact Assessment ( EIA ) with the State Pollution Control Board and the Ministry of Environment and Forests ( MOEF ). The relevant authority will assess the impact of the project on the environment before granting clearance. The clearance may be granted subject to certain conditions/alterations required to be made in the project. Environment (Protection) Act, 1986 ( EP Act ) The EP Act was enacted as a general legislation to safeguard the environment from all sources of pollution by enabling coordination of the activities of the various regulatory agencies concerned, to enable creation of an authority with powers for environmental protection, regulation of discharge of environmental pollutants etc. The purpose of the EP Act is to act as an umbrella legislation designed to provide a frame work for Central government co-ordination of the activities of various central and state authorities established under previous laws, such as Water Act and Air Act. It includes water, air and land and the interrelationships which exist among water, air and land, and human beings and other living creatures, plants, micro-organisms and property. Air (Prevention and Control of Pollution) Act, 1981 ( Air Act ) The Air Act has been enacted to provide for the prevention, control and abatement of air pollution. The statute was enacted with a view to protect the environment and surroundings from any adverse effects of the pollutants that may emanate from any factory or manufacturing operation or activity. It lays down the limits with regard to emissions and pollutants that are a direct result of any operation or activity. Periodic checks on the factories are mandated in the form of yearly approvals and consents from the corresponding pollution control boards in the state. Water (Prevention and Control of Pollution) Act, 1974 ( Water Act ) The Water Act was enacted in 1974 in order to provide for the prevention and control of water pollution by factories and manufacturing industries and for maintaining or restoring the wholesomeness of water. The Water Act prohibits the use of any stream or well for the disposal of polluting water, in violation of standards set down by the State Pollution Control Board. The Water Act requires that approvals be obtained from the corresponding pollution control boards in the state. Water (Prevention and Control of Pollution) Cess Act, 1977 ( Water Cess Act ) The Water Cess Act has been enacted to provide for the levy and collection of a cess on water consumed by persons carrying on certain industries and by local authorities with a view to augment the resources of Central and State Pollution Control Board for the prevention and control of water pollution, constituted under the Water Act. The Bio Medical Waste (Management and Handling) Rules, 1998 ( BMW Rules ) The BMW Rules apply to all persons who generate, transport, treat, dispose or handle bio-medical waste in any form. The BMW Rules mandate every occupier of an institution generating bio-medical waste to take steps to ensure that such waste is handled without any adverse effect to human health and environment and to set up biomedical waste treatment facilities as prescribed under the BMW Rules. The BMW Rules further require such persons to apply to the prescribed authority for grant of authorization and submit an annual report to the prescribed authority 78

80 and also to maintain records related to the generation, collection, storage, transportation, treatment, disposal, and/ or any form of handling of bio-medical waste in accordance with the BMW Rules and the guidelines issued thereunder. The Manufacturing, Storage & Import of Hazardous Chemicals Rules, 1989 ( MSIHC Rules ) The MSIHC Rules, as amended in the year 2000, stipulate that an occupier in control of an industrial activity has to provide evidence for having identified the major accident hazards and taking adequate steps to prevent such major accidents and to limit their consequences to persons and the environment. Further, the occupier has an obligation to show that he has provided necessary information, training and equipment including antidotes to the persons working on the site to ensure their safety. Also, the occupier is under an obligation to notify the concerned authority on the occurrence of a major accident on the site or pipeline within 48 hours. The Hazardous Wastes (Management, Handling and Transboundary Movement) Rules, 2008 ( Hazardous Waste Rules ) The Hazardous Waste Rules define the term hazardous waste and any person who has control over the affairs of a factory or premises or any person in possession of the hazardous waste is classified as an occupier. In terms of the Hazardous Waste Rules, occupiers have been, inter alia, made responsible for safe and environmentally sound handling of hazardous wastes generated in their establishments and are required to obtain license/authorisation from the respective state pollution control board for generation, processing, treatment, package, storage, transportation, use, collection, destruction, conversion, offering for sale, transfer or the like of the hazardous waste. Noise Pollution (Regulation and Control) Rules, 2000 The Noise Pollution (Regulation and Control) Rules, 2000 seek to regulate and control the noise producing and generating sources including from industrial activity. In terms of the Environment Protection Rules, 1986, as amended from time to time, the maximum permissible sound pressure level for new diesel generator sets with rated capacity up to 1000 Kilovolt Ampere, manufactured on or after January 1, 2005 shall be 75 db(a) at one meter from the enclosure surface. Integral acoustic enclosure should be provided at the manufacturing stage itself. Every manufacturer / importer of diesel generator sets is further required to have valid certificates of Type Approval and Conformity of Production for each year, for all the product models being manufactured / imported from January 1, The Central Pollution Control Board is the nodal agency. Public Liability Insurance Act, 1991 ( Public Liability Act ) The Public Liability Act as amended, imposes liability on the owner or controller of hazardous substances for any damage arising out of an accident involving such hazardous substances. A list of hazardous substances covered by the legislation has been enumerated by the Government by way of a notification. The owner or handler is also required to take out an insurance policy insuring against liability under the legislation. The rules made under the Public Liability Act mandate that the employer has to contribute towards the Environment Relief Fund, a sum equal to the premium paid on the insurance policies. This amount is payable to the insurer. The Explosives Act, 1884 ( The Explosives Act ) The Explosives Act, as amended, regulates the manufacture, possession, use, sale, transport, import and export of explosives and empowers the Central Government to make rules for the regulation and prohibition of these activities in relation to any specified class of explosives. Persons lawfully involved in these activities are required to obtain a license from the appropriate authority in terms of the provisions of the Explosives Act. C. LABOUR LAWS We are required to comply with certain labour and industrial laws, which includes the Factories Act, 1948, Industries (Development and Regulation) Act, 1951, Industrial Disputes Act, 1947, the Employees Provident Funds and Miscellaneous Provisions Act 1952, the Minimum Wages Act, 1948, the Payment of Bonus Act, 1965, 79

81 Workmen Compensation Act, 1923, the Payment of Gratuity Act, 1972, Contract Labour (Regulation and Abolition) Act, 1970, the Payment of Wages Act, 1948 and the amongst others. D. INTELLECTUAL PROPERTY LAWS Intellectual property in India enjoys protection under both common law and statute. The following laws relating to intellectual property also applies to our Company: The Trade Marks Act, 1999 ( Trademark Act ) The Trade Marks Act which came into force on December 30, 1999 governs the law pertaining to trade marks in India. A trade mark is essentially any mark capable of being represented graphically and distinguishing goods or services of one person from those of others and includes a device, brand, heading, label, ticket, name, signature, word, letter, numeral, shape of goods, packaging or combination of colours or combination thereof. In India, trademarks enjoy protection under both statutory and common law. Indian trademarks law permits the registration of trademarks for goods and services. Certification trademarks and collective marks can also be registered under the Trademark Act. The Registrar of Trademarks is the authority responsible for registration of the trademarks, settling opposition proceedings and rectification of the register of trademarks. The Trademark (Amendment) Act 2010 has been enacted to cover Indian nationals as well as foreign nationals to secure simultaneous protection of trademarks in other countries. Registration of a trademark grants the owner a right to exclusively use the trademark as a mark of goods and services and prevents the fraudulent use of deceptively similar marks by any third party. Indian Copyright Act, 1957 ( Copyright Act ) The Copyright Act provides for registration of copyrights, transfer of ownership and licensing of copyrights, and infringement of copyrights and remedies available in that respect. The Copyright Act affords copyright protection to original literary, dramatic, musical or artistic works, cinematograph films, and sound recordings. Once registered, copyright protection lasts for 60 years from the death of the author, subsequent to which the work falls in the public domain and any act of reproduction of the work by any person other than the author would not amount to infringement. The remedies available in the event of infringement of copyright include civil proceedings for damages, account of profits, injunction and the delivery of infringing copies to the copyright owner, as well as criminal remedies, including imprisonment of the accused and imposition of fines and seizure of infringing copies. While copyright registration is not a prerequisite for acquiring or enforcing a copyright, registration creates a presumption favouring ownership of the copyright by the registered owner. The Patents Act, 1970 ( Patents Act ) The Patents Act governs the patent regime in India. India is a signatory to the Trade Related Agreement on Intellectual Property Rights ( TRIPS ); India recognizes both product as well as process patents. The new regime provides for: Patent protection period of 20 years; Recognition of product patents in respect of food, medicine and drugs; Patent protections allowed on imported products; and Under certain circumstances, the burden of proof in case of infringement of process patents may be transferred to the alleged infringer. An application for a patent can be filed in any of the 4 patent offices in India. The Design Act, 2000 ( Design Act ) The Design Act came into force in May 2001 to consolidate and amend the law relating to protection of designs. A design refers to the features of shape, configuration, pattern, ornamentation or composition of lines or colours applied to any article, in two or three dimensional or both forms. In order to register a design, it must be new and original and must not be disclosed to the public anywhere in India or any other country by publication in tangible form or in any other way prior to the filing date. A design should be significantly distinguishable from known designs or combination of known designs in order for it to be registered. A registered design is valid for a period of 80

82 ten years after which can be renewed for a second period of five years, before the expiration of the original period of ten years. After such period the design is made available to the public by placing it in the public domain. In addition to the domestic laws, India is a party to several international intellectual property related instruments including the Patent Co-operation Treaty, 1970, the Paris Convention for the Protection of Industrial Property, 1883, and as a member of the World Trade Organisation, India is a signatory to the Agreement on Trade Related aspects of Intellectual Property Rights, Our Company s intellectual property rights primarily include patents and trademarks for its various products and process. Our Company spends considerable time and effort on developing new products and rely upon various forms of intellectual property legislation to protect the process as well as the products. E. TAXATION LAWS The Central Sales Tax Act, 1956 ( Central Sales Tax Act ) Central Sales Tax Act, as amended, formulates principles for determining (a) when a sale or purchase takes place in the course of inter-state trade or commerce; (b) when a sale or purchase takes place outside a State and (c) when a sale or purchase takes place in the course of imports into or export from India. The Central Sales Tax Act provides for levy, collection and distribution of taxes on sales of goods in the course of inter-state trade or commerce and also declares certain goods to be of special importance in inter-state trade or commerce and specifies the restrictions and conditions to which state laws imposing taxes on sale or purchase of such goods of special importance (called as declared goods) shall be subject. Central sales tax is levied on interstate sale of goods. Sale is considered to be interstate when (a) sale occasions movement of goods from one state to another or (b) is effected by transfer of documents during their movement from one state to another. Central sales tax is payable in the state from which movement of goods commences (that is, from which goods are sold). The tax collected is retained by the state in which it is collected. The Central Sales Tax Act is administered by sales tax authorities of each State. The liability to pay tax is on the dealer, who may or may not collect it from the buyer. Law on Service Tax There is no specific legislation on the regulation of service tax as on date and the provisions contained in chapters V and VA (Section 64 to 96-I) of the Finance Act 1994 govern the levy of service tax. Service tax is a tax payable on services provided by the service provider to the Government of India. The Ministry of Finance on June 1, 2015 vide Notification no. 14/2015, amended the current rate of service tax and increased it to 14% from the erstwhile effective rate of 12.36%. The tax gets attracted on the provision of the services, whereas the charge crystallizes only on receipt of the consideration. Service tax is payable both on receipt and actual basis. As the levy of service tax is on the provision of service, the services provided before the date of the levy coming into being would not be liable. Law on Value Added Tax ( VAT ) VAT is a tax on the final consumption of goods or services and is ultimately borne by the consumer. The term value addition implies the increase in value of goods and services at each stage of production or transfer of goods and services. It is a multi-stage tax with the provision to allow input tax credit on tax at an earlier stage, which can be appropriated against the VAT liability on subsequent sale. This input tax credit in relation to any period means setting off the amount of input tax by a registered dealer against the amount of his output tax. The VAT liability of the dealer/manufacturer is calculated by deducting input tax credit from tax collected on sales during the payment period. If the tax credit exceeds the tax payable on sales in a month, the excess credit will be carried over to the end of next fiscal year. If there is any excess unadjusted input tax credit at the end of second year, then the same will be eligible for refund. VAT is basically a state subject, derived from Entry 54 of the State List, for which the states are sovereign in taking decisions. The state governments, through taxation departments, carry out the responsibility of levying and collecting VAT in the respective states. The Central Government facilitates the successful implementation of VAT. The Ministry of Finance is the main agency for levying and implementing VAT, both at the Centre and the State level. 81

83 Other Laws Our Company must also comply at all times with the provisions of various other laws, rules and regulations including The Hazardous Wastes (Management, Handling and Transboundary Movement) Rules, 2008, The Manufacture, Storage and Import of Hazardous Chemicals Rules, 1989, The Chemical Accidents (Emergency Planning Preparedness and Response) Rules, 1996, The Bio-Medical Waste (Management and Handling) Rules, 1998, The Public Liability Insurance Act, 1991, The Legal Metrology Act, 2009, The Explosives Act, 1884 and The Explosive Rules, 1983, Importer Exporter Code along with the Foreign Trade (Development & Regulation) Act, 1992, The Factories Act, 1948, The Boilers Act, 1923, Indian Boiler Regulations, 1950, The Bombay Prohibition Act, 1949, The Petroleum Act, 1934, The Maharashtra State Tax on Profession, Trades, Callings and Employment Act, 1975, labour laws including The Minimum Wages Act, 1948, The Payment of Bonus Act, 1965, The Employee State Insurance Act, 1948, The Contract Labour (Regulation and Abolition) Act, 1970, The Employees Provident Fund and Miscellaneous Provisions Act, 1952, legislations relating to shops and commercial establishments, electricity and other revenue and tax legislations. 82

84 HISTORY AND CERTAIN CORPORATE MATTERS Our Company was originally incorporated as ANG Lifesciences India Private Limited on June 14, 2006 with the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh as a private limited Company under the Companies Act, On conversion into public limited Company the name of our Company was changed to ANG Lifesciences India Limited pursuant to special resolution passed at the Extra Ordinary General Meeting held on January 18, 2010 and a fresh certificate of incorporation dated March 02, 2010 issued by the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh. Our company was further converted into private limited Company and the name of our Company was changed to ANG Lifesciences India Private Limited pursuant to special resolution passed at the Extra Ordinary General Meeting held on August 31, 2010 and a fresh certificate of incorporation was issued by Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh dated September 22, Subsequently, on conversion into public limited Company the name of our company again changed to ANG Lifesciences India Limited pursuant to special resolution passed at the Extra Ordinary General Meeting held on May 04, 2016 and a fresh certificate of incorporation dated May 18, 2016 issued by the Registrar of Companies, Chandigarh. Our Corporate Identification Number is U24230PB006PLC The promoters of our Company are Mr. Rajesh Gupta and Mrs. Saruchi Gupta. Our Company is primarily engaged in the business of manufacturing and marketing of finished pharmaceutical formulation in the form of sterile dry powder injection vials. The Registered Office of our Company is situated at Darbara Complex, SCO 113, First Floor, District Shopping Centre B Block, Ranjit Avenue, Amritsar Changes in the Registered Office of our Company since inception From To Date of Change Reason for Change 312 Ganpati Tower Lawrence Road, Amritsar , Punjab, India 342-A, Shastri Nagar, Opp. B. R. Modern School, Amritsar , Punjab, India Administrative Purpose 342-A, Shastri Nagar, Opp. B. R. Modern School, Amritsar , Punjab, India Main Objects of our Company Darbara Complex, SCO 113, First Floor, District Shopping Centre, B Block, Ranjit Avenue, Amritsar , Punjab, India Administrative Purpose The object clauses of the Memorandum of Association of our Company enable us to undertake the activities for which the funds are being raised in the present Issue. Furthermore, the activities of our Company which we have been carrying out until now are in accordance with the objects of the Memorandum. The objects of our Company are: To carry on the business of manufacturers, marketing, traders, importers, exporters, distributors, dealer, retailer, commission agents of all kinds of Pharmaceutical Products, Medicine, Herbal, Allopathic, Homeopathic, Tonic, Syrups, Ayurvedic, feeds, supplements, medical supplements, test control medicines, allopathic pharmaceutical. Changes in the Memorandum of Association The following changes have been made in the Memorandum of Association of our Company since inception: Date of Meeting Particulars Clause V of the MOA was amended to reflect the increase in authorised share capital from Rs Lacs divided into 10,00,000 Equity Shares of Rs.10 each to Rs Lacs divided into 32,50,000 Equity shares of Rs.10 each 83

85 Date of Meeting Particulars Clause V of the MOA was amended to reflect the increase in authorised share capital from Rs Lacs divided into 32,50,000 Equity Shares of Rs. 10 each to Rs Lacs divided into 35,50,000 Equity shares of Rs.10 each Clause I of the Memorandum of Association was altered by inserting the name ANG Lifesciences India Limited pursuant to conversion into public limited Company in place of ANG Lifesciences India Private Limited. Clause V of the MOA was amended to reflect the increase in authorised share capital from Rs Lacs divided into 35,50,000 Equity shares of Rs. 10 each to Rs Lacs divided into 37,00,000 Equity shares of Rs. 10 each Clause I of the Memorandum of Association was altered by inserting the name ANG Lifesciences India Private Limited pursuant to conversion into private limited Company in place of ANG Lifesciences India Limited. Clause I of the Memorandum of Association was altered by inserting the name ANG Lifesciences India Limited pursuant to conversion into public limited Company in place of ANG Lifesciences India Private Limited. Clause V of the MOA was amended to reflect the increase in authorised share capital from Rs Lacs divided into 37,00,000 Equity shares of Rs. 10 each to Rs Lacs divided into 55,00,000 Equity shares of Rs. 10 each Major Events and Milestones The table below sets forth the key events in the history of our Company: Year Particulars Incorporation of our Company on June 14, Commenced commercial production of the Company Robust jump in the turnover of the Company by 140% as compared to previous year Commenced our export sales, Government supplies and turnover increased by 112% as compared to previous year Commenced direct sale of medicines in PAN India covering hospitals, Doctors through stockists Company certified with WHO and GMP norms and continued to growth in the turnover Corporate Profile of our Company For details in relation to our corporate profile including details of our business, geographical presence, growth, competition, products, capacity build-up, technology, and managerial competence, please see sections entitled Our Business and Our Management on pages 68 and 87, of this Draft Prospectus. Time and Cost Overruns in Setting Up Projects: As on the date of this Draft Prospectus, there have been no time and cost overruns in any of the projects undertaken by our Company. Revaluation of Assets Our Company has not revalued its assets since its incorporation. Holding Company of our Company Our Company has no holding company as on the date of filing of this Draft Prospectus. 84

86 Subsidiary of our Company Our Company does not have any subsidiary Company. Injunctions or Restraining Orders There are no injunctions/ restraining orders that have been passed against the Company. Details regarding Acquisition of Business/Undertakings, Mergers, Amalgamation etc. There are no mergers, amalgamation, etc. with respect to our Company and we have not acquired any business/undertakings till date. Changes in the Activities of our Company during the Last Five Years There has been no change in the business activities of our Company during the last five years from the date of this Draft Prospectus. Capital raising activities through Equity or Debt For details of the equity capital raising of our Company, please refer to the chapter titled Capital Structure beginning on page 40 of this Draft Prospectus. We have not done any debt issuances since incorporation till date. Changes in the Management There has been no change in the management in last 3 years. Shareholders Agreements Our Company has not entered into any shareholders agreement as on date of filing of this Draft Prospectus. Strikes and Lock-Outs Our Company has, since incorporation, not been involved in any labour disputes or disturbances including strikes and lock- outs. As on the date of this Draft Prospectus, our employees are not unionized. Other Agreements Our Company has not entered into any specific or special agreements except that have been entered into in ordinary course of business as on the date of filing of this Draft Prospectus. Collaboration Our Company has not entered into any collaboration with any third party as per regulation (VIII) B (1) (c) of part A Schedule VIII of SEBI (ICDR) Regulations, Strategic Partner Our Company does not have any strategic partner as on the date of filing of this Draft Prospectus. Financial Partner Our Company does not have any financial partner as on the date of filing of this Draft Prospectus. Defaults or Rescheduling of Borrowings with Financial Institutions or Banks 85

87 There have been no defaults or rescheduling of borrowings with financial institutions or banks as on the date of this Draft Prospectus except, rescheduling of Company s borrowings from Punjab National Bank alongwith payment terms, pursuant to request for rescheduling being made by our Company. Our Company s business was adversely affected by restructuring of our board and overall industrial slowdown. Consequently our Company made an application to Punjab National Bank for the reschedulement of the loans. Our lender, Punjab National Bank, has rescheduled the existing term loans availed by us, aggregating to Rs Lacs including sanction of Funded Interest Term Loan of Rs Lacs vide letter dated January 05, For further details in this regard, please see the chapters titled Statement of Financial Indebtedness on page 133 of this Draft Prospectus. Number of Shareholders Our Company has 16 shareholders on date of this Draft Prospectus. Guarantees provided by our Promoters, our Promoter group and our Group Companies/ Entities Other than the guarantees given to our lenders and as disclosed in the section Statement of Financial Indebtedness on page 133 of this Draft Prospectus, our Promoters have not given any guarantees to third parties that are outstanding as on the date of filing of this Draft Prospectus. 86

88 Board of Directors OUR MANAGEMENT Under our Articles of Association, our Company is required to have not less than three (3) Directors and not more than fifteen (15) Directors. Our Company currently has 5 Directors on Board. The following table sets forth current details regarding our Board of Directors: Name, Father s name, Address, Occupation, Nationality, tenure & DIN Mr. Rajesh Gupta S/o: Sarwan Kumar Age: 45 Yrs Designation: Managing Director Term: Appointed as the Managing Director for a period of 3 years w.e.f to Address: House No. 85, Guru Nanak Avenue, Majitha Road, Amritsar , Punjab, India. Occupation: Business PAN: AAQPG4797C Nationality: Indian DIN: Mrs. Saruchi Gupta D/o: Rajinder Kumar Mittal Age : 40 Yrs Designation: Whole Time Director Term: Appointed as the Whole Time Director for a period of 3 years w.e.f Address: House No. 85, Guru Nanak Avenue, Majitha Road, Amritsar , Punjab, India. Occupation: Business PAN: ALAPG5323R Nationality: Indian DIN: Mrs. Nipur Gupta D/o: Bishan Kumar Gupta Age: 35 Yrs Designation: Non Executive and Non Independent Director Term: Liable to retire by rotation Address: 538, First Floor, Sector 11, Panchkula , Haryana, India Occupation: Business PAN: AOPPG3569M Nationality: Indian DIN: Mr. Pawanjit Singh S/o: Kanwaljit Singh Age: 49 Designation: Non Executive and Independent Director Address: House No. 3438, Street No. 3, Rock House, Putlighar, Azad Nagar, Amritsar , Punjab, India. Occupation: Business PAN:ACUPS4040C Nationality: Indian DIN: Date of Appointment Appointed as Director since inception of the Company subsequently appointed as Managing Director vide resolution in the AGM dated Appointed as Director since subsequently appointed as Whole Time Director vide resolution in the AGM dated Appointed as Director since Appointed as Director since Other Directorships Nil Nil Nil Nil 87

89 Name, Father s name, Address, Occupation, Nationality, tenure & DIN Mr. Sukhpal Singh S/o: Arjan Singh Age: 43 Yrs Designation: Non Executive and Independent Director Address: A-701, A Block, New Amritsar, Amritsar , Punjab, India. Occupation: Business PAN: ABMPS4053N Nationality: Indian DIN: Notes: As on the date of this Draft Prospectus: Date of Appointment Appointed as Director since Other Directorships Nil 1. None of the above mentioned Directors are on the RBI List of willful defaulters as on date. 2. Further, none of our Directors are or were directors of any company whose shares were (a) suspended from trading by stock exchange(s) for more than 3 months during the five years prior to the date of filing this Draft Prospectus or (b) delisted from the stock exchanges. 3. None of the Promoters, Persons forming part of our Promoter Group, Directors or persons in control of our Company, has been or is involved as a promoter, director or person in control of any other company, which is debarred from accessing the capital market under any order or directions made by SEBI or any other regulatory authority. Brief Biographies of our Directors Mr. Rajesh Gupta, aged 45 years, is the Promoter and Managing Director of our Company. He has obtained degree of Civil Engineering from Thaper Institute of Engineering and Technology, Patiala in the year Initially he started his career with the construction business and he embarked his career in the Pharmaceutical industry considering its growth and potential. In the year 2006, he founded our Company and since inception he is on the board of our Company. He further appointed as a Managing Director with effect from October 01, He has more than 20 years of overall experience in the areas of management, marketing strategies and overall administration control. He is a visionary and guides our Company and management at all the stages of its development and strategic decisions. He has major contribution to take the Company to a commendable position in the market. Mrs. Saruchi Gupta, aged 40 years, is the Whole Time Director and Chief Financial Officer and one of the Promoters of our Company. She is a commerce graduate from Guru Nanak Dev University, Amritsar. She joined our Company in April 2011 and further appointed as Whole Time Director with effect from October 01, 2016 and as a CFO with effect October 06, Presently her responsibilities in our Company include overseeing the corporate finance, accounts, statutory audit and other financial activities of our Company. She looks after the day today accounting system, tax and other liasioning work with various authorities. Mrs. Nipur Gupta, aged 35 years, is a Non Executive and Non Independent Director of our Company. She is commerce graduate from Guru Nanak Dev University. She has experience of 5 years in the area of administration and control. She is appointed as a Non Executive and Non Independent Director of our company since May 02, Mr. Pawanjit Singh, aged 49 years, is Non Executive and Independent Director of our Company. He is undergraduate and into construction business. He has more than 25 years of experience in the area of management, marketing and administration. He is appointed as a Non Executive and Independent Director of our company since May 02,

90 Mr. Sukhpal Singh, aged 43 years, is Non Executive and Independent Director of our Company. He has successfully passed the examination conducted by Indian Institute of Architects and he is an Associate Member of Indian Institute of Architects (by examination). He is practicing architect and has more than 15 years of experience in the area of architecture services, advisory services, and administration of business. He is appointed as a Non Executive and Independent Director of our company since May 02, Confirmations There are no arrangements or understanding with major shareholders, customers, suppliers or any other entity, pursuant to which any of the Directors or Key Management Personnel were selected as a Director or member of the senior management. The Directors of our Company have not entered into any service contracts with our Company which provides for benefits upon termination of employment. None of the Directors is or was a director of any listed company during the last five years preceding the date of filing of this Draft Prospectus, whose shares have been or were suspended from being traded on the BSE or the NSE, during the term of their directorship in any such company. None of the Directors is or was a director of any listed company which has been or was delisted from any recognized stock exchange in India during the term of their directorship in such company. None of our Directors is or was a director of any company who have made an application to the relevant registrar of Companies, for striking off its name. Nature of Family Relationship among Directors There is no relationship amongst the directors except that Mr. Rajesh Gupta and Mrs. Saruchi Gupta are husband and wife. Borrowing Powers of the Directors In accordance with the Articles of Association and pursuant to the AGM of our Company held on , the Board is authorised to borrow money, mortgage, hypothecate and/or charge all of our Company s immovable and movable properties, present and future, in such sum form or manner as the Board may think fit for securing loans already obtained or that may be obtained from our Company s banker or any other banks, financial institution or any other lending institutions or persons, provided that the total amount of money or monies so borrowed (apart from temporary loans obtained or to be obtained from our Company s bankers in the ordinary course of business), by our Company shall not, at any time, exceed the Rs Crores. Remuneration to our Directors Details of remuneration paid to our Directors during Fiscal 2016 are set forth in the table below: Sr. No. Name of Director Remuneration (Rs. in Lacs) 1. Mr. Rajesh Gupta Mrs. Saruchi Gupta 3.60 Terms of Appointment of our Directors Executive Directors Name Mr. Rajesh Gupta Designation Managing Director Period Appointed for a period of three years w.e.f to Present Remuneration Rs. 50,000 per month 89

91 Name Mrs. Saruchi Gupta Designation Whole Time Director Period Appointed for a period of three years w.e.f to Present Remuneration Rs. 30,000 per month There is no definitive and /or service agreement that has been entered into between our Company and the directors in relation to their appointment. Non Executive Directors Currently, non executive Directors are not being paid any remuneration apart from payment of sitting fees. We also confirm that no remuneration being paid to Independent Directors apart from payment of sitting fees. Further, no Remuneration has been paid to our Non Executive Directors during the financial year ended March 31, Changes in our Board of Directors during the last three (3) years The changes in the Directors during last three (3) years are as follows: Name Date of appointment Date of cessation Reason Mr. Rajesh Gupta Change in designation, appointment as Managing Director Mrs. Saruchi Gupta Change in designation, appointment as Whole Time Director Mr. Sukhpal Singh Appointment as Non Executive and Independent Director Mr. Pawanjit Singh Appointment as Non Executive Independent Director Mrs. Nipur Gupta Appointment as Non Executive and Non Independent Director Shareholding details of the Directors in our Company As per the Articles of Association of our Company, a Director is not required to hold any qualification shares. The following table details the shareholding of our Directors as on the date of this Draft Prospectus: Name of the Director No. of Equity Shares Pre-Issue percentage Shareholding Mr. Rajesh Gupta 36,70, Mrs. Saruchi Gupta 10, Interest of Directors All the Directors of our Company may be deemed to be interested to the extent of sitting fees and/or other remuneration if any, payable to them for attending meetings of the Board or a committee thereof as well as to the extent of reimbursement of expenses if any payable to them under the Articles of Association. All the Directors may also be deemed to be interested in the Equity Shares of our Company, if any, held by them, their relatives or by the companies or firms or trusts in which they are interested as directors / members / partners or that may be subscribed for and allotted to them, out of the present Issue and also to the extent of any dividend payable to them and other distributions in respect of the said Equity Shares. 90

92 All the Directors may be deemed to be interested in the contracts, agreements/arrangements entered into or to be entered into by our Company with any other company in which they have direct /indirect interest or any partnership firm in which they are partners. Our Directors may also be regarded interested to the extent of dividend payable to them and other distributions in respect of the Equity Shares, if any, held by them or by the companies / firms / ventures promoted by them or that may be subscribed by or allotted to them and the companies, firms, in which they are interested as Directors, members, partners and Promoters, pursuant to this Issue. Our Directors Mr. Rajesh Gupta and Mrs. Saruchi Gupta are interested to the extent of being Promoter of our Company. For further details please refer section titled Our Promoters and Promoter Group and Group Companies / Entities on page 98 and page 102 of this Draft Prospectus. Property Interest Except as stated otherwise in this Draft Prospectus, our Company has not entered into any Contract, Agreements or Arrangements during the preceding two years from the date of the Prospectus in which the Directors are interested directly or indirectly and no payments have been made to them in respect of the contracts, agreements or arrangements which are proposed to be entered into with them. Please refer to Annexure XXI Statement of Related Party Transaction page 130 of this Draft Prospectus. Corporate Governance Our Company stands committed to good corporate governance practices based on the principles such as accountability, transparency in dealings with our stakeholders, emphasis on communication and transparent reporting. We have complied with the requirements of the applicable regulations, including the Listing Agreement to be executed with the Stock Exchange and the SEBI Regulations, in respect of corporate governance including constitution of the Board and Committees thereof. The corporate governance framework is based on an effective independent Board, separation of the Board s supervisory role from the executive management team and constitution of the Board Committees, as required under law. We have a Board constituted in compliance with the Companies Act and the SEBI Regulations in accordance with best practices in corporate governance. The Board functions either as a full Board or through various committees constituted to oversee specific operational areas. Our executive management provides the Board detailed reports on its performance periodically. Currently our Board has Five (5) Directors. The constitution of our Board is in compliance with the requirements of SEBI Regulations. The following committees have been formed in compliance with the corporate governance norms: A) Audit Committee B) Nomination & Remuneration Committee C) Stakeholder Relationship Committee Audit Committee Our Company has constituted an Audit Committee, pursuant to Section 177 of the Companies Act, 2013 read with Regulation 18 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, vide resolution passed in the meeting of the Board of Directors held on October 06, The committee presently comprises following three (3) directors. Sr. No. Name of the Director Status Nature of Directorship 1. Mr. Pawanjit Singh Chairman Non-Executive Independent Director 91

93 2. Mr. Sukhpal Singh Member Non-Executive Independent Director 3. Mrs. Saruchi Gupta Member Whole Time Director Role of Audit Committee The terms of reference of the Audit Committee are given below: 1. The recommendation for appointment, remuneration and terms of appointment of auditors of the company. 2. Review and monitor the auditor s independence and performance and effectiveness of audit process. 3. Examination of the financial statement and the auditor s report thereon. 4. Approval or any subsequent modification of transactions of the company with related parties. 5. Scrutiny of inter-corporate loans and investments. 6. Valuation of undertakings or assets of the company, wherever it is necessary. 7. Evaluation of internal financial controls and risk management system. 8. Monitoring the end use of funds raised through public offers and related matters. 9. To investigate any activity within its terms of reference. 10. To seek information from any employee. 11. To obtain outside legal or other professional advice. 12. To secure attendance of outsiders with relevant expertise, if it considers necessary. 13. Oversight of the Company s financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient, and credible. 14. Recommending the appointment, and removal of external auditors, fixation of audit fee and also approval for payment of any other services. 15. Reviewing, with the management, the annual financial statements before submission to the board for approval, with particular reference to: (a) The Board s report under sub-section (3) of section 134 shall disclose the composition of an Audit Committee and where the Board had not accepted any recommendation of the Audit Committee, the same shall be disclosed in such report along with the reasons therefor. (b) Changes, if any, in accounting policies and practises and reasons for the same. (c) Major accounting entries involving estimates based on the exercise of judgement by management. (d) Significant adjustments made in the financial statements arising out of audit findings. (e) Compliance with listing and other legal requirements relating to financial statements. (f) Disclosure of any related party transactions. (g) (h) Qualifications in the draft audit report. Matters required to be included in the Directors Responsibility Statement to be included in the Board s report in terms of clause (2AA) of section 217 of the Companies Act, 1956 or Section 134 of the Companies Act, Reviewing, with the management, the quarterly financial statements before submission to the board for approval. 17. Reviewing the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit. 18. Discussion with internal auditors any significant findings up there on. 19. Reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the board. 20. Discussion with statutory auditors before the audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern. 21. To look into the reasons for substantial defaults in the payment to the depositors, debenture holders, shareholders, (in case of non payment of declare dividends) and creditors. 22. To review the functioning of the Whistle Blower mechanism, in case if the same is existing. 23. Approval of appointment of CFO (i.e., the whole-time Finance Director or any other person heading the finance function or discharging that function) after assessing the qualifications, experience & 92

94 background, etc. of the candidate. 24. Carrying out any other function as mentioned in the terms of reference of the Audit Committee. 25. Mandatorily reviews the following information: Management discussion and analysis of financial condition and results of operations; Statement of significant related party transactions (as defined by the audit committee), submitted by management; Management letters / letters of internal control weaknesses issued by the statutory auditors; Internal audit reports relating to internal control weaknesses; and The appointment, removal and terms of remuneration of the Chief internal auditor shall be subject to review by the Audit Committee 26. Review the Financial Statements of its Subsidiary company, if any. 27. Review the composition of the Board of Directors of its Subsidiary Company, if any. 28. Review the use/application of funds raised through an issue (public issues, right issues,preferential issues etc) on a quarterly basis as a part of the quarterly declaration of financial results. Further, review on annual basis statements prepared by the Company for fund utilized for purposes other than those stated in the offer document. In addition, to carry out such other functions/powers as may be delegated by the Board to the Committee from time to time. Nomination & Remuneration Committee Our Company has constituted a Nomination & Remuneration committee pursuant to the provisions of Section 178(1) of the Companies Act, 2013 read with Regulation 19 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, vide resolution passed at the meeting of the Board of Directors held on October 06, The committee presently comprises following three (3) directors. No. Name of the Director Status Nature of Directorship 1. Mr. Sukhpal Singh Chairman Non-Executive Independent Director 2. Mr. Pawanjit Singh Member Non-Executive Independent Director 3. Mrs. Nipur Gupta Member Non-Executive Non Independent Director The terms of reference of the Nomination & remuneration committee while formulating the policy ensure as follows: The level and composition of remuneration is reasonable and sufficient to attract, retain and motivate directors of the quality required to run the company successfully. Relationship of remuneration to performance is clear and meets appropriate performance benchmarks, and Remuneration to directors, key managerial personnel and senior management involves a balance between fixed and incentive pay reflecting short and long-term performance objectives appropriate to the working of the company and its goals. Stakeholder Relationship Committee Our Company has constituted a Stakeholder Relationship Committee pursuant to the provisions of Section 178(5) of the Companies Act, 2013 read with Regulation 20 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, vide resolution passed at the meeting of the Board of Directors held on October 06, The committee presently comprises following three (3) directors. Sr. No. Name of the Director Status Nature of Directorship 1. Mrs. Nipur Gupta Chairman Non-Executive Non Independent Director 93

95 2. Mrs. Saruchi Gupta Member Whole Time Director 3. Mr. Pawanjit Singh Member Non-Executive Independent Director Role of Stakeholder Relationship Committee The Stakeholder Relationship Committee of our Board look into: Allotment, transfer of shares including transmission, splitting of shares, changing joint holding into single holding and vice versa, issue of duplicate shares in lieu of those torn, destroyed, lost or defaced or where the cages in the reverse for recording transfers have been fully utilized. Issue of duplicate certificates and new certificates on split/consolidation/renewal, etc. and Review the process and mechanism of redressal of shareholders/investors grievance and suggest measures of improving the system of redressal of shareholders/investors grievances. Non-receipt of share certificate(s), non-receipt of declared dividends, non-receipt of interest/dividend warrants, non-receipt of annual report and any other grievance/complaints with company or any officer of the company arising out in discharge of his duties. Oversee the performance of the Registrar & Share Transfer Agent and also review and take note of complaints directly received and resolved them. Oversee the implementation and compliance of the code of conduct adopted by the company for prevention of Insider Trading for Listed Companies as specified in the Securities & Exchange Board of India(Probation of Insider Trading) Regulations, 1992 as amended from time to time. Any other power specifically assigned by the Board of Directors of the Company from time to time by way of resolution passed by it in a duly conducted meeting Carrying out any other function contained in the equity listing agreements as and when amended from time to time. Our Company has adopted following policies: 1. Code of conduct 2. Code of practices and Procedures for fair disclosure of unpublished price sensitive information 3. Whistle Blower Policy and Vigil Mechanism 4. Related Party Transaction Policy 5. Policy for preservation of documents and archival of documents 6. Policy for prevention of sexual harassment 94

96 Organisation Chart Managing Director Directors General Manager (Plant) H. R. Manager Warehouse In-charge Production Manager GM Quality H. R. Executive Warehouse Assistant (RM, PPM & SPM) Production Executive QC Manger QA Manger Sr. Production Officer QC Executive QA Executive Production Officer QC Chemist QA Officer 95

97 OUR KEY MANAGERIAL PERSONNEL Our key managerial personnel, as defined under Section 2(51) of the Companies Act, 2013, consist of: 1. Mr. Rajesh Gupta, Managing Director; 2. Mrs. Saruchi Gupta Whole Time Director and Chief Financial Officer; 3. Mr. Chandan Kapoor, Company Secretary and Compliance Officer In addition to the persons mentioned above, our key managerial personnel, consist of Mr. Anoop Kumar Shrivastava who is designated as Deputy General Manager Plant in the Company. Brief Profile of Key Managerial Personnel: Mr. Rajesh Gupta, aged 45 years, is the Managing Director of our Company. For more details please refer chapter titled Our Management on page 87 of this draft Prospectus. For details of compensation paid to him during Fiscal 2016, refer Terms of Appointment and Compensation of our Directors on page 89 of this Draft Prospectus. Mrs. Saruchi Gupta, aged 40 years, is the Whole Time Director and Chief Financial Officer of our Company. For more details please refer chapter titled Our Management of our Directors on page 87 of this draft Prospectus. For details of compensation paid to him during Fiscal 2016, refer Terms of Appointment and Compensation of our Directors on page 89 of this Draft Prospectus. Mr. Anoop Kumar Shrivastava, aged 35 years is working as Deputy General Manager Plant in our Company. He has completed Bachelor of Science from VBS Purvanchal University, Jaunpur. He is associated with our Company since May His responsibilities include administration of overall plant operations, quality assurance of products, timely production and despatch of goods. He is permanent employee of our Company, and his present gross salary is Rs Lacs p.a. Mr. Chandan Kapoor, aged 27 years, is Company Secretary & Compliance Officer of our Company. He is an associate member of Institute of Companies Secretaries of India. He has joined our Company on October 06, His scope of work and responsibilities include vetting of agreements, preparation of minutes, drafting of resolutions, preparation and updating of various statutory registers, and compliance with the provisions of Companies Act. Fiscal 2016, he did not receive any remuneration as he has been appointed on and with effect from October His gross salary is Rs Lacs p.a. Status of Key Managerial Personnel All our key managerial personnel are permanent employees of our Company. Family Relationship between Key Managerial Personnel None of the key managerial personnel is having family relation with each other except Mr. Rajesh Gupta and Mrs. Saruchi Gupta are husband and wife. Arrangements and Understanding with Major Shareholders None of our key managerial personnel have been appointed on our Board pursuant to any arrangement with our major shareholders, customers, suppliers or others. Shareholding of the Key Managerial Personnel As on date, none of the key managerial persons are holding Equity Shares of our Company except as set forth in the table below: Name of Key Managerial Personnel No. of Shares Mr. Rajesh Gupta 36,70,515 Mrs. Saruchi Gupta 10,000 96

98 Bonus or Profit Sharing Plan for the Key Managerial Personnel There is no profit sharing plan for the key managerial personnel. Our Company makes bonus payments to the employees based on their performances, which is as per their terms of appointment. Loans to Key Managerial Personnel There is no loans outstanding against key managerial personnel as on date. Interest of Key Managerial Personnel The key managerial personnel of our Company do not have any interest in our Company other than to the extent of the remuneration or benefits to which they are entitled to as per their terms of appointment, reimbursement of expenses, incurred by them during the ordinary course of business and to the extent of Equity Shares held by them in our Company, if any. Except as disclosed in this Draft Prospectus, none of our key managerial personnel have been paid any consideration of any nature from our Company, other than their remuneration. Changes in Key Managerial Personnel of our Company during the Last Three (3) Years Except mentioned below, no changes in the key managerial personnel of our Company during the last three (3) years. Name Date of Appointment / Cessation Reason Mr.Rajesh Gupta Appointment as Managing Director Mrs. Saruchi Gupta Appointment as Whole Time Director Mrs. Saruchi Gupta Appointment as CFO Mr. Chandan Kapoor Appointment as Company Secretary Employees Stock Option Scheme Our Company does not have any Employee Stock Option Scheme/ Employee Stock Purchase Scheme as on the date of filing of this Draft Prospectus. Payment or Benefit to our Officers Except for the payment of normal remuneration for the services rendered in their capacity as employees of our Company, no other amount or benefit has been paid or given within the two (2) preceding years or intended to be paid or given to any of them. Employees The details about our employees appear under the Paragraph titled Our Business- Human Resource on page 73 of this Draft Prospectus. 97

99 OUR PROMOTERS AND PROMOTER GROUP The Promoters of our Company are Mr. Rajesh Gupta and Mrs. Saruchi Gupta 1. Mr. Rajesh Gupta Mr. Rajesh Gupta, aged 45 years, is the Promoter and Managing Director of our Company. He has obtained degree of Civil Engineering from Thaper Institute of Engineering and Technology, Patiala in the year For more details please refer chapter titled Our Management beginning from Page 87 of this Draft Prospectus. Residential Address House No. 85, Guru Nanak Avenue, Majitha Road, Amritsar , Punjab, India. Occupation Business Permanent Account Number AAQPG4797C Passport Number N Driving License Number PB Voters Identity Card JZT Mrs. Saruchi Gupta Mrs. Saruchi Gupta, aged 40 years, is the Whole Time Director and Chief Financial Officer and one of the Promoters of our Company. She is a commerce graduate from Guru Nanak Dev University, Amritsar. For more details please refer chapter titled Our Management beginning from Page 87 of this Draft Prospectus. Residential Address Occupation Permanent Account Number Passport Number Driving License Number Voters Identity Card House No. 85, Guru Nanak Avenue, Majitha Road, Amritsar , Punjab, India. Business ALAPG5323R N NA JZT Other Undertakings and Confirmations Our Company undertakes that the details of Permanent Account Number, bank account number and passport number of the Promoters will be submitted to the SME platform of BSE Exchange, where the securities of our Company are proposed to be listed at the time of submission of Draft Prospectus. Common Pursuits of our Promoters Our Promoters have not promoted any Promoter Group / Group Companies which are engaged in the line of business similar to our Company as on the date of this Draft Prospectus. For details of our Promoter Group and Group Companies refer to Section titled Our Promoter and Promoters Group and Group Companies/Entities on page 98 and 102 of this Draft Prospectus. We shall adopt the necessary procedures and practices as permitted by law to address any conflicting situations, as and when they may arise. 98

100 Interest of the Promoters Our promoters are interested in our Company to the extent that they have promoted the Company, to the extent of their shareholding, for which they are entitled to receive the dividend declared, and other distribution in respect of Equity Shares if any, by our Company. For details on shareholding of our Promoter in our Company, see sections Capital Structure and Our Management on pages 40 and 87, respectively. Further, our Promoters who are also our Directors may be deemed to be interested to the extent of fees, remuneration and/or reimbursement of expenses payable to them for services rendered to us in accordance with the provisions of the Companies Act, terms of the Articles and their terms of appointment. Except as stated herein and as stated in Annexure XXI Related Party Transactions appearing under section titled Financial Information beginning on page 107 of this Draft Prospectus, we have not entered into any contract, agreements or arrangements during the preceding two years from the date of this Draft Prospectus in which the Promoters are directly or indirectly interested and no payments have been made to them in respect of these contracts, agreements or arrangements which are proposed to be made to them. Interest in the property of our Company Our Promoters have no interest in any property acquired or proposed to be acquired by our Company within the two years from the date of this Draft Prospectus, or in any transaction by our Company. Payment amounts or benefit to our Promoters during the last two years No payment has been made or benefit given to our Promoters in the two years preceding the date of this Draft Prospectus except as mentioned / referred to in this chapter and in the section titled Our Management, Financial Information, Related Party Transactions and Capital Structure on page nos. 87, 107, 105 and 40 respectively of this Draft Prospectus. Further as on the date of this Draft Prospectus, there is no bonus or profit sharing plan for our Promoters. Confirmations For details of legal and regulatory proceedings involving our Promoter, please refer to the section titled Outstanding Litigation and Material Developments on page 148. Our Promoters have not been declared a willful defaulter by the RBI or any other governmental authority and there are no violations of securities laws committed by our Promoters in the past or are pending against them. Other ventures of our Promoters Save and except as disclosed in the section titled Our Promoters and Promoter Group and Group Companies / Entities beginning on page 98 & 102 respectively of this Draft Prospectus, there are no ventures promoted by our Promoters in which they have any business interests/ other interests. Litigation details pertaining to our Promoters For details on litigations and disputes pending against the Promoters and defaults made by the Promoters please refer to the section titled Outstanding Litigations and Material Developments beginning on page 148 of this Draft Prospectus. Shareholding of the Promoters and Promoter Group in our Company Except as disclosed in Capital Structure, none of the members of our Promoter Group hold any Equity Shares as on the date of filing of this Draft Prospectus. 99

101 Related Party Transactions For the transactions with our Promoter Group entities, please refer to Annexure XXI Related Party Transactions of Financial Information beginning on page 107 of this Draft Prospectus. Except as stated in Annexure XXI Related Party Transactions of Financial Information beginning on page 107 of this Draft Prospectus, and as stated therein, our Promoters or any of the Promoter Group Entities do not have any other interest in our business. Companies with which the Promoters are disassociated in the last three years Our Promoters Mr. Rajesh Gupta and Mrs. Saruchi Gupta have not disassociated themselves from any of the Companies, firms or other entities during the last three years preceding the date of this draft Prospectus. 100

102 Our Promoter Group In addition to the Promoters named above, the following individuals and entities form a part of the Promoter Group: Individuals forming part of Promoter Group In terms of SEBI (ICDR) Regulations, the following immediate relatives, due to their relationship with our Promoters are part of our Promoter Group in terms of Regulation 2(1) (zb) (ii) of SEBI (ICDR) Regulations Promoter Mr. Rajesh Gupta Mrs. Saruchi Gupta Mother Smt. Sudesh Kumari Mrs. Samishta Mittal Father - Mr. Rajinder Kumar Mittal Spouse Mrs. Saruchi Gupta Mr. Rajesh Gupta Brother(s) - Mr. Rohit Mittal Sister(s) Ms. Madhu Arora Ms. Stuti, Ms. Daizy Son (s) Mast. Abhishek Gupta Mast. Abhishek Gupta Daughter(s) Ms. Aastha Gupta Ms. Aastha Gupta Spouse Father Mr. Rajinder Kumar - Spouse Mother Mrs. Samishta Mittal Smt. Sudesh Kumari Spouse Brother(s) Mr. Rohit Mittal - Spouse Sister(s) Ms. Stuti, Ms. Daizy Ms. Madhu Arora Entities form part of our Promoter Group In terms of SEBI (ICDR) Regulations, the following entities part of our Promoter Group in terms of Regulation 2(1) (zb) (iv) of SEBI (ICDR) Regulations. Companies forming part of the Promoter Group - ANG Healthcare India Private Limited Hindu Undivided Families or Firm forming part of the Promoter Group - G.D. Foods and Caterers Trusts forming part of the Promoter Group None Others forming part of the Promoter Group Srishti Interiors Proprietary concern 101

103 GROUP COMPANIES / ENTITIES Pursuant to the requirement of SEBI ICDR Regulations, the Group Companies include entities covered under the applicable accounting standards, being AS 18 (as identified under the Restated Financial Statements) and also other entities as considered material by the Board of the Company. As per Materiality Policy on Group Companies approved in the meeting of the Board of Directors of our company held on October 06, 2016 the Group Company shall be considered material for the purpose of disclosure in this Draft Prospectus of the Company if Such company /Entity is included in the list of related parties under AS 18 (as identified under the restated financial statements) and in terms of Regulation 2(1) (zb) (iv) of SEBI (ICDR) Regulations. Sr. No. Name of Entity Status 1 ANG Healthcare India Private Limited Private Limited Company 2 G.D. Foods and Caterers Partnership Firm 3 Srishti Interiors Proprietary concern 1. ANG Healthcare India Private Limited (AHIPL) ANG Healthcare India Private Limited was incorporated on April 25, 2016 under the Companies Act 2013 with the Registrar of Companies, Himachal Pradesh. Date of Incorporation CIN U24230HP2016PTC PAN AAOCA3292R Registered Office Village Kishanpura, PO Manpura Baddi, Nalagarh Road, Tehsil Nalagarh, Solan, Himachal Pradesh Board of Directors Mr. Neeraj Gupta Ms. Sudesh Kumari Main Objects To carry on the business of Manufacturers, Traders, importers, exporters, distributors, retailers, commission agents and marketing of all kinds of Pharmaceutical Products, Medicines, Veterinary Medicines, Herbal and Allopathic medicines, Homeopathic medicines, Ayurvedic medicines, biochemical, electrolytic drugs, surgical equipments, Pharmaceutical chemicals, medical equipments and to do all other things which are incidental, ancillary or conducive to the aforesaid objects. Shareholding Pattern of the Company is as mentioned below: Sr. No. Name No. of Shares % of Shareholding 1 Mr Niraj Gupta 25,00, Ms. Sudesh Kumari 25,00, Total 50,00, Interest of our Promoters Ms. Sudesh Kumari, mother of our Promoter Mr. Rajesh Gupta, holds 25,00,000 Equity Shares constituting 50% of the shareholding in ANG Healthcare India Private Limited. Financial Information AHIPL is recently incorporated and yet to make its first financial report. 102

104 2. G.D. Foods and Caterers G.D. Foods and Caterers is a partnership firm formed with the intention of carrying on business of restaurants, snack or coffee shops, take aways, outdoor catering and other allied services vide partnership deed dated March 18, Interest of our Promoters The share in the profits or losses of G. D. Foods and Caterers will be apportioned to its partners, which includes our Promoter Mr. Rajesh Gupta, in the following ratio: Sr. No. Name of Partner Profit Sharing (%) 1 Mr. Rajesh Gupta Mr. Sukhjit Pal Singh Dhillon Total Financial Information The Firm is recently incorporated and yet to make its first financial report. 3. Srishti Interiors Srishti Interiors is a Proprietary Concern formed with the intention of carrying on business of interior decoration, and other allied services. Interest of our Promoters Our Promoter Mr. Rajesh Gupta, is the sole proprietor of Srishti Interiors. Financial Information Particulars FY FY FY Total Income Net Profit/(Loss) (32.11) (90.20) (25.98) Interest of Group Entities in our Company Our group entities ANG Healthcare India Private Limited, G. D. Foods and Caterers and Srishti Interiors do not have any interest in - the promotion of our Company - any property acquired by our Company within the last two years or proposed to be acquired by our Company - in any transaction for acquisition of land, construction of building and supply of machinery No part of the Issue Proceeds is payable to our group entities mentioned above. Undertaking / Confirmations Our Promoters and Group Entities have further confirmed that they have not been declared as wilful defaulters by the RBI or any other government authority and there have been no violations of securities laws committed by them in the past and no proceedings pertaining to such penalties are pending against them except as stated under chapters Risk Factors, Our Promoters and Promoter Group Group Companies / Entities and Outstanding Litigations and Material Developments on pages 11, 98, 102 and 148 of this Draft Prospectus, respectively. Additionally, none of our Promoters and Group Companies have been restrained from accessing the capital market 103

105 for any reasons by the SEBI or any other authorities except as stated under chapters Risk Factors, Our Promoters and Promoter Group Group Companies / Entities and Outstanding Litigations and Material Developments on pages 11, 98, 102 and 148 of this Draft Prospectus, respectively. Common Pursuits Our Company and our group Company ANG Healthcare India Private Limited are authorized to carry on similar business activities. Though, presently our Group company is not carrying out a business activity similar to our business, we do not have any non compete agreement in place for the same. A conflict of interest may arise in future between our company and our Group Company and for associated risk factor please refer page 11 of this Draft Prospectus Litigation/ Defaults For details relating to legal proceedings involving the Promoters and Members of the Promoter Group, see the section titled Outstanding Litigations and Material Developments beginning on page 148 of this Draft Prospectus. Related Business Transaction within the Group and Significance on Financial Performance There are no business transactions between our Company and the Promoter Group entities except as stated under section titled as Related Party Transactions on page 105 of this Draft Prospectus. Sale or Purchase between our company and our Group Companies/Entities Other than as discussed under the section titled Related party transactions on page 105 of this Draft Prospectus, there are no sales or purchases between our Company and any Company in the Group Companies / Entities, wherein sales / purchase exceed in value aggregate of 10% of the total sales or purchases of our Company. Sick Companies There are no Companies in our Promoter group listed above which have been declared as a sick company under the SICA. There are no winding up proceedings against any of Promoter Group Companies. Further, no application has been made by any of them to RoC to strike off their name. Defunct Group Companies and Entities None of our Promoter Group Companies / Entities has remained defunct and no application has been made to the Registrar of Companies for striking off their name from the register of companies, during the five years preceding the date of filing of this Draft Prospectus. 104

106 RELATED PARTY TRANSACTIONS For details please refer to Annexure XXI -Related Party Transactions forming part of the chapter titled Financial Information beginning on page 107 of this Draft Prospectus. 105

107 DIVIDEND POLICY Under the Companies Act, our Company can pay dividends upon a recommendation by our Board of Directors and approval by a majority of the shareholders at the General Meeting. The shareholders of our Company have the right to decrease or not to increase the amount of dividend recommended by the Board of Directors. The dividends may be paid out of profits of our Company in the year in which the dividend is declared or out of the undistributed profits or reserves of previous fiscal years or out of both. The Articles of Association of our Company also gives the discretion to our Board of Directors to declare and pay interim dividends. There are no dividends declared by our Company since last five years Our Company does not have any formal dividend policy for the Equity Shares. The declaration and payment of dividend will be recommended by our Board of Directors and approved by the shareholders of our Company at their discretion and will depend on a number of factors, including the results of operations, earnings, capital requirements and surplus, general financial conditions, applicable Indian legal restrictions and other factors considered relevant by our Board of Directors. 106

108 SECTION V - FINANCIAL INFORMATION AUDITOR S REPORT ON RESTATED FINANCIAL STATEMENTS Independent Auditors' report as required by Section 26 of Companies Act, 2013 read with Rule 4 of Companies (Prospectus and Allotment of Securities) Rules, 2014 To The Board of Directors ANG Lifesciences India Limited, Darbara complex, SCO 113, First Floor, District Shopping Complex, B block, Ranjit Avenue, Amritsar , Punjab 1. We have examined the attached Restated Summary Statement of Assets and Liabilities of ANG Lifesciences India Limited, (hereinafter referred to as the Company ) as at September 30, 2016, March 31, 2016, 2015, 2014, 2013 and 2012, Restated Summary Statement of Profit and Loss and Restated Summary Statement of Cash Flow for the period / financial year ended on September 30, 2016, March 31, 2016, 2015, 2014, 2013 and 2012, (collectively referred to as the Restated Summary Statements or Restated Financial Statements ) annexed to this report and initialed by us for identification purposes. These Restated Financial Statements have been prepared by the management of the Company and approved by the Board of Directors of the company in connection with the Proposed Initial Public Offering (IPO) on SME Platform of BSE Limited ( BSE ). 2. These Restated Summary Statements have been prepared in accordance with the requirements of: (i) (ii) Section 26 of the Companies Act, 2013( the Act ) read with Companies (Prospectus and Allotment of Securities) Rules 2014; The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations 2009 ( ICDR Regulations ) issued by the Securities and Exchange Board of India ( SEBI ) in pursuance to Section 11 of the Securities and Exchange Board of India Act, 1992 and related amendments / clarifications from time to time; 3. We have examined such Restated Financial Statements taking into consideration: (i) (ii) The terms of reference to our engagements with the Company requesting us to carry out the assignment, in connection with the Draft Prospectus/ Prospectus being issued by the Company for its proposed Initial Public Offering of equity shares in SME Platform of BSE Limited( IPO or SME IPO ); and The Guidance Note on Reports in Company Prospectus (Revised) issued by the Institute of Chartered Accountants of India ( Guidance Note ). 4. The Restated Financial Statements of the Company have been extracted by the management from the Audited Financial Statements of the Company for the year ended on March 31, 2016, 2015, 2014, 2013 and 2012 and special purpose Interim period Audited Financial Statements for the period ended September 30, 2016 which have been approved by the Board of Directors. 5. In accordance with the requirements of the Act including the rules made there under, ICDR Regulations, Guidance Note and Engagement Letter, we report that: (i) The Restated Statement of Asset and Liabilities of the Company as at September 30, 2016, March 31, 2016, 2015, 2014, 2013 and 2012, examined by us, as set out in Annexure I to this report read with significant accounting policies in Annexure IV has been arrived at after making such adjustments and regroupings to the audited financial statements of the Company, as in our opinion were appropriate and more fully described in Notes to the Restated Summary Statements to this Report. 107

109 (ii) (iii) (iv) The Restated Statement of Profit and Loss of the Company for the period / financial year ended on September 30, 2016, March 31, 2016, 2015, 2014, 2013 and 2012, examined by us, as set out in Annexure II to this report read with significant accounting policies in Annexure IV has been arrived at after making such adjustments and regroupings to the audited financial statements of the Company, as in our opinion were appropriate and more fully described in Notes to the Restated Summary Statements to this Report. The Restated Statement of Cash Flow of the Company for the period / financial year ended on September 30, 2016, March 31, 2016, 2015, 2014, 2013 and 2012, examined by us, as set out in Annexure III to this report read with significant accounting policies in Annexure IV has been arrived at after making such adjustments and regroupings to the audited financial statements of the Company, as in our opinion were appropriate and more fully described in Notes to Restated Summary Statements to this Report. As per Accounting Standard 15, Employee Benefits issued by the Institute of Chartered Accountants of India, the Company is required to assess its gratuity liability each year and make provision for gratuity liability. However the Company has not provided for gratuity liability in the financials. 6. Based on our examination, we are of the opinion that the Restated Financial Statements have been prepared: (i) (ii) (iii) (iv) Using consistent accounting policies for all the reporting periods. Adjustments for prior period and other material amounts in the respective financial years/period to which they relate. There are no extra-ordinary items that need to be disclosed separately in the accounts and requiring adjustments. The Independent Audit Report Issued by Bhupinder Singh & Associates as on March31,2013 & March 31, 2014 has following qualification. The balances of the trade receivables, trade payables and loans and advances are subject to confirmation/reconciliation and subsequent adjustments, if any. As such we are unable to express any opinion as to the effect thereof on the financial statements for the year. The consequential effect of the above on assets and liabilities as at 31 st March, 2013 & 31 st March, 2014 and on loss for the year ended 31 st March, 2013 & 31 st March, 2014 is not ascertainable. The above qualification does not envisage any adjustment in the Restated Financial Statements of the Company for the year ended 31st march, 2013 & 31st march, There are no audit qualifications in the Audit Reports issued by the Statutory Auditors for the period / financial year ended on September 30, 2016, March 31, 2016, 2015, and 2012 which would require adjustments in this Restated Financial Statements of the Company. 7. Audit for the period / financial year ended on September 30, 2016, March 31, 2016, 2015, was conducted by Ajay K. Khanna & Company, Chartered Accountants, for the year ended March , was conducted by BSV Associates, Chartered Accountants, for the year ended March , and for the year ended March 31, 2012 was conducted by Bhupinder Singh & Associates Chartered Accountants. The financial report included for these years is based solely on the report submitted by them. Further financial statements for the period / financial year ended on September 30, 2016 and March 31, 2016 have been re-audited by us as per the relevant guidelines. 108

110 8. We have also examined the following other financial information relating to the Company prepared by the Management and as approved by the Board of Directors of the Company and annexed to this report relating to the Company for the period / financial year ended on September 30, 2016, March 31, 2016, 2015, 2014, 2013 and 2012 proposed to be included in the Draft Prospectus / Prospectus ( Offer Document ). Annexure of Restated Financial Statements of the Company:- (i) Summary Statement of Assets and Liabilities, as Restated as appearing in ANNEXURE I; (ii) (iii) (iv) (v) (vi) Summary Statement of Profit and Loss, as Restated as appearing in ANNEXURE II; Summary Statement of Cash Flow as Restated as appearing in ANNEXURE III; Significant Accounting Policies as Restated as appearing in ANNEXURE IV; Details of Share Capital as Restated as appearing in ANNEXURE V to this report; Details of Reserves and Surplus as Restated as appearing in ANNEXURE VI to this report; (vii) Details of Long Term Borrowings as Restated as appearing in ANNEXURE VII to this report; (viii) Details of Deferred Tax Asset/Liability as Restated as per ANNEXURE VIII to this report; (ix) (x) (xi) Details of Short Term Borrowings as Restated as appearing in ANNEXURE IX to this report; Details of Trade Payables as Restated as appearing in ANNEXURE X to this report; Details of Other Current Liabilities as Restated as appearing in ANNEXURE XI to this report; (xii) Details of Short Term Provisions as Restated as appearing in ANNEXURE XII to this report; (xiii) Details of Fixed Assets as Restated as appearing in ANNEXURE XIII to this report; (xiv) Details of Non Current Investments as Restated as appearing in ANNEXURE XIV to this report; (xv) Details of Inventories as Restated as appearing in ANNEXURE XV to this report; (xvi) Details of Trade Receivables as Restated as appearing in ANNEXURE XVI to this report; (xvii) Details of Cash & Cash Equivalents as Restated as appearing in ANNEXURE XVII to this report; (xviii) Details of Short Term Loans & Advances as Restated as appearing in ANNEXURE XVIII to this report (xix) Details of Revenues as Restated as appearing in ANNEXURE XIX to this report; (xx) Details of Other Income as Restated as appearing in ANNEXURE XX to this report; (xxi) Details of Related Party Transactions as Restated as appearing in ANNEXURE XXI to this report; (xxii) Details of Significant Accounting Ratios as Restated as appearing in ANNEXURE XXII to this report; (xxiii) Capitalisation Statement as at September 30, 2016 as Restated as appearing in ANNEXURE XXIII to this report; (xxiv) Statement of Tax Shelters as Restated as appearing in ANNEXURE XXIV to this report; 9. The report should not in any way be construed as a re-issuance or re-dating of any of the previous audit reports issued by any other Firm of Chartered Accountants nor should this report be construed as a new opinion on any of the financial statements referred to therein. 10. We have no responsibility to update our report for events and circumstances occurring after the date of the report. 11. In our opinion, the above financial information contained in Annexure I to XXIV of this report read with the respective Significant Accounting Polices and Notes to Restated Summary Statements as set out in Annexure IV are prepared after making adjustments and regrouping as considered appropriate and have been prepared in accordance with the Act, ICDR Regulations, Engagement Letter and Guidance Note. 12. Our report is intended solely for use of the management and for inclusion in the Offer Document in connection with the SME IPO. Our report should not be used, referred to or adjusted for any other purpose except with our consent in writing. 109

111 For Vishal H. Shah & Associates Chartered Accountants FRN W Sd/- Vishal H. Shah Proprietor Membership No Place: Mumbai Date: January 05,

112 Sr. No. A B C D E F STATEMENT OF ASSETS AND LIABILITIES AS RESTATED Particulars As at September 30, As at March 31, ANNEXURE - I (Rs. in Lacs) EQUITY AND LIABILITIES Shareholders Funds a. Share Capital b. Reserves & Surplus (56.67) (97.03) (141.32) (135.11) Share Application Money Pending Allotment Non Current Liabilities a. Long Term Borrowings , b. Deferred Tax Liabilities c. Other Long Term Liabilities d. Long Term Provisions Current Liabilities a. Short Term Borrowings b. Trade Payables 1, , c. Other Current Liabilities , d. Short Term Provisions T O T A L 3, , , , , , ASSETS Non Current Assets a. Fixed Assets i. Tangible Assets 1, , , , , , Less: Accumulated Depreciation ii. Intangible Assets iii. Intangible Assets under development iv. Capital Work in Progress Net Block , , b. Deferred Tax Assets (Net) c. Non-current Investments d. Other Non current assets Current Assets a. Current Investment b. Inventories c. Trade Receivables 1, , d. Cash and Cash Equivalents e. Short Term Loans & Advances f. Other Current Assets T O T A L 3, , , , , ,

113 STATEMENT OF PROFIT AND LOSS AS RESTATED Sr. No. Particulars September 30, ANNEXURE - II (Rs. in Lacs) For the period ended March 31, A INCOME Revenue from Operations 2, , , , , Other Income Total Income (A) 2, , , , , B EXPENDITURE Cost of Material Consumed 2, , , , , Purchase of Stock in Trade Changes in inventories of (94.47) (20.80) (87.18) (43.34) (32.02) (27.81) finished goods, traded goods and work-in-progress Employee benefit expenses Finance costs Depreciation and amortisation expense Other Expenses Total Expenses (B) 2, , , , , C Profit before extraordinary (199.60) items and tax Extraordinary items D Profit before tax (199.60) Tax expense : (i) Current tax Less:MAT Credit - (3.09) (5.43) (0.45) - - (ii) Deferred tax (1.44) (28.43) (iii) Tax in respect of earlier year E Total Tax Expense (28.43) F Profit for the year (D-E) (6.21) (171.16) 112

114 STATEMENT OF CASH FLOW AS RESTATED Particulars September 30, ANNEXURE- III (Rs. in Lacs) For the period ended March 31, Net Profit before tax as per Profit And (199.60) Loss A/c Adjusted for: Depreciation & Amortisation Interest & Financial Charges Profit on Sale of Fixed Assets Interest earned - (4.94) (4.61) (4.35) (1.96) (0.51) Operating Profit Before Working Capital Changes Adjusted for (Increase)/ Decrease: Inventories (95.41) (31.10) (162.65) (141.74) (46.35) Trade Receivables (81.57) (1,009.54) (325.74) (195.05) Short Term Loans & Advances (101.87) (205.34) (144.72) 2.18 (21.27) Other Non Current Assets (3.35) Trade Payables (244.28) Other Current Liabilities (1,009.34) Short Term Provisions Cash Generated From Operations (759.14) Before Extra-Ordinary Items Add:- Extra-Ordinary Items Cash Generated From Operations (759.14) Direct Tax Paid (45.99) (42.19) (8.38) (9.25) - - Net Cash Flow from/(used in) (759.14) Operating Activities: (A) Cash Flow From Investing Activities: Purchase of Fixed Assets (50.51) (130.86) (70.39) (67.26) (35.31) (54.81) Sale of Fixed Asset Investments in non-current investments Interest & Financial Charges (69.32) (165.94) (165.94) (150.82) (183.30) (157.02) Interest earned Net Cash Flow from/(used in) (119.83) (291.86) (231.72) (213.74) (216.66) (211.33) Investing Activities: (B) Cash Flow from Financing Activities: Proceeds from Long Term borrowings (45.95) (130.17) (165.61) (122.58) (547.37) (net) Proceeds from Short Term borrowings (25.89) (45.06) (net) Increase in Capital Reserve Net Cash Flow from/(used in) (71.84) (88.61) (142.64) (547.37) Financing Activities ( C) Net Increase/(Decrease) in Cash & Cash (7.71) (8.07) Equivalents (A+B+C) Cash & Cash Equivalents As At Beginning of the Year Cash & Cash Equivalents As At End of the Year

115 ANNEXURE IV (A) RESTATED SIGNIFICANT ACCOUNTING POLICIES AND NOTES TO ACCOUNTS: CORPORATE INFORMATION ANG Lifesciences India Limited was incorporated in the year 2006 and it is engaged in manufacturing of pharmaceuticals. A. Basis of preparation of Financial Statements: The restated summary statement of assets and liabilities of the Company as at September 30, 2016, March 31, 2016, 2015, 2014, 2013 and 2012 and the related restated summary statement of profits and loss and cash flows for the period / years ended September 30, 2016, March 31, 2016, 2015, 2014, 2013 and 2012 (herein collectively referred to as ('Restated Summary Statements') have been compiled by the management from the audited financial statements of the Company for the period /years ended on September 30, 2016, March 31, 2016, 2015, 2014, 2013 and 2012, approved by the Board of Directors of the Company. Restated Summary Statements have been prepared to comply in all material respects with the provisions of section 26 of the Companies Act, 2013 read with Companies (Prospectus and Allotment of Securities) Rules, 2014, Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 ( the SEBI Regulations ) issued by SEBI and Guidance note on Reports in Companies Prospectus (Revised). Restated Summary Statements have been prepared specifically for inclusion in the offer document to be filed by the Company with the SME Platform of BSE in connection with its proposed Initial public offering of equity shares. The Company s management has recast the financial statements in the form required by Schedule III of the Companies Act, 2013 for the purpose of restated summary statements. B. Use of Estimates: The preparation of financial statements requires management to make estimates and assumptions that affect amounts in the financial statements and reported notes thereto. Actual results could differ from these estimates. Differences between the actual result and estimates are recognized in periods in which the results are known/ materialized. C. Fixed Assets: Fixed assets are stated at cost of acquisition or construction less accumulated depreciation and impairment loss, if any. The cost of an asset comprises of its purchase price and any directly attributable cost of bringing the assets to working condition for its intended use. Expenditure on additions, improvements and renewals is capitalized and expenditure for maintenance and repairs is charged to profit and loss account. D. Depreciation: Depreciation on fixed assets is calculated on written down value (WDV) basis for all tangible and intangible assets using the rates arrived at based on the method prescribed under Schedule II of the Companies Act, 2013 for the period / year ended September 30, 2016 and March 31, 2016, For the year ended on March 31, 2014, 2013, 2012 and 2011 depreciation has been charged on WDV for all tangible and intangible assets using the rates prescribed under Schedule XIV of the Companies Act, E. Valuation of Inventories: Inventory of traded goods is at cost or net realizable value whichever is lower. F. Valuation of Investments: i. Investments that are readily realizable and intended to be held for not more than a year are classified as current investments. All other investments are classified as long term investments. 114

116 ii. Current Investments are carried at lower of cost and fair value determined on an individual investment basis. iii. Long-term investments are carried at cost. However, provision for diminution in value is made to recognize a decline other than temporary in the value of investments. G. Revenue Recognition: Revenue is recognized to the extent it is probable that the economic benefits will flow to the company and the revenue can be reliably measured. Sale of Goods Sales are recognized, net of returns and trade discounts, on transfer of significant risks and rewards of ownership to the buyer which generally coincides with the delivery of goods to customers. Revenue from Other Sources Other Incomes have been recognized on accrual basis. H. Employee Benefits: i. Short Term Employee Benefits: All employee benefits payable within twelve months of rendering of services are classified as short term benefits. Benefits include salaries, wages, awards, ex-gratia, performance pay, etc. and are recognized in the period in which the employee renders the related service. Liability on account of encashment of leave, Bonus to employee is considered as short term compensated expense provided on actual. ii. Post Employment Benefit : Defined Contribution Plan: Provident fund is a defined contribution scheme established under a State Plan. The contributions to the scheme are charged to the profit & loss account in the year when the contributions to the fund are due. As per Accounting Standard 15, Employee Benefits issued by the Institute of Chartered Accountants of India, the Company is required to assess its gratuity liability each year and make provision for gratuity liability. However the Company has not provided for gratuity liability in the financials. I. Earnings Per Share Basic earnings per share is computed by dividing the net profit after tax for the year after prior period adjustments attributable to equity shareholders by the weighted average number of equity shares outstanding during the year. J. Taxation & Deferred Tax Provision for Current Tax is made in accordance with the provision of Income Tax Act, Deferred tax is recognized on timing differences between taxable & accounting income / expenditure that originates in one period and are capable of reversal in one or more subsequent period(s). K. Contingent Liabilities / Provisions Contingent liabilities are not provided in the accounts and are disclosed separately in notes on accounts. 115

117 Presentation and disclosure of financial statements During the year ended March 31, 2012, the Revised Schedule VI notified under the Act, had become applicable to the Company, for preparation and presentation of its financial statements. Accordingly, the Company has prepared the financial statements for the year ended March 31, 2012 onwards in accordance with Revised Schedule VI of the Act. The adoption of Revised Schedule VI of the Act does not impact recognition and measurement principles followed for preparation of financial statements. However, it has significant impact on presentation and disclosures made in the financial statements. The Company has also reclassified the figures for the years ended March 31, 2011 in accordance with the requirements of Revised Schedule VI of the Act, to the extent possible. ANNEXURE IV (B) NOTES ON RECONCILIATION OF RESTATED PROFITS (Rs in Lacs) Adjustments for Net profit/(loss) after Tax as per (5.69) (148.00) Audited Profit & Loss Account Adjustments for: Current Tax (3.62) (9.40) Deferred Tax (0.44) (3.91) (1.55) (23.17) Net Profit/ (Loss) After Tax as Restated (6.21) (171.16) Explanatory notes to the above restatements made in the audited financial statements of the Company for the respective years. Adjustments having impact on Profit 1. Provision for Tax - The taxes were not provided as per Income Tax Return Filed. Further there was difference in MAT Credit claimed and booked in accounts. 2. Deferred Tax There was difference in calculation of Deferred Tax on account of difference in depreciation as per books and as per working done for deferred Tax. As a result the deferred tax asset / liability has been restated. Adjustments having no impact on Profit Material Regrouping W.E.F. April , Schedule III notified under the Companies Act, 2013 has become applicable to the Company for preparation and presentation of its financial statements. Revised Schedule VI notified under the Companies Act, 1956 became applicable to the Company from April 1, 2011, for preparation and presentation of its financial statements. The adoption of Schedule III / Revised Schedule VI does not impact recognition and measurement principles followed for preparation of financial statements. There is no significant impact on the presentation and disclosures made in the financial statements on adoption of Schedule III as compared to Revised Schedule VI. The Company has reclassified the figures for the previous financial year ended March 31, 2011 in accordance with the requirements of Schedule III. Appropriate adjustments have been made in the restated Summary Statements, wherever required, by a reclassification of the corresponding items of income, expenses, assets, liabilities and cash flows in order to bring them in line with the groupings as per the audited financial statements of the Company, prepared in accordance with Schedule III and the requirements of the Securities and Exchange Board of India (Issue of Capital & Disclosure Requirements) Regulations, 2009 (as amended). 116

118 DETAILS OF SHARE CAPITAL AS RESTATED Particulars As at September 30, As at March 31, ANNEXURE- V (Rs in Lacs) EQUITY SHARE CAPITAL : AUTHORISED SHARE CAPITAL Equity Shares of Rs 10/- Each % Pref. Shares of Rs 10/-Each T O T A L ISSUED, SUBSCRIBED AND PAID UP SHARE CAPITAL Equity Shares of Rs 10/- Each T O T A L RECONCILIATION OF NUMBER OF SHARES OUTSTANDING AT THE END OF THE YEAR Particulars As at September 30, As at March 31, Equity shares at the beginning of the year Add: Shares Issued during the year Equity shares at the end of the year DETAILS OF RESERVES AND SURPLUS AS RESTATED Particulars PROFIT AND LOSS ANNEXURE- VI (Rs in Lacs) As at As at March 31, September 30, As per last financial statements (81.67) (122.03) (141.32) (135.11) Add/(Less): Net Profit after Tax for the (6.21) (171.16) year Less: Amount of assets written off - - (0.04) Less: Effect of Transitional Provision of Deferred Tax (AS22) T O T A L (81.67) (122.03) (141.32) (135.11) CAPITAL RESERVE Opening Balance Add: Current Year Transfer Less: Written Back in Current Year Closing Balance T O T A L (56.67) (97.03) (141.32) (135.11) 117

119 DETAILS OF LONG TERM BORROWINGS AS RESTATED Particulars As at September 30, 118 As at March 31, ANNEXURE- VII (Rs in Lacs) Secured Loan Term Loan Punjab National Bank - Restructured Loan Punjab National Bank - Restructured Loan Punjab National Bank - Restructured Loan Punjab National Bank FITL Loan DHFL Sub Total (a) Vehicle Loan Punjab National Bank Punjab National Bank Punjab National Bank Sub Total (b) Total Term Loans Deposits (Unsecured) Deposits (Secured) Total Other Loans T O T A L , Nature of Security and Terms of Repayment for Long Term Borrowings: Particulars Security Terms of Payment Punjab National Bank - Restructured Loan Rs Lacs Punjab National Bank - Restructured Loan Rs Lacs Punjab National Bank - Restructured Loan Rs Lacs Punjab National Bank FITL Loan Rs Lacs (a) Guaranteed by the directors of the company and third party guarantees. (b) First pari-passu charge over the land and building and the entire plant and machinery of the company. ----do do do monthly installments starting from Oct 2013, First 18 Installments of Rs /- each, Next 36 Installments of Rs /- each, Last 6 Installments of Rs /- each, ends in Sep monthly installments starting from Oct 2013, First 18 Installments of Rs /- each, Next 36 Installments of Rs /- each, Last 6 Installments of Rs /- each, ends in Sep monthly installments starting from Oct 2013, First 18 Installments of Rs /- each, Next 36 Installments of Rs /- each, Last 6 Installments of Rs /- each, ends in Sep monthly installments starting from Oct 2013, 1st Installments of Rs Lacs

120 each, Next 5 Installments of Rs Lacs each, Next 8 Installments of Rs Lacs each, Next 4 Installments of Rs Lacs each, Next 24 Installments of Rs Lacs each, Next 17 Installments of Rs Lacs each, Last Installments of Rs Lacs ends in Sep 2018 DHFL Business Loan Rs Lacs ----do monthly instalments Punjab National Bank Vehicle Secured against Loan Rs Lacs hypothecation of Vehicle Punjab National Bank Vehicle ----do Loan Rs Lacs Punjab National Bank Vehicle ----do Loan Rs Lacs 84 monthly installments starting from Dec 2015 Installments of Rs ends in Nov 36 monthly installments starting from Oct 2015 Installments of Rs ends in Sep 84 monthly installments starting from Sep 2016 Installments of Rs ends in Aug DETAILS OF DEFERRED TAX ASSET/LIABILITY AS RESTATED Particulars As at September 30, As at March 31, ANNEXURE- VIII (Rs in Lacs) Related to Fixed Assets Depreciation & Amortisation (60.17) (81.91) Due to Interest disallowed u/s 43B (48.38) (48.38) (63.06) (72.53) (77.07) (41.68) Deferred Tax Liability (net) after adjustments Incremental Deferred Tax (asset) / charge for the year (4.41) (15.77) (31.91) (53.15) (1.44) (53.15) DETAILS OF SHORT TERM BORROWING AS RESTATED Particulars As at September 30, As at March 31, ANNEXURE- IX (Rs in Lacs) Secured Working capital loans form Punjab National Bank payable on demand -Cash Credit T O T A L Nature of Security and Terms of Repayment for Short Term Borrowings Particulars Security Terms of Payment Punjab National Bank Cash Credit Rs Lacs Secured by hypothecation of stock of raw material, WIP, Finished goods and receivables of the company. Repayable on demand with annual renewal. The rate of Interest is 14% p.a.which is subject to change from time to time as per Bank/RBI guidelines. 119

121 DETAILS OF TRADE PAYABLES AS RESTATED Particulars As at September 30, As at March 31, ANNEXURE- X (Rs in Lacs) Micro & Small Enterprises Trade Payables (Including acceptances) 1, , T O T A L 1, , DETAILS OF OTHER CURRENT LIABILITIES AS RESTATED Particulars As at September 30, ANNEXURE- XI (Rs in Lacs) As at March 31, Sundry creditors for capital goods Sundry creditors for Expenses PNB C/C PNB ILC Tata Capital Car Loan PNB T/L PNB T/L PNB T/L PNB T/L PNB T/L PNB T/L PNB FITL Reliance Capital Ltd Overdue Installments A) Interest accrued and due on borrowings B) Other Payables(specify nature) Audit fees payable Advance from Customers Electricity Expenses TDS Payable Salary and Reimbursements ESIC EPF Payable VAT Payable T O T A L ,

122 DETAILS OF SHORT TERM PROVISIONS AS RESTATED Particulars As at September 30, ANNEXURE- XII (Rs in Lacs) As at March 31, Telephone Expenses Traveling Expenses Overtime Income Tax T O T A L

123 DETAILS OF FIXED ASSETS AS RESTATED ANNEXURE- XIII Upto Fixed Assets Gross Block Accumulated Depreciation Net Block As at Additions As at Upto for the year Upto As at Deductio ns / Adjustm ents As at Tangible Assets Building Misc Fixed Assets Plant & Machinery Air Compressor & Dryer Air Conditioner Boiler Borewell Computers Electric Installation Furniture & Fixtures Tools & Instruments Infrastructure Line (Electricity) Office Telephone & Security Sys. Vehicle Bus & Car Motor Cycle LCD IPAD Mobile Phone Car Land Total 1, ,

124 FY Fixed Assets Gross Block Accumulated Depreciation Net Block As at Additions As at Upto for the year Upto As at Deductio ns / Adjustme nts As at Tangible Assets Building Misc Fixed Assets Plant & Machinery Air Compressor & Dryer Air Conditioner Boiler Borewell Computers Electric Installation Furniture & Fixtures Tools & Instruments Infrastructure Line (Electricity) Office Telephone & Security Sys. Vehicle Bus & Car Motor Cycle LCD IPAD Mobile Phone Car Land Total 1, ,

125 FY Fixed Assets Gross Block Accumulated Depreciation Net Block As at Additions/ (Disposals) As at Upto for the year As at Deductions / Adjustment Upto As at Tangible Assets Building Misc Fixed Assets Plant & Machinery Air Compressor & Dryer Air Conditioner Boiler Borewell Computers Electric Installation Furniture & Fixtures Tools & Instruments Infrastructure Line (Electricity) Office Telephone & Security Sys. Vehicle Bus & Car Motor Cycle LCD IPAD Mobile Phone Land Total 1, ,

126 FY Fixed Assets Gross Block Accumulated Depreciation Net Block As at Additions As at Upto for the year Upto As at Deductions / Adjustment As at Tangible Assets Building Misc Fixed Assets Plant & Machinery Air Compressor & Dryer Air Conditioner Boiler Borewell Computers Electric Installation Furniture & Fixtures Tools & Instruments Infrastructure Line (Electricity) Office Telephone & Security Sys. Vehicle Bus & Car Motor Cycle LCD IPAD Mobile Phone Land Total 1, , ,

127 FY Fixed Assets Gross Block Accumulated Depreciation Net Block As at Additions As at Upto for the year Upto As at Deductio ns / Adjustme nts As at Tangible Assets Building Misc Fixed Assets Plant & Machinery Air Compressor & Dryer Air Conditioner Boiler Borewell Computers Electric Installation Furniture & Fixtures Tools & Instruments Infrastructure Line (Electricity) Office Telephone & Security Sys. Vehicle Bus & Car Land Total 1, , , ,

128 FY Fixed Assets Gross Block Accumulated Depreciation Net Block As at Additions As at Upto for the year Upto As at Deducti ons / Adjust ments As at Tangible Assets Building Misc Fixed Assets Plant & Machinery Air Compressor & Dryer Air Conditioner Boiler Borewell Computers Electric Installation Furniture & Fixtures Tools & Instruments Infrastructure Line (Electricity) Office Telephone & Security Sys. Vehicle Bus & Car Land Total 1, , , ,

129 DETAILS OF NON-CURRENT INVESTMENTS AS RESTATED Particulars As at September 30, ANNEXURE- XIV (Rs in Lacs) As at March 31, Investments Aggregate amount of unquoted Investments DETAILS OF INVENTORIES AS RESTATED Particulars As at September 30, ANNEXURE- XV (Rs in Lacs) As at March 31, a. Raw Materials and components (Valued at Cost or Market Price whichever is less) b. Work-in-progress (Valued at Cost or Market Price whichever is less) c. Finished Goods (Valued at Cost or Market Price whichever is less) T O T A L DETAILS OF TRADE RECEIVABLES AS RESTATED Particulars As at September 30, ANNEXURE- XVI (Rs in Lacs) As at March 31, Over Six Months-unsecured,considered good 1, Others , T O T A L 1, , DETAILS OF CASH AND CASH EQUIVALENTS AS RESTATED Particulars As at September 30, ANNEXURE- XVII (Rs in Lacs) As at March 31, Cash and Bank Balances FDR with Bank T O T A L

130 DETAILS OF SHORT TERM LOAN AND ADVANCES AS RESTATED Particulars As at September 30, As at March 31, ANNEXURE- XVIII (Rs in Lacs) Advance to others Advance to Suppliers VAT Accrued Interest Prepaid Bank Guarantee Subsidy Receivable Mat Credit Entitlement Excise Duty Refund AMC Prepaid TDS/TCS Receivable Earnest Money Tender Prepaid LC Charges Prepaid Insurance T O T A L DETAILS OF REVENUE FROM OPERATIONS AS RESTATED ANNEXURE- XIX (Rs in Lacs) Particulars September 30, For the period ended March 31, REVENUE FROM OPERATIONS Sale of products (Medicines) 2, , , , , Other operating revenues T O T A L 2, , , , , DETAILS OF OTHER INCOME AS RESTATED ANNEXURE- XX (Rs in Lacs) Particulars September 30, For the period ended March 31, Nature Other Income Interest Income & Non operating income Net Profit Before Tax (199.60) as Restated Percentage 0.43% 9.47% 15.74% 26.77% 24.82% (0.26%) Source of Income Interest income Recurring and related to business activity. Miscellaneous Income Recurring and related to business activity T O T A L

131 DETAILS OF RELATED PARTY TRANSACTIONS AS RESTATED ANNEXURE- XXI Particulars Rajesh Gupta Saruchi Gupta G.D. Foods ANG Healthcare India Pvt. Ltd. ANG Healthcare India Pvt. Ltd. Shrishti Interior Nature of Transacti on Directors Remunar ation Directors Remunar Amoun t of transact ion during the period ended Sept 30, 2016 Amount outstandi ng as on Sept 30,2016 (Payable )/ Receivab le Amount of transacti on during the period year March 31, 2016 Amount outstandi ng as on March 31,2016 (Payable )/ Receivab le ation Advance s Loans Taken Loan Given / Repaid Purchase (92.82) (170.41) Amount of transacti on during the period year March 31, 2015 Amount outstandi ng as on March 31,2015 (Payable )/ Receivab le Amount of transacti on during the period year March 31, 2014 Amount outstandi ng as on March 31,2014 (Payable )/ Receivab le Amount of transacti on during the period year March 31, 2013 Amount outstandi ng as on March 31,2013 (Payable )/ Receivab le Amount of transacti on during the period year March 31, 2012 Purchase 5.72 Loan (150.56) (Rs in Lacs) Amount outstandi ng as on March 31,2012 (Payable )/ Receivab le (77.41) 130

132 SUMMARY OF ACCOUNTING RATIOS AS RESTATED ANNEXURE- XXII (Rs in Lacs) Particulars For the period ended March 31, Restated PAT as per P& L Account (6.21) (171.16) Weighted Average Number of Equity Shares at the end of the Year Number of Equity Shares outstanding at the end of the Year Net Worth Earnings Per Share Basic & Diluted (0.17) (4.65) Return on Net Worth (%) 23.69% 34.69% 12.97% 7.11% (2.74)% (73.42)% Net Asset Value Per Share (Rs) Calculation of Ratios Basic and Diluted Earning per Share (EPS) (Rs.) Return on Networth (%) Net Asset Value per Equity Share (Rs.) Restated Profit after tax available to Equity Shareholders Weighted Average Number of Equity Shares at the end of the period Restated Profit after tax available to Equity Shareholders Restated Networth of Equity Shareholders Restated Networth to Equity Shareholders Number of Equity Shares outstanding at the end of the year/period CAPITALISATION STATEMENT AS AT SEPTEMBER 30, 2016 ANNEXURE - XXIII (Rs in Lacs) Particulars Pre Issue Post Issue Borrowings Short Term Debt Current Maturity of Long Term Liability Long Term Debt Total debts 1, , Shareholders Funds Equity Share Capital Reserve and surplus - as restated , Total Shareholders Funds , Long Term Debt / Shareholders Funds Total debt / Shareholders Funds

133 STATEMENT OF TAX SHELTERS Particulars Period ended Sept 30, 2016 Year ended March 31, 2016 Year ended March 31, 2015 Year ended March 31, 2014 ANNEXURE - XXIV (Rs in Lacs) Year Year ended ended March March 31, , 2012 Profit before tax as per books (A) (199.60) Tax Rate as per Income Tax (%) 33.06% 33.06% 30.90% 30.90% 30.90% 30.90% MAT Rate (&) 20.39% 20.39% 19.06% 19.06% 19.06% 19.06% Adjustments : Permanent Differences(B) Donation Expenses on which TDS not deducted & Interest ESIC & PF Total Permanent Differences(B) Income considered separately (C) Total Income considered separately (C) Timing Differences (D) Difference between tax depreciation and book depreciation (6.49) (48.31) (46.93) Difference due to expenses allowable/ - (47.52) (31.79) (13.55) disallowable u/s 43B Total Timing Differences (D) 6.48 (46.58) (38.28) Net Adjustments E = (B+C+D) 6.56 (41.14) (33.00) Tax expense / (saving) thereon 2.00 (13.00) (10.00) Income from Other Sources Income from Other Sources (F) Income/(Loss) (G=A+E+F) (105.76) Less: Loss b/f (H) (194.72) (78.31) Less: Deduction u/s 80IC (I) (59.73) (54.27) (8.14) (11.17) - - Taxable Income/(Loss) (G-H-I) Income/(Loss) as per MAT (199.60) Less: Unabsorbed Depreciation or (15.02) business loss Taxable Income/(Loss) as per MAT (199.60) Income Tax as per Income Tax Income Tax as per MAT Tax paid as per normal or MAT Normal MAT MAT MAT N.A. N.A. 132

134 STATEMENT OF FINANCIAL INDEBTEDNESS Brief details on the financial indebtedness of ANG Lifesciences India Limited as on September 30, 2016 is as under: (Amount in Lacs) Nature of borrowings Amount Secured Unsecured Total Secured Loan Name of Lender Punjab Nationa l Bank Punjab Nationa l Bank Purpo se Busin ess Busin ess Date of Sanction /Restructu re Sanctio ned Amoun t Rate of interest 05/01/ Base Rate %=13.10% 05/01/ Base Rate %=13.10% Security offered/ Collateral Securities offered (a) Guaranteed by the directors of the company and third party guarantees. (b) First pari-passu charge over the land and building and the entire plant and machinery of the company. (a) Guaranteed by the directors of the company and third party guarantees. (b) First pari-passu charge over the land and building and the entire plant and machinery of the company. (Amount in Lacs) Re-payment Outstandi ng amount as on monthly installments starting from Oct 2013, First 18 Instalments of Rs /- each, Next 36 Instalments of Rs /- each, Last 6 Instalments of Rs /- each, ends in Sep monthly installments starting from Oct 2013, First 18 Instalments of Rs /- each, Next 36 Instalments of Rs /- each, Last 6 Instalments of Rs /- each, ends in Sep 2018 Punjab Nationa l Bank Busin ess 05/01/ Base Rate %=13.10% (a) Guaranteed by the directors of the company and third party guarantees. (b) First pari-passu charge over the land and building and the entire plant and 60 monthly instalments starting from Oct 2013, First 18 Instalments of Rs /- each, Next 36 Instalments of Rs /- each, Last 6 Instalments

135 Punjab Nationa l Bank Punjab Nationa l Bank Punjab Nationa l Bank Punjab Nationa l Bank FITL Loan Car Loan Car Loan Car Loan DHFL Busin ess Loan Punjab Nationa l Bank Worki ng Capita l 05/01/ Base Rate %=13.10% machinery of the company. (a) Guaranteed by the directors of the company and third party guarantees. (b) First pari-passu charge over the land and building and the entire plant and machinery of the company. 30/11/ % (a) Guaranteed by the directors of the company and third party guarantees. (b) First pari-passu charge over the land and building and the entire plant and machinery of the company. 03/09/ % Hypothecation of Vehicle 03/08/ % Hypothecation of Vehicle 31/07/ % Hypothecation of Plant and Machinery 24/11/ Base Rate %=13.10% a) Guaranteed by the directors of the company and third party guarantees. (b) First pari-passu of Rs /- each, ends in Sep monthly instalments starting from Oct 2013, 1st Instalment of Rs Lacs each, Next 5 Instalment of Rs Lacs each, Next 8 Instalment of Rs Lacs each, Next 4 Instalment of Rs Lacs each, Next 24 Instalment of Rs Lacs each, Next 17 Instalment of Rs Lacs each, Last Instalment of Rs Lacs ends in Sep monthly instalments starting from Dec 2015 Instalment of Rs ends in Nov monthly instalments starting from Oct 2015 Instalment of Rs ends in Sep monthly instalments starting from Sep 2016 Instalment of Rs ends in Aug monthly instalments of Rs /- Repayable on demand

136 charge over the land and building and the entire plant and machinery of the company. Total Rs Restrictive Covenants The above loan agreements include various restrictive covenants in relation to certain actions to be undertaken by our Company and for which prior approval of the Bank is required. The major restrictive covenants are mentioned below: a) Effect any change in the capital structure of the Company b) Formulate any scheme of amalgamation or reconstruction c) Undertake any new projector expansion or modernization schemes or make any capital expenditure d) Enter into borrowing arrangements either on secured or unsecured basis with any other bank e) Undertake guarantee obligations on behalf of any other borrower/organization f) Create any charge, lien or encumbrance over its undertaking or any part thereof in favour of any financial institution bank borrower firm or persons g) Sale, assign mortgage alienate or otherwise dispose of any of the assets of the Company charged to bank h) Transfer of controlling interest or make any drastic change in the management set up Unsecured Loan (Amount in Lacs) Sr. No. Name of Lender Outstanding amount as on Part A 1 Abhishek Industries Arun Bhanot Bimlavati Boor Chand Chamanlal Davinder Kumari Gauri Arora Guljinder Singh Harman Arora Heritage Projects J.K. Builders Jay Kay Traders Kunal Dammi Arun Kumar Madhu Arora Neeraj Gupta Preet Industries Ravi Goel S.S. Bhola Srishti Infrastructure Sukhleen Kaur Surjit Singh The Garden Store Yukti Dhammi 2.00 Total (A) Part B 135

137 1 Aagaz Society Guru Raja Pharma Sales Kirti Healthcare Ashirwad Medicines Blue Star Enterprises BVM Pharma Dhanlaxmi Dipak Pharmaceuticals Gayatri Medicates Gayatri Pharma Guru Bandhu Enterprises KayMS Pharma Lekhana Pharma Life Genetics Medichem Surgicals R. K. Enterprises Royal Remedies Shrinath Sumukha Pharma Other Miscellaneous 4.37 Total B Total (A) + (B)

138 MANAGEMENT DISCUSSION & ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of our financial condition and results of operations together with our audited restated financial statements prepared in accordance with paragraph B of Part II of Schedule II to the Companies Act and SEBI (ICDR) Regulations, including the schedules, annexure and notes thereto and the reports thereon of each of the financial years ended March 31, 2012, 2013, 2014, 2015 & 2016 and for the period ended September 30, 2016 in the chapter titled "Financial Information" on page 107 of this Draft Prospectus. The following discussion relates to our Company and, unless otherwise stated, is based on our restated financial statements, which have been prepared in accordance with Indian GAAP, the Accounting Standards and other applicable provisions of the Companies Act and the SEBI (ICDR) Regulations. Our financial year ends on March 31 of each year so accordingly all references to a particular financial year are to the twelve months ended March 31 of that year. Industry Overview The Global Pharmaceutical Industry According to the Economic Intelligence Unit (EIU), pharmaceutical sales are projected to increase an average of 6.9 percent annually over , outpacing the estimated global health care spending rate of 5.2 percent during that same period. Total pharma revenues are expected to increase from $1.23 trillion in 2014 to $1.61 trillion in In addition to oncology drugs, the cardiovascular therapeutic class will likely prosper, with four of the 10 projected blockbusters drugs belonging to the category. Spending on midmarket prescription drugs used for treating common chronic diseases is likely to stagnate as prices fall. Demand for generic drugs will continue to rise as payors take advantage of patent expiries to reduce costs. The Indian Pharmaceutical Industry Introduction The Indian pharmaceuticals market is the third largest in terms of volume and thirteenth largest in terms of value#. Branded generics dominate the pharmaceuticals market, constituting nearly 70 to 80 per cent of the market. India is the largest provider of generic drugs globally with the Indian generics accounting for 20 per cent of global exports in terms of volume. Of late, consolidation has become an important characteristic of the Indian pharmaceutical market as the industry is highly fragmented. India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers who have the potential to steer the industry ahead to an even higher level. Presently over 80 per cent of the antiretroviral drugs used globally to combat AIDS (Acquired Immuno Deficiency Syndrome) are supplied by Indian pharmaceutical firms. The UN-backed Medicines Patent Pool has signed six sub-licences with Aurobindo, Cipla, Desano, Emcure, Hetero Labs and Laurus Labs, allowing them to make generic anti-aids medicine Tenofovir Alafenamide (TAF) for 112 developing countries. 137

139 Overview Leading pharma producer Indian pharmaceutical sector accounts for about 2.4 percent of the global pharmaceutical industry in value terms and 10 percent in volume terms One of the highest exports India accounts for 20 percent of global exports in generics Among fastest growing industriess Rapidly growing healthcare sector Growing generics market Ranked 5th in terms of attracting FDI The country s pharmaceutical industry is expected to expand at a CAGR of percent over to reach USD 55 billion Indian healthcare sector, one of the fastest growing sectors,is expected to advance at a CAGR of 17 percent to reach USD 250 billion over The generics market is expected to grow to USD 26.1 billion by 2016 from USD 14.2 billion in 2015; India s generics market has immense potential for growth Cumulative FDI inflows worth USD13.3 billion from April 2000 to May 15 Attracted 5.19 percent of the total FDIs into India from April 2000 to May 15 Business Overview Our company ANG Lifesciences India Limited incorporated in the year 2006, engaged in the business of manufacturing and marketing of finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials. We carry out our production through our state-of-the-art manufacturing unit spread over 45,000 Sq. Ft. situated at Village Kishan pura, P.O. Manpura Baddi Nalagarh Road, Tehsil Nalagarh, Dist. Solan, Himachal Pradesh. Presently, our total built up area of 45,000 Sq. Ft. is dedicated to manufacturing of Dry Powder Injectables. Our manufacturing unit is well equipped with the most modern and validated manufacturing and analytical equipments and detailed standard operating procedures (SOP s) are in place with respect to Quality management, Personnel, Premises, Equipment, Documentation, Production, Complaints and Self Inspection/Audits. Our company is ISO-9001:2008 certified and has the most modern & sophisticated plant, equipments, technique and manpower. The planning and construction of plant has been done to conform to the regulatory requirements as per the norms of WHO G.M.P. and G.L.P. as per schedule-m (revised). We manufacture our products in compliance with GMP requirements. We have dedicated area, machinery, facilities and advanced equipments for manufacturing of B-Lactum & Non-B Lactum products as per GMP Norms. The production block provides appropriate personnel and material flow. As per GMP norms, all the production processes are documented and validated to establish the accuracy of the procedures and the control measures. Our production capacity is 2,100 Lacs Pcs per annum on three shift basis. Our products include sterile dry powder vials for Anti Biotics, Anti Ulcerant, Gluco inflammatory, Anti malarial and Anesthetic. corticoid and Anti 138

140 FACTORS AFFECTING OUR FUTURE RESULTS OF OPERATIONS Our results of operations could potentially be affected by the following factors amongst others: Our Relationships with Customers We believe in client retention and derive a significant proportion of our revenues from repeat business. We have long-term relationships with our key customers and our sales to these customers are conducted on the basis of purchase orders that they place with us from time to time. Most of our customers provide us with forecasts of order volumes that help us estimate our production volumes and our revenue for that particular product or business line. We believe that our ability to establish and strengthen client relationships will be an important factor in our future growth and our ability to continue increasing our profitability. Sales volume of our Products, Launches of New Products and Pricing of our Products The key growth driver for increase in our results of operations has been the volume growth of our existing products Actual volumes and specifications of customer orders are fixed only if and when customers place purchase orders with us. Our actual production volumes may differ significantly from our estimates due to variations in customer demand for our products. Further, since the number of purchase orders that our customers place with us may differ from year to year, which may adversely affect our revenues margins and, as a result, our results of operations Production Costs and Quality of our Manufacturing Facilities Our ability to maintain our position as a low-cost producer and increase our cost competitiveness is dependent on the efficient management of our production costs. The availability of key raw materials at competitive prices is critical and price fluctuations may adversely affect our margins and, as a result, our results of operations. Additionally, any significant changes in excise duties levied on raw materials and finished products and changes in salary costs of our employee could have an adverse effect on our financial condition and results of operations. In addition, in order to maximize our profits, we must maintain an appropriate standard of quality in our manufacturing facilities equipment and processes. Attaining and maintaining this level of quality requires considerable expense and planning. If we are unable to achieve and preserve the necessary level of quality in our manufacturing processes and facilities in the future, our financial condition and results of operations may be adversely affected. Competition from other industry players Our products face intense competition from products commercialized or under development by competitors in all our therapeutic areas. Our business, prospects, results of operations and financial condition could be adversely affected if our competitors gain significant market share at our expense in areas in which we are focused. Many of our competitors may have greater financial, manufacturing, research and development, marketing and other resources, more experience in obtaining regulatory approvals, greater geographic reach, broader product ranges and stronger sales forces. Accordingly, our results of operations depend significantly on various factors such as the demand for our products in the markets we operate in, our ability to manage our growth strategy and expansion plans, including our ability to grow our exports and our ability to grow and manage our distribution network in India. Macroeconomic Factors Macroeconomic factors, both in the Indian and international contexts, such as economic instability, political uncertainty, social upheavals or acts of God could influence our business. In addition, fluctuations in interest rates, exchange rates and inflation would have an effect on certain key aspects of our operations, including on the costs of our raw materials, the prices at which we can sell our pharmaceutical products, our finance costs required to fund our operations and profit margins. 139

141 Summary of the Results of Operation The following table sets forth select financial data from restated standalone profit and loss accounts for the period ended September 30, 2016 and for the years ended March 31, 2016, 2015, 2014, and 2013 and the components of which are also expressed as a percentage of total income for such periods. Particulars September 30, For the period ended March 31, 2016 % of Total Income 2016 % of Total Income 2015 % of Total Income 2014 % of Total Income 2013 % of Total Income INCOME Revenue from Operations 2, % 5, % 3, % 3, % 1, % Other Income % % % % % Total Income (A) 2, % 5, % 3, % 3, % 1, % EXPENDITURE Cost of Material Consumed 2, % 4, % 2, % 2, % 1, % Changes in inventories of (94.47) (3.17%) (20.80) (0.38%) (87.18) (2.36%) (43.34) (1.25%) (32.02) (1.97%) finished goods, traded goods and work-in-progress Employee Benefit Expenses % % % % % Finance costs % % % % % Depreciation and amortisation % % % % % expense Other Expenses % % % % % Total Expenses (B) 2, % 5, % 3, % 3, % 1, % Profit before extraordinary % % % % % items and tax (C ) Extraordinary items Profit before tax (D ) % % % % % Tax expense : (i) Current tax % % % % % Less: MAT Credit - - (3.09) (0.06%) (5.43) (0.15%) (0.45) (0.01%) % (ii) Deferred tax (1.44) (0.05%) % % % % (iii) Tax in respect of earlier year Total Tax Expense (E) % % % % % Profit for the year (D-E) % % % % (6.21) (0.38%) 140

142 Key Components of Our Profit And Loss Statement Revenue from operations Revenue from operations comprises of revenue from manufacture and sale of pharmaceutical formulations. Other Income Other income primarily comprises Interest Income, Profit on Sale of Fixed Assets, Income from job work by our company etc. Cost of Raw Material consumed Cost of materials consumed comprises cost of raw materials for manufacturing our products and packing materials as adjusted for inventory levels. Changes in inventories Changes in inventories represent changes in inventory levels of finished goods, traded goods and work in progress. Employee benefits expense Employee benefit expense includes salaries and wages, staff welfare expenses, bonus, Directors remuneration and Contribution to Provident Fund. Finance Costs Finance cost comprises Interest on Indebtedness, bank and other Finance charges. Depreciation and amortization expenses We recognize depreciation and amortization expense on a Written down value method as per the provisions set forth in the Companies Act Other expenses Other expenses consist of Other Manufacturing and Administrative Expenses. Financial Performance for the Six Months period ended September 30, 2016 Income Revenue from Operations During the period ended September 30, 2016 our Revenue from Operations is Rs. 2, Lacs which is 99.97% of Total Income. Other Income During the period ended September 30, 2016 our Other Income is Rs Lacs which is 0.03% of Total Income. Expenditure Total Expenses The Total Expenditure for the period ended September 30, 2016 is Rs. 2, Lacs which is about 93.53% of the Total Income.

143 Cost of Material Consumed Our Company has incurred Rs. 2, Lacs for cost of Material consumed during the period ended September 30, 2016 which is about % of the Total Income. Changes in inventory Changes in the inventory of finished goods, work in progress during the period ended September 30, 2016 is Rs. (94.47) Lacs which is about (3.17) % of the Total Income. Employee Benefits Expenses Our Company has incurred Rs Lacs as employee benefit expenses during the period ended September 30, 2016 which is about 7.66% of the Total Income. Finance Costs Finance cost for the period ended September 30, 2016 is Rs Lacs which is about 2.33% of the Total Income. Depreciation and Amortization Expenses Depreciation for the period ended September 30, 2016 is Rs Lacs calculated as per companies Act, is about 1.77% of the Total Income. Other Expenses Our Company has incurred Rs Lacs for the period ended September 30, 2016 which is about 12.40% of the Total Income. Profit before Tax The Profit before tax for the for the period ended September 30, 2016 stood at Lacs which is 6.47% of the Total Income Profit after Tax The Profit after Tax for the for the period ended September 30, 2016 stood at Lacs which is 4.97% of the Total Income Since, the results are for Six Months, Comparison with previous financial year would not reflect actual performance of the Company so the comparison has not been provided. COMPARISON OF THE FINANCIAL PERFORMANCE OF FISCAL 2016 WITH FISCAL 2015 Income Revenue from Operations During the F.Y the Revenue from Operations of our company increased to Rs. 5, Lacs as against Rs. 3, Lacs for the F.Y , representing increase of 49.08%. Such increase was attributed to increased volumes of sales due to marketing initiatives taken by the Company. Other Income During the F.Y the Other Income of our company increased to Rs Lacs as against Rs Lacs for the F.Y , representing increase by %. Such increase was attributed to increase in non operating income viz. job work done by our Company. 142

144 Expenditure Total Expenses The Total Expenditure for the F.Y increased to Rs. 5, Lacs from Rs. 3, Lacs during the F.Y The increase of 45.62% is in line with increase in scale of operations. Raw Material Consumed Our Company has incurred Rs. 4, Lacs as cost of material consumed during the F.Y as against Rs.2, Lacs during the FY The increase of 48.36% was due increased volume of operations during the year. Changes in inventories A Change in inventory is Rs. (20.80) Lacs during the F.Y as against Rs. (87.18) Lacs during the FY The decrease of % was due to better inventory management by our Company. Employee Benefits Expenses The employee benefit expense comprises of salaries, allowances, and other benefits to the employees. Our Company has incurred Rs Lacs as employee benefit expenses during the FY as compared to Rs Lacs during the FY The increase of 46.20% as compared to previous year is due to increase in employee cost due to revision in salaries and wages during the year. Finance Costs: Finance cost for the FY incurred Rs Lacs similar to Rs Lacs of the FY due to better management control. Depreciation and Amortization Expense Depreciation for the FY stood at Rs Lacs the same was Rs Lacs for the FY The increase by 11.98% is mainly due to increase in capital expenditure by our Company. Other Expenses Our Company has incurred Rs Lacs during the FY on Other Expenses as compared to Rs Lacs during FY The increase of 28.98% is due increase in volume of operations of the Company. Profit before Tax The Profit before tax for the FY increased to Rs Lacs from Rs Lacs in FY The increase of % is due to increase in volume of operations and increased margins due to efforts of management. Profit after Tax The Profit after Tax for the FY stood at Rs Lacs as against Rs Lacs for the FY The increase of % is due to increase in volume of operations and increased margins due to efforts of management. COMPARISON OF THE FINANCIAL PERFORMANCE OF FISCAL 2015 WITH FISCAL 2014 Income Revenue from Operations During the F.Y the Revenue from Operations of our company increased to Rs. 3, Lacs as against Rs. 3, Lacs for the F.Y , representing increase of 6.79%. Such increase was in the normal course of business. 143

145 Other Income During the F.Y the Other Income of our company decreased to Rs Lacs as against Rs Lacs for the F.Y , representing decrease by 20.91%. Such decrease was attributed to decrease in non operating income viz. job work income. Expenditure Total Expenses The Total Expenditure for the F.Y increased to Rs. 3, Lacs from Rs. 3, Lacs during the F.Y The increase of 6.33% is in line with scale of operations of the Company. Raw Material Consumed Our Company has incurred Rs. 2, Lacs as cost of raw material consumed during the F.Y as against Rs. 2, Lacs during the FY The increase of 6.71% is in line with increase in scale of operations of the Company. Changes in Inventories Change in inventory is Rs. (87.18) Lacs during the F.Y as against Rs. (43.34) Lacs during the FY The increase of % was due to increase in holding levels of inventories. Employee Benefits Expenses The employee benefit expense comprises of salaries, allowances, and other benefits to the employees. Our Company has incurred Rs Lacs as employee benefit expenses during the FY as compared to Rs Lacs during the FY The increase of 97.09% as compared to previous year is due to increase in employee cost due appointment of new marketing staff and revision of salaries and wages to existing manpower. Finance Costs Finance cost for the FY increased to Rs Lacs as against Rs Lacs of the FY The increase of % is mainly due to increase in borrowings. Depreciation and Amortization Expenses Depreciation for the FY stood at Rs Lacs the same was Rs Lacs for the FY The decrease by 68.98% is mainly due to effect of additional depreciation during the FY in compliance of provisions of the Companies Act, 2013 and the same was regularised during the FY Other Expenses Our Company has incurred Rs Lacs during the FY on Other Expenses as compared to Rs Lacs during FY The increase of 56.77% is mainly due to increase in marketing, travelling expenses Profit before Tax The Profit before tax for the FY increased to Rs Lacs from Rs Lacs in FY The increase of 34.54% is mainly due to increased margins with the effort of better management control. Profit after Tax The Profit after tax for the FY increased to Rs Lacs from Rs Lacs in FY The increase of % is mainly due to increased margins with the effort of better management control. COMPARISON OF THE FINANCIAL PERFORMANCE OF FISCAL 2014 WITH FISCAL

146 Income Revenue from Operations During the F.Y the Revenue from Operations of our company increased to Rs. 3, Lacs as against Rs. 1, Lacs for the F.Y , representing increase of %. Such increase was attributed to increased volumes of sales due to marketing initiatives taken by the Company. Other Income During the F.Y the Other Income of our company increased to Rs Lacs as against Rs Lacs for the F.Y , representing increase of %.The increase in mainly due to increase in job work income of the Company. Expenditure Total Expenses The Total Expenditure for the F.Y increased to Rs. 3, Lacs from Rs. 1, Lacs during the F.Y The increase of % is in line with the overall increase in operations during the FY Raw Material Consumed Our Company has incurred Rs. 2, Lacs as Raw Material Consumed during the F.Y as against Rs. 1, Lacs during the FY The increase of % is due to increase in volume of sales and is in line with increase in scale of operations. Changes in inventory Changes in inventory is Rs. (43.34) Lacs during the F.Y as against Rs. (32.02) Lacs during the FY The increase of % was due to increase in the holding levels of inventories by the Company. Employee Benefits Expenses Our Company has incurred Rs Lacs during the FY on Employee Benefit Expenses as compared to Rs Lacs during the FY The increase of % as compared to FY is due to increase in Manpower in the Company and increase in salaries and wages. Finance Costs Finance cost for the FY decreased to Rs Lacs as against Rs Lacs of the FY The decrease of % is due to decrease in borrowings. Depreciation and Amortization Expenses Depreciation for the FY stood at Rs Lacs for the FY the same was Rs Lacs. The increase by % is attributed to effect of additional depreciation during the FY due to change in method of depreciation from SLM to WDV method in compliance of provisions of the Companies Act, Other Expenses Our Company has incurred Rs Lacs on Other Expenses during the FY as compared to Rs Lacs during FY The increase of 66.69% is mainly due to overall increase in the pricing trend. Profit before Tax The Profit before tax for the FY increased to Rs Lacs from Rs Lacs in FY The increase of % is due to overall increased operations and better management control. 145

147 Profit after Tax The Profit after Tax for the FY stood at Rs Lacs as against loss of Rs Lacs for the FY representing increase of % due to overall increased operations and better management control. INFORMATION REQUIRED AS PER ITEM (2) (IX) (E) (5) OF PART A OF SCHEDULE VIII TO THE SEBI REGULATIONS: An analysis of reasons for the changes in significant items of income and expenditure is given hereunder: Unusual or infrequent events or transactions There are no unusual or infrequent events or transactions that have significantly affected operations of the Company. Significant economic changes that materially affected or are likely to affect income from continuing operations There are no significant economic changes that materially affected Company s operations or are likely to affect income from continuing operations. Any slowdown in the growth of Indian economy or future volatility in global commodity prices, could affect the business, including the future financial performance, shareholders funds and ability to implement strategy and the price of the Equity Shares. Known trends or uncertainties that have had or are expected to have a material adverse impact on sales, revenue or income from continuing operations. Apart from the Risks disclosed under the section titled Risk Factors no known trends or uncertainties are envisaged or are expected to have a material adverse impact on sales, revenue or income from continuing operations to Company s knowledge. Future changes in relationship between costs and revenues in case of events such as future increase in labor or material cost or prices that will cause material change. Other than as described in the sections entitled Risk Factors and this Management s Discussion and Analysis of Financial Condition and Results of Operations on pages 11 and 137, respectively, of this Draft Prospectus, to our knowledge there are no known factors which will have a material adverse impact on our operations or finances. The extent to which material increases in net sales / revenue is due to increase in sales volume, introduction of new products or services or increased sales prices The increase in revenues is by and large linked to increases in volume of all the activities carried out by the Company. Total turnover of each major industry segment in which the Company operated The Company operates in single segment in context of accounting standards 17 on Segment Reporting issued by ICAI. Status of any publicly announced New Products or Business Segment The Company has not announced any new products or business segment. The extent to which our Company s business is seasonal Our business is not seasonal in nature. Competitive conditions The pharmaceuticals market is highly competitive and fragmented, and we face competition from various domestic and international manufacturers. Moreover, as we seek to diversify into new geographical areas globally, we may face competition from existing players that have presence in respective markets. In order to counter the competition, our focus would be to provide products that would be in consonance with technical and quality 146

148 requirements of our customer as well as by trying to offer a competitive pricing model without compromise on the quality. Any significant dependence on a single or few suppliers or customers We are not under threat of dependence from any single supplier or customer. Details of material developments after the date of last balance sheet i.e. September 30, 2016 No circumstances have arisen since the date of last financial statement until the date of filing this Draft Prospectus, which materially and adversely affect or are likely to affect the operations or profitability of our Company, or value of its assets, or its ability to pay its liability within next twelve months. There is no subsequent development after the date of the Auditor s Report, which will have a material impact on the reserves, profits, earnings per share and book value of the Equity Shares of the Company. 147

149 SECTION VI: LEGAL AND OTHER INFORMATION OUTSTANDING LITIGATIONS AND MATERIAL DEVELOPMENTS Except as stated in this section, (i) there are no winding up petitions, outstanding litigations, suits, criminal or civil prosecutions, statutory or legal proceedings including those for economic offences, tax liabilities, show cause notices or legal notices pending against our Company or against any other company whose outcome could have a materially adverse effect on the business, operations, cash flows or financial position of our Company, and (ii) there are no defaults including non-payment or overdue of statutory dues, overdues to banks or financial institutions, defaults against banks or financial institutions or rollover or rescheduling of loans, defaults in creation of full security as per the terms of issue/other liabilities, proceedings initiated for economic, civil or any other offences (including past cases where penalties may or may not have been awarded and irrespective of whether they are specified under paragraph (1) of Part I of Schedule XIII of the Companies Act, 1956 and under paragraph (a) of Part I of Schedule V of the Companies Act, 2013) other than unclaimed liabilities of our Company except as stated below, and (iii) no disciplinary action has been taken by SEBI or any stock exchange against our Company, Directors or Promoters (iv) there are no past cases in which penalties were imposed by the authorities concerned on our Company, Promoters, Group Companies and Directors; and (v) no disciplinary action has been taken by SEBI or any stock exchange against our Company, Directors, Promoters and Group Companies. I. LITIGATION INVOLVING OUR COMPANY A. Litigation against our Company 1. Litigation involving Criminal Laws i. M/s SterChem ( Complainant ) has filed a Complaint bearing No. 789/15 before the Court of Sh. Loveleen, MM-02, Court No. 4, Main Building, Patiala House Court, New Delhi under Section 138 of the Negotiable Instruments Act, 1881 alleging dishonour of six cheques (bearing Nos dated for a sum of Rs. 15,00,000/-, dated for a sum of Rs. 10,00,000/-, dated 18 th April, 2015 for a sum of Rs. 10,00,000/-, dated for a sum of Rs. 10,00,000/-, dated for a sum of Rs. 10,00,000/-, dated for a sum of Rs. 10,00,000/- aggregating to Rs. 65,00,000/-) against the Company. The Hon ble Court has issued summons in the said Complaint and the matter is currently pending. ii. M/s Pravin Pharma ( Complainant ) has filed a Complaint bearing C.C. No /SS/2015 before the Court of Ld. Metropoiltan Magistrate, 50 th Court, Vikhroli, Mumbai under Section 138 read with section 142 of the Negotiable Instruments Act, 1881 alleging dishonour of four cheques (bearing Nos dated for a sum of Rs. 10,52,130/-, dated for a sum of Rs, 4,06,731/-, dated for a sum of Rs. 1,60788/- and dated for a sum of Rs. 3,72,725/-)against M/s A.K. Biotech Pvt. Ltd. & Ors. including our Company along with our Directors. The Hon ble Court has issued summons in the said Complaint and the matter is currently pending. iii. M/s Covalent Laboratories (Pvt.) Ltd. ( Complainant ) has filed a Complaint bearing No. Crl. M.P. No of 2016 before the XIV Addl. Chief Metropolitan Magistrate at Nampally, Hyderabad under section 138 of the Negotiable Instruments Act, 1881 alleging dishonour of one cheque (bearing Nos dated for a sum of Rs. 21,51,462/-) against our Company. The Hon ble Court has issued summons in the said Complaint and the matter is currently pending. iv. M/s Indus Biotech India ( Complainant ) has filed a Complaint bearing No. 295 of 2016 before the court of Jr. Division/JM1C Panipat, Punjab under section 138 of the Negotiable Instruments Act, 1881 alleging dishonour of two cheques (bearing No dated for a sum of Rs. 3,61,449/- and No dated for a sum of Rs. 4,81,595/-) against our Company. The Hon ble Court has issued summons in the said Complaint and the matter is currently pending. 2. Litigation Involving Actions by Statutory/Regulatory Authorities NIL 3. Litigation involving Tax Liabilities (i) Direct Tax Liabilities 148

150 Sr. Amount in dispute/demanded * (in Rs.) Type of Direct Tax No. of cases No. 1. Income Tax 2 9,87,450/- *To the extent quantifiable a) Notice dated June 16, 2011 issued to the Company for the Assessment Year A demand notice dated June 16, 2011for an amount of Rs. 9,49,820/- (Nine Lakhs Forty Nine Thousand Eight Hundred and Twenty only) was issued by the Assessing Officer to the Company under Section 143 (1) of the Income Tax Act, 1961 with respect to the return of income filed by the Company for the assessment year Thereafter, no further steps have been taken and the matter is currently pending. b) Notice dated June 30, 2016 issued to the Company for the Assessment Year A demand notice dated June 30, 2016 for an amount of Rs. 37,630/- (Thirty Seven Thousand Six Hundred Thirty only) was issued by the Assessing Officer to the Company under Section 143 (1) of the Income Tax Act, 1961 with respect to the return of income filed by the Company for the assessment year Thereafter, no further steps have been taken and the matter is currently pending. (ii) Indirect Taxes Liabilities NIL 4. Other Pending Litigations NIL B. Litigation filed by our Company 1. Litigation Involving Criminal Laws NIL 2. Litigation Involving Actions by Statutory/Regulatory Authorities NIL 3. Litigation involving Tax Liabilities (i) Direct Tax Liabilities NIL (ii) Indirect Taxes Liabilities NIL 4. Other Pending Litigations NIL II. LITIGATION RELATING TO OUR DIRECTORS A. Litigation against our Directors 1. Litigation Involving Criminal Laws Except as disclosed in the Part I(A)(1) relating to matters involving Mr. Rajesh Gupta and Ms. Saruchi Gupta Directors of the Company, there are no other litigations involving criminal laws against the Directors of the Company. 2. Litigation Involving Actions by Statutory/Regulatory Authorities NIL 149

151 3. Litigation involving Tax Liabilities (i) Direct Tax Liabilities Sr. No. Type of Direct Tax No. of cases Amount in dispute/demanded * (in Rs.) 1. Income Tax 5 23,34,630/- *To the extent quantifiable a) Notice dated March 31, 2010 issued to Mr. Rajesh Gupta for the Assessment Year A demand notice dated March 31, 2010 for an amount of Rs. 9,50,396/- (Rupees Nine Lakhs Fifty Thousand Three Hundred and Ninety Six only) was issued by the Assessing Officer to Mr. Rajesh Gupta under Section 245 [under section code 143(3)] of the Income Tax Act, 1961 with respect to furnishing incomplete/inaccurate return of income filed by him for the assessment year Further, a demand notice dated February 03, 2012 for an amount of Rs. 6,56,890/- (Rupees Six Lakhs Fifty Six Thousand Eight Hundred and Ninety only) was issued by the Assessing Officer to Mr. Rajesh Gupta under Section 245 (under section code 154) of the Income Tax Act, 1961 with respect to the return of income for furnishing incomplete/inaccurate return of income filed by him for the assessment year Thereafter, no further steps have been taken and the matter is currently pending. b) Notice dated November 29, 2013 issued to Mr. Rajesh Gupta for the Assessment Year A demand notice dated November 29, 2013 for an amount of Rs. 5,07,260/- (Rupees Five Lakhs Seven Thousand Two Hundred and Sixty only) was issued by the Assessing Officer to Mr. Rajesh Gupta under Section 245 (under section code 154) of the Income Tax Act, 1961 with respect to the return of income for furnishing incomplete/inaccurate return of income filed by him for the assessment year Thereafter, no further steps have been taken and the matter is currently pending. c) Notice dated March 14, 2012 issued to Mr. Rajesh Gupta for the Assessment Year A demand notice dated March 14, 2012 for an amount of Rs. 6,54,910/- (Rupees Six Lakhs Fifty Four Thousand Nine Hundred and Ten only) was issued by the Assessing Officer to Mr. Rajesh Gupta under Section 245 (under section code 143(1)a) of the Income Tax Act, 1961 with respect to the return of income not filed by him or for furnishing incomplete/inaccurate return of income filed by him for the assessment year Thereafter, no further steps have been taken and the matter is currently pending. d) Notice dated March 31, 2015 issued to the Company for the Assessment Year A demand notice dated March 31, 2015 for an amount of Rs. 4,42,430/- (Rupees Four Lakhs Forty Two Thousand Four Hundred and Thirty only) was issued by the Assessing Officer to Mr. Rajesh Gupta under Section 245 (under section code 143(3)) of the Income Tax Act, 1961 with respect to the return of income not filed by him or for furnishing incomplete/inaccurate return of income filed by him for the assessment year Thereafter, an Appeal was preferred against the said order dated March 31, The Appeal is still pending. e) Notice dated March 31, 2016 issued to Mr. Rajesh Gupta for the Assessment Year A demand notice dated 31 st March, 2016 for an amount of Rs. 73,140/- (Rupees Seventy Three Thousand One Hundred and Forty only) was issued by the Assessing Officer to Mr. Rajesh Gupta under Section 245 (under section code 143(3)) of the Income Tax Act, 1961 with respect to the return of income not filed by him or for furnishing incomplete/inaccurate return of income filed by him for the assessment year Thereafter, no further steps have been taken and the matter is currently pending (ii) Indirect Taxes Liabilities NIL 4. Other Pending Litigations NIL B. Litigation filed by our Directors 1. Litigation Involving Criminal Laws NIL 150

152 2. Litigation Involving Actions by Statutory/Regulatory Authorities NIL 3. Litigation involving Tax Liabilities (i) Direct Tax Liabilities NIL (ii) Indirect Taxes Liabilities NIL 4. Other Pending Litigations NIL III. LITIGATION RELATING TO OUR PROMOTERS A. Litigation against our Promoters 1. Litigation Involving Criminal Laws Except as disclosed in the Part 1(A)(1) relating to matters involving Mr. Rajesh Gupta and Ms. Saruchi Gupta Promoters of the Company, there are no other litigations involving criminal laws against the Promoters of the Company. 2. Litigation Involving Actions by Statutory/Regulatory Authorities NIL 3. Litigation involving Tax Liabilities (i) Direct Tax Liabilities Except as disclosed in the Part II(A)(3) relating to matters involving Mr. Rajesh Gupta Promoter of the Company, there are no other litigations involving criminal laws against the Promoters of the Company. (ii) Indirect Taxes Liabilities NIL 4. Other Pending Litigations NIL B. Litigation filed by our Promoters 1. Litigation Involving Criminal Laws NIL 2. Litigation Involving Actions by Statutory/Regulatory Authorities NIL 3. Litigation involving Tax Liabilities (i) Direct Tax Liabilities NIL 151

153 (ii) Indirect Taxes Liabilities NIL 4. Other Pending Litigations NIL IV. LITIGATION INVOLVING OUR GROUP ENTITIES A. Litigation against our Group Entities 1. Litigation Involving Criminal Laws NIL 2. Litigation Involving Actions by Statutory/Regulatory Authorities NIL 3. Litigation involving Tax Liabilities (i) Direct Tax Liabilities NIL (ii) Indirect Taxes Liabilities NIL 4. Other Pending Litigations NIL B. Litigation filed by our Group Entities 1. Litigation Involving Criminal Laws NIL 2. Litigation Involving Actions by Statutory/Regulatory Authorities NIL 3. Litigation involving Tax Liabilities (i) Direct Tax Liabilities NIL (ii) Indirect Taxes Liabilities NIL 4. Other Pending Litigations NIL 152

154 AMOUNTS OWED TO SMALL SCALE UNDERTAKINGS AND OTHER CREDITORS Details of dues to micro and small enterprises as defined under the Micro, Small and Medium Enterprises Development, 2006 As of September 30, 2016, the principal amount remaining unpaid is NIL. There are no cases of dues to micro and small enterprises as defined under the Micro, Small and Medium Enterprises Development, Material Creditors of our Company having an amount outstanding as on September 30, 2016 is more than Lakhs, being 5% of the Company s trade payables as per the last audited financial statements of our Company There are no Material Creditors as per the last audited financial statements i.e. as on September 30, 2016, other than 5 creditors with an outstanding amount of Rs Lakhs. For further details, please see website at Information provided on the website of our Company is not a part of this draft Prospectus and should not be deemed to be incorporated by reference. Anyone placing reliance on any other source of information, including our Company s website, would be doing so at its own risk. Outstanding Litigations involving the Company, or involving any other person or company whose outcome may have a material adverse effect on the Company s results of operations or financial position. Except as described above, as on date of this Prospectus, there are no outstanding litigations involving the Company and its, associates or involving any other person or company whose outcome may have a material adverse effect on the Company s results of operations or financial position. There are no litigations or legal actions, pending or taken, by any Ministry or Department of the Government or a statutory authority against our Promoters during the last 5 (five) years. Except as stated above under the Section titled Outstanding Litigation and Material Developments Litigations against our Directors Litigation Involving Actions by Statutory/Regulatory Authorities, there are no litigations or legal actions, pending or taken, by any Ministry or Department of the Government or a statutory authority against our Promoters during the last 5 (five) years. Pending proceedings initiated against our Company for economic offences. There are no pending proceedings initiated against our Company for economic offences. Inquiries, investigations etc. instituted under the Companies Act, 2013 or any previous company s enactment in the last 5 (five) years against our Company. There are no inquiries, investigations etc. instituted under the Companies Act or any previous company s enactment in the last 5 (five) years against our Company. Material Fraud against our Company in the last 5 (five) years There has been no material fraud committed against our Company in the last 5 (five) years. Fines imposed or compounding of offences for default There are no fines imposed or compounding of offences done in the last 5 (five) years immediately preceding the year of this Draft Prospectus for the Company for default or outstanding defaults. Material developments occurring after last balance sheet date Except as disclosed elsewhere in this Prospectus, there have been no material developments that have occurred after the Last Balance Sheet Date. For further details, please see the chapter titled Management Discussions and Analysis of Financial Conditions and Result of Operations beginning on page 137 of this Draft Prospectus. 153

155 Except as described above, as on date of this Draft Prospectus, there are no outstanding litigations involving the Company or involving any other person or company whose outcome may have a material adverse effect on the Company s results of operations or financial position. 154

156 GOVERNMENT AND OTHER APPROVALS Our Company has received the necessary licenses, permissions and approvals from the Central and State Governments and other government agencies/regulatory authorities/certification bodies required to undertake the Issue or continue our business activities. In view of the approvals listed below, we can undertake the Issue and our current business activities and no further major approvals from any governmental/regulatory authority or any other entity are required to be undertaken, in respect of the Issue or to continue our business activities. It must, however, be distinctly understood that in granting the above approvals, the Government of India and other authorities do not take any responsibility for the financial soundness of our Company or for the correctness of any of the statements or any commitments made or opinions expressed in this behalf. The main objects clause of the Memorandum of Association of our Company and the objects incidental, enable our Company to carry out its activities. Approvals for the Issue 1. The Board of Directors have, pursuant to Section 62(1)(c) of the Companies Act 2013, by a resolution passed at its meeting held on September 03, 2016 authorized the Issue, subject to the approval of the shareholders and such other authorities as may be necessary. 2. The shareholders of our Company have, pursuant to Section 62(1)(c) of the Companies Act 2013, by a special resolution passed in the Annual General Meeting held on September 30, 2016 authorized the Issue. 3. Approval dated [ ] from the BSE for listing of the Equity Shares issued by our Company pursuant to the Issue. 4. The ISIN of our Company is INE236W Approvals pertaining to Incorporation, name and constitution of our Company 1. Certificate of Incorporation dated June 14, 2006 issued by the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh in the name of ANG Lifesciences India Private Limited. 2. A fresh Certificate of Incorporation pursuant to the conversion of our Company into a public limited company was issued on March 2, 2010 by the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh. 3. A fresh Certificate of Incorporation pursuant to the conversion of our Company into a private limited company was issued on September 22, 2010 by the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh. 4. A fresh Certificate of Incorporation pursuant to the conversion of our Company into a public limited company from was issued on May 18, 2016 by the Registrar of Companies, Chandigarh. 5. The Corporate Identification Number (CIN) of our Company is U24230PB2006PLC General Approvals Sr. No. Approval 1 License to work a factory 2 License to manufacture for sale or for distribution of drugs other than those specified in Schedules C and C (1) and X under the Drugs and Cosmetics Rules, 1945 at premises situated at Vill: Kishanpura, Nalagarh Road, Baddi, Distt. Solan (H.P.) Authority Himachal Pradesh Government, Labour Department State Drugs Controller, Drug Licence and Controlling Authority, District Solan, Himachal Pradesh Reference/ Registration No. L&E(FAC) Date Expiry Date 01/01/2012 From to MB/08/710 18/07/ /07/

157 3 License to manufacture for sale or for distribution of drugs specified in Schedules C and C (1) excluding those specified in schedule X under the Drugs and Cosmetics Rules, 1945 at premises situated at Village Kishanpura, Nalagarh Road, Baddi, Distt. Solan (H.P.) Certificate of compliance with Good Manufacturing Practices issued as per WHO TRS No. 908 of for manufacture of general category Parenteral (SVP) and cytotoxic category White Bulk Drugs (APIs) 5 Good Laboratory Certificate under the provision of Schedule L-1 of the Drugs & Cosmetics Rules, Acknowledgement of Entrepreneur Memorandum State Drugs Controller, Drug Licence and Controlling Authority, District Solan, Himachal Pradesh State Drugs Controller, Controlling cum Licensing Authority Health & Family Welfare Department, Himachal Pradesh Government of Himachal Pradesh, Department of Industries MB/08/710 18/07/ /07/2018 MB/08/710 21/08/ /08/2017 MB/08/710 21/08/ /08/ /03/2011 NA 7 ISO Care Certification Private Limited CCPL/QMS/ /02/ /02/ Certificate of Registration under Employee State Insurance Act, 1948 Employee State Insurance Corporation HP /10/2009 Valid until cancelled 9 Certificate of Registration under Employees Provident Funds & Miscellaneous Provisions Act, Certificate of Importer- Exporter Code (IEC) Employee Provident Fund Organization Foreign Trade Development Officer, Ministry of Commerce and Industry, Govt. Of India HP /04/ /06/2007 Valid until cancelled Valid until cancelled Tax Related Approvals Sr. No. Approval Authority Reference/ Registration No. Date Expiry Date 1 Permanent Account Number (PAN) 2 Tax Deduction Account Number (TAN) Income Tax Department, Government of India Income Tax Department, Government of India AAHCA5390H - PTLA12597E - Valid until cancelled Valid until cancelled 156

158 3 Central Excise Registration Certificate for manufacture of excisable goods at Kishanpura, Solan, Himachal Pradesh Assistant Commissioner of Central Excise & Customs, Division Shimla AAHCA5390HEM001 23/07/2013 Valid until cancelled - 4 Certificate of registration under the Himachal Pradesh VAT Act 2005, 5 Certificate of Registration as Dealer under the Central Sales Tax Act, 1956 Assessing Authority, Excise and Taxation Department, Himachal Pradesh Assessing Authority, Excise & Taxation Department /07/ /07/ Service Tax Central Board of Excise and Customs AAHCA5390HSD001 06/08/2013 Till the business is discontinued Intellectual Property Rights Approvals Our Company has applied for registration and trademark approvals for various products under class including classes 5 and 35 granted by the Registrar of Trademarks under the Trademarks Act, 1999 in India, out of which the following 5 have been registered: Sr. No. 1 ACEFTRIA 2 3 ANGOPERA 4 5 Trademark Application No. Class Pending Government Approvals Our Company has applied for the following government approvals: Nature of approval /renewal Description Renewal for Consent under Section 21 of Air (Prevention and Control of Pollution) Act, 1981, under Section 25 of Water (Prevention and Control of Pollution) Act, 1974 and Authorization under Sub Rule (3) of Rule 5 of Hazardous Waste (Management, Handling and Transboundary Movement) Rules, Issuing authority Himachal Pradesh State Pollution Control Board. Date of acknowledgement of renewal application / Date of renewal application Application for renewal dated 18 th September, 2015 acknowledged on 5 th October,

159 Our Company has applied for registration of our logo with the Trademarks Registry, which is under process. The details of the same are as mentioned below: Sr. No. Particulars of Mark Word/Label Mark/ Device Mark Application No. Date of filing Class Status 1. Trademark Applied 2. Trademark Applied 158

160 Authority for the Issue SECTION VII- OTHER REGULATORY AND STATUTORY DISCLOSURES Our Board of Directors have vide resolution dated September 03, 2016 authorized the Issue, subject to the approval by the shareholders of our Company under Section 62(1)(c) of the Companies Act, The shareholders have authorized the Issue, by passing a Special Resolution at the Annual General Meeting held on September 30, 2016 in accordance with the provisions of Section 62(1)(c) of the Companies Act, The Company has obtained approval from BSE vide letter dated [ ] to use the name of BSE in this Issue Document for listing of equity shares on the SME platform of the BSE. BSE is the designated stock exchange. Prohibition by SEBI Our Company, our Promoters, our Promoters Group, our Directors or any of the Company s Associates or Group Companies and Companies with which the Directors of the Company are associated as Directors or Promoters, are currently not prohibited from accessing or operating in the capital market under any order or direction passed by SEBI, have not been debarred from accessing or operating in the capital market by the Board (SEBI) or any other regulatory or governmental authority. The listing of any securities of our Company has never been refused by any of the stock exchanges in India. None of our Promoters, Promoter Group, Directors has ever been part of Promoters, Promoter Group, Directors of any other Company which is debarred from accessing the capital market under any order or directions made by the Board (SEBI) or any other regulatory or governmental authority. None of our Directors are in any manner associated with the securities market and there has been no action taken by SEBI against our Directors or any entity in which our Directors are involved as promoters or directors. Prohibition by RBI Neither our Company, our Promoters, our Promoter Group, our Group Companies, relatives of our Promoters (as defined under the Companies Act), our Directors and Companies with which our Directors are associated as directors or promoters have not been declared as willful defaulters by RBI / government authorities and there are no violations of securities laws committed by them in the past and no proceedings are pending against them. Association with Securities Market We confirm that none of our Directors are associated with the securities market in any manner except for trading on day to day basis for the purpose of investment. Eligibility for the Issue Our Company is an Unlisted Issuer in terms of the SEBI (ICDR) Regulations; and this Issue is an Initial Public Issue in terms of the SEBI (ICDR) Regulations. This Issue is being made in terms of Regulation 106 (M) (1) of Chapter XB of the SEBI (ICDR) Regulations, 2009, as amended from time to time, whereby, an issuer whose post issue face value capital does not exceed ten crore rupees, shall issue shares to the public and propose to list the same on the Small and Medium Enterprise Exchange ("SME Exchange", in this case being the SME Platform of BSE). We confirm that: a) In accordance with Regulation 106(P) of the SEBI (ICDR) Regulations, this Issue has been hundred percent underwritten and that the Lead Manager to the Issue has underwritten more than 15% of the Total Issue Size. For further details pertaining to said underwriting, please refer to General Information Underwriting on page 37 of this Draft Prospectus. b) In accordance with Regulation 106(R) of the SEBI (ICDR) Regulations, we shall ensure that the total number of proposed allottees in the Issue is greater than or equal to fifty, otherwise, the entire application money will be refunded forthwith. If such money is not repaid within eight days from the date our Company becomes liable to repay it, then our 159

161 Company and every officer in default shall, on and from expiry of eight days, be liable to repay such application money, with interest as prescribed under Section 40 of the Companies Act, c) In accordance with Regulation 106(O) the SEBI (ICDR) Regulations, we have not filed any Draft Offer Document with SEBI nor has SEBI issued any observations on our Offer Document. Also, we shall ensure that our Lead Manager submits the copy of Prospectus along with a Due Diligence Certificate including additional confirmations as required to SEBI at the time of filing the Prospectus with Stock Exchange and the Registrar of Companies. d) In accordance with Regulation 106(V) of the SEBI (ICDR) Regulations, we have entered into an agreement with the Lead Manager and Market Maker to ensure compulsory Market Making for a minimum period of three years from the date of listing of equity shares offered in this Issue. For further details of the arrangement of market making please refer to General Information Details of the Market Making Arrangements for this Issue on page 37 of this Draft Prospectus. We further confirm that we shall be complying with all the other requirements as laid down for such an Issue under Chapter X-B of SEBI (ICDR) Regulations, as amended from time to time and subsequent circulars and guidelines issued by SEBI and the Stock Exchange. As per Regulation 106(M)(3) of SEBI (ICDR) Regulations, 2009, the provisions of Regulations 6(1), 6(2), 6(3),, Regulation 8, Regulation 9, Regulation 10, Regulation 25, Regulation 26, Regulation 27 and Sub-regulation (1) of Regulation 49 of SEBI (ICDR) Regulations, 2009 shall not apply to us in this Issue. Our Company is also eligible for the Issue in accordance with eligibility norms for Listing on SME Exchange / Platform BSE circular dated April 01, 2015, which states as follows: BSE ELIGIBILITY NORMS: ( 1. The Company has Net Tangible Assets of at least Rs. 3 Crore as per the latest audited financial results. 2. The Company has Net Worth (excluding revaluation reserve) of at least Rs. 3 Crores as per the latest audited financial results. 3. The Company has Track record of distributable profits in terms of sec. 123 of Companies Act, 2013 for at least two years out of immediately preceding three financial years and each financial year has a period of at least 12 months. Or has a Networth of at least Rs. 5 Crores. 4. The distributable Profit, Net tangible Assets and Net worth of the Company as per the restated financial statements is as set forth below:- (Rs. In Lacs) Particulars September 30, March 31, March 31, March 31, Distributable Profits* Net Tangible Assets** Net Worth*** * Distributable profits have been computed in terms section 123 of the Companies Act, 2013, Extraordinary income will not be considered for the purpose of calculating distributable profits. ** Net tangible assets are defined as the sum of all net assets (i.e. non current assets, current assets less current liabilities) of our Company, excluding deferred tax asset and intangible assets as defined in Accounting Standard 26 (AS 26) issued by the Institute of Chartered Accountants of India. *** Net Worth has been defined as the aggregate of the paid up share capital, share application money (excluding the portion included in other current liabilities) and reserves and surplus excluding revaluation reserve and after deducting miscellaneous expenditure, if any 5. Other Requirements i. The post-issue paid up capital of the company shall be at least Rs. 3 crore. 160

162 As on the date of this Draft Prospectus, the paid up capital of the Company is Rs Crores and the Post Issue Capital of our Company shall be Rs Crores which is in excess of Rs. 3 Crore. ii. The company shall mandatorily facilitate trading in demat securities and enter into an agreement with both the depositories. Our Company has entered into the tripartite agreements with CDSL and is in the process of entering into tripartite agreements with NSDL along with our Registrar for facilitating trading in dematerialized mode. iii. Companies shall mandatorily have a website. Our Company has a live and operational website: iv. There is no change in the promoters of the Company in the preceding one year from date of filing application to BSE for listing on SME segment. There is no change in the promoter/s of the Company in the preceding one year from date of filing application to BSE for listing on SME segment. 6. Certificate from the applicant company / promoting companies stating the following: a. The Company has not been referred to the Board for Industrial and Financial Reconstruction (BIFR). Our Company has not been referred to the Board for Industrial and Financial Reconstruction (BIFR). b. There is no winding up petition against the company that has been accepted by a court. There is no winding up petition against our Company that has been accepted by a court or liquidator has been appointed. DISCLAIMER CLAUSE OF SEBI IT IS TO BE DISTINCTLY UNDERSTOOD THAT SUBMISSION OF OFFER DOCUMENT TO SEBI SHOULD NOT IN ANY WAY BE DEEMED OR CONSTRUED THAT THE SAME HAS BEEN CLEARED OR APPROVED BY SEBI. SEBI DOES NOT TAKE ANY RESPONSIBILITY EITHER FOR THE FINANCIAL SOUNDNESS OF ANY SCHEME OR THE PROJECT FOR WHICH THE ISSUE IS PROPOSED TO BE MADE OR FOR THE CORRECTNESS OF THE STATEMENTS MADE OR OPINIONS EXPRESSED IN THE OFFER DOCUMENT. THE LEAD MERCHANT BANKER, GUINESS CORPORATE ADVISORS PRIVATE LIMITED, HAS CERTIFIED THAT THE DISCLOSURES MADE IN THE OFFER DOCUMENT ARE GENERALLY ADEQUATE AND ARE IN CONFORMITY WITH SEBI (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2009 IN FORCE FOR THE TIME BEING. THIS REQUIREMENT IS TO FACILITATE INVESTORS TO TAKE AN INFORMED DECISION FOR MAKING AN INVESTMENT IN THE PROPOSED ISSUE. IT SHOULD ALSO BE CLEARLY UNDERSTOOD THAT WHILE THE COMPANY IS PRIMARILY RESPONSIBLE FOR THE CORRECTNESS, ADEQUACY AND DISCLOSURE OF ALL RELEVANT INFORMATION IN THIS DRAFT PROSPECTUS, THE LEAD MERCHANT BANKER, GUINESS CORPORATE ADVISORS PRIVATE LIMITED IS EXPECTED TO EXERCISE DUE DILIGENCE TO ENSURE THAT THE COMPANY DISCHARGES ITS RESPONSIBILITY ADEQUATELY IN THIS BEHALF AND TOWARDS THIS PURPOSE, THE LEAD MERCHANT BANKER, GUINESS CORPORATE ADVISORS PRIVATE LIMITED HAS FURNISHED, A DUE DILIGENCE CERTIFICATE DATED MARCH 21, 2017 WHICH READS AS FOLLOWS: 1) WE HAVE EXAMINED VARIOUS DOCUMENTS INCLUDING THOSE RELATING TO LITIGATION LIKE COMMERCIAL DISPUTES, PATENT DISPUTES, DISPUTES WITH COLLABORATORS, ETC. AND OTHER MATERIAL IN CONNECTION WITH THE FINALISATION OF THIS DRAFT PROSPECTUS PERTAINING TO THE SAID ISSUE; 161

163 2) ON THE BASIS OF SUCH EXAMINATION AND THE DISCUSSIONS WITH THE ISSUER, ITS DIRECTORS AND OTHER OFFICERS, OTHER AGENCIES, AND INDEPENDENT VERIFICATION OF THE STATEMENTS CONCERNING THE OBJECTS OF THE ISSUE, PRICE JUSTIFICATION AND THE CONTENTS OF THE DOCUMENTS AND OTHER PAPERS FURNISHED BY THE ISSUER, WE CONFIRM THAT: (A) (B) (C) THE PROSPECTUS FILED WITH THE BOARD IS IN CONFORMITY WITH THE DOCUMENTS, MATERIALS AND PAPERS RELEVANT TO THE ISSUE; ALL THE LEGAL REQUIREMENTS RELATING TO THE ISSUE AS ALSO THE REGULATIONS GUIDELINES, INSTRUCTIONS, ETC. FRAMED/ISSUED BY THE BOARD, THE CENTRAL GOVERNMENT AND ANY OTHER COMPETENT AUTHORITY IN THIS BEHALF HAVE BEEN DULY COMPLIED WITH; AND THE DISCLOSURES MADE IN THIS DRAFT PROSPECTUS ARE TRUE, FAIR AND ADEQUATE TO ENABLE THE INVESTORS TO MAKE A WELL INFORMED DECISION AS TO THE INVESTMENT IN THE PROPOSED ISSUE AND SUCH DISCLOSURES ARE IN ACCORDANCE WITH THE REQUIREMENTS OF THE COMPANIES ACT, 1956, THE COMPANIES ACT, 2013 (TO THE EXTENT NOTIFIED), THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2009 AND OTHER APPLICABLE LEGAL REQUIREMENTS. 3) WE CONFIRM THAT BESIDES OURSELVES, ALL THE INTERMEDIARIES NAMED IN THIS DRAFT PROSPECTUS ARE REGISTERED WITH THE BOARD AND THAT TILL DATE SUCH REGISTRATION IS VALID. 4) WE HAVE SATISFIED OURSELVES ABOUT THE CAPABILITY OF THE UNDERWRITERS TO FULFIL THEIR UNDERWRITING COMMITMENTS. 5) WE CERTIFY THAT WRITTEN CONSENT FROM PROMOTERS HAS BEEN OBTAINED FOR INCLUSION OF THEIR SPECIFIED SECURITIES AS PART OF PROMOTERS CONTRIBUTION SUBJECT TO LOCK-IN AND THE SPECIFIED SECURITIES PROPOSED TO FORM PART OF PROMOTERS CONTRIBUTION SUBJECT TO LOCK-IN SHALL NOT BE DISPOSED / SOLD / TRANSFERRED BY THE PROMOTERS DURING THE PERIOD STARTING FROM THE DATE OF FILING OF THE PROSPECTUS WITH THE BOARD TILL THE DATE OF COMMENCEMENT OF LOCK-IN PERIOD AS STATED IN THIS DRAFT PROSPECTUS. 6) WE CERTIFY THAT REGULATION 33 OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2009, WHICH RELATES TO SPECIFIED SECURITIES INELIGIBLE FOR COMPUTATION OF PROMOTERS CONTRIBUTION, HAS BEEN DULY COMPLIED WITH AND APPROPRIATE DISCLOSURES AS TO COMPLIANCE WITH THE SAID REGULATION HAVE BEEN MADE IN THIS DRAFT PROSPECTUS. 7) WE UNDERTAKE THAT SUB-REGULATION (4) OF REGULATION 32 AND CLAUSE (C) AND (D) OF SUB-REGULATION (2) OF REGULATION 8 OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2009 SHALL BE COMPLIED WITH. WE CONFIRM THAT ARRANGEMENTS HAVE BEEN MADE TO ENSURE THAT PROMOTERS CONTRIBUTION SHALL BE RECEIVED AT LEAST ONE DAY BEFORE THE OPENING OF THE ISSUE. WE UNDERTAKE THAT AUDITORS CERTIFICATE TO THIS EFFECT SHALL BE DULY SUBMITTED TO THE BOARD. WE FURTHER CONFIRM THAT ARRANGEMENTS HAVE BEEN MADE TO ENSURE THAT PROMOTERS CONTRIBUTION SHALL BE KEPT IN AN ESCROW ACCOUNT WITH A SCHEDULED COMMERCIAL BANK AND SHALL BE RELEASED TO THE ISSUER ALONG WITH THE PROCEEDS OF THE PUBLIC ISSUE. - NOT APPLICABLE 8) WE CERTIFY THAT THE PROPOSED ACTIVITIES OF THE ISSUER FOR WHICH THE FUNDS ARE BEING RAISED IN THE PRESENT ISSUE FALL WITHIN THE MAIN OBJECTS LISTED IN THE OBJECT CLAUSE OF THE MEMORANDUM OF ASSOCIATION OR OTHER CHARTER OF 162

164 THE ISSUER AND THAT THE ACTIVITIES WHICH HAVE BEEN CARRIED OUT UNTIL NOW ARE VALID IN TERMS OF THE OBJECT CLAUSE OF ITS MEMORANDUM OF ASSOCIATION. 9) WE CONFIRM THAT NECESSARY ARRANGEMENTS HAVE BEEN MADE TO ENSURE THAT THE MONEYS RECEIVED PURSUANT TO THE ISSUE ARE KEPT IN A SEPARATE BANK ACCOUNT AS PER THE PROVISIONS OF SUB-SECTION (3) OF SECTION 40 OF THE COMPANIES ACT, 2013 AND THAT SUCH MONEYS SHALL BE RELEASED BY THE SAID BANK ONLY AFTER PERMISSION IS OBTAINED FROM THE STOCK EXCHANGE MENTIONED IN THIS DRAFT PROSPECTUS. WE FURTHER CONFIRM THAT THE AGREEMENT ENTERED INTO BETWEEN THE BANKERS TO THE ISSUE AND THE ISSUER SPECIFICALLY CONTAINS THIS CONDITION. - NOTED FOR COMPLIANCE 10) WE CERTIFY ALL THE SHARES SHALL BE ISSUED IN DEMATERIALIZED FORM IN COMPLIANCE WITH THE PROVISIONS OF SECTION 29 OF THE COMPANIES ACT, 2013 AND THE DEPOSITORIES ACT, 1996 AND THE REGULATIONS MADE THEREUNDER. 11) WE CERTIFY THAT ALL THE APPLICABLE DISCLOSURES MANDATED IN THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2009 HAVE BEEN MADE IN ADDITION TO DISCLOSURES WHICH, IN OUR VIEW, ARE FAIR AND ADEQUATE TO ENABLE THE INVESTOR TO MAKE A WELL INFORMED DECISION. 12) WE CERTIFY THAT THE FOLLOWING DISCLOSURES HAVE BEEN MADE IN THIS DRAFT PROSPECTUS: (A) (B) AN UNDERTAKING FROM THE ISSUER THAT AT ANY GIVEN TIME, THERE SHALL BE ONLY ONE DENOMINATION FOR THE EQUITY SHARES OF THE ISSUER AND AN UNDERTAKING FROM THE ISSUER THAT IT SHALL COMPLY WITH SUCH DISCLOSURE AND ACCOUNTING NORMS SPECIFIED BY THE BOARD FROM TIME TO TIME. 13) WE UNDERTAKE TO COMPLY WITH THE REGULATIONS PERTAINING TO ADVERTISEMENT IN TERMS OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2009 WHILE MAKING THE ISSUE. 14) WE ENCLOSE A NOTE EXPLAINING HOW THE PROCESS OF DUE DILIGENCE HAS BEEN EXERCISED BY US IN VIEW OF THE NATURE OF CURRENT BUSINESS BACKGROUND OR THE ISSUER, SITUATION AT WHICH THE PROPOSED BUSINESS STANDS, THE RISK FACTORS, PROMOTERS EXPERIENCE, ETC. 15) WE ENCLOSE A CHECKLIST CONFIRMING REGULATION-WISE COMPLIANCE WITH THE APPLICABLE PROVISIONS OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2009, CONTAINING DETAILS SUCH AS THE REGULATION NUMBER, ITS TEXT, THE STATUS OF COMPLIANCE, PAGE NUMBER OF THIS DRAFT PROSPECTUS WHERE THE REGULATION HAS BEEN COMPLIED WITH AND OUR COMMENTS, IF ANY. 16) WE ENCLOSE STATEMENT ON PRICE INFORMATION OF PAST ISSUES HANDLED BY MERCHANT BANKER, AS PER FORMAT SPECIFIED BY THE BOARD THROUGH CIRCULAR. 17) WE CERTIFY THAT PROFITS FROM RELATED PARTY TRANSACTIONS HAVE ARISEN FROM LEGITIMATE BUSINESS TRANSACTIONS THE FILING OF THIS OFFER DOCUMENT DOES NOT, HOWEVER, ABSOLVE OUR COMPANY FROM ANY LIABILITIES UNDER SECTION 34 OR SECTION 36 OF THE COMPANIES ACT, 2013 OR FROM THE REQUIREMENT OF OBTAINING SUCH STATUTORY AND/OR OTHER CLEARANCES AS MAY BE REQUIRED FOR THE PURPOSE OF THE PROPOSED ISSUE. SEBI FURTHER RESERVES THE RIGHT TO TAKE UP AT ANY POINT OF TIME, WITH THE LEAD MANAGER ANY IRREGULARITIES OR LAPSES IN THE OFFER DOCUMENT. 163

165 ADDITIONAL CONFIRMATIONS/ CERTIFICATION TO BE GIVEN BY MERCHANT BANKER IN DUE DILIGENCE CERTIFICATE TO BE GIVEN ALONG WITH OFFER DOCUMENT REGARDING SME EXCHANGE (1) WE CONFIRM THAT NONE OF THE INTERMEDIARIES NAMED IN THIS DRAFT PROSPECTUS HAVE BEEN DEBARRED FROM FUNCTIONING BY ANY REGULATORY AUTHORITY. (2) WE CONFIRM THAT ALL THE MATERIAL DISCLOSURES IN RESPECT OF THE ISSUER HAVE BEEN MADE IN DRAFT PROSPECTUS AND CERTIFY THAT ANY MATERIAL DEVELOPMENT IN THE ISSUER OR RELATING TO THE ISSUE UP TO THE COMMENCEMENT OF LISTING AND TRADING OF THE SPECIFIED SECURITIES OFFERED THROUGH THIS ISSUE SHALL BE INFORMED THROUGH PUBLIC NOTICES/ ADVERTISEMENTS IN ALL THOSE NEWSPAPERS IN WHICH PRE-ISSUE ADVERTISEMENT AND ADVERTISEMENT FOR OPENING OR CLOSURE OF THE ISSUE HAVE BEEN GIVEN. (3) WE CONFIRM THAT THE ABRIDGED PROSPECTUS CONTAINS ALL THE DISCLOSURES AS SPECIFIED IN THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, NOTED (4) WE CONFIRM THAT AGREEMENTS HAVE BEEN ENTERED INTO WITH THE DEPOSITORIES FOR DEMATERIALISATION OF THE SPECIFIED SECURITIES OF THE ISSUER. (5) WE CERTIFY THAT AS PER THE REQUIREMENTS OF FIRST PROVISO TO SUB-REGULATION (4) OF REGULATION 32 OF SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2009, CASH FLOW STATEMENT HAS BEEN PREPARED AND DISCLOSED IN THIS DRAFT PROSPECTUS. NOT APPLICABLE (6) WE CONFIRM THAT UNDERWRITING AND MARKET MAKING ARRANGEMENTS AS PER REQUIREMENTS OF REGULATION [106P] AND [106V] OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2009 HAVE BEEN MADE. Note: The filing of this Draft Prospectus does not, however, absolve our Company from any liabilities under section 34 and section 36 of the Companies Act, 2013 or from the requirement of obtaining such statutory and / or other clearances as may be required for the purpose of the proposed Issue. SEBI further reserves the right to take up at any point of time, with the LM any irregularities or lapses in this Draft Prospectus. All legal requirements pertaining to the Issue will be complied with at the time of registration of the Prospectus with the Registrar of Companies, Chandigarh in terms of Section 26 and 30 of the Companies Act,

166 Statement on Price Information of Past Issues handled by Guiness Corporate Advisors Private Limited: Sr. No. Issuer Name Issue size (Rs. in cr.) Issue price (Rs.) Listing Date Opening Price on listing date +/- % change in closing price, [+/- % change in closing benchmark]- 30th calendar days from listing +/- % change in closing price, [+/- % change in closing benchmark]- 90th calendar days from listing +/- % change in closing price, [+/- % change in closing benchmark]- 180th calendar days from listing 1 Gala Print City Limited % 0.00% -2.92% [-1.33%] [-5.62%] [-2.73%] 2 P. B. Films Limited % % % [+6.38%] [+0.33%] [-1.43%] % 41.50% % Nintec Systems Limited [-0.43%] [+7.48%] [+7.19%] % 5.56% 7.22% Shanti Educational Initiatives Limited [+5.86%] [+7.42%] [+0.45%] 5 Kwality Pharmaceuticals Limited % 15.11% 75.11% [+1.15%] [-0.78%] [-1.83%] 6 Riddhi Steel and Tube Limited % -3.03% % [-2.57%] [-6.55%] [+3.77%] 7 Aditya Consumer Marketing Limited % 40.67% NA [-4.45%] [-0.88%] 8 India Green Reality Limited % 18.67% NA [-6.25%] [-2.72%] 9 Aditya Vision Ltd % 16.67% NA [+1.45%] [+11.04%] 10 Super Fine Knitters Limited % NA NA [+2.15%] Notes 1. 30th calendar day has been taken as listing date plus 29 calendar days, 90th calendar day has been taken as listing date plus 89 calendar days, 180th calendar day has been taken as listing date plus 179 calendar days 2. Where the 30th day / 90th day / 180th of a particular year falls on a BSE trading holiday, the immediately following trading day has been considered. 3. Where the 30th day / 90th day /180th of a particular year falls on the day when there is no trade in equity share of the Company, preceding trading day has been considered. 4. BSE SENSEX has been considered as the benchmark index. 165

167 Summary Statement on Price Information of Past Issues handled by Guiness Corporate Advisors Private Limited: Financial Year Total no. of IPOs Total Funds raised (Rs. in cr.) Nos. of IPOs trading at discount as on 30th calendar day from listing date Over Between Less than 25% Nos. of IPOs trading at premium as on 30th calendar day from listing date Over Between Less than 25% Nos. of IPOs trading at discount as on 180th calendar day from listing date Over Between Less than 25% Nos. of IPOs trading at premium as on 180th calendar day from listing date Over Between Less than 25% 50% 25 50% 50% 25 50% 50% 25 50% 50% 25 50% April 1, NA NA 1 NA 2 5 NA NA 1 2 NA 1 date of filing of this Draft Prospectus NA NA 1 NA NA 2 NA 1 2 NA NA NA NA NA 2 NA 1 1 NA 1 1 NA NA 2 Track records of past issues handled by the Guiness Corporate Advisors Private Limited For details regarding the track record of the Guiness Corporate Advisors Private Limited, as specified under Circular reference CIR/MIRSD/1/2012 dated January 10, 2012 issued by the SEBI, please refer to the website of Guiness Corporate Advisors Private Limited at 166

168 Disclaimer Clause of BSE BSE Limited ( BSE ) has given vide its letter dated [ ], permission to this Company to use its name in this offer document as one of the stock exchanges on which this company s securities are proposed to be listed on the SME Platform. BSE has scrutinized this offer document for its limited internal purpose of deciding on the matter for granting the aforesaid permission to this company. BSE does not in any manner:- i. Warrant, certify or endorse the correctness or completeness of any of the contents of this offer document; or ii. Warrant that this company s securities will be listed or will continue to be listed on BSE; or iii. Take any responsibility for the financial or other soundness of this Company, its Promoters, its management or any scheme or project of this Company; And it should not for any reason be deemed or construed that this offer document has been cleared or approved by BSE. Every person who desires to apply for or otherwise acquires any securities in this Company may do so pursuant to independent inquiry, investigations and analysis and shall not have any claim against BSE whatsoever by reason of loss which may be suffered by such person consequent to or in connection with such subscription/acquisition whether by reason of anything stated or omitted to be stated herein or for any other reason whatsoever. Disclaimer from our Company, Directors and the Lead Manager Our Company, its Directors, and the Lead Manager accept no responsibility for statements made otherwise than those contained in this Draft Prospectus or, in case of the Company, in any advertisements or any other material issued by or at our Company s instance and anyone placing reliance on any other source of information including our website would be doing so at his or her own risk. Caution The Lead Manager accepts no responsibility, save to the limited extent as provided in the MOU for Issue Management entered into among the Lead Manager and our Company dated December 05, 2016, the Underwriting Agreement December 05, 2016 entered into among the Underwriter and our Company and the Market Making Agreement dated December 05, 2016 entered into among the Lead Manager, Market Maker and our Company. All information shall be made available by us and the Lead Manager to the public and investors at large and no selective or additional information would be available for a section of the investors in any manner whatsoever including at road show presentations, in research or sales reports or at collection centers or elsewhere. The Lead Manager and their respective associates and affiliates may engage in transactions with, and perform services for, our Company, affiliates or associates or third parties in the ordinary course of business and have engaged, or may in future engage, in investment banking transactions with our Company, affiliates or associates or third parties, for which they have received, and may in future receive, compensation. Note: Investors who apply in the Issue will be required to confirm and will be deemed to have represented to our Company, the Underwriters and their respective directors, officers, agents, affiliates and representatives that they are eligible under all applicable laws, rules, regulations, guidelines and approvals to acquire Equity Shares of our Company and will not offer, sell, pledge or transfer the Equity Shares of our Company to any person who is not eligible under applicable laws, rules, regulations, guidelines and approvals to acquire Equity Shares of our Company. Our Company, the Underwriters and their respective directors, officers, agents, affiliates and representatives accept no responsibility or liability for advising any investor on whether such investor is eligible to acquire Equity Shares of our Company. Disclaimer in respect of Jurisdiction This Issue is being made in India to persons resident in India {including Indian nationals resident in India who are majors, HUFs, companies, corporate bodies and societies registered under the applicable laws in India and authorized to invest in shares, Indian Mutual Funds registered with SEBI, Indian financial institutions, commercial banks, regional rural banks, co-operative banks (subject to RBI permission), or trusts under the applicable trust law and who are authorized under their constitution to hold and invest in shares, public financial institutions as specified in section 4A of the Companies Act, state industrial development corporations, Venture Capital Funds (VCFs) registered with SEBI, Insurance Companies registered with Insurance and Regulatory Development Authority, Provident Funds (subject to applicable law) with minimum corpus 167

169 of Rs. 2,500 Lacs and pension funds with minimum corpus of Rs. 2,500 Lacs, and to permitted non residents including FIIs, eligible NRIs, multilateral and bilateral development financial institutions, foreign venture capital investors registered with SEBI and eligible foreign investors provided they are eligible under all applicable laws and regulations to hold Equity Shares of our Company. This Draft Prospectus does not, however, constitute an offer to sell an invitation to subscribe to or purchase Equity Shares offered hereby in any other jurisdiction to any person to whom it is unlawful to make an offer or invitation in such jurisdiction. Any person into whose possession this Draft Prospectus comes is required to inform him or herself about and to observe, any such restrictions. Any dispute arising out of this Issue will be subject to the jurisdiction of appropriate court(s) in Amritsar only. No action has been or will be taken to permit a public offering in any jurisdiction where action would be required for that purpose. Accordingly, the Equity Shares represented thereby may not be offered or sold, directly or indirectly, and this Draft Prospectus may not be distributed, in any jurisdiction, except in accordance with the legal requirements applicable in such jurisdiction. Neither the delivery of this Draft Prospectus nor any sale hereunder shall, under any circumstances, create any implication that there has been any change in the affairs of our Company since the date hereof or that the information contained herein is correct as of any time subsequent to this date. Disclaimer clause under rule 144A of the U.S. Securities Act The Equity Shares have not been and will not be registered under the U.S. Securities Act 1933, as amended (the Securities Act ) or any state securities laws in the United States and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S of the Securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Accordingly, the Equity Shares will be offered and sold (i) in the United States only to qualified institutional buyers, as defined in Rule 144A of the Securities Act, and (ii) outside the United States in offshore transactions in reliance on Regulation S under the Securities Act and in compliance with the applicable laws of the jurisdiction where those offers and sales occur. The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Applicants may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction. Further, each applicant where required agrees that such applicant will not sell or transfer any Equity Shares or create any economic interest therein, including any off-shore derivative instruments, such as participatory notes, issued against the Equity Shares or any similar security, other than pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with applicable laws and legislations in each jurisdiction, including India. Filing This Draft Prospectus is being filed with BSE SME Platform, P. J. Towers, Dalal Street, Fort, Mumbai This Draft Prospectus shall not be filed with SEBI, nor will SEBI issue any observation on the offer document in term of Reg. 106(M) (3). However, a copy of the Prospectus shall be filed with SEBI at the SEBI Northern Regional Office, 5th Floor, Bank of Baroda Bldg, 16 Sansad Marg, New Delhi A copy of the Prospectus, along with the documents required to be filed under Section 26 of the Companies Act, 2013 will be delivered to the RoC situated at Corporate Bhawan, Plot No.4 B, Sector 27 B, Madhya Marg, Chandigarh Listing In terms of Chapter XB of the SEBI (ICDR) Regulations, 2009, application shall be made to SME Platform of BSE for obtaining permission for listing of the Equity Shares being offered and sold in the Issue on its SME Platform after the allotment in the Issue. If the permissions to deal in, and for an official quotation of, the Equity Shares are not granted by BSE, our Company will forthwith repay, all moneys received from the applicants in pursuance of the Prospectus. If such money is not repaid within the prescribed time, then our Company and every officer in default shall be liable to repay the money, with interest, as prescribed under applicable law. Our Company shall ensure that all steps for the completion of the necessary formalities for listing and commencement of trading at the SME Platform of BSE mentioned above are taken within 6 (six) Working Days of the Issue Closing Date. 168

170 The Company has obtained approval from BSE vide letter dated [.] to use the name of BSE in this Offer document for listing of equity shares on SME Platform of BSE. Consents Consents in writing of: (a) the Directors, the Company Secretary and Compliance Officer, Chief Financial Officer, the Statutory Auditor, Peer Review Auditor; the Banker(s) to the Company; and (b) the Lead Manager, Underwriters, Market Makers, Bankers to the Issue, Registrar to the Issue, Legal Advisor to the Issue to act in their respective capacities, have been obtained and shall be filed along with a copy of the Prospectus with the RoC, as required under Sections 26 of the Companies Act, 2013 and such consents shall not be withdrawn up to the time of delivery of the Prospectus for registration with the RoC. Expert Opinion Except the report of the Peer Reviewed Auditor on the Restated Financial Statements and report of the Statutory Auditor on the Statement of Tax Benefits included in this Draft Prospectus, our Company has not obtained any other expert opinion. Public Issue Expenses The Management estimates an expense or Rs Lacs towards Issue expenses. The expenses of this Issue include, among others, underwriting and management fees, selling commission, printing and distribution expenses, and payment to other intermediaries such as legal advisor, peer review auditor, Registrar to the Issue etc. and other out of pocket expenses.the estimated Issue expenses are as follows: Sr. No. Particulars 1. Issue management fees including fees selling commissions, brokerages, and payment to other intermediaries such as Legal Advisors, Registrars and other out of pocket expenses. Rs. in Lacs % of Total Expenses % of Total Issue Size Printing & Stationery, Distribution, Postage, etc Advertisement & Marketing Expenses Regulatory & Other Expenses Total Fees Payable to Lead Manager to the Issue The total fees payable to the Lead Manager will be as per the MoU between our Company and Lead Manager, copy of which is available for inspection at the Registered Office of our Company. Fees Payable to the Registrar to the Issue The fees payable by the Company to the Registrar to the Issue for processing of application, data entry, printing of CAN/, preparation of refund data on magnetic tape, printing of bulk mailing register will be as per the Memorandum of Understanding signed with the Company, copy of which is available for inspection at the Registered Office of our Company. The Registrar to the Issue will be reimbursed for all out-of-pocket expenses including cost of stationery, postage, stamp duty and communication expenses. Adequate funds will be provided by the Company to the Registrar to the Issue to enable them to send allotment advice by registered post/ speed post/ under certificate of posting. Underwriting Commission, Brokerage and Selling Commission The underwriting commission and the selling commission for the Issue are as set out in the Underwriting Agreement amongst the Company and Underwriter. The underwriting commission shall be paid as set out in the Underwriting Agreement based on the Issue price and the amount underwritten in the manner mentioned on page 37 of this Draft Prospectus. 169

171 Commission and Brokerage paid on previous Issues of our Equity Shares Since this is the Initial Public Issue of the Company, no sum has been paid or has been payable as commission or brokerage for subscribing to or procuring or agreeing to procure subscription for any of the Equity Shares since inception of the Company. Capital Issue during the last three years Our Company and its Group Companies have not made any capital issue viz. initial public offering, rights issue or composite issue during the last three years. Previous Public or Rights Issue There have been no public or rights issue by our Company during the last five years. Previous Issues of Equity Shares otherwise than for cash Except as stated in the section titled Capital Structure on page 40 of this Draft Prospectus, we have not made any previous issues of shares for consideration otherwise than for cash. Promise vis-à-vis performance Our Company is an Unlisted Issuer in terms of the SEBI (ICDR) Regulations, and this Issue is an Initial Public Offering in terms of the SEBI (ICDR) Regulations. Therefore, data regarding promise versus performance is not applicable to us. None of the Group Entities has made public issue of equity shares during the period of ten years immediately preceding the date of filing draft offer document with the BSE. Outstanding Debentures or Bonds and Redeemable Preference Shares and other Instruments There are no outstanding debentures or bonds or redeemable preference shares and other instruments issued by the Company as on the date of this Draft Prospectus. Stock Market Data for our Equity Shares This being an Initial Public Offering of the Equity Shares of our Company, the Equity Shares are not listed on any stock exchange. Investor Grievances and Redressal System The Company has appointed Big Share Services Private Limited as the Registrar to the Issue, to handle the investor grievances in co-ordination with the Compliance Officer of the Company. All grievances relating to the present Issue may be addressed to the Registrar with a copy to the Compliance Officer, giving full details such as name, address of the applicant, number of Equity Shares applied for, amount paid on application and name of bank and branch. The Company would monitor the work of the Registrar to ensure that the investor grievances are settled expeditiously and satisfactorily. The Registrar to the Issue, namely, Big Share Services Private Limited, will handle investor s grievances pertaining to the Issue. A fortnightly status report of the complaints received and redressed by them would be forwarded to the Company. The Company would also be co-coordinating with the Registrar to the Issue in attending to the grievances to the investor. The Company assures that the Board of Directors in respect of the complaints, if any, to be received shall adhere to the following schedules: Sr. No. Nature of Complaint Time Table 1. Non receipt of Demat Credit of Shares Within 7 days of receipt of complaint subject to production of satisfactory evidence 2. Any other complaint in relation to Public Issue Within 7 days of receipt of complaint with all relevant details. 170

172 Redressal of investors grievance is given top priority by the Company. The Committee oversees redressal of complaints of shareholders/investors and other important investor related matters. The Company has adequate arrangements for redressal of investor complaints as follows: Share transfer/ dematerialization/ rematerialization are handled by professionally managed Registrar and Transfer Agent, appointed by the Company in terms of SEBI s direction for appointment of Common Agency for physical as well as demat shares. The Registrars are constantly monitored and supported by qualified and experienced personnel of the Company. We have appointed Mr. Chandan Kapoor, as Company Secretary and Compliance Officer and he may be contacted in case of any pre-issue or post-issue problems. He can be contacted at the following address: Mr. Chandan Kapoor, Company Secretary & Compliance Officer, Address: Darbara Complex, SCO 113, First Floor, District Shopping Centre B Block, Ranjit Avenue, Amritsar Tel: , ; cs@anglifesciences.com Investors can contact the Compliance Officer or the Registrar to the Issue or the Lead Manager in case of any pre-issue or post-issue related problems, such as non-receipt of letters of Allotment, credit of Allotted Equity Shares in the respective beneficiary accounts etc. Further, our Board has constituted a Stakeholders Relationship Committee comprising our Directors, which is responsible for redressal of grievances of the security holders of our Company. For more information, see Our Management on page 87 of this Draft Prospectus. Pursuant to the press release no. PR. No. 85/2011 dated June 8, 2011, SEBI has launched a centralized web based complaints redress system SCORES. This would enable investors to lodge and follow up their complaints and track the status of redressal of such complaints from anywhere. For more details, investors are requested to visit the website Changes in Auditors Except as stated below, there is no change in the Auditors in the last three years: Date From To Reason BSV Associates, Ajay K Khanna & Due to Pre Chartered Company, Chartered occupation Accountants, Accountants, Capitalization of reserves or profits during last five (5) years. Our Company has not capitalized any reserve during last five (5) years. Revaluation of assets during the last five (5) years Our Company has not revalued its assets during the last five (5) years. 171

173 SECTION VIII ISSUE RELATED INFORMATION TERMS OF THE ISSUE The Equity Shares being offered are subject to the provisions of the Companies Act, SEBI (ICDR) Regulations, 2009 our Memorandum and Articles of Association, the terms of this Draft Prospectus, the Prospectus, the Application Form, the Revision Form, the Confirmation of Allocation Note and other terms and conditions as may be incorporated in the allotment advices and other documents/certificates that may be executed in respect of this Issue. The Equity Shares shall also be subject to laws as applicable, guidelines, notifications and regulations relating to the issue of capital and listing and trading of securities issued from time to time by SEBI, the Government of India, the Stock Exchanges, the RBI, RoC and/or other authorities, as in force on the date of the Issue and to the extent applicable. Ranking of Equity Shares The Equity Shares being offered shall be subject to the provisions of the Companies Act, our Memorandum and Articles of Association and shall rank pari-passu in all respects with the existing Equity Shares including in respect of the rights to receive dividends and other corporate benefits, if any, declared by us after the date of Allotment. For further details, please refer to the section titled Main Provisions of the Articles of Association on page 217 of this Draft Prospectus. Mode of Payment of Dividend The declaration and payment of dividend will be as per the provisions of Companies Act, the Articles of Association and the provisions of the Listing Agreement executed with the Stock Exchange, and shall be recommended by the Board of Directors and the shareholders at their discretion and will depend on a number of factors, including but not limited to earnings, capital requirements and overall financial condition of our Company. We shall pay dividends in cash and as per provisions of the Companies Act For further details, please refer to the section titled Dividend Policy on page 106 of this Draft Prospectus. Face Value and Issue Price The Equity Shares having a face value of Rs. 10/- each are being offered in terms of this Draft Prospectus at the price of Rs. 80/- per Equity Share. The Issue Price is determined by our Company in consultation with the Lead Manager and is justified under the section titled Basis for Issue Price on page 55 of this Draft Prospectus. At any given point of time there shall be only one denomination of the Equity Shares of our Company, subject to applicable laws. Rights of the Equity Shareholders Subject to applicable laws, rules, regulations and guidelines, the equity shareholders shall have the following rights: Right to receive dividend, if declared; Right to attend general meetings and exercise voting powers, unless prohibited by law; Right to vote on a poll either in person or by proxy; Right to receive offers for rights shares and be allotted bonus shares, if announced; Right to receive surplus on liquidation; Right of free transferability; and Such other rights, as may be available to a shareholder of a listed public company under the Companies Act, terms of Listing Agreements with Stock Exchange and the Memorandum and Articles of Association of the Company. For a detailed description of the main provision of the Articles of Association of our Company relating to voting rights, dividend, forfeiture and lien and / or consolidation / splitting, etc., please see the section titled "Main Provisions of Articles of Association " beginning on page 217 of this Draft Prospectus. Minimum Application Value; Market Lot and Trading Lot In terms of section 29 of the Companies Act, 2013, the Equity Shares shall be allotted only in dematerialized form. In terms of existing SEBI ICDR Regulations, trading in the Equity Shares shall only be in dematerialized form for all investors. 172

174 The trading of the Equity Shares will happen in the minimum lot size of 1,600 Equity Shares in terms of the SEBI circular No. CIR/MRD/DSA/06/2012 dated February 21, 2012 and the same may be modified by BSE from time to time by giving prior notice to investors at large. Allocation and allotment of Equity Shares through this Issue will be done in multiples of 1,600 Equity Share subject to a minimum allotment of 1,600 Equity Shares to the successful applicants. Minimum Number of Allottees The minimum number of Allottees in this Issue shall be 50 shareholders. In case the minimum number of prospective Allottees is less than 50, no allotment will be made pursuant to this Issue and the monies collected shall be refunded within 15 days of closure of Issue. Joint Holders Where two or more persons are registered as the holders of any Equity Shares, they will be deemed to hold such Equity Shares as joint-holders with benefits of survivorship. Nomination Facility to Investor In accordance with Section 72 of the Companies Act, 2013, the sole or first applicant, along with other joint applicant, may nominate any one person in whom, in the event of the death of sole applicant or in case of joint applicant, death of all the applicants, as the case may be, the Equity Shares allotted, if any, shall vest. A person, being a nominee, entitled to the Equity Shares by reason of the death of the original holder(s), shall in accordance with Section 72 of the Companies Act, 2013, be entitled to the same advantages to which he or she would be entitled if he or she were the registered holder of the Equity Share(s). Where the nominee is a minor, the holder(s) may make a nomination to appoint, in the prescribed manner, any person to become entitled to Equity Share(s) in the event of his or her death during the minority. A nomination shall stand rescinded upon a sale of equity share(s) by the person nominating. A buyer will be entitled to make a fresh nomination in the manner prescribed. Fresh nomination can be made only on the prescribed form available on request at the Registered Office of our Company or to the Registrar and Transfer Agents of our Company. In accordance with Section 72 of the Companies Act, 2013, any person who becomes a nominee by virtue of Section 72 of the Companies Act, 2013, shall upon the production of such evidence as may be required by the Board, elect either: to register himself or herself as the holder of the Equity Shares; or to make such transfer of the Equity Shares, as the deceased holder could have made. Further, the Board may at any time give notice requiring any nominee to choose either to be registered himself or herself or to transfer the Equity Shares, and if the notice is not complied with within a period of ninety days, the Board may thereafter withhold payment of all dividends, bonuses or other moneys payable in respect of the Equity Shares, until the requirements of the notice have been complied with. In case the allotment of Equity Shares is in dematerialized form, there is no need to make a separate nomination with us. Nominations registered with the respective depository participant of the applicant would prevail. If the investors require changing the nomination, they are requested to inform their respective depository participant. Period of Operation of Subscription List of Public Issue ISSUE OPENS ON ISSUE CLOSES ON [ ] [ ] Minimum Subscription This Issue is not restricted to any minimum subscription level. This Issue is 100% underwritten. If the Issuer does not receive the subscription of 100% of the Issue through this offer document including devolvement of Underwriters within sixty days from the date of closure of the Issue, the Issuer shall forthwith refund the entire subscription amount received. If there is a delay beyond eight days after the Issuer becomes liable to pay the amount, the Issuer shall pay interest prescribed under section 40 of the Companies Act,

175 In accordance with Regulation 106 P (1) of the SEBI (ICDR) Regulations, our Issue shall be hundred percent underwritten. Thus, the underwriting obligations shall be for the entire hundred percent of the Issue through the Prospectus and shall not be restricted to the minimum subscription level. In accordance with Regulation 106(R) of the SEBI (ICDR) Regulations, our Company shall ensure that the number of prospective allottees to whom the Equity Shares will allotted will not be less than 50 (Fifty). Further, the minimum application size in terms of number of specified securities shall not be less than Rupees One Lac per application. Arrangements for Disposal of Odd Lots The trading of the Equity Shares will happen in the minimum contract size of 1,600 shares. However, the Market Maker shall buy the entire shareholding of a shareholder in one lot, where value of such shareholding is less than the minimum lot size allowed for trading on the SME platform of BSE. Restrictions, If any, on Transfer and Transmission of Shares or Debentures and on their Consolidation or Splitting. For a detailed description in respect of restrictions, if any, on transfer and transmission of shares and on their consolidation / splitting, please refer to the section titled Main Provisions of the Articles of Association on Page no. 217 of this Draft Prospectus. Option to receive Equity Shares in Dematerialized Form As per section 29 of Companies Act 2013, allotment of Equity Shares will be made only in dematerialised form. Migration to Main Board Our Company may migrate to the main board of BSE from SME platform of BSE on a later date subject to the following: a) If the Paid up Capital of the Company is likely to increase above Rs. 25 crores by virtue of any further issue of capital by way of rights, preferential issue, bonus issue etc. (which has been approved by a special resolution through postal ballot wherein the votes cast by the shareholders other than the promoters in favour of the proposal amount to at least two times the number of votes cast by shareholders other than promoter shareholders against the proposal and for which the Company has obtained in-principal approval from the main board), we shall have to apply to BSE for listing our shares on its main board subject to the fulfillment of the eligibility criteria for listing of specified securities laid down by the main board. OR b) If the Paid up Capital of the company is more than Rs. 10 crores but below Rs. 25 crores, we may still apply for migration to the main board if the same has been approved by a special resolution through postal ballot wherein the votes cast by the shareholders other than the promoters in favour of the proposal amount to at least two times the number of votes cast by shareholders other than promoter shareholders against the proposal. Market Making The shares offered through this Issue are proposed to be listed on the SME Platform of BSE (SME Exchange), wherein the Lead Manager to this Issue shall ensure compulsory Market Making through the registered Market Maker of the SME Exchange for a minimum period of three years from the date of listing on the SME Platform of BSE. For further details of the agreement entered into between the Company, the Lead Manager and the Market Maker please refer to General Information - Details of the Market Making Arrangement for this Issue" on page 37 of this Draft Prospectus. In accordance with the SEBI Circular No.CIR/MRD/DSA/31/2012 dated November 27, 2012; it has decided to make applicable limits on the upper side for the Market Maker during market making process taking into consideration the Issue size in the following manner: Issue size Buy quote exemption threshold (including mandatory initial inventory of 5% of issue size) Re-entry threshold for buy quotes (including mandatory initial inventory of 5% of issue size) 174

176 Upto Rs. 20 Crore, (as applicable in our 25% 24% case) Rs. 20 Crore to Rs. 50 Crore 20% 19% Rs. 50 Crore to Rs. 80 Crore 15% 14% Above Rs. 80 Crore 12% 11% Further, the following shall apply to market makers while managing their inventory during the process of market making: The exemption from threshold shall not be applicable for the first three months of market making and the market maker shall be required to provide two way quotes during this period irrespective of the level of holding. Any initial holdings over and above such 5% of issue size would not be counted towards the inventory levels prescribed. Apart from the above mandatory inventory, only those shares which have been acquired on the platform of the exchange during market making process shall be counted towards the Market Maker's threshold. Threshold limit will take into consideration, the inventory level across market makers The Market Maker shall give two way quotes till it reaches the upper limit threshold; thereafter it has the option to give only sell quotes. Two way quotes shall be resumed the moment inventory reaches the prescribed re-entry threshold. In view of the Market Maker obligation, there shall be no exemption/threshold on downside. However, in the event the Market Maker exhausts its inventory through market making process on the platform of the exchange, the concerned stock exchange may intimate the same to SEBI after due verification. New Financial Instruments The Issuer Company is not issuing any new financial instruments through this Issue. Jurisdiction Exclusive jurisdiction for the purpose of this Issue is with the competent courts / authorities in Amritsar, India. The Equity Shares have not been and will not be registered under the US Securities Act of 1933 ( Securities Act ) or any state securities laws in the United States, and may not be offered or sold within the United States (as defined in Regulation S under the Securities Act), except pursuant to an exemption from or in a transaction not subject to, registration Issues and sales occur. The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and applications may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction. 175

177 ISSUE STRUCTURE This Issue is being made in terms of Regulation 106(M)(1) of Chapter XB of SEBI (ICDR) Regulations, 2009, as amended from time to time, whereby, an issuer whose post-issue face value capital does not exceed ten Crores rupees shall issue shares to the public and propose to list the same on the Small and Medium Enterprise Exchange ( SME Exchange, in this case being the SME Platform of BSE). For further details regarding the salient features and terms of such an Issue please refer the section titled Terms of the Issue and Issue Procedure on page 172 and 178 of this Draft Prospectus. Following is the Issue structure: Public Issue of 15,00,800 Equity Shares of Rs.10/- each for cash at a price of Rs.80/- per Equity Share (including a Share premium of Rs. 70/- per Equity Share) aggregating to Rs Lacs The Issue comprises reservation of 76,800 Equity Shares for subscription by the designated Market Maker ( the Market Maker Reservation Portion ) and Net Issue to Public of 14,24,000 Equity Shares ( the Net Issue ). Particulars of the Issue Net Issue to Public* Market Maker Reservation Portion Number of Equity Shares 14,24,000 Equity Shares 76,800 Equity Shares available for allocation Percentage of Issue Size available for allocation Basis of Allotment 94.88% of the Issue size 5.12% of the Issue size Proportionate subject to minimum allotment of 1,600 Equity Shares and further allotment in multiples of 1,600 Equity Shares each. Firm Allotment For further details please refer to the section titled Issue Procedure Basis of Allotment on page 210 of this Draft Prospectus. Mode of Application Through ASBA Process Only Through ASBA Process Only Minimum Application Size For QIB and NII: Such number of Equity Shares in multiples of 1,600 Equity Shares such that the Application Value exceeds Rs. 2,00,000/- 76,800 Equity Shares For Retail Individuals: 1,600 Equity Shares Maximum Application For QIB and NII: 76,800 Equity Shares Size The maximum application size is the Net Issue to public subject to limits the investor has to adhere under the relevant laws and regulations as applicable. For Retail Individuals: Such number of Equity Shares in multiples of 1,600 Equity Shares such that the Application Value does not exceed Rs. 2,00,000/-. Mode of Allotment Dematerialized Form only Dematerialized Form only Trading Lot 1,600 Equity Shares 1,600 Equity Shares, However the Market Maker may accept odd lots if any in the market as required under the SEBI (ICDR) Regulations, Terms of Payment The entire Application Amount will be payable at the time of submission of the Application Form. *As per Regulation 43(4) of the SEBI (ICDR) Regulations, as amended, as present Issue is a fixed price Issue the Allocation in the net Issue to the public category shall be made as follows: 176

178 a) Minimum fifty percent to retail individual investors; and b) Remaining to i. Individual applicants other than retail individual investors; and ii. Other investors including corporate bodies or institutions, irrespective of the number of specified securities applied for; c) The unsubscribed portion in either of the categories specified in (a) or (b) above may be allocated to the applicants in the other category. If the retail individual investor category is entitled to more than fifty per cent on proportionate basis, accordingly the retail individual investors shall be allocated that higher percentage. Withdrawal of the Issue The Company, in consultation with the LM, reserves the right not to proceed with the Issue at any time before the Issue Opening Date, without assigning any reason thereof. Notwithstanding the foregoing, the Issue is also subject to obtaining the following: 1. The final listing and trading approvals of BSE for listing of Equity Shares offered through this issue on its SME Platform, which the Company shall apply for after Allotment and, 2. The final ROC approval of the Prospectus after it is filed with the ROC. In case, the Company wishes to withdraw the Issue after Issue opening but before allotment, the Company will give public notice giving reasons for withdrawal of Issue. The public notice will appear in two widely circulated national newspapers (One each in English and Hindi) and one in regional newspaper. The Lead Manager, through the Registrar to the Issue, will instruct the SCSBs to unblock the ASBA Accounts within one Working Day from the day of receipt of such instruction. The notice of withdrawal will be issued in the same newspapers where the pre-issue advertisements have appeared and the Stock Exchange will also be informed promptly. If our Company withdraws the Issue after the Issue Closing Date and subsequently decides to undertake a public offering of Equity Shares, our Company will file a fresh offer document with the stock exchange where the Equity Shares may be proposed to be listed. Issue Programme Issue Opening Date Issue Closing Date [ ] [ ] Applications and any revisions to the same will be accepted only between a.m. and 5.00 p.m. (Indian Standard Time) during the Issue Period at the Application Centres mentioned in the Application Form except that on the Issue Closing Date applications will be accepted only between a.m. and 3.00 p.m. (Indian Standard Time). Applications will be accepted only on Working day i.e. all trading days of stock exchanges excluding Sunday and bank holidays as per SEBI circular No. SEBI/HO/CFD/DIL/CIR/P/2016/26 dated January 21,

179 ISSUE PROCEDURE All Applicants should review the General Information Document for Investing in Public Issues prepared and issued in accordance with the circular (CIR/CFD/DIL/12/2013) dated October 23, 2013 notified by SEBI (the General Information Document ) included below under section Part B General Information Document, which highlights the key rules, processes and procedures applicable to public issues in general in accordance with the provisions of the Companies Act, 1956, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts (Regulation) Rules, 1957 and the SEBI Regulations as amended. The General Information Document has been updated to include reference to the Securities and Exchange Board of India (Foreign Portfolio Investors) Regulations, 2014, SEBI Listing Regulations, 2015 and certain notified provisions of the Companies Act, 2013, to the extent applicable to a public issue. The General Information Document is also available on the websites of the Stock Exchange and the Lead Manager. Please refer to the relevant provisions of the General Information Document which are applicable to the Issue. Pursuant to the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) (Fifth Amendment) Regulations, 2015, there have been certain changes in the issue procedure for initial public offerings including making ASBA Process mandatory for all investors, allowing registrar, share transfer agents, collecting depository participants and stock brokers to accept application forms. Further, SEBI, by its circular (CIR/CFD/POLICYCELL/11/2015) dated November 10, 2015, reduced the time taken for listing after the closure of an issue to six working days. These changes are applicable for all public issues which open on or after January 1, We shall make appropriate changes to the Issue Procedure section and other sections of this Draft Prospectus and the Prospectus prior to filing with RoC. Please note that the information stated/covered in this section may not be complete and/or accurate and as such would be subject to modification/change. Our Company and the Lead Manager do not accept any responsibility for the completeness and accuracy of the information stated in this section and the General Information Document. Our Company and the Lead Manager would not be liable for any amendment, modification or change in applicable law, which may occur after the date of this Draft Prospectus. Applicants are advised to make their independent investigations and ensure that their Applications do not exceed the investment limits or maximum number of Equity Shares that can be held by them under applicable law or as specified in this Draft Prospectus and the Prospectus. Fixed Price Issue Procedure Part A The Issue is being made under Regulation 106 (M) (1) of Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 via Fixed Price Process. Applicants are required to submit their Applications to designated intermediaries. In case of QIB Applicants, the Company in consultation with the Lead Manager may reject Applications at the time of acceptance of Application Form provided that the reasons for such rejection shall be provided to such Applicant in writing. In case of Non Institutional Applicants and Retail Individual Applicants, our Company would have a right to reject the Applications only on technical grounds. Investors should note that according to section 29(1) of Companies Act, 2013, allotment of Equity Shares to all successful Applicants will only be in dematerialized form. The Application Forms which do not have the details of the Applicant s depository account including DP ID, PAN and Beneficiary Account Number shall be treated as incomplete and liable to be rejected. In case DP ID, Client ID and PAN mentioned in the Application Form and entered into the electronic application system of the stock exchanges by the Brokers (including sub-brokers) do not match with the DP ID, Client ID and PAN available in the depository database, the application is liable to be rejected. Applicants will not have the option of getting allotment of the Equity Shares in physical form. The Equity Shares on allotment shall be traded only in the dematerialized segment of the Stock Exchange. Applicants are required to ensure that the PAN (of the sole/ first Applicant) provided in the Application Form is exactly the same as the PAN of the person(s) in whose name the relevant beneficiary account is held. In case of joint Applications, the Application Form should contain only the name of the first Applicant whose name should also appear as the first holder of the beneficiary account held in joint names. The signature of only such first Applicant would be required in the Application Form and such first Applicant would be deemed to have signed on behalf of the joint holders. 178

180 Application Form Copies of the Application Form and the abridged prospectus will be available at the offices of the Lead Manager, the Designated Intermediaries, and Registered Office of our Company. An electronic copy of the Application Form will also be available for download on the websites of the Lead Manager, SCSBs, the BSE ( the terminals of the Registered Brokers, the RTAs and the CDPs at least one day prior to the Issue Opening Date. Pursuant to SEBI Circular dated November 10, 2015 and bearing Reference No. CIR/CFD/POLICYCELL/11/2015 which shall be applicable for all public issues opening on or after January 01, 2016, all the investors shall apply through ASBA Mode only. Applicants must provide bank account details and authorisation to block funds in the relevant space provided in the Application Form and the Application Forms that do not contain such details are liable to be rejected. Applicants shall ensure that the Applications are made on Application Forms bearing the stamp of the Designated Intermediary, submitted at the Collection Centres only (except in case of electronic Application Forms) and the Application Forms not bearing such specified stamp are liable to be rejected. The prescribed colour of the Application Form for various categories is as follows: Category Colour * Resident Indians and Eligible NRIs applying on a non-repatriation basis (ASBA) White Non-Residents and Eligible NRIs applying on a repatriation basis (ASBA) Blue * Excluding electronic Application Forms Applicants shall only use the specified Application Form for the purpose of making an Application in terms of this Draft Prospectus. Pursuant to SEBI Circular dated November 10, 2015 and bearing Reference No. CIR/CFD/POLICYCELL/11/2015, an investor intending to subscribe to this Issue shall submit a completed application form to any of the following intermediaries (collectively called as Designated Intermediaries ) Sr. No. Designated Intermediaries 1. SCSB with whom the bank account is maintained which is to be blocked 2. Syndicate Member (including sub syndicate member) 3. A stock broker registered with a recognized stock exchange (and whose name is mentioned on the website of the stock exchange as eligible for this activity) ( broker ) 4. A depository participant (DP) (whose name is mentioned on the website of the stock exchange as eligible for this Activity) 5. A registrar to an Issue and Share transfer agent (RTA) (whose name is mentioned on the website of the stock exchange as eligible for this Activity) The aforesaid intermediary shall, at the time of receipt of application, give an acknowledgement to investor, as a proof of having accepted the application form in physical or electronic mode respectively. Processing of Applications by Designated Intermediaries Applications submitted to SCSBs: After accepting the form, SCSB shall capture and upload the relevant details in the electronic bidding system as specified by the Stock Exchange and block the necessary funds available in the bank account as specified in the application form to the extent of application money specified. Applications submitted to other than SCSBs: After accepting the form, respective intermediary shall capture and upload the relevant details in the electronic bidding system of the stock exchange. Post uploading, they shall forward a schedule as per prescribed format alongwith the application forms to designated branches of the respective SCSBs for blocking of funds within one day of closure of Issue. Applicants shall submit the application forms either in physical or electronic form to the SCSBs authorising blocking funds that are available in the bank account specified in the application form used by applicants. 179

181 Availability of Prospectus and Application Forms The Memorandum Form 2A containing the salient features of the Prospectus together with the Application Forms and copies of the Prospectus may be obtained from the Registered office of our Company, Lead Manager to the Issue, Registrar to the Issue and the collection centres of the Bankers to the Issue, as mentioned in the Application Form. The application forms may also be downloaded from the website of BSE Limited i.e. Who can Apply Persons eligible to invest under all applicable laws, rules, regulations and guidelines; 1. Indian nationals resident in India who are not incompetent to contract in single or joint names (not more than three) or in the names of minors as natural/legal guardian; 2. Hindu Undivided Families or HUFs, in the individual name of the Karta. The Applicant should specify that the application is being made in the name of the HUF in the Application Form as follows: Name of Sole or First applicant: XYZ Hindu Undivided Family applying through XYZ, where XYZ is the name of the Karta. Applications by HUFs would be considered at par with those from individuals; 3. Companies, Corporate Bodies and Societies registered under the applicable laws in India and authorized to invest in the Equity Shares under their respective constitutional and charter documents; 4. Mutual Funds registered with SEBI; 5. Eligible NRIs on a repatriation basis or on a non-repatriation basis, subject to applicable laws. NRIs other than Eligible NRIs are not eligible to participate in this Offer; 6. Indian Financial Institutions, Scheduled Commercial Banks, Regional Rural Banks, Co-operative Banks (subject to RBI permission, and the SEBI Regulations and other laws, as applicable); 7. FIIs and sub-accounts registered with SEBI, other than a sub-account which is a foreign corporate or a foreign individual under the QIB portion; 8. Sub-accounts of FIIs registered with SEBI, which are foreign corporate or foreign individuals only under the Non- Institutional applicant s category; 9. FPIs other than Category III foreign portfolio investor; 10. Category III foreign portfolio investors, which are foreign corporates or foreign individuals only under the Non Institutional Investors (NIIs) category; 11. Limited Liability Partnerships (LLPs) registered in India and authorized to invest in equity shares; 12. Venture Capital Funds registered with SEBI; 13. Foreign Venture Capital Investors registered with SEBI; 14. Eligible QFIs; 15. Multilateral and Bilateral Development Financial Institutions; 16. State Industrial Development Corporations; 17. Trusts/Societies registered under the Societies Registration Act, 1860, as amended, or under any other law relating to Trusts and who are authorized under their constitution to hold and invest in equity shares; 180

182 18. Scientific and/or Industrial Research Organizations authorized to invest in equity shares; 19. Insurance Companies registered with Insurance Regulatory and Development Authority, India; 20. Provident Funds with minimum corpus of Rs. 25 Crores and who are authorized under their constitution to hold and invest in equity shares; 21. Pension Funds with minimum corpus of Rs. 25 Crores and who are authorized under their constitution to hold and invest in equity shares; 22. National Investment Fund set up by resolution no. F. No. 2/3/2005-DDII dated November 23, 2005 of Government of India published in the Gazette of India; 23. Nominated Investor and Market Maker 24. Insurance funds set up and managed by army, navy or air force of the Union of India 25. Any other person eligible to apply in this Issue, under the laws, rules, regulation, guidelines and policies applicable to them and under Indian laws. As per the existing policy of the Government of India, OCBs cannot participate in this Offer. Applications not to be made by: 1. Minors (except through their Guardians) 2. Partnership firms or their nominations 3. Foreign Nationals (except NRIs) 4. Overseas Corporate Bodies Option to subscribe in the Issue a. As per Section 29 of the Companies Act, 2013, allotment of Equity Shares will in dematerialized form only. b. The equity shares, on allotment, shall be traded on Stock Exchange in demat segment only. c. A single application from any investor shall not exceed the investment limit/minimum number of specified securities that can be held by him/her/it under the relevant regulations/statutory guidelines and applicable law. The information below is given for the benefit of the applicants. Our Company and the Lead Manager do not accept responsibility for the completeness and accuracy of the information stated. Our Company and the Lead Manager is not liable for any amendments or modification or changes in applicable laws or regulations, which may occur after the date of this Draft Prospectus. Applicants are advised to make their independent investigations and ensure that the number of Equity Shares applied for does not exceed the limits prescribed under laws or regulations. Participation by Associates/Affiliates of LM The LM, Market Maker and the Underwriter, if any shall not be entitled to subscribe to this Issue in any manner except towards fulfilling their underwriting and market making obligations. However, associates and affiliates of the LM, if any may subscribe to or purchase Equity Shares in the Issue, in the category as may be applicable to the applicants, where the allotment is on a proportionate basis in such subscription, may be on their own account or behalf of their clients. Application by Indian Public Including Eligible NRI s Applying on Non-Repatriation Application must be made only in the names of Individuals, Limited Companies or Statutory Corporations/ Institutions and not in the names of Minors (except through their Legal Guardians), Foreign Nationals, Non Residents (except for those 181

183 applying on non-repatriation), Trusts (unless the Trust is registered under the Societies Registration Act, 1860 or any other applicable Trust laws and is authorized under its constitution to hold shares and debentures in a Company), Hindu Undivided Families, Partnership firms or their nominees. In case of HUFs application shall be made by the Karta of the HUF. An applicant in the Net Public Category cannot make an application for that number of securities exceeding the number of securities offered to the public. In case of Application by Eligible NRIs applying on non-repatriation basis, the payments must be made through Indian Rupee Drafts purchased abroad or cheques or bank drafts, for the amount payable on application remitted through normal banking channels or out of funds held in NRE Accounts or FCNR Accounts, maintained with banks authorised to deal in foreign exchange in India, along with documentary evidence in support of the remittance or out of a NRO Account of a Non-Resident Applicant applying on a non-repatriation basis. Applications by Eligible NRIs on Repatriation basis Application Forms have been made available for eligible NRIs at our registered office. Only Applications accompanied by payment in Indian Rupees or freely convertible foreign exchange will be considered for Allotment. Eligible NRIs intending to make payment through freely convertible foreign exchange and applying on a repatriation basis could make payments through Indian Rupee drafts purchased abroad or cheques or bank drafts or by debits to their Non-Resident External ( NRE ) Account or Foreign Currency Non-Resident ( FCNR ) Accounts, maintained with banks authorised by the RBI to deal in foreign exchange. Eligible NRIs applying on a repatriation basis are advised to use the Application Forms meant for Non-Residents, accompanied by a bank certificate confirming that the payment has been made by debiting to the NRE or FCNR account, as the case may be. Payment for Applications by nonresident Applicant, applying on a repatriation basis will not be accepted out of Foreign Currency Non-Resident ( NRO ) accounts. Payment by drafts should be accompanied by a bank certificate confirming that the draft has been issued by debiting an NRE or FCNR or NRO Account. Applications by Eligible NRIs for a payment amount of up to Rs. 2,00,000 would be considered under the Retail Portion for the purposes of allocation and Applications for a payment amount of more than Rs. 2,00,000 would be considered under Non-Institutional Portion for the purposes of allocation. Application by Mutual Funds As per the current regulations, the following restrictions are applicable for investments by mutual funds: No mutual fund scheme shall invest more than 10% of its net asset value in the Equity Shares or equity related instruments of any Company provided that the limit of 10% shall not be applicable for investments in index funds or sector or industry specific funds. No mutual fund under all its schemes should own more than 10% of any Company s paid up share capital carrying voting rights. In case of a Mutual Fund, a separate Application can be made in respect of each scheme of the Mutual Fund registered with SEBI and such Applications in respect of more than one scheme of the Mutual Fund will not be treated as multiple Applications provided that the Applications clearly indicate the scheme concerned for which the Application has been made. Applications by FPIS, FIIS AND QFIS On January 7, 2014, SEBI notified the SEBI FPI Regulations pursuant to which the existing classes of portfolio investors namely 'foreign institutional investors' and 'qualified foreign investors' will be subsumed under a new category namely 'foreign portfolio investors' or 'FPIs'. RBI on March 13, 2014 amended the FEMA Regulations and laid down conditions and requirements with respect to investment by FPIs in Indian companies. In terms of the SEBI FPI Regulations, an FII who holds a valid certificate of registration from SEBI shall be deemed to be a registered FPI until the expiry of the block of three years for which fees have been paid as per the SEBI FII Regulations. Accordingly, such FIIs can participate in this Issue in accordance with Schedule 2 of the FEMA Regulations. An FII shall not be eligible to invest as an FII after registering as an FPI under the SEBI FPI Regulations. Further, a QFI can continue to buy, sell or otherwise deal in securities until January 6, 2015 or until the QFI obtains a certificate of registration as FPI, whichever is earlier. Such QFIs shall be eligible to participate in this Issue in accordance with Schedule 8 of the FEMA Regulations and are required to apply under the Non-Institutional Applicants category. 182

184 In terms of the SEBI FPI Regulations, the Issue of Equity Shares to a single FPI or an investor group (which means the same set of ultimate beneficial owner(s) investing through multiple entities) is not permitted to exceed 10% of our post- Issue Equity Share capital. Further, in terms of the FEMA Regulations, the total holding by each FPI shall be below 10% of the total paid-up Equity Share capital of our Company and the total holdings of all FPIs put together shall not exceed 24% of the paid-up Equity Share capital of our Company. The aggregate limit of 24% may be increased up to the sectoral cap by way of a resolution passed by the Board of Directors followed by a special resolution passed by the Shareholders of our Company. In terms of the FEMA Regulations, for calculating the aggregate holding of FPIs in a company, holding of all registered FPIs as well as holding of FIIs (being deemed FPIs) shall be included. As of now, in accordance with the foreign investment limits applicable to us the total foreign investment including FII investment cannot exceed the sectoral cap applicable to us (being 100% of our total post Issue paid-up capital). Further, the existing individual and aggregate investment limits for QFIs in an Indian company are 5% and 10% of the paid up capital of an Indian company, respectively. FPIs are permitted to participate in the Issue subject to compliance with conditions and restrictions which may be specified by the Government from time to time. Subject to compliance with all applicable Indian laws, rules, regulations, guidelines and approvals in terms of Regulation 22 of the SEBI FPI Regulations, an FPI, other than Category III foreign portfolio and unregulated broad based funds, which are classified as Category II foreign portfolio investor by virtue of their investment manager being appropriately regulated, may Issue or otherwise deal in offshore derivative instruments (as defined under the SEBI FPI Regulations as any instrument, by whatever name called, which is issued overseas by a FPI against securities held by it that are listed or proposed to be listed on any recognised stock exchange in India, as its underlying) directly or indirectly, only in the event (i) such offshore derivative instruments are issued only to persons who are regulated by an appropriate regulatory authority; and (ii) such offshore derivative instruments are issued after compliance with 'know your client' norms. An FPI is also required to ensure that no further issue or transfer of any offshore derivative instrument is made by or on behalf of it to any persons that are not regulated by an appropriate foreign regulatory authority. Applications by SEBI registered Venture Capital Funds and Foreign Venture Capital Investors As per the current regulations, the following restrictions are applicable for SEBI Registered Venture Capital Funds and Foreign Venture Capital Investors: The SEBI (Venture Capital) Regulations, 1996 and the SEBI (Foreign Venture Capital Investor) Regulations, 2000 prescribe investment restrictions on venture capital funds and foreign venture capital investors registered with SEBI. Accordingly, whilst the holding by any individual venture capital fund registered with SEBI in one Company should not exceed 25% of the corpus of the venture capital fund, a Foreign Venture Capital Investor can invest its entire funds committed for investments into India in one Company. Further, Venture Capital Funds and Foreign Venture Capital Investors can invest only up to 33.33% of the investible funds by way of subscription to an initial public Issue. Applications by Limited Liability Partnerships In case of applications made by limited liability partnerships registered under the Limited Liability Partnership Act, 2008, a certified copy of certificate of registration issued under the Limited Liability Partnership Act, must be attached to the Application Form. Failing this, our Company reserves the right to reject any application, without assigning any reason thereof. Limited liability partnerships can participate in the Issue only through the ASBA process. APPLICATIONS Applications by Insurance Companies In case of applications made by insurance companies registered with the IRDA, a certified copy of certificate of registration issued by IRDA must be attached to the Application Form. Failing this, our Company reserves the right to reject any application, without assigning any reason thereof. The exposure norms for insurers, prescribed under the Insurance Regulatory and Development Authority (Investment Scheme) (5th Amendment) Regulations, 2013, as amended (the IRDA Investment Regulations ), are broadly set forth below: a) equity shares of a company: the least of 10% of the investee company s subscribed capital (face value) or 10% of the respective fund in case of life insurer or 10% of investment assets in case of general insurer or reinsurer; b) the entire group of the investee company: the least of 15% of the respective fund in case of a life insurer or a general insurer or reinsurer or 15% of investment assets in all companies belonging to the group; and c) The industry sector in which the investee company operates: the least of 15% of the respective fund in case of a life insurer or a general insurer or reinsurer or 15% of investment assets. 183

185 In addition, the IRDA partially amended the exposure limits applicable to investments in public limited companies in the infrastructure and housing sectors, i.e. December 26, 2008, providing, among other things, that the exposure of an insurer to an infrastructure company may be increased to not more than 20%, provided that in case of equity investment, a dividend of not less than 4% including bonus should have been declared for at least five preceding years. This limit of 20% would be combined for debt and equity taken together, without sub ceilings. Further, investments in equity including preference shares and the convertible part of debentures shall not exceed 50% of the exposure norms specified under the IRDA Investment Regulations. Application by Provident Funds/ Pension Funds In case of applications made by provident funds/pension funds, subject to applicable laws, with minimum corpus of Rs. 2,500 Lacs, a certified copy of certificate from a chartered accountant certifying the corpus of the provident fund/ pension fund must be attached to the Application Form. Failing this, our Company reserves the right to reject any application, without assigning any reason thereof. Applications by Banking Companies In case of Applications made by banking companies registered with RBI, certified copies of: (i) the certificate of registration issued by RBI, and (ii) the approval of such banking company s investment committee are required to be attached to the Application Form, failing which our Company reserves the right to reject any Application without assigning any reason. The investment limit for banking companies as per the Banking Regulation Act, 1949, as amended, is 30.00% of the paid up share capital of the investee company or 30.00% of the banks own paid up share capital and reserves, whichever is less (except in certain specified exceptions, such as setting up or investing in a subsidiary, which requires RBI approval). Further, the RBI Master Circular of July 1, 2015 sets forth prudential norms required to be followed for classification, valuation and operation of investment portfolio of banking companies. Applications by SCSBs SCSBs participating in the Offer are required to comply with the terms of the SEBI circulars dated September 13, 2012 and January 2, Such SCSBs are required to ensure that for making applications on their own account using ASBA, they should have a separate account in their own name with any other SEBI registered SCSBs. Further, such account shall be used solely for the purpose of making application in public issues and clear demarcated funds should be available in such account for such applications. Application under Power of Attorney In case of applications made pursuant to a power of attorney by limited companies, corporate bodies, registered societies, Mutual Funds, insurance companies and provident funds with minimum corpus of Rs. 25 Crores (subject to applicable law) and pension funds with a minimum corpus of Rs. 25 Crores a certified copy of the power of attorney or the relevant resolution or authority, as the case may be, along with a certified copy of the memorandum of association and articles of association and/or bye laws must be lodged with the Application Form. Failing this, our Company reserves the right to accept or reject any application in whole or in part, in either case, without assigning any reason therefore. In addition to the above, certain additional documents are required to be submitted by the following entities: (a). With respect to applications by Mutual Funds, a certified copy of their SEBI registration certificate must be lodged along with the Application Form. Failing this, our Company reserves the right to accept or reject any application, in whole or in part, in either case without assigning any reasons thereof. (b). With respect to applications by insurance companies registered with the Insurance Regulatory and Development Authority, in addition to the above, a certified copy of the certificate of registration issued by the Insurance Regulatory and Development Authority must be lodged with the Application Form as applicable. Failing this, our Company reserves the right to accept or reject any application, in whole or in part, in either case without assigning any reasons thereof. (c). With respect to applications made by provident funds with minimum corpus of Rs. 25 Crores (subject to applicable law) and pension funds with a minimum corpus of Rs. 25 Crores, a certified copy of a certificate from a chartered 184

186 accountant certifying the corpus of the provident fund/pension fund must be lodged along with the Application Form. Failing this, our Company reserves the right to accept or reject such application, in whole or in part, in either case without assigning any reasons thereof. Our Company in its absolute discretion, reserves the right to relax the above condition of simultaneous lodging of the power of attorney along with the Application Form, subject to such terms and conditions that our Company, the lead manager may deem fit. Our Company, in its absolute discretion, reserves the right to permit the holder of the power of attorney to request the Registrar to the Issue that, for the purpose of printing particulars on the Allotment Advice / CANs / letters and mailing of the same notifying the unblocking of the bank accounts of ASBA applicants, the Demographic Details given on the Application Form should be used (and not those obtained from the Depository of the application). In such cases, the Registrar to the Issue shall use Demographic Details as given on the Application Form instead of those obtained from the Depositories. The above information is given for the benefit of the Applicants. The Company and the LM are not liable for any amendments or modification or changes in applicable laws or regulations, which may occur after the date of this Draft Prospectus. Applicants are advised to make their independent investigations and ensure that the number of Equity Shares applied for do not exceed the applicable limits under laws or regulations. Maximum and Minimum Application Size (a) For Retail Individual Applicants The Application must be for a minimum of 1,600 Equity Shares and in multiples of 1,600 Equity Share thereafter, so as to ensure that the Application Price payable by the Applicant does not exceed Rs. 2,00,000. In case of revision of Applications, the Retail Individual Applicants have to ensure that the Application Price does not exceed Rs. 2,00,000. (b) For Other Applicants (Non Institutional Applicants and QIBs): The Application must be for a minimum of such number of Equity Shares such that the Application Amount exceeds Rs. 200,000 and in multiples of 1,600 Equity Shares thereafter. An Application cannot be submitted for more than the Issue size. However, the maximum Application by a QIB investor should not exceed the investment limits prescribed for them by applicable laws. Under existing SEBI Regulations, a QIB or Non Institution Applicant cannot withdraw or lower its Application at any stage of Issue. In case of revision in Applications, the Non Institutional Applicants, who are individuals, have to ensure that the Application Amount is greater than Rs. 2,00,000 for being considered for allocation in the Non Institutional Portion. Applicants are advised to ensure that any single Application from them does not exceed the investment limits or maximum number of Equity Shares that can be held by them under applicable law or regulation or as specified in this Draft Prospectus. Information for the Applicants: 1. Our Company and the Lead Manager shall declare the Issue Opening Date and Issue Closing Date in the Prospectus to be registered with the RoC and also publish the same in two national newspapers (one each in English and Hindi) and in a regional newspaper with wide circulation. This advertisement shall be in prescribed format. 2. Our Company will file the Prospectus with the RoC at least 3 (three) days before the Issue Opening Date. 3. Copies of the Application Form along with Abridge Prospectus and copies of the Prospectus will be available with the, the Lead Manager, the Registrar to the Issue, and at the Registered Office of our Company. Electronic Application Forms will also be available on the website of the Stock Exchange. 4. Any applicant who would like to obtain the Prospectus and/ or the Application Form can obtain the same from our Registered Office. 185

187 5. Applicants who are interested in subscribing for the Equity Shares should approach Designated Intermediaries to register their applications. 6. Application Forms submitted directly to the SCSBs should bear the stamp of the SCSBs and/or the Designated Branch, or the respective Designated Intermediaries. Application Form submitted by Applicants whose beneficiary account is inactive shall be rejected. 7. The Application Form can be submitted either in physical or electronic mode, to the SCSBs with whom the ASBA Account is maintained, or other Designated Intermediaries (Other than SCSBs). SCSBs may provide the electronic mode of collecting either through an internet enabled collecting and banking facility or such other secured, electronically enabled mechanism for applying and blocking funds in the ASBA Account. 8. Applicants applying directly through the SCSBs should ensure that the Application Form is submitted to a Designated Branch of SCSB, where the ASBA Account is maintained. Applications submitted directly to the SCSBs or other Designated Intermediaries (Other than SCSBs), the relevant SCSB, shall block an amount in the ASBA Account equal to the Application Amount specified in the Application Form, before entering the ASBA application into the electronic system. 9. Except for applications by or on behalf of the Central or State Government and the Officials appointed by the courts and by investors residing in the State of Sikkim, the Applicants, or in the case of application in joint names, the first Applicant (the first name under which the beneficiary account is held), should mention his/her PAN allotted under the Income Tax Act. In accordance with the SEBI Regulations, the PAN would be the sole identification number for participating transacting in the securities market, irrespective of the amount of transaction. Any Application Form without PAN is liable to be rejected. The demat accounts of Applicants for whom PAN details have not been verified, excluding persons resident in the State of Sikkim or persons who may be exempted from specifying their PAN for transacting in the securities market, shall be suspended for creditǁ and no credit of Equity Shares pursuant to the Issue will be made into the accounts of such Applicants. 10.The Applicants may note that in case the PAN, the DP ID and Client ID mentioned in the Application Form and entered into the electronic collecting system of the Stock Exchange do not match with PAN, the DP ID and Client ID available in the Depository database, the Application Form is liable to be rejected. Method and Process of Applications 1. The Designated Intermediaries shall accept applications from the Applicants during the Issue Period. 2. The Issue Period shall be for a minimum of 3 Working Days and shall not exceed 10 Working Days. The Issue Period may be extended, if required, by an additional three Working Days, subject to the total Issue Period not exceeding 10 Working Days. 3. During the Issue Period, Applicants who are interested in subscribing to the Equity Shares should approach the Designated Intermediaries to register their applications. 4. The Applicant cannot apply on another Application Form after applications on one Application Form have been submitted to the Designated Intermediaries. Submission of a second Application form to either the same or to another Designated Intermediaries will be treated as multiple applications and is liable to rejected either before entering the application into the electronic collecting system or at any point prior to the allocation or Allotment of Equity Shares in this Issue. 5. Designated Intermediaries accepting the application forms shall be responsible for uploading the application along with other relevant details in application forms on the electronic bidding system of stock exchange and submitting the form to SCSBs for blocking of funds (except in case of SCSBs, where blocking of funds will be done by respective SCSBs only). All applications shall be stamped and thereby acknowledged by the Designated Intermediaries at the time of receipt. 6. The Designated Intermediaries will enter each application option into the electronic collecting system as a separate application and generate a TRS and give the same to the applicant. 7. Upon receipt of the Application Form, submitted whether in physical or electronic mode, the Designated Intermediaries shall verify if sufficient funds equal to the Application Amount are available in the ASBA Account, as mentioned in the Application Form, prior to uploading such applications with the Stock Exchange. 186

188 8. If sufficient funds are not available in the ASBA Account, the Designated Intermediaries shall reject such applications and shall not upload such applications with the Stock Exchange. 9. If sufficient funds are available in the ASBA Account, the SCSB shall block an amount equivalent to the Application Amount mentioned in the Application Form and will enter each application option into the electronic collecting system as a separate application and generate a TRS for each price and demand option. The TRS shall be furnished to the Applicant on request. 10. The Application Amount shall remain blocked in the aforesaid ASBA Account until finalization of the Basis of Allotment and consequent transfer of the Application Amount against the Allotted Equity Shares to the Public Issue Account, or until withdraw/ failure of the Issue or until withdrawal/ rejection of the Application Form, as the case may be. Once the Basis of Allotment if finalized, the Registrar to the Issue shall send an appropriate request to the Controlling Branch of the SCSB for unblocking the relevant ASBA Accounts and for transferring the amount allocable to the successful Applicants to the Public Issue Account. In case of withdrawal/ failure of the Issue, the blocked amount shall be unblocked on receipt of such information from the Registrar to the Issue. Terms of Payment / Payment Instructions The entire Issue Price of Rs. 80/- per share is payable on application. All the applicants are required to use ASBA facility to make the payment. In case of allotment of lesser number Equity Shares than the number applied, the Registrar shall instruct the SCSBs to unblock the excess amount paid on application to the applicants. SCSBs will transfer the amount as per the instruction of the Registrar to the Public Issue Account, the balance amount after transfer will be unblocked by the SCSBs. The applicants should note that the arrangement with Banker to the Issue or the Registrar is not prescribed by SEBI and has been established as an arrangement between our Company, Banker to the Issue and the Registrar to the Issue to facilitate collections from the Applicants. Payment mechanism The applicants shall specify the bank account number in their Application Form and the SCSBs shall block an amount equivalent to the Application Amount in the bank account specified in the Application Form. The SCSB shall keep the Application Amount in the relevant bank account blocked until withdrawal/ rejection of the Application or receipt of instructions from the Registrar to unblock the Application Amount. However Non Retail Applicants shall neither withdraw nor lower the size of their applications at any stage. In the event of withdrawal or rejection of the Application Form or for unsuccessful Application Forms, the Registrar to the Issue shall give instructions to the SCSBs to unblock the application money in the relevant bank account within one day of receipt of such instruction. The Application Amount shall remain blocked in the ASBA Account until finalization of the Basis of Allotment in the Issue and consequent transfer of the Application Amount to the Public Issue Account, or until withdrawal/ failure of the Issue or until rejection of the Application by the ASBA Applicant, as the case may be. Please note that pursuant to SEBI circular CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015 potential investors shall invest in the public issue through ASBA Mode only. Electronic Registration of Applications 1. The Designated Intermediaries will register the applications using the on-line facilities of the Stock Exchange. 2. The Designated Intermediaries will undertake modification of selected fields in the application details already uploaded before 1.00 p.m. of next Working Day from the Issue Closing Date. 3. The Designated Intermediaries shall be responsible for any acts, mistakes or errors or omissions and commissions in relation to, (i) the applications accepted by them, (ii) the applications uploaded by them (iii) the applications accepted but not uploaded by them or (iv) With respect to applications by Applicants, applications accepted and uploaded by any Designated Intermediary other than SCSBs, the Application form along with relevant schedules shall be sent to the SCSBs or the Designated Branch of the relevant SCSBs for blocking of funds and they will be responsible for blocking the necessary 187

189 amounts in the ASBA Accounts. In case of Application accepted and uploaded by SCSBs, the SCSBs or the Designated Branch of the relevant SCSBs will be responsible for blocking the necessary amounts in the ASBA Accounts 4. Neither the Lead Managers nor our Company nor the Registrar to the Issue, shall be responsible for any acts, mistakes or errors or omission and commissions in relation to (i) the applications accepted by any Designated Intermediaries (ii) the applications uploaded by any Designated Intermediaries or (iii) the applications accepted but not uploaded by any Designated Intermediaries 5. The Stock Exchange will offer an electronic facility for registering applications for the Issue. This facility will available at the terminals of Designated Intermediaries and their authorized agents during the Issue Period. The Designated Branches or agents of Designated Intermediaries can also set up facilities for off-line electronic registration of applications subject to the condition that they will subsequently upload the off-line data file into the online facilities on a regular basis. On the Issue Closing Date, the Designated Intermediaries shall upload the applications till such time as may be permitted by the Stock Exchange. This information will be available with the Lead Manager on a regular basis. 6.With respect to applications by Applicants, at the time of registering such applications, the Syndicate members, DPs and RTAs shall forward a Schedule along with the Application Forms to Designated Branches of the SCSBs for blocking of funds. 7. With respect to applications by Applicants, at the time of registering such applications, the Designated Intermediaries shall enter the following information pertaining to the Applicants into in the on-line system: Name of the Applicant; IPO Name: Application Form Number; Investor Category; PAN (of First Applicant, if more than one Applicant); DP ID of the demat account of the Applicant; Client Identification Number of the demat account of the Applicant; Number of Equity Shares Applied for; Bank Account details; Locations of the Banker to the Issue or Designated Branch, as applicable, and bank code of the SCSB branch where the ASBA Account is maintained; and Bank account number 8. In case of submission of the Application by an Applicant through the Electronic Mode, the Applicant shall complete the above-mentioned details and mention the bank account number, except the Electronic ASBA Application Form number which shall be system generated. 9. The aforesaid Designated Intermediaries shall, at the time of receipt of application, give an acknowledgment to the investor, by giving the counter foil or specifying the application number to the investor, as a proof of having accepted the application form in physical as well as electronic mode. The registration of the Application by the Designated Intermediaries does not guarantee that the Equity Shares shall be allocated / allotted either by our Company. 10.Such acknowledgment will be non-negotiable and by itself will not create any obligation of any kind. 11.In case of Non Retail Applicants and Retail Individual Applicants, applications would not be rejected except on the technical grounds as mentioned in this Draft Prospectus. The Designated Intermediaries shall have no right to reject applications, except on technical grounds. 12. The permission given by the Stock Exchange to use their network and software of the Online IPO system should not in any way be deemed or construed to mean that the compliance with various statutory and other requirements by our Company and/or the Lead Manager are cleared or approved by the Stock Exchanges; nor does it in any manner warrant, certify or endorse the correctness or completeness of any of the compliance with the statutory and other requirements nor does it take any responsibility for the financial or other soundness of our company; our Promoter, our management or any scheme or project of our Company; nor does it in any manner warrant, certify or endorse the correctness or completeness 188

190 of any of the contents of this Draft Prospectus, nor does it warrant that the Equity Shares will be listed or will continue to be listed on the Stock Exchanges. 13. The Designated Intermediaries will be given time till 1.00 p.m. on the next working day after the Issue Closing Date to verify the DP ID and Client ID uploaded in the online IPO system during the Issue Period, after which the Registrar to the Issue will receive this data from the Stock Exchange and will validate the electronic application details with Depository s records. In case no corresponding record is available with Depositories, which matches the three parameters, namely DP ID, Client ID and PAN, then such applications are liable to be rejected. 14. The SCSBs shall be given one day after the Issue Closing Date to send confirmation of Funds blocked (Final certificate) to the Registrar to the Issue. 15. The details uploaded in the online IPO system shall be considered as final and Allotment will be based on such details for applications. Allocation of Equity Shares The Issue is being made through the Fixed Price Process where in 76,800 Equity Shares shall be reserved for Market Maker. 14,24,000 Equity Shares will be allocated on Proportionate basis to Retail Individual Applicants, subject to valid applications being received from Retail Individual Applicants at the Issue Price. The balance of the Net Issue will be available for allocation on proportionate basis to Non Retail Applicants. Under-Subscription if any, in any category, would be allowed to be met with spill-over from any other category or combination of categories at the discretion of our Company in consultation with the Lead Managers and the Stock Exchange. Allocation to Non-Residents, including Eligible NRIs, Eligible QFIs, FIIs and FVCIs registered with SEBI, applying on repatriation basis will be subject to applicable law, rules, regulations, guidelines and approvals. In terms of SEBI Regulations, Non Retail Applicants shall not be allowed to either withdraw or lower the size of their applications at any stage. Allotment Status details shall be available on the website of the Registrar to the Issue. General Instructions Do s: Check if you are eligible to apply; Read all the instructions carefully and complete the applicable Application Form; Ensure that the details about Depository Participant and Beneficiary Account are correct as Allotment of Equity Shares will be in the dematerialized form only; Each of the Applicants should mention their Permanent Account Number (PAN) allotted under the Income Tax Act, 1961; Ensure that the Demographic Details (as defined) are updated, true and correct in all respects; Ensure that the name(s) given in the Application Form is exactly the same as the name(s) in which the beneficiary account is held with the Depository Participant. Ensure that you have funds equal to the application amount in the ASBA account maintained with SCSB before submitting the application form under the ASBA process the respective member of the Syndicate (in the specified locations), the SCSBs, the registered broker (at the Broker Centres), the RTA ( at the Designated RTA Locations) or CDP ( at the Designated CDP Locations); Instruct your respective Banks to release the funds blocked in the ASBA Account under the ASBA process; Ensure that the Application Form is signed by the account holder in case the applicant is not the account holder, ensure that you have mentioned the correct bank account number in the Application Form; Ensure that the Application Forms are delivered by the applicants within the time prescribed as per the Application Form and the Prospectus; Ensure that you have requested for and receive a TRS; 189

191 Ensure that you request for a receive a stamped acknowledgement of the Application Form for all your application options; All Investors submit their applications through the ASBA process only; Ensure that you receive an acknowledgement from the concerned Designated Intermediary, for the submission of your Application Form; and The Application Form is liable to be rejected if the above instructions, as applicable, are not complied with. Don ts: Do not Apply for lower than the minimum Application size; Do not Apply /revise Application Amount to less than or higher than the Issue Price; Do not Apply on another Application Form after you have submitted an Application to the designated intermediaries; Do not pay the Application Amount in cash, cheque, by money order or by postal order or by stock invest; The payment of the Application Amount in any mode other than blocked amounts in the bank account maintained with an SCSB shall not be accepted; Do not send Application Forms by post; instead submit the same to the Designated Intermediaries only; Do not Apply for an Application Amount exceeding Rs.200,000 if you are applying under the Retail category; Do not fill up the Application Form such that the Equity Shares applied for exceeds the Issue size and/ or investment limit or maximum number of the Equity Shares that can be held under the applicable laws or regulations or maximum amount permissible under the applicable regulations or under the terms of the Prospectus; Do not submit the General Index Register number instead of the PAN; Do not instruct your respective banks to release the funds blocked in the ASBA Account for any other purpose; Do not submit incorrect details of the DP ID, Client ID and PAN or provide details for a beneficiary account which is suspended or for which details cannot be verified by the Registrar to the Issue; Do not submit Applications on plain paper or on incomplete or illegible Application Forms or on Application Forms in a colour prescribed for another category of Applicant; Do not submit an Application in case you are not eligible to acquire Equity Shares under applicable law or your relevant constitutional documents or otherwise; Do not Apply if you are not competent to contract under the Indian Contract Act, 1872, as amended (other than minors having valid depository accounts as per Demographic Details provided by the Depositories); Do not withdraw your Application or lower the size of your Application (in terms of quantity of the Equity Shares or the Application Amount) at any stage, if you are a QIB or a Non-Institutional Investor; Do not submit more than five Application Forms per ASBA Account; The Application Form is liable to be rejected if the above instructions, as applicable, are not complied with. Other Instructions Joint Applications in the case of Individuals Applications may be made in single or joint names (not more than three). In the case of joint Applications, all payments will be made out in favour of the Applicant whose name appears first in the Application Form or Revision Form. All communications will be addressed to the First Applicant and will be dispatched to his or her address as per the Demographic Details received from the Depository. Multiple Applications An Applicant should submit only one Application (and not more than one) for the total number of Equity Shares required. Two or more Applications will be deemed to be multiple Applications if the sole or First Applicant is one and the same. In this regard, the procedures which would be followed by the Registrar to the Issue to detect multiple applications are given below: 190

192 i. All applications are electronically strung on first name, address (1st line) and applicant s status. Further, these applications are electronically matched for common first name and address and if matched, these are checked manually for age, signature and father/ husband s name to determine if they are multiple applications ii. Applications which do not qualify as multiple applications as per above procedure are further checked for common DP ID/ beneficiary ID. In case of applications with common DP ID/ beneficiary ID, are manually checked to eliminate possibility of data entry error to determine if they are multiple applications. iii. Applications which do not qualify as multiple applications as per above procedure are further checked for common PAN. All such matched applications with common PAN are manually checked to eliminate possibility of data capture error to determine if they are multiple applications. In case of a mutual fund, a separate Application can be made in respect of each scheme of the mutual fund registered with SEBI and such Applications in respect of more than one scheme of the mutual fund will not be treated as multiple Applications provided that the Applications clearly indicate the scheme concerned for which the Application has been made. In cases where there are more than 20 valid applications having a common address, such shares will be kept in abeyance, post allotment and released on confirmation of know your client norms by the depositories. The Company reserves the right to reject, in our absolute discretion, all or any multiple Applications in any or all categories. Permanent Account Number or PAN Pursuant to the circular MRD/DoP/Circ 05/2007 dated April 27, 2007, SEBI has mandated Permanent Account Number ( PAN ) to be the sole identification number for all participants transacting in the securities market, irrespective of the amount of the transaction w.e.f. July 2, Each of the Applicants should mention his/her PAN allotted under the IT Act. Applications without this information will be considered incomplete and are liable to be rejected. It is to be specifically noted that Applicants should not submit the GIR number instead of the PAN, as the Application is liable to be rejected on this ground. Submission of Application Form All application forms duly completed shall be submitted to the designated intermediaries. The aforesaid intermediaries shall, at the time of receipt of application, give an acknowledgement to investor, by giving the counterfoil or specifying the application number to the investor, as a proof of having accepted the application form, in physical or electronic mode, respectively. Right to Reject Applications In case of QIB Applicants, the Company in consultation with the LM may reject Applications provided that the reasons for rejecting the same shall be provided to such Applicant in writing. In case of Non Institutional Applicants, Retail Individual Applicants who applied, the Company has a right to reject Applications based on technical grounds. Procedure and Time Schedule for Transfer of Equity Shares The Issue will be conducted through the Fixed Price Method pursuant to which the designated intermediaries will accept Applications for the Equity Shares during the Issue Period. The Issue Period will commence on [ ] and expire on [ ]. Following the expiration of the Issue Period, our Company, in consultation with the Lead Manager, will determine the basis of allotment and entitlement to allotment based on the applications received and subject to the confirmation by the Stock Exchange. Successful Applicants will be provided with a confirmation of their allocation for the Equity Shares within a prescribed time. The SEBI (ICDR) Regulations, 2009 require our Company to complete the allotment to successful Applicants within 4 days of the expiration of the Issue Period. The Equity Shares will then be credited and allotted to the investors demat accounts maintained with the relevant depository participant. Upon approval by the Stock Exchange, the Equity Shares will be listed and trading will commence. As per the RBI regulations, OCBs are not permitted to participate in the Issue. There is no reservation for Non Residents, NRIs, FIIs and foreign venture capital funds and all Non Residents, NRI, FII and Foreign Venture Capital Funds applicants will be treated on the same basis with other categories for the purpose of allocation. 191

193 Impersonation Attention of the applicants is specifically drawn to the provisions of sub section (1) of Section 38 of the Companies Act, 2013 which is reproduced below: Any person who: a. makes or abets making of an application in a fictitious name to a company for acquiring, or subscribing for, its securities; or b. makes or abets making of multiple applications to a company in different names or in different combinations of his name or surname for acquiring or subscribing for its securities; or c. otherwise induces directly or indirectly a company to allot, or register any transfer of, securities to him, or to any other person in a fictitious name, shall be liable for action under section 447 of the said Act. Signing of Underwriting Agreement Vide an Underwriting Agreement dated December 05, 2016 this issue is 100% Underwritten. Filing of the Prospectus with the ROC The Company will file a copy of the Prospectus with the RoC in terms of 26 of the Companies Act, Pre-Issue Advertisement Subject to Section 30 of the Companies Act, 2013 the Company shall, after registering the Prospectus with the RoC, publish a pre-issue advertisement, in the form prescribed by the SEBI Regulations, in one widely circulated English language national daily newspaper; one widely circulated Hindi language national daily newspaper and one regional newspaper with wide circulation. This advertisement, in addition to the information that has to be set out in the statutory advertisement, shall indicate the Issue Price. Issuance of a Confirmation of Allocation Note ( CAN ) 1. Upon approval of the basis of allotment by the Designated Stock Exchange, the Lead Manager or Registrar to the Issue shall send to the Brokers a list of their Applicants who have been allocated Equity Shares in the Issue. 2. The Registrar will then dispatch a CAN to their Applicants who have been allocated Equity Shares in the Issue. The dispatch of a CAN shall be deemed a valid, binding and irrevocable contract for the Applicant. Designated Date and Allotment of Equity Shares (a) Designated Date: On the Designated Date, the SCSBs shall transfer the funds represented by allocation of Equity Shares into the Public Issue Account with the Bankers to the Issue. (b) Issuance of Allotment Advice: Upon approval of the Basis of Allotment by the Designated Stock Exchange, the Registrar shall upload the same on its website. On the basis of the approved Basis of Allotment, the Issuer shall pass necessary corporate action to facilitate the Allotment and credit of Equity Shares. Applicants are advised to instruct their Depository Participant to accept the Equity Shares that may be allotted to them pursuant to the Issue. (c) The dispatch of Allotment Advice shall be deemed a valid, binding and irrevocable contract. (d) Issuer will ensure that: (i) the Allotment of Equity Shares; and (ii) credit of shares to the successful Applicants Depository Account will be completed within six Working Days of the Issue Closing Date. The Issuer also ensures the credit of shares to the successful Applicant s depository account is completed within five Working Days from the Issue Closing Date. Disposal of Applications and Application Moneys and Interest in Case of Delay The Company shall ensure the dispatch of Allotment advice and give benefit to the beneficiary account with Depository Participants and submit the documents pertaining to the Allotment to the Stock Exchange within two working days of date of Allotment of Equity Shares. 192

194 The Company shall use best efforts to ensure that all steps for completion of the necessary formalities for listing and commencement of trading at SME Platform of BSE where the Equity Shares are proposed to be listed are taken within 6 working days of closure of the Issue. In accordance with the Companies Act, the requirements of the Stock Exchange and the SEBI Regulations, the Company further undertakes that: 1) Allotment of Equity Shares shall be made within 3 (three) working days of the Issue Closing Date; 2) Giving of Instructions for refund by unblocking of amount via ASBA not later than 4(four) working days of the Issue Closing Date, would be ensured; and 3) If such money is not repaid within eight days from the date our Company becomes liable to repay it, then our Company and every officer in default shall, on and from expiry of eight days, be liable to repay such application money, with interest as prescribed under SEBI (ICDR) Regulations, the Companies Act, 2013 and applicable law. Further, in accordance with Section 40 of the Companies Act, 2013, the Company and each officer in default may be punishable with fine and/or imprisonment in such a case. Undertakings by our Company The Company undertakes the following: 1) That the complaints received in respect of the Issue shall be attended to by us expeditiously and satisfactorily; 2) That all steps will be taken for the completion of the necessary formalities for listing and commencement of trading at the Stock Exchange where the Equity Shares are proposed to be listed within 6 (six) Working days of Issue Closing Date; 3) Allotment will be made or the Application money will be refunded within six Working Days from the Issue Closing Date or such lesser time as specified by SEBI or the application money will be refunded to the Applicants forthwith, failing which interest will be due to be paid to the Applicants at the rate of 15% per annum for the delayed period; 4) Where refunds are made through electronic transfer of funds, a suitable communication shall be sent to the Applicant within six Working Days from the Issue Closing Date, giving details of the bank where refunds shall be credited along with amount and expected date of electronic credit of refund; 5) That funds required for making refunds to unsuccessful Applicants as per the mode(s) disclosed shall be made available to the Registrar to the Issue by our Company; 6) That if the Company do not proceed with the Issue, the reason thereof shall be given as a public notice to be issued by our Company within two days of the Issue Closing Date. The public notice shall be issued in the same newspapers where the pre-issue advertisements were published. The stock exchange on which the Equity Shares are proposed to be listed shall also be informed promptly; 7) That the certificates of the securities/refund orders to Eligible NRIs shall be dispatched within specified time; 8) That no further issue of Equity Shares shall be made till the Equity Shares offered through the Prospectus are listed or until the Application monies are unblocked on account of non-listing, under subscription etc. and 9) That if the Company withdraws the Issue after the Issue Closing Date, our Company shall be required to file a fresh offer document with the RoC/ SEBI, in the event our Company subsequently decides to proceed with the Issuer; 10)Adequate arrangements shall be made to collect all Application Forms from the Applicants. Utilization of Issue Proceeds The Board of Directors of our Company certifies that: 1) All monies received out of the Issue shall be credited/ transferred to a separate bank account other than the bank account referred to in sub section (3) of Section 40 of the Companies Act 2013; 193

195 2) Details of all monies utilized out of the Issue referred above shall be disclosed and continue to be disclosed till the time any part of the Issue proceeds remains unutilized, under an appropriate head in our balance sheet of our company indicating the purpose for which such monies have been utilized; 3) Details of all unutilized monies out of the Issue, if any shall be disclosed under the appropriate separate head in the balance sheet of our company indicating the form in which such unutilized monies have been invested; 4) Our Company shall comply with the requirements of SEBI Listing Regulations in relation to the disclosure and monitoring of the utilization of the proceeds of the Issue; 5) Our Company shall not have recourse to the Issue Proceeds until the approval for listing and trading of the Equity Shares from the Stock Exchange where listing is sought has been received and Withdrawal of the Issue Our Company, in consultation with the LM reserves the right not to proceed with the Issue at anytime, including after the Issue Closing Date but before the Board meeting for Allotment, without assigning any reason. Notwithstanding the foregoing, the Issue is also subject to obtaining the final listing and trading approvals of the Stock Exchange, which the Company shall apply for after Allotment. In case, the Company wishes to withdraw the Issue after Issue Opening but before allotment, the Company will give public notice giving reasons for withdrawal of Issue. The public notice will appear in two widely circulated national newspapers (one each in English and Hindi) and one in regional newspaper. The Stock Exchanges where the Equity Shares are proposed to be listed shall also be informed promptly. If the Company withdraws the Issue after the Application Closing Date, the Company will be required to file a fresh Issue Document with the Stock Exchange. Equity Shares in Dematerialised Form with NSDL or CDSL To enable all shareholders of the Company to have their shareholding in electronic form, the Company had signed the following tripartite agreements with the Depositories and the Registrar and Share Transfer Agent: (a) Agreement dated [ ] between NSDL, the Company and the Registrar to the Issue; (b) Agreement dated December 07, 2016 between CDSL, the Company and the Registrar to the Issue; The Company s shares bear an ISIN No. INE 236W01016 An Applicant applying for Equity Shares must have at least one beneficiary account with either of the Depository Participants of either NSDL or CDSL prior to making the Application. The Applicant must necessarily fill in the details (including the Beneficiary Account Number and Depository Participant s identification number) appearing in the Application Form or Revision Form. Communications All future communications in connection with the Applications made in this Issue should be addressed to the Registrar to the Issue quoting the full name of the sole or First Applicant, Application Form number, Applicants Depository Account Details, number of Equity Shares applied for, date of Application form, name and address of the Designated Intermediary where the Application was submitted and a copy of the acknowledgement slip. Investors can contact the Compliance Officer or the Registrar to the Issue in case of any pre Issue or post Issue related problems such as non receipt of letters of allotment, credit of allotted shares in the respective beneficiary accounts etc. 194

196 Part B GID General Information Document for Investing in Public Issues This General Information Document highlights the key rules, processes and procedures applicable to public issues in accordance with the provisions of the Companies Act, 2013 and Companies Act, 1956 to the extent applicable, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts (Regulation) Rules, 1957 and the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, Applicants should not construe the contents of this General Information Document as legal advice and should consult their own legal counsel and other advisors in relation to the legal matters concerning the Issue. For taking an investment decision, the Applicants should rely on their own examination of the Issuer and the Issue, and should carefully read the Prospectus before investing in the Issue. Section 1: Purpose of the General Information Document (GID) This document is applicable to the public issues undertaken through to the Fixed Price Issues. The purpose of the General Information Document for Investing in Public Issues is to provide general guidance to potential Applicants in IPOs, on the processes and procedures governing IPOs, undertaken in accordance with the provisions of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 ( SEBI ICDR Regulations, 2009 ). Applicants should note that investment in equity and equity related securities involves risk and Applicant should not invest any funds in the Issue unless they can afford to take the risk of losing their investment. The specific terms relating to securities and/or for subscribing to securities in an Issue and the relevant information about the Issuer undertaking the Issue are set out in the Prospectus filed by the Issuer with the Registrar of Companies ( RoC ). Applicants should carefully read the entire Prospectus and the Application Form and the Abridged Prospectus of the Issuer in which they are proposing to invest through the Issue. In case of any difference in interpretation or conflict and/or overlap between the disclosure included in this document and the Prospectus, the disclosures in the Prospectus shall prevail. The Prospectus of the Issuer is available on the websites of stock exchanges, on the website(s) of the LM to the Issue and on the website of Securities and Exchange Board of India ( SEBI ) at For the definitions of capitalized terms and abbreviations used herein Applicants may refer to the section Definitions and Abbreviations on page 2 of this Draft Prospectus. 2.1 Initial public offer (IPO) SECTION 2: Brief introduction to IPOs on SME Exchange An IPO means an offer of specified securities by an unlisted Issuer to the public for subscription and may include an Offer for Sale of specified securities to the public by any existing holder of such securities in an unlisted Issuer. For undertaking an IPO, an Issuer is inter-alia required to comply with the eligibility requirements of in terms of either Regulation 26(1) or Regulation 26(2) or the Applicable Regulations of Chapter XB of the SEBI ICDR Regulations, 2009, as amended. For details of compliance with the eligibility requirements by the Issuer Applicants may refer to the Prospectus. The Issuer may also undertake IPO under of chapter XB of the SEBI (ICDR) Regulations, wherein as per, Regulation 106M (1): An issuer whose post-issue face value capital does not exceed ten crores rupees shall issue its specified securities in accordance with provisions of this Chapter. Regulation 106M (2): An issuer, whose post issue face value capital, is more than ten crores rupees and up to twenty five crores rupees, may also issue specified securities in accordance with provisions of this Chapter. The present Issue is being made under Regulation 106M (1) of Chapter XB of SEBI (ICDR) Regulations. 2.2 Other Eligibility Requirements In addition to the eligibility requirements specified in paragraphs 2.1, an Issuer proposing to undertake an IPO or an FPO is required to comply with various other requirements as specified in the SEBI ICDR Regulations, 2009, the Companies Act, 2013 and the Companies Act, 1956 to the extent applicable (the Companies Act ), The Securities 195

197 Contracts (Regulation) Rules, 1957 (the SCRR ), industry- specific regulations, if any, and other applicable laws for the time being in force. Following are the eligibility requirements for making an SME IPO under Regulation 106M (1) of Chapter XB of SEBI (ICDR) Regulation: (a) (b) (c) (d) (e) (f) In accordance with regulation 106(P) of the SEBI (ICDR) Regulations, Issue has to be 100% underwritten and the LM has to underwrite at least 15% of the total issue size. In accordance with Regulation 106(R) of the SEBI (ICDR) Regulations, total number of proposed allottees in the Issue shall be greater than or equal to fifty, otherwise, the entire application money will be refunded forthwith. If such money is not repaid within eight days from the date the company becomes liable to repay it, than the Company and every officer in default shall, on and from expiry of eight days, be liable to repay such application money, with interest as prescribed under section 40 of the Companies Act, 2013 In accordance with Regulation 106(O) the SEBI (ICDR) Regulations, Company is not required to file any Offer Document with SEBI nor has SEBI issued any observations on the Offer Document. The Lead Manager shall submit the copy of Prospectus along with a Due Diligence Certificate including additional confirmations as required to SEBI at the time of filing the Prospectus with Stock Exchange and the Registrar of Companies. In accordance with Regulation 106(V) of the SEBI ICDR Regulations, the LM has to ensure compulsory market making for a minimum period of three years from the date of listing of Equity Shares offered in the Issue. The Issuer shall have Net Tangible assets of at least Rs. 3 crore as per the latest audited financial results. The Net worth (excluding revaluation reserves) of the Issuer shall be at least Rs. 3 crore as per the latest audited financial results. (g) The Issuer should have a track record of distributable profits in terms of section 123 of Companies Act, 2013 for two out of immediately preceding three financial years or it should have net worth of at least Rs. 5 Crores. (h) (i) (j) (k) (l) (m) (n) The Post-issue paid up capital of the Issuer shall be at least Rs. 3 Crore. The Issuer shall mandatorily facilitate trading in demat securities. The Issuer should not been referred to Board for Industrial and Financial Reconstruction. No petition for winding up is admitted by a court or a liquidator has not been appointed of competent jurisdiction against the Company. No material regulatory or disciplinary action should have been taken by any stock exchange or regulatory authority in the past three years against the Issuer. The Company should have a website. There has been no change in the promoter(s) of the Company in the one year preceding the date of filing application to BSE for listing on SME segment. Issuer shall also comply with all the other requirements as laid down for such an Issue under Chapter X-B of SEBI (ICDR) Regulations and subsequent circulars and guidelines issued by SEBI and the Stock Exchange. As per Regulation 106(M)(3) of SEBI (ICDR) Regulations, 2009, the provisions of Regulations 6(1), 6(2), 6(3), Regulation 8, Regulation 9, Regulation 10, Regulation 25, Regulation 26, Regulation 27 and Sub regulation (1) of Regulation 49 of SEBI (ICDR) Regulations, 2009 shall not apply to this Issue. Thus Company is eligible for the Issue in accordance with regulation 106M (1) and other provisions of chapter XB of the SEBI (ICDR) Regulations as the post issue face value capital should not exceed ten crores. Company also complies with the eligibility conditions laid by the SME Platform of BSE for listing of our Equity Shares 2.3 Types of Public Issues Fixed Price Issues and Book Built Issues In accordance with the provisions of the SEBI ICDR Regulations, 2009, an Issuer can either determine the Issue Price through the Book Building Process ( Book Built Issue ) or undertake a Fixed Price Issue ( Fixed Price Issue ). An Issuer may mention Floor Price or Price Band in the RHP (in case of a Book Built Issue) and a Price or Price Band in this Draft Prospectus (in case of a fixed price Issue) and determine the price at a later date before registering the Prospectus with the Registrar of Companies. 196

198 The cap on the Price Band should be less than or equal to 120% of the Floor Price. The Issuer shall announce the Price or the Floor Price or the Price Band through advertisement in all newspapers in which the pre-issue advertisement was given at least five Working Days before the Issue Opening Date, in case of an IPO and at least one Working Day before the Issue Opening Date, in case of an FPO. The Floor Price or the Issue price cannot be lesser than the face value of the securities. Applicants should refer to the Prospectus or Issue advertisements to check whether the Issue is a Book Built Issue or a Fixed Price Issue. 2.4 Issue Period The Issue may be kept open for a minimum of three Working Days (for all category of Applicants) and not more than ten Working Days. Applicants are advised to refer to the Application Form and Abridged Prospectus or Prospectus for details of the Issue Period. Details of Issue Period are also available on the website of Stock Exchange(s). 2.5 Migration to Main Board SME Issuer may migrate to the Main Board of Stock Exchange from the SME Exchange at a later date subject to the following: (a) If the Paid up Capital of the Company is likely to increase above Rs. 25 crores by virtue of any further issue of capital by way of rights, preferential issue, bonus issue etc. (which has been approved by a special resolution through postal ballot wherein the votes cast by the shareholders other than the Promoter in favour of the proposal amount to at least two times the number of votes cast by shareholders other than promoter shareholders against the proposal and for which the company has obtained in-principal approval from the main board), the Company shall apply to Stock Exchange for listing of its shares on its Main Board subject to the fulfilment of the eligibility criteria for listing of specified securities laid down by the Main Board. Or (b) If the Paid up Capital of the company is more than 10 crores and upto Rs. 25 crores, the Company may still apply for migration to the main board if the same has been approved by a special resolution through postal ballot wherein the votes cast by the shareholders other than the Promoter in favour of the proposal amount to at least two times the number of votes cast by shareholders other than promoter shareholders against the proposal. 2.6 Flowchart of Timelines A flow chart of process flow in Fixed Price Issues is as follows: 197

199 Section 3: Category of Investors eligible to participate in an Issue Each Applicant should check whether it is eligible to apply under applicable law. Furthermore, certain categories of Applicants, such as NRIs, FIIs/FPIs, QFIs and FVCIs may not be allowed to apply in the Issue or to hold Equity Shares, in excess of certain limits specified under applicable law. Applicants are requested to refer to the Prospectus for more details. Subject to the above, an illustrative list of Applicants is as follows: Indian nationals resident in India who are competent to contract under the Indian Contract Act, 1872, in single or joint names (not more than three); Applications belonging to an account for the benefit of a minor (under guardianship); Hindu Undivided Families or HUFs, in the individual name of the Karta. The Applicant should specify that the Application is being made in the name of the HUF in the Application Form/Application Form as follows: Name of sole or first Applicant: XYZ Hindu Undivided Family applying through XYZ, where XYZ is the name of the Karta. Applications by HUFs may be considered at par with Applications from individuals; Companies, corporate bodies and societies registered under applicable law in India and authorised to invest in equity shares; QIBs; NRIs on a repatriation basis or on a non-repatriation basis subject to applicable law ; Qualified Foreign Investors subject to applicable law; Indian Financial Institutions, regional rural banks, co-operative banks (subject to RBI regulations and the SEBI ICDR Regulations, 2009 and other laws, as applicable); FIIs and sub-accounts registered with SEBI, other than a sub-account which is a foreign corporate or foreign individual, applying under the QIBs category; Sub-accounts of FIIs registered with SEBI, which are foreign corporates or foreign individuals only under the Non 198